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Introduction
The experimental work to "be described in this thesis was
performed while investigating the role of immune mechanisms in
the pathogenesis of Idiopathic Thrombocytopenic Purpura. The
problem was first examined using conventional immunological
techniques, as, since Evans & Duane (1950) drew attention to
the similarity in behaviour between acquired haemolytie
anaemia of immune origin and idiopathic thrombocytopenic
purpura, many workers have claimed to have demonstrated
specific platelet antibodies or agglutinins in blood derived
from oases of idiopathic thrombocytopenia.
The methods used by individual investigators have varied
but, while apparently successful and reliable in the hands
of their originators, many have not produced reliable results
in other centres. The majority have based their methods on
conventional red blood cell agglutination techniques, and,
having substituted platelets for red cells, have observed the
presence or absence of platelet agglutination in varying
systems. But unlike red blood cells, platelets clump as
part of their normal physiological role in the process of
blood coagulation. When whole blood is removed from the
body and allowed to clot in vitro, the platelets clump or
agglutinate and eventually undergo lysis as fibrin is formed.
Therefore, the initial step in this investigation was to
re-examine this latter process in the light of modern knowledge
in order to determine, if not the exact nature, the properties
of the factor or factors in "blood coagulation which controlled
platelet agglutination.
If platelet agglutination could he induced specifically
immune agglutinins in cases of thrombocytopenic purpura,
presumably the mechanism must be different from that which
occurs during dotting and thus at least two types of
agglutination must exist.
As the techniques used to determine the presence or
absenoe of platelet agglutination in vitro necessitated
separating platelets from the other cellular elements of the
blood and, in some instances, from their own plasma, it was
also essential to decide what factors might alter or clump
the platelets non-specifically during these procedures.
By applying this information it was possible to decide
on a theoretically optimum technique for demonstrating
specific platelet agglutinating factors in the blood derived
from oases with unexplained thrombocytopenia, fhis
established, it was essential to discover whether such
specific platelet agglutinating factors might exist in normal
bloodj then it was possible to proceed to the examination
of blood derived from cases of thrombocytopenia, with or
without purpura, to confirm, if possible, the existence of
platelet agglutinating faotors in such oases, their relation¬
ship to the type and duration of the disease, and the effect
of therapy on those cases with demonstrable anti-platelet
%
•fan+n-rs in their blood.
The work, incorporated in this thesis lias been carried
out since January 1955 during the tenure of the post of
Graduate Assistant in the Department of Haematolcgy, Radcliffe
Infirmary, Oxford (Dr. E.G. Macfarlane, P.S.S.).
All the experimental work has been performed by myself
without any technical assistance. Certain reagents have
been provided and certain blood groups determined by other
workers in the department and due acknowledgement is made for
this assistance. The diagnoses of the specific defects of
blood coagulation factors in the blood of the many patients
used in the following experiments were made by Dr. Rosemary
Biggs.
The experimental work of this thesis is unpublished with
the exception of the following*
(i) The experiments relating to Complement and viscous
metamorphosis described in Chapter I? have been
incorporated in a letter to the Editor of fFATUHE
on 'The Relationship of Complement to Blood
Coagulation.* Sharp, A.A. (1957)- Hature, Lond.,
179, 632.
(ii) The experiments describing the effect of animal
ant ihaemophilio globulin on human and other
species' platelets have been described in a paper
entitled 'The Toxioity and Pate of Injected Animal
Antihaemophilio Globulin.* Sharp, A.A, and
Bidwell, E. (1957). Lancet, ii, 359.
# 4 ♦
(iii) The entire experimental data in Chapter HI and
certain experiments from Chapter IV have been
incorporated in a paper entitled 'Platelet Viscous
Metamorphosis - A study of the relationship to
fibrin formation.* Sharp, A.A. (195$)• Brit. J.
Haemat. In press.
(This latter paper was accepted by Professor
J.V. Dacie in June 1957 and will be published
in January 1958)*
The photographs used to illustrate certain aspects of
the experimental work of this thesis were printed from
negatives prepared by myself.
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cellular elements of the blood. This discovery was soon
confirmed by Hayem (1? 78, 1882, 1883) and Bizzozero (1882)
and revolutionised the experimental approach to blood
coagulation. Here at last was some factor, necessary for
blood coagulation, that could be observed by the naked eye
or with the aid of a microscope. Both Hayem (1878) and
Bizzozero (1882) observed the striking property of platelets
to clump and disintegrate in association with the clotting
... .
of the blood, and they inferred that the platelets were an
essential part of the mechanism of coagulation. These
opinions were questioned by Bberth & Schimmelbusoh (1Q88)
who pointed out that, if the platelets and platelet clumping
were an integral part of fibrin formation, intravascular
platelet clumping should provoke fibrin formation in the
adjacent blood; this sequence they did not observe•.
Almost simultaneously with the recognition of blood
platelets, and their suggested role in blood coagulation,
it was realised that cellular and tissue debris played an
important role in blood clotting in wounds and it was shown
that these products, when introduced into the blood stream,* *
would produce intravascular clotting (Wooldridge 1883 a & b,
1889).
Tet another important milestone in the history of blood
clotting followed with the discovery of the importance of
the role of ionised calcium in blood coagulation. This
discovery led to the 'classical theory' of blood coagulation
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coagulation proposed "by Morawitz (1905)* The latter believed
four factors must be present before fibrin formation could
occur and his theory may be represented diagramatically by
the following*





'Thromboplastin', Morawitz considered, was derived from
either the blood platelets or the tissues. This 'classical*
theory started an era in blood coagulation research which
lasted for more than three decades. In this period
evidence for and against the participation of platelets in
blood coagulation was advanced and new theories of the
mechanism of blood coagulation were propounded but not
accepted universally.
Wooldridge (1889) considered that platelets were not
independent elements of the blood but precipitated globulins,
and that they had no function in the mechanism of blood
coagulation. The work of Kemp (1884) and Burker (1904),
however, established both the independent nature of blood
platelets and their role in blood coagulation. When
Wright (1910) suggested that platelets originated from the
megakaiyooytes of the "bone marrow, their presence as individual
elements of the "blood was accepted by the majority of workers
in this field.
Alternatives to the 'Classical theory' were proposed.
Theory of Bordet
Bordet & Delange (1912), postulating a 4-factor theory of
'
hlood ooagulation, considered that there was an inert precursor
'
"proserozyme" in the blood, which was activated to "serozyme"
in the presence of calcium| this process being initiated by
'contact' with a foreign surface. Serozyme then, they thought,
reacted with eytozyme to form thrombin which in turn converted
.
fibrinogen to fibrin. Cytozyme or thromboplastin, they
considered, originated in the tissue or the platelets.
Other theories at variance with those of Mcrawitz and
i
Bordet & Delange were propounded by Holf (1908) and Howell (1912)»
Theory of Self
Sfolf (1908) thought that five factors were required for
normal blood coagulation, namely, throabokinase (throrabo-
I
plastin), calcium, thrombozym®, thrombogen, and fibrinogen.
Thrombozyme and thrombogen, both constituting what was usually
called "prothrombin", were activated by plasma thrombokinase,
a lipoprotein having the came properties as tissue
thrombokinase, to form thrombin. This, as in the
other theories, converted the fibrinogen to fibrin.
Thrombozyme, he thought, was present in th© platelets, leucocytes,
vascular endothelial cells and the bloodf 'Thrombogene',
derived from the liver, was also circulating in the blood,
tissue cells, in his opinion, did not contain thrombozyme
but accelerated coagulation in some non-specific way.
Theory of Howell
Howell (1910) considered that thromboplastin derived
from tissues neutralised an antiprothrombin to release
prothrombin. The latter, reacting with calcium, generated
thrombin. Later he assumed that the newly discovered
anticoagulant, heparin (Howell & Holt, 1913), was synonymous
with his antiprothrombin. The platelets, he considered,
supplied both thromboplastin and prothrombinj that they
contained these factors was also suggested by Bayne-Jones
(1912).
In all these theories, the platelets were believed to
play a major role in the mechanism of blood coagulation.
Platelets and the Speed of Blood Coagulation
The role of platelets in blood coagulation was further
clarified by the observation that when platelets are
artificially removed from plasma by oentrifuging or filtration,
"
the clotting time of the platelet free plasma is considerably
longer than that of platelet rich plasma (Sourd & Pagniez
1906| Cramer & Pringle 1913f L©e & Vincent 19Hf Hess 19171
Tait & Gr©eP1926). The extraction of platelets from blood
10
by passage through a Berkefeld filter, may deprive the blood
of more than platelets alone, and it is now known that such
filtration will remove other coagulation factors and so
prolong the clotting time. The use of silicone coated
glassware (Jaques, Pldlar, Pelsted & MacDonald 1946) greatly-
facilitated the removal of platelets from the blood in an
undamaged state.by centrifugation. Patton, Ware & Seegers
(1948), using this technique, were able to produce samples
of dog plasma which, collected without anticoagulant and
centrifuged at high speed, remained fluid for 72 hours.
The coagulation time of human plasma in glass can also be
prolonged by complete removal of the platelets (Brinkhous
1947)• In older to achieve this prolongation of the
clotting time, nearly all the platelets must be removed from
the blood. The whole blood clotting time will remain con¬
stant over a wide range of platelet concentrations and is
prolonged rarely in clinical thrombocytopenia (Quick,
Shanberge & Stefanini 1949)*
Platelets and Thrombin Generation
If platelets are merely reduced in number, and not
removed completely, the clotting time of blood or plasma is
not altered significantly from the normal. Thrombin
generation is, however, markedly reduced and, as prothrombin
is not consumed, abnormally large amounts of the latter are
left in the serum after clotting is complete (Quick &
Favre-Gilly 1949)* This observation was confirmed by
11 -
Alexander & De Vriea (1949)» Conley, Hartman & Morse (1949) t
and Merskey (1950). Conley at al (1949) showed that even a
fall in the platelet count from 350»000 to 260,000/ou.mm.
decreased significantly the amount of prothrombin consumed
during clotting.
Platelets and Thromboplastin
In the classical theory, as postulated by Morawita (1905)>
thromboplastin or thrombokinase, released by the platelets
or tissues, was considered to convert prothrombin directly.
Only Uolf considered that thromboplastin might react with
more than one factor before thrombin was generated from
prothrombin. It was realised gradually that platelets had
little direct thromboplastin activity as measured by com¬
parison with tissue thromboplastin, (Quick 1947$ Ware,
Fahey & Seegers 1948?), and it beoaze apparent that platelets
or their thromboplastic component must aot with some other
factor or factors prior to activating prothrombin to thrombin.
Howell (1912) first suggested that the thromboplastic
component of platelets was related to oephalin and this
observation was confirmed by Bordet (1920), Mills (1927),
and Chargaff, Bancroft & Brown (1936). This work ha©
assumed new importance with the isolation of the thromboplastic
phospholipoid component from the platelets which has been
identified as the fraction concerned in the conversion of
prothrombin to thrombin (Creveld & Paxilssen 1952?
Stefanini & Campbell 1954? Alkjaersig, Abe & Seegers 1955)*
A phosphatide (phospholipid) component of soy bean has been
shown to have equal activity (Chargaff ot al 1936) and to
correct the clotting defect in thrombocytopenic blood (White,
Lagen, Aggeler & Geyer 1953)» Similar material has been
derived from human brain which can be substituted for
platelets in 'in vitro' blood coagulation experiments (Bell
& Alton 1954)* Further, it has been claimed that the active
fraction of these phospholipoids is phosphatidyl-ethamolamine.
This has been shown to be capable of acting as a platelet
substitute (Robinson & Poole 1956? Garrett 1956) and this
fraction may also represent the 'thromboplastin' component
of platelets (O'Brien 1956). There is considerable doubt,
however, that this is so (Biggs & Bidwell 1957)*
Other Coagulation Factors in Platelets
Ware, Fahey & Seegers (1948) demonstrated that plate¬
lets, as well as having thromboplastin activity, contained
two other distinct factors which influenced Blood coagulation,
namely platelet factors 1 and 2. Both these factors were
distinct from the thromboplastin component and were found in
saline or water extracts of normal platelets (C reveld.
Eaulssen 1951).
Factor 1 appeared to accelerate the action of the
thromboplastin on prothrombin to form thrombin. Factor 2
accelerated the rate at which thrombin would convert
fibrinogen to fibrin. Platelet factor 3 w&s considered to
, ....
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"be the phospholipid 1 thromboplastin* component already
discussed (Creveld & Sauls sen 1952). These authors considered
that factor 3 also had anti-heparin activity hut this has been
shown to he a property of a separate factor (Beutsch, Johnson
& Seegers 1955)• In addition Ware, Fahey & Seegers (1948)
claimed that they found in water soluble platelet extracts a
thrombin clottable fraction which apparently was not
fibrinogen. This was called platelet factor 5 by Crevald
(1954). I* has still to be proved conclusively that this
factor is not fibrinogen.
In addition to these factors, platelets have been shown
to carry an anti-fibrinolysin (Johnson & Schneider 1953i
Creveld 19541 Stefanini & Murphy 1956). 5-^droxytryptamine
(Serotonin) is also contained in platelets and, while having
marked vasoconstrictive properties and probably contributing
indirectly to in vivo coagulation in haemostasia and thrombosis,
it has not yet "been shown to have any direct effect on the
actual coagulation mechanism (Bounameaux & Lecomte 19541
Zucker & Borrelli 1955 a & b). It has been claimed that
5-H.f. is the principle responsible for clot retraction in
bovine plasma (Fenichel & Seegers 1955) "but this has not yet
been shown to be the case in human blood (Magalini &
Stefanini 1955).
Adenosine triphosphate (Bom 1956), adrenaline and
noradrenaline (Weil-Malherbe & Bone 1954), and glutamic
oxalacetic transaminase (Magalini & Stefanini 1956) have also
"been isolated from platelets but, so far, their influence,
if any, on "blood coagulation has not bean determined.
Platelets and the Concept of Intrinsic Plasma Thromboplastin
Formation
When blood is collected carefully without any tissue
contamination, it will clot firmly in a glass tube. This
fact suggested that the blood must have an intrinsic
prothrombin converting mechanism independent of tissue
thromboplastin. This intrinsic thromboplastin system takes
5-6 minutes to produce fibrin while tissue thromboplastin
will act in 12 - 15 seconds. At first sight this suggested
relatively little thromboplastic activity and the platelets
were thought to provide what little thromboplastin appeared
to be available. Quick (1947) and Brinkhous (1947) provided
evidence to show that 'antihaemophilic globulin*, a factor
present in normal blood, but specifically reduced or absent
in classical haemophilia, was essential for the coagulation
promoting or prothrombin converting activity of platelets.
As knowledge of blood coagulation developed, further factors
were isolated which also appeared to react with platelets
and augment their thromboplastic effect. Factor V (Owren
1947) was discovered during the investigation of a case of
apparent congenital prothrombin deficiency ^ a WOEaari 0f 29.
The defect in this patient was, however, corrected by
artificial prothrombin free plasma (adsorbed with aluminum
hydroxide) as well as normal plasma, Owren showed that,
- 15 ~
when isolated in a relatively purs state, factor V was
essential for the conversion of prothrombin to thrombin by
both tissue and platelet thromboplastin. That platelet
factor 1 is in fact adsorbed factor V has been shown hy
Hjort, Rapaport & Owren (1955)* Yet another prothrombin
conversion factor was found in prothrombin-free serum (Owen
& Bollman 1948) which was deficient in the blood of patients
treated with •ooumarln' anticoagulants. This was named
proconvertin by Owren (1951) or Factor VII (Koller, Loeliger
& Duckert 1951)* This latter name has been generally
adopted in the British literature. Although factor VII was
originally thought to be essential for the action of both
platelet and tissue thromboplastin on prothrombin, it is now
accepted that its sole function is the potentiation of the
action of tissue thromboplastin (Koller 1955)•
In 1952, Biggs, Douglas, Macfarlane, Bacie, Pitney,
Merskey & O'Brien, and White, Aggeler, GlendenAing, Page,
Leake <5b Bates independently discovered a further factor
necessary for normal blood coagulation,which they called
respectively Christmas Factor and Plasma Thromboplastin
Component (PTC). It had become apparent that not all cases
of classical haemophilia could be explained by a defect of
antihaamophilic globulin and thin now factor was found to be
diminished or absent in these cases) the olinioal syndrome
being named Christmas disease by Biggs et al (1952).
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Rosenthal, Dreskin & Rosenthal (1955) have defined a
further factor which when partially or totally absent from the
blood, is associated with a mild haemophilia-like syndrome.
This they named Plasma Thromboplastin Antecedent (FTA). This
factor was shown to be distinct from AHG or Christmas factor.
Lastly, it has been claimed by Ratnoff & Colopy (1955)»
Prick & Hagen (1956) and Ramot, Singer, Heller & Zimmerman
(1956) that yet another factor exists which is apparently
essential for normal blood clotting and prothrombin con¬
sumption, and which has different properties to A.H.G.,
Christmas factor and Rosenthal^ factor (FTA). When this
factor is absent from the blood, there is no associated
impairment of physiological haemostasis and patients with
this defect are apparently normal. This has been called
the 'Hageman'factor. The significance and the exact mode of
•
, ...
action of these latter two factors is, as yet, obscure, but
from the accumulated evidence all these factors would appear
to react together with the platelets to form an intrinsic
blood thromboplastin.
Originally, Biggs, Douglas & Maefarlane (1953b) showed that
if platelets were incubated for several minutes with A.H.G*,
Paotor V and Christmas factor, a thromboplastin was generated
which was capable of clotting normal plasma in 8 - 10 seconds.
Paotor VII was thought originally to participate in this
reaction but, since thromboplastin generation procedes
normally in some cases in which Pactor VII is absent (Koller
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19551 Ackroyd 1955), it is, as already stated, thought to
"be necessary only for the acticn of tissue thromboplastin.
Biggs et al (1953b) used aluminium hydr02d.de adsorbed
plasma to provide A.B.G. and factor V and serum to provide
Christmas factor in their in vitro thromboplastin generating
mixture and it is probable that these test components may also
have contained the PLT.A. end Hageman factors now known to be
essential for normal intrinsic thromboplastin generation.
The participation of five or more factors, in a reaction
requiring several minutes to complete, suggested that they
reacted in stages. While a defect of any one plasma or
serum factor would prolong this phase and diminish the amount
of thromboplastin generated, a deficiency in the number of
platelets only diminished the amount of thromboplastin
generated but did not apparently prolong the interval before
'
thromboplastin started to b© formed (Biggs, Douglas &
Macfarlane 1953 a & b).
Evidence was obtained to suggest that intermediate
stages of thromboplastin formation could, in fact, be detected
experimentally. It was thought that A.H.G., Christmas
factor and platelets must first react to form an intermediate
product which, in turn, reacted with factor V to form active
intrinsic thromboplastin? calcium being required for all
stages (Biggs et al 1953 a & bj Bergsagel 195^9 Bergsagel
& Bougie 1955).
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Thus, it has "been established beyond all reasonable
doubt that platelets and their constituent factors are
essential for normal intrinsic blood thromboplastin formation
and normal blood coagulation.
Platelet Agglutination and Blood Coagulation
There has been general agreement that platelet dis¬
integration plays an important part in the mechanism of blood
coagulation. Stefanini (1953) thought that it constituted
the first step and fundamental step in the entire process.
While it was thought originally that the platelets, by
disintegration, converted prothrombin to thrombin (Morawitz
19051 Bordet 1920) or directly released thrombin (Tait &
Burke 1926), it is now known that their products of
disintegration participate in the much more complex inter¬
action with other factors before prothrombin is converted to
thrombin (see p. 16),
While this has been accepted, it does not agree with the
observation that white thrombi, made up of disintegrating
platelets, form in damaged blood vessels without the clotting
of the adjacent blood (Eberth & Schimmelbusoh 1888} Burke &
Tait 1926} Pickering 1928).
The formation of fibrin is usually the only visible
change observed when blood clots but if platelet rich plasma
freed from red cells is allowed to clot it is apparent that
fibrin formation is preceded by sudden clumping of the
platelets (Tait & Burke 1926). This phenomenon has been
recognised since the platelets were first discovered and
was described by Hayem (1878), Bizsozero (1882) and Lberth
& Schimmelbusch (1886). The latter authors coined the tem
viscous metamorphosis ('viscose metamorpch.se1) to desoribe
this change.
It is of historied, interest to note that prior to this
viscous metamorphosis of platelets had been observed by Osier
(1874). He described the typical morphological changes
observed in vitro and in vivo experiments, without appreciating
their significance, and thought they might be pathognomonic
of the 'exanthema'. Banvier (1873) noted the presenoe of
granular elements in the fibrin mesh work in clotted blood
but thought they were a form of early fibrin.
Hayam (1878) noted that 'haematoblasts' or platelets
became irregular, angled and etiolated during the process of
blood coagulation, and fine delicate filaments projected
from their surface. The platelets then formed masses which,
in turn, became refraotile, as the outline of individual
platelets became more confused. Bizzozer 0 (1882) described
granular disintegration of the platelets as the only visible
change in the formed elements of the blood when removed from
the blood vessels and their observations led them to conclude
that identical changes took place in vivo in the blood when a
blood vessel was damaged. The platelets, normally quite
separate in the blood stream, came together at the point of
injury and formed a mass covering the damaged area and, as
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small embolic clumps were broken off this mass by the blood
stream, more platelets were added (Bizsozero 18825 Eberth
& Schimraelbusoh 1886). Hayem (1882) thought that fibrin
eventually formed round these masses, but this was not con¬
firmed by Eberth & Sehimmelbusch (1888).
Hayem (1882) also showed that foreign material intro¬
duced in the blood vessels were covered rapidly with granular
material consisting of clumped platelets*
The term •viscous metamorphosis' (VM) was revived by
Wright & Hinct (191?) who, in a most extensive study of this
phenomenon, showed that fresh serum was capable of inducing
cell changes of VH in washed platelets derived from rabbits
and humans. They also observed this phenomenon in clotting
plasma. They reaffirmed the importance of calcium ions in
this process thus confirming the previous observations of
Mayer (1907), Cramer & Pringle (1913) and Zucker (1913).
Their observations suggested that this process took place in
two stages, namely agglutination of the platelets and 'viscous
metamorphosis' proper. They thought that the former
represented the finer grades of viscous metamorphosis. Their
experiments were too detailed to review completely here but
further reference will be made to them during discussion of
the experimental work of this thesis.
Other authors have described the morphological changes of
VM. Mayer (190?) called the large platelet clumps
"forme ds granules accoles sans structure." Aynaud (1911a)
described the sequence of platelet
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changes occurring during coagulation. Stubel (1914)
clearly illustrated this process hy a study of the platelets
using darkground microscopy. Using the same method, Tait
& Burke (1926) observed VM in 'native* platelet rich plasma,
prepared without the addition of an anticoagulant, and noted
the extrusion of granules by the platelets in this process.
Thpy thought that fibrin appeared along the pathway taken by
these moving granules which they considered were composed of
thrombin. Serial observations led them to conclude that
there was a definite tine relationship between the platelet
changes and the formation of fibrin.
The presence of released granules was confirmed by
Ferguson (1934) who, however, considered that fibrin was
formed in the free plasma and not in relation to the
platelets or their granules. He also confirmed that calcium
was necessary for this reaction. Further descriptions were
given by Cramer & Bannorman (1929) and Tocantins (1938).
Platelet viscous metamorphosis has been studied by
electron microscopy (Bessis & Burstein 1948| Bloom 1955f
Alexsandrowicz, Blicharski & Felbynowski 1954I Braunsteiner,
Fellinger & Pakesch 1954), and phase contrast microscopy
(Bessi & Tabuis 195'if Bergsagel 1956f Setna & Rosenthal
195«).
Numerous attempts were made to define the factor or
factors responsible for those changes.
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Hayem (1882) considered that trauma instigated the
mechanism of VS. Aynaud (1911a) postulated that tissue
extracts contained extremely active platelet agglutinins or
lysins. Roskam (1922) first suggested that the dumping of
platelets was due to the flocculation of plasma proteins in
"1'atmosphere plasmatique" around the platelets, and it was
suggested that the material formed was fibrin (Apitz 1939)•
Fonio (1923 & 1940) was the first to suggest that thrombin
mi^it be capable of producing platelet viscous metamorphosis,
probably converting fibrinogen to fibrin. This view has
been widely accepted.
The theory that peri-platelet fibrin formation was
responsible for VM was discarded when it was shown that, in
congenital afibrinogenaemia, VM evolved normally (Hnniger,
& Franty 1946). Alexander, Goldstein, Bloh, Le Bollooh,
Diamond & Borges (1954) have recently confirmed this
observation.
The interaction of antihaemophi1io globulin and platelets
in the formation of thromboplastin has already been discussed.
Brinkhous (1947) considered that as A.H.O. required platelets
before it could convert prothrombin to thrombin, it was the
'thrombocytolysin• responsible for platelet breakdown.
Qaiok (1947) proposed the exactly opposite view and held
that platelet activated 'thromboplastinogon1 (A.H.G.) to
thromboplastin.
Quick (1951) and Quick & Eusaey (1952) renewed Ponio's
that,
hypothesis "by postulating in the initial stages of blood
coagulation, trace amounts of thrombin were generated, which,
while being insufficient for the conversion of fibrinogen to
fibrin, were capable of inducing VM in platelets. By virtue
of this mechanism these authors considered that thrombin had
an accumulative auto-catalytic action on the speed of blood
coagulation. This hypothesis has received strong support
from numerous workers who have observed the ability of
thrombin to induce VM in platelets (Stefanini 1951 & 1953$
lobertiSj Paseyro & Seissig 1953? Desforges & Bigelow 1954$
Zucker & Borrelli 1955c; Bounameaux 1955 & 195Tb).
The latter three worker's and Bergsagel (1956) did observe
that human thrombin had no effect on washed platelets separated
from their plasma. In addition, some of the previous claims
were invalidated by Bergsagelfs (1956) observation that,
while human thrombin had no effect on washed platelets,
bovine thrombin produced strong agglutination. He considered
that this discrepancy was due either to an interspecies
reaction on the part of bovine thrombin,or to the presence of
some impurity in bovine thrombin; such as an intermediate
product of thromboplastin formation.
The recognition of the essential role of platelets or
their products of disintegration in the generation of
intrinsic plasma thromboplastin (Brinkhous 1947$ Quick 1947$
Biggs, Douglas & Maofarlane 1953 a & bf Bergsagel & Hougie
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1956) Bergsagel (1956) to suggest that a specific inter¬
mediate product of thromboplastin generation was formed by
the interaction of Christinas factor, calcium and A.H.G., and
that this was the factor responsible for inducing platelet VM
and releasing a powerful coagulant. His experiments can,
however, be criticised on the grounds that he demonstrated
this phenomenon in a highly artificial coagulant mixture
containing pig A.H.G., serum and calcium. The conditions
existing in this were far removed from those of normal blood.
Contrary to all these previous opinions of the mechanism
of platelet VM in blood coagulation, Mann, Hum & lathieson
(1949) •»& Erfcelens (1956) considered tbat no visible
platelet change occurred until after fibrin had formed.
The influence of foreign or water wettable surfaces on
platelets and their disintegration will be considered
separately in Chapter VIE.
Platelets and the Mechanism of Haemostasia
Ho discussion of the role of the blood platelets in the
physiological mechanisms of the body and their relationship
to blood coagulation, would be complete without some
reference to the •mechanism' of haemostasia.
It has already been shown how early workers believed
that platelets played the most important role in haemostasia
by blocking any breach in the vessel walls by virtue of their
ability to undergo VM in the damaged segment and in the
extravasated blood. Hayem (1882) showed that,
if he partially sectioned the jugular vein of the dog, the
wound became filled with a granular mass of platelets
surrounded by fibrin ,and haemorrhage ceased* Prom this
observation and those of BizzozjSero (1882) and Eberth &
Schimmelbusch (1886), it was generally accepted that platelets
together with fibrin formed a mechanical plug to stem the
flow of blood from damaged vessels.
Macfarlane (1941) dissented from this accepted theory and
pointed out that it failed to provide an acceptable explanation
for the failure of haemostasia in many haemorrhagic diatheses.
He stressed the role of the capillary in haemostasia and, from
his experimental work, deduced that capillary contraction
was an important faotor in the control of haemorrhage. This
contraction, as it passed off, was replaced by fibrin which
formed in exfcravasated blood. The platelets, he relegated
to a subsidiary role and considered their only function wa3
to contribute their blood clotting components at the site
of injury. His hypothesis was supported by the previous
work of Lewis (1923) who had observed that active capillary
contraction did occur and, in fact, was capable of exerting
considerable pressure. Sanders, Elbert St Plorey (1940) had
also supported this contention by observing capillary oon-
traction in rabbit ears following experimental trauma.
Marjorie Zuoker (1947) restored interest in the role of
platelets in haemostasia by observing haemostasia in the
meso-appendlx of the rat. She observed that when vessels
were sectioned completely they hied from both central and
peripheral endsj gradually the stumps -were occluded by
masses of platelets which protruded into the wounds. In the
arteries and large venules vaso-constriction occurred as the
platelet plugs formed. Vaso-constriction also occurred in
Vessels.
the adjoining undamaged If vaso-constriction passed off
prematurely, bleeding recommenced around the platelet plug.
She also observed that, while fibrin could not be demonstrated
.
in relation to the platelet plug, the platelets in the latter
fused to form an amorphous mass. These observations were
confirmed by H.D. Buoker (1949) in a histological study of
wounds in human skin. In damaged pre-capillary arterioles
and venules, but not in capillaries, he found definite platelet
masses, which had apparently undergone viscous metamorphosis,
protruding into the wound. While no intravascular fibrin
could be detected, it was observed in the exfcravasated blood
in the wound and the walls of the wound track were lined by
scattered clumps of platelets. In thrombocytopenic patients
'
he found that fibrin alone, without platelets, appeared to
be capable of producing adequate haemostasia. Platelet
VM, he thought, commenced within 30 seconds of damage being
inflicted on vessels. The role of platelets in haemostasia
has been affirmed by Luis (1951) and Pulton, Akers & Lutz
(1953) in studies on the vessels in the hamster oheek pouch.
These workers have filmed these changes and illustrated very
dearly the striking intravascular platelet dumping when
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vessels in the hamster oheek pouch are cut or damaged. (This
film was shown in Oxford by Dr. Desai who had bean associated
with the above workers).
Chen & Tsai (194®) observing the haemostatic mechanism in
the web of the frog's foot and in the rabbit, put forward yet
another theory for vascular haemost&sis. They observed
contraction of capillaries in the frog but considered that
pressure or cutting these vessels provoked adhesion between
the lining endothelial cells. They stressed the importance
of vascular contraction In arteries and arterioles but in
venules platelet plugs appeared to play the more important role
in stemming the flow of blood when the vessels were cut.
The ability of damaged vessels to contract had been
• - ... >
observed by Magnus (1923) as well as M.B. Zucker (1947) and
H.D. Zuoker (1948). Janeway & Park (1912) and Janeway,
Richardson & Park (1918) observed that serum contained a vaso¬
constrictive factor which did not appear to be epinephrine
(adrenaline) and Tsai, McBride & Zucker (1944) and Zucker (1944)
:
observed that this factor apparently originated in the platelets.
The nature of this material was discovered by two sequences
of coincidental research. Rapport, Green & Page (1948) and
Rapport (1949) purified this serum constrictor and found
that it contained equimolar parts of creatine, sulphuric acid,
and indole derivatives. Tentatively they suggested it might
be 5-hydrorytiyptamine (5~H.f.) or 'serotonin'. Rand & Raid
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(1951) confirmed that this 'serotonin' did. come from
platelets.
Almost simultaneously Si-spam©r and Asero (1952) demon¬
strated that 5-H.T* was the hormone secreted by the entero-
ohromaffin cells of the intestine. Eapidly these two
observations ware united and led to confirmation of the
presence of 5-&.T. in platelets which had vaao-constrictive
properties (Zucker, Friedman & Rapport 1954j Humphrey &
Jaques 19941 Haxdisty & Stacey 1955)*
Humphrey & Toh (1954) showed that platelets took up
5-K.T. secreted by the entero-chromaffin system rather
than forming it in situ.
Udenfriend & Weistach (1954) considered that this 5-K.T.
was released from the platelets wnen they were ruptured and
the release of this hormone also accompanied physiological
platelet VM (Zucker & Borrelli 1955$«
Tims it is now generally accepted that 5-H.T. or serotonin,
being capable of contracting arteries and arterioles in its
pure form, is the vaso-constrictive agent responsible for
haemostatic vaso-constriction. Also it is probable that
platelet VI releases 5-H.T. from the platelets (Zucker &
Borrelli 19559-
This discourse has shown haemostasia is a complex
mechanism but the known features may be summarised as follows.
When blood vessels are damaged by trauma, haemorrhage
may be stopped l^ys
1# the platelets undergoing viscous metamorphosis
forming mechanical plugs and releasing agents responsible for
2. vaso-constriction of arteries, arterioles and venules
3. the fomation of fibrin;
4. capillary contraction either related to (2) or as a
separate mechanism, and
5* endothelial adhesion in crushed vessels*
. I ' , ' - '4 ,j " ' "'I'",
Whatever the role of fibrin it is apparently not
essential for immediate or primary haemostasia but is
necessary for permanent haemostasia.
All or some of these factors may operate in a given
instance of trauma but it is probable that, while all may
.
act synergistieally in the normal individual, the failure of
any one factor may be compensated by the increased activity
.
of another. This problem must be viewed with oaution, as
it is by no means certain that the mechanism, as observed in
experimental animals, is synonymous with that in humans.
Beither has it been pfoven that the 'mechanism' of haemo
in the superficial vessels of the dermis is identical to that
in the deep tissues or viscera.
In some instances when the circulating blood platelets
are reduced in numbers an abnormal haemorrhagio tendency
ensues. This is usually characterised by a failure of the
primary haemostatic mechanism as shown by a prolongation of
the bleeding time. Also there le often abnormal fragility o
the superficial capillaries of the skin.
-
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4e this failure of the haemostatic mechanism does not
occur in eve17 case of thrombocytopenia it must "be assumed that,
when it does occur,it is the result of at least two concomitant
defects, one of the capillary walls, the other of the platelets
themselves. The haemorrhage orobably is the result of an
escape of blood through the defect in the capillary wall and,
the platelet3 being reduced in number or absent, the platelet
plug does not form to repair or cover the defect, Furthermore
it is reasonable to assume that where the platelets are
reduced in number the vasoconstrictive agents released would
also be decreased in amount or completely absent.
The abnormal bleeding in these thrombocytopenic syndromes
will cease in any given site only as fibrin is formed to
repair the breach in or around the affected vessel. As
fibrin formation is not so dependent on platelet numbers,
fibrin will form in nearly normal time in spite of severe
thrombocytopenia. If platelets are completely absent from
the peripheral blood, this mechanism may also fall, but it
is probable that a complete absence of circulating platelets
occurs only in exceptional cases such as true bone marrow
aplasia or terminal acute leukaemia. In these examples a
such more sever© and intractable form of spontaneous
haemorrhage is encountered.
If the blood platelets are present in normal numbers,
but have abnormal function, a similar failure of the primary
haemostatic mechanism may be found.
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A congenital or acquired defect of one or more of the
plasma or serum coagulation factors necessary for intrinsic
thromboplastin formation is often accompanied by a more
sever® haemorrhagic tendency than that encountered in the
thrombocytopenic syndromes. Unlike the latter, there is
seldom a defect in the mechanism of primary haemostasia.
Thus, while trauma does provoke a normal blood loss, this
stops in normal time only to restart after a variable period.
It must be presumed, in these cases, that the platelet plug
and vaso-constrictiv® mechanisms function normally but, a3
imperfect or no fibrin is formed at th® site of the trauma,
its reinforcing action fails and so secondary haemorrhage
occurs. The intractable nature of this secondary haemorrhage
such as is seen following trauma in cases of haemophilia,
suggests that, once the primary haemostatic mechanism has
passed off, it cannot reappear at the primary site unless
fresh trauma occurs.
While this does explain the type of haemorrhage in
certain syndromes, anomalies do exist which are encountered
too frequently tc be ignored.
2h some oases of severe haemophilia there is a failure
of the primary haemostatic mechanism as measured by the
bleeding time, in spite of the presence of a normal number
of normally functioning platelets. Also in some examples of
athxosibccytopenic purpura, a failure of primary haemostasia
is associated with a normal number of apparently normal
functioning platelets and a low level of ant-ihaemophilio
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globulin. In spite of tile latter, these oases do not
usually show severe secondary haemorrhage. Further, severe
and intractable spontaneous haemorrhage can occur from
dilated capillaries in hereditary telangiectasia where platelet
numbers and function and coagulation are all entirely normal.
In such cases the primary mechanism of haemostasia only fails
when an abnormal vessel is damaged, but once started, blood
loss will continue in spite of apparent normal fibrin
formation in the shed blood. This does stress that the role
of capillary contraction in haemostasia requires further
investigation.
The overwhelming difficulty in research into this problem
has been the inability to observe blood vessels in vivo in
other than experimental animals. In the human the only
vessels that can be visualised are the capillaries in the
nail bed, the skin, and the conjunctival and retinal
membranes of the eye. Also it appears to be impossible,
at present, to definitely differentiate fibrin from platelets
by any orthodox histological means. Until these problems
are solved, this subject will continue to be one of
controversy.
This review has. showedthat platelets play an essential
part, together with other plasma coagulation factors, in the
initial sequence of blood coagulation and thromboplastin
formation, as well as in the mechanism of haemostasia. But
it was not at all dear exactly when or where the platelets
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or their disintegration products acted in the sequence of
blood coagulation and what factor or factoars controlled the
evolution of viscous metamorphosis. As it was essential
that these mechanisms be more fully understood before any
attempt could be made to determine whether agglutinating
factors, other than those existing in the coagulating
mechanism, were present in the blood of patients with
idiopathic or other foarras of thrombocytopenic purpura, it
appeared to be worth while to are-examine these problems in
the light of nodeam knowledge.
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CHAPTER II
Viscous Metamorphosis and Platelet Agglutination
When ■whole blood is allowed to clot in vitro the only
visible change is the formation of fibrin.
If the red cells are removed, and platelet rich plasma
is observed as it clots, fibrin formation is preceded by
sudden and obvious clumping of the platelets. This change
is called "viscous metamorphosis" by some workers or
"platelet agglutination" by others. There is confusion in
the existing literature as to the exact definition of these
terns and it will be stressed in the course of this thesis
that they are not synonymous, but that one may easily be
mistaken for the other.
In the experimental work to be described the term
"viscous metamorphosis" (VM) will be used to include all the
characteristic morphological changes .that platelets undergo
during the process of blood coagulation. The term
"platelet agglutination" will be employed to describe the
simple clumping of unaltered platelets, a process morpho¬
logically distinct from viscous metamorphosis.
To compare these two phenomena,platelet changes were
first observed in clotting normal platelet rich native
plasma. The separation of platelets in such plasma was
achieved hy cooling the collected blood in siliconed tubes
oontained in melting ice in a small thermos flask. The red
cells were removed hy low-speed centrifuging at 0°C (see
Appendix A, p. 11 ). ly this technique it was possible to
obtain platelet rich plasma, free from anticoagulant, which
did not dot for several hours if kept at 0°C, Samples of
the plasma were placed in glass tubes and allowed to clot by
warming to 37°C| the tube being agitated to allow the
platelets to collide.
Hormal Visoous Metamorphosis (Phase Contrast Microscopy)
As the platelet rich native plasma was warmed to 37°C
the platelets could be observed forming microscopic clumps
which gradually increased in size until they were eventually
emmeshed in fibrin as it formed. Attempts to observe this
sequence taking place in microscopic preparations were
unsuccessful as the pressure of the coverslip, necessary for
good phase-contrast microscopy, prevented the platelets
colliding with each other, and thus their ability to undergo
typical VM. Therefore serial samples both fixed and unfixed,
taken from the tubes as the platelet rich plasma clotted,
were examined by phase-contrast microscopy. The first
visible change involving individual platelets took place at
the periphery of these cells, where pseudopodia, in the form
of filaments, developed. As the platelets started to clump,
they were Joined together by union of these filaments, and,
as they did so, the size of the individual platelets increased.
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The clumps further increased in size to form granular masses
of platelets in which the majority of platelets had lost their
individual outlines (Pigs. 1 & 2). A striking feature of
this change was the tenacious and irreversible union of one
platelet with the other hy means of hyaline "bands, so that
one platelet merged imperceptibly with its neighbour (Pigs. 3
& 4)« These illustrations do suggest that these platelet
clumps were flat and pancake-like, tut this appearance was
induced by pressure on the coverslip prior to photomicrography
and does not represent the true sequence of morphological
changes. In fact, the platelet clumps were irregular
spherical masses, a state impossible to illustrate satis¬
factorily by phase contrast microphotograpby. In the early
stages of VM only some of the platelets were incorporated
into these masses and numerous individual platelets could be
seen lying free in the plasma. Gradually the latter either
adhered to already existing clumps or formed fresh clumps.
Once these large granular masses had formed, the
platelets in their centres started to lyse and change into
amorphous structureless material (Pigs. 5 & 6). In parallel
with these changes, granular material, apparently originating
from the periphery of the platelet masses, appeared
suddenly in the plasma (Pig. 7) • As VI developed more and
more of these granules appeared until, just prior to fibrin
formation, the plasma contained numerous small granules
undergoing violent Brownian movement. Further, it was
Figure 1
(Phase contrast x 1100)
Early Viscous Metamorphosis
The typical granular mass of platelets formed in the
early stages of VM.
\
(Blase contrast x 1100)
Viscous Metamorphosis
A granular oass of fused platelets in which the
individual platelets have commenced to merge with one
another.
(Phase contrast z 5500)
ffrffff?8 3 » fr
T1,800",8 Metamorphosis
A higher magnification of the platelet clump showing
that the platelets adhere to one another fcy means of hyaline




(Phase contrast at 5500)
(Phase contrast x 1100)
Figures 5 & 6
Viaooua Metamorphosis
More advanced platelet lysis and the formation of
amorphous debris in the centre of each clump.
Phase contrast x 1100)
Figure 7
(Phase contrast x 2200)
Viscous Metamorphosis
Platelet granules being released from the periphery 0f
the platelet olump.
- 37 -
evident that some factor limited the size of the platelet
masses as, once the latter had reached a certain size, they
did not adhere to each other or unclumped platelets, A
typical example of a dump which had reached maximum size is
illustrated in Pig. 8.
Fibrin was seen to form first in the intervening plasma
and in close relationship to the released granules. Appearing
first as small crystal-like rosettes of fibres, the fibres _
rapidly joined the platelet masses together by adhering to
the periphery of the clumps (Pig. 8).
Once fibrin had formed, the metamorphosed platelets
underwent yet further changes. Around the periphery of the
clumps small clear white 'balloons1 formed, which pushed their
way slowly outwards between the fibres of fibrin. Some
eventually became detached and were seen to float free from
the platelet dumps (Pigs. 8, 9 & 10). This change was not
fully developed until approximately 30 minutes after fibrin
had formed. These balloons also formed in the centre of
the platelet masses (Pig. 11).
The changes that have been described are thought to be
typical of "viscous metamorphosis" and are entirely different
from the sequence of "platelet agglutination".
Platelet Agglutination (Phase Contrast Microscopy)
As this property of platelets will be studied in the
experimental work of this thesis, it is convenient to
Figure 8
(Phase contrast x 1100)
Late Viscous Metamorpfosis
A typical platelet clump in plasma showing the distribution
of fibrin fibres. Small white 'balloons' are present around
the periphery of the clump and some have escaped into the
surrounding plasma (native plasma).
9
(Phase Contrast x 5500)
figures ,? & ,1,0
Late Viscous Metamorphosis
The formation of white 'halloone' at the periphery of the
platelet clump. Each 'balloon' is extruded between the adhering
fibres of fibrin. Some 'balloons' are lying apart from the
clump. (Native plasma).




(Phase contrast x 5500)
fote Viscous Metamorphoses
She formation of white balloons in the centre of the
platelet mass. (Native plasma)
describe the typical morphological appearances along with
those of viscous metamorphosis.
Platelet agglutination was induced in vitro by anti-
human platelet rabbit serum (Appendix 3» P* 31)• After
suitable treatment to remove those coagulation factors that
might induce VM (see Chapter 5 and "Platelet Agglutination
Test" Appendix A, p. 14 ), the sera were added to washed human
platelet suspensions and the morphological changes observed
during and after 1 hour's incubation of the mixtures at room
i
temperature.
Within fifteen minutes of the antiserum being added to
the platelets the latter formed small clumps or agglutinates
(Pigs. 12 & 13), In these the individual platelets were
easily distinguishable and, unlike VM, all the platelets had
agglutinated, first into small clumps of two or three platelets,
and then by these uniting, into larger clumps; no free
unagglutinated platelets could be seen. The platelet
clumps did not appear to form irregular' spheres and, once
agglutinated, no other morphological changes took place even
after 2 hour's incubation. After standing for several hours
• -• •' " ™
at room temperature some swelling and lysis of individual
platelets was observed. These changes, however, were also
seen in platelet suspensions, to whioh no agglutinating sera
had been added, after storage for similar periods.
(Phase Contrast x 1100)
ffifiurea || & 1?
Imr^e Platelet Agglutination
ffce plat©1sts have retained their individuality and no
lysis or fusion has taken place.
13
(Phase Contrast x 1100)
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CHAPTER in
Platelet Viscous Metamorphosis and its
Relationship to Fibrin Formation
While the morphological changes of platelet viscous
metamorphosis (VM) ha-jo attracted the attention of numerous
workers, very little attention has "been paid to direct
observation of this phenomenon in relation to fibrin
formation. Aynaud (1911a) called the onset of VM rtle
premier temps de coagulation" and Tait & Burke (1926)
suggested that VM did hear time relationship to fibrin
formation. Personal observation of normal platelet rich
plasma as it clotted, suggested that this latter conclusion
was correct. A study of this phenomenon in abnormal plaama
was thought to be likely to provide information of importance.
Therefore platelet VM was observed in both normal plasma and
in plasma derived from patients in whom the existence of
congenital or acquired defects of essential coagulation
factors had been established. Platelet rich native plasma
was used in these experiments (Appendix A, p. 11 Experiment 1,
Appendix Bt p. 1 )
Hormal Platelet Rich Plasma
The evolution of VM was studied in 32 normal people.
'
i, i • ; , - •<;
I
In all, VM followed the typical sequence already described.
The time of onset of the first visible platelet clumping and
fibrin formation were recorded (Table 1).
TABLE I Experiment 1 Appendix B, p»1
The relationship of viscous metamorphosis to fibrin
formation in normal and abnormal plasma.
0*5 ml. platelet rich native plasma was allowed to clot



























































































1 66 - 1061 - 995 -
FACTOR V 1 25 -«a» 485 - 460 ma
CIRCULATIirO
ANTICOAGULANTS








421 295-550 527 357-640 106 32 - 203
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These observations were made either by observing these
changes in the tubes by naked eye or, alternatively, by-
taking serial samples at 30 second intervals in order to
observe the morphological changes by phase contrast micro¬
scopy (Appendix A, p. 8 )• by this method it was evident
that a definite time sequence evolved between the onset of
the platelet clumping and fibrin formation. While the
interval betv/een the start of VI and fibrin formation was
relatively constant the time of onset varied considerably
(Table t) and this was also true for the ©peed at which this
change evolved.
Haemophilia Plasma (Table 1)
Platelet rich native plasma was obtained from patients
'
with varying degrees of severity of haemophilia. 15 indivi¬
dual samples wara examined and, in all, VI began normally and
in the normal time. Fibrin formation was delayed in every
instance, according to coagulation time of the plasma and the
interval between VM and fibrin formation was significantly
greater than in normals (Table 1).
In platelet rich plasma from those patients with moderate
or severe haemophilia, the platelet clumps once formed began
to break up and disappear before fibrin formed, only to
reappear within seconds of fibrin formation. Some of this
disappearance was due to adhesion of occasional clumps to the
glass, but microscopic observation of the plasma confirmed
that the majority of platelet clumps had partially broken up.
-41 -
Christmas Disease
Seven individual samples were examined from patients with
diminished or absent Christmas factor (Table 1), In all, VM
showed a sequence and intensity identical to the normal process.
As in the haemophilia samples, Vffi and fibrin formation were
dissociated to a significant degree.
Phenylinanedione ("Dinlevari Treated Cases
Four cases receiving therapeutic doses of Dindevan
(Phenylinanedione) were examined (Table 1). The blood from
such cases is deficient in Factor VII (Walker & Hunter 1954).
All showed normal VM. One example, with an induced defect
of 22$ as measured by the Proconvertin and Prothrombin
technique (Owren & Aas 1951) showed no significant variation
from the normal range. Three cases with a severe defect
(0-10$) showed significant dissociation between VM and fibrin
formation.
Heparinissd Hozmal Plasma
Blood was examined 30 minutes after the intravenous
administration of 5»000 units heparin into a normal person
(Table 1), VM took place normally but, as in cases of
moderate or severe haemophilia, the tenacity of the clumps
was impaired and they tended to break up before fibrin formed.
Again the interval between VK and fibrin formation was
prolonged.
Factor V Deficiency
Platelet rich native plasma from a patient with a marked
- 42
congenital deficiency in Factor V was observed as it clotted.
VII occurred normally within 1 minute, but fibrin formation
was delayed and a definite dissociation between VM and fibrin
formation existed (Table 1}«
Circulating Anticoagulant
One patient was examined in whom a high level of
circulating anticoagulant inhibited the formation of
thromboplastin (probably by direct action on antihaemophilic
globulin). In this case the platelets underwent VI in
normal time (Table 1) but, as in haemophilia and hepariniaed
blood, the clumps tended to break up and, after 10 minutes
had elapsed, had virtually disappeared. Fibrin formation
was delayed and, although fibrin appeared in 45 minutes, it
was still forming at 90 minutes.
fhrombocyt openia
In plasma prepared from two cases of idiopathic
thrombocytopenia (21,000 and 34,000 platelets/cu.mm.) no
platelet VS could be detected. Microscopic examination did
however show morphological changes in individual platelets
and granules were released into the plasma. The latter were
so few that their platelet origin was uncertain.
Von fillebxand'a Disease
Five cases of Von Willebrand,s disease wore examined,
in which no abnormality of VK was detected (Table 1),
although the interval between the onset of VI and fibrin
43 —
formation was slightly longer than in the normal series.
All had prolonged "bleeding times, normal platelet
counts and strong family histories of dominant nan sex-linked
inheritance. All, however, showed mild defects of anti—
haemophilic globulin in their plasma.
Rosenthal's Syndrome (Plasma Thromboplastin Antecedent
Deficiency). (Rosenthal, Dreskin & Rosenthal, 1955)*
Three cases were examined with a coagulation defect of
the same type as that described by Rosenthal et al. In all
three, VM was different from that seen in all the other
groups in that the onset of platelet clumping was delayed
until just prior to fibrin formation, when the normal
morphological changes suddenly took place. The interval
"between the start of VI and fibrin formation was shorter
than in the normal series (Table t).
— 44 *
CHAPTER IV
Faotors Influencing Visoous MetataorohosiB An
Hormal Native Plasma
The Effect of Various Anticoagulants on IToroal VM
Honsal platelat rich, native plasma was treated with
various additions to establish their influence on VM
Appendix B.p.O
(Experiment 2j/(Table II).
Heparin did not inhibit VM unless used in large amounts
but did prevent fibrin formation. Heodymnium (3-sulpho-iso
nicotinate) inhibited VM without preventing fibrin formation.
Decalcifying salts inhibit both VM and fibrin formation,
while soya bean trypsin inhibitor had no effect on VM but
delayed fibrin formation.
Calcium and Viscous Metamorphosis
As sodium citrate, sodium oxalate and disodium versenate,
used in strengths which prevent fibrin formationfalso
inhibited VM, it was necessary to determine whether the
action of these salts was due to their calcium binding
capacity or due to a direct action on the platelets themselves
Appendix B,p.a")
(Experiment 3»/(Table III).
The results obtained do show that the inhibitory action of
these salts is due solely to their ability to combine with
calcium salts and that calcium i3 essential for normal VM.
TABLE n Experiment 2 Appendix B, p. 1
The effect of various anticoagulants on viscous
metamorphosis in normal platelet rich native plasma.
To 0,5
0,5 ml
ml amounts of normal platelet rich nat:
>f additions to defined final concentr?


















Normal Saline - + ♦ 4*45 *
M Heparin 0,1 u/ml <¥ + delayed 30'
M •t 1 u/ml + -
W « 5 u/ml +












































TABLE HI Experiment 3 Appendix B, p. g
The role of calcium in viscous metamorphosis.
To 0.5 ml. platelet rich plasma previously treated with
citrate, oxalate, or disodium versene was added 0.5 ml M/40










Citrate 3.8$ 60 226 166
Oxalate 1.34$ 47 242 195 I
Disodium
Versene If5$ 45 301 256
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Optimum Calcium Strength for Viscous Metamorphosis
The optimum strength of calcium required for VM and
Appendix B,p»2
fibrin formation was determined (Experiment ki/(Table IV),
This experiment demonstrated that the addition of trace
amounts of calcium, insufficient for normal coagulation, would
allow VM to evolve normally.
Viscous Metamorphosis in Becalcifled Citrate Plasma
It might reasonably be argued that the platelet changes
observed in native plasma might be due to blood coagulation
proceeding slowly during the separation of the 'native1
plasma from whole blood. Theoretically this migjtet occur as
no anticoagulant is added to the blood. Therefore, parallel
samples from the same venepuncture were examined; on® was
citrated immediately, the other was cooled rapidly and
platelet rich native plasma obtained.
The oitrated sample was centrifuged at 1400g for 10 minutes
and platelet rich citrated plasma obtained. This was now
recalcified and the platelet changes observed in relation to
fibrin formation in parallel with the changes in the native
plasma 3aaplo (Table V )♦ (EXPERIMENT 5» Appendix B, p, 3)*
It was at once evident that there was no significant
difference between the two samples, and therefore it was
unlikely that any latent coagulation was talcing place while
native plasma was being prepared.
The Momhology of VI in Reoalcified Citrate Plasma
When platelet rich citrated plasma was allowed to clot
the
TABLE IV Experiment 4 Appendix B, p. 2
The optimum strength of calcium for normal viscous
metamorphosis.
To 0.5 ml. citrated platelet rich plasma was added 0.5 ml
CaCl- in doubling dilutions. The development of normal VM




























TABLE V Experiment 5 Appendix B, p. 3
Compazison of the sequence of viscous metamorphosis in
normal platelet rich native plasma and in normal platelet
rich reoalcified plasma.
Platelc-t Rich Native Plasma
+ equal volume 0,85$ saline
Platelet rich citrated













1 35 285 40 302
2 25 272 20 185
3 30 315 22 182
4 15 155 18 175




at 37°C after recalcification, VM developed with the identical
morphological changes described in Chapter n (Pigs. 14 & 15)*
But, afthr fibrin formation, the 'balloons' that appeared
around the periphery of the platelet clumps were dark grey in
colour (Pigs. 16 & 17) and no clear white 'balloons* were
observed.
Complement and Platelet VM
The inter-relationship of Complement with the blood
coagulation system has invited the interest of numerous
workers and, while it was originally thought that prothrombin
and the C'^ fraction of Complement were identical (Bordet
1920j Fuchs 1921), this has since been disproved (Boulanger
& Rice 1951? Mara, Bayerle & Skibba 1949)* It has been
shown that the complement levels in serum, derived from cases
with severe defects of antihaemophilic globulin, Christmas
factor, Factor V and VII were similar to those found in
normal serum (Sharp 1957)*
In the experiments previously described, a process of
oellular agglutination and partial lysis involving platelets
has been observed and it was important to determine whether
Complement was destroyed or fixed during this process.
Therefore sera obtained from platelet rich and platelet free
samples of normal plasma were examined for their titre of
Somplement.
As it was possible that Qomplement might act in this




Early viscous metaiaorphosis (reoalcified platelet-rich
citrate plasm).
Figure 15
(Phase contrast x 5500)
Viscous Metamorphosis
Platelet fusion and lysis in typical viscous
Hjetaaaorphosis (recaloified platelet—rich citrate plasma).
(Phase Co^b^st * 5500)
gig***? 16 &1J
Late Viscous Metamorphosis
Dark grey 'balloons' forming around the periphery of the
clump* The platelet granules have become arranged around the
periphery of the 'balloons* (recalcified platelet rich
citrate plasma)*
Compare with Pigs. 8, 9, 10).
**6^ IT
(Phase Contrast x 5500)
TABIEVExperiment6Appendix,.3.













































































































































































were made from blood obtained from severe haemophilias,
Christmas disease, congenital factor V deficiency and cases
treated with Dindevan (factor VII deficiency), (Experiment 6", Appendix B^.i).
'Table VI).
The titre of Complement in serum derived from platelet
rich plasty did not differ significantly from that obtained
from platelet free plasma. This applied to both normal and
abnormal plasma. Therefore it is not unreasonable to presume
from these results that Gocrolement is not essential for
physiological platelet VM.
The results of the experiments described in Chapters III
and IV may be summarised as follows s
(1) VM in both normal platelet rich 'native1 plasma
and recalcified plasma shows a definite tin® relationship to
fibrin formation and the absence of certain essential
I
coagulation factors prolongs the invsrval between the onset
of VM and the formation of fibrin,
(2) VM does not occur normally in thrombocytopenia or in
plasma derived from cases of Rosenthal'3 sjmdrome. In
haemophilia and in the presence of a circulating anticoagulant
and heparin an apparent qualitative difference exists in that
the platelet clumps once formed appeared to break up before
fibrin appeared.
(3) Calcium is essential for VM and the optimal
concentration required appears to b© lower than that necessary
for fibrin formation.
(k) VM ia not inhibited by small concentrations of
heparin but ia by strong concentrations. Soya bean trypsin
inhibitor similarly has no inhibitory effect but Heodymium
will inhibit VM yet only delay fibrin formation.
(5) 7he morphological changes of VM developing in
recaloified platelet rioh oitrate plasma, are essentially
the same as those in normal native plasma.
(6) Complement does not appear to be utilised during
the sequence of VM in plasma.
- 49 -
CH/LFTEE V
The Action of Serum on Platelets
When washed platelets are added to fresh serum they
rapidly undergo changes identical to those recorded in
'
Chapter II. This ability of seium to initiate viscous
i • • •
metamorphosis (VM) in washed platelets was originally described
by Wright & Minot (131?) who, to a detailed and thorough
investigation defined some of the properties of this serum
factor and showed that, in light of their knowledge of'
blood coagulation at that time, it was apparently a separate
factor. The importance of their findings has been neglected
until recently, when a revived interest in V® stimulated
Bergsagel (1956) to repeat some of their experiments. He
suggested that the factor in serum responsible for VM had
similar properties to an intermediate product of thromboplastin
formation and was probably the same. Stefantoi & Silverberg
(1951)» however, considered that when platelets are added to
fresh serum they stimulate the residual prothrombin to form
,
thrombin which to tum will produce platelet agglutination (or
VM), The action of thrombin on platelets will be discussed
later but both Wright et al (1917) and Bergsagel specifically
denied that thrombin was the factor concerned in serum VM.
This activity of serum was therefor© re-examined in an
attempt to decide which factor or factors, remaining to the
serum after blood coagulation has occurred, were capable of
- 50 -
inducing VM in platelets. If whole "blood was allowed to
olot in glass at 37°C the ability of the resultant serum to
produce VM was extremely variable.
The first step was to decide uoon a technique which would
.
allow reproducible results in terms of the speed and intensity
of reaction.
Quite empirically it was decided to test sera derived
from unaltered platelet rich native plasma clotted in glass
tubes at 37 c and incubated for 1 hour after the formation of
fibrin. fhe fibrin clot was removed and the resultant serum
tested for activity against washed platelets (Appendix A, p.14)*
By using this technique it was found that normal sera were
il k . . *1— . ' - . 4
able to induce platelet agglutination and VM in suspensions
five
of washed platelets withityminutes.
The Effect of Platelet numbers on the Activity of Serum VM
Factor
It has been claimed both, by Wright & Minot (1917) that
serum derived from platelet rich plasma had more agglutinating
factor than that derived from platelet poor plasma. Lusoher
(1956) has claimed that the opposite is true.
In order to determine which of these claims was correct,
•• ■ ■ . j :•/ ,d" ... . • , . . .
the ability of sera from platelet rich and platelet free
samples of the same plasma were tested and quantitatively
assessed by titration (Experiment 17° Appendix B? p. 7).
This experiment has shown that the presence or absence
of platelets in the plasma from which the serum is derived,
- 51 -
does not appear to influence the ability of serum to induce
VM in the platelets (Table VII).
Washed Platelets and Seam VK
In assessing the ability of serum to agglutinate washed
platelets, it was essential to determine whether repeated
washing of the platelets could destroy their ability to react
with the VM factor in the serum (Experiment $| Appendix 5").
Washed platelet suspensions were prepared as described in
Appendix A, p» 13 • After each wash they were resuspended and
a sample tested against fresh serum (Table VIII),
The platelets lost their ability to react with fresh
and,
serum after surprisingly few washes/in order to measure the
ability of a serum to induce VM in platelets, the latter must
not be washed more than twice* The process of washing must
remove some substance from the platelets which must react with
the serum factor. As the platelets appeared to be
relatively unaltered morphologically, even after 10 washes, it
is probable that this factor or factors are removed from the
surface of the platelet.
The Influence of the Density of Platelet Suspensions on
Serum Induced VM
Early in these experiments it was observed that VI could
not be produced in weak platelet suspensions by fresh serum.
Therefore an optimum density of platelets must exist before
VM can evolve normally.
TABUS VII Experiment J Appendix B, pj*»
The effect of platelet numbers on the activity of serum
viscous metamorphosing factor.
Platelet rich and platelet free samples of normal native
plasma were allowed to clot at 37°C and after incubation for
1 hour at 57°C the fibrin was removed and the serum was tested
for VM factor activity.
Titre of VM Factor
Normal Plasma Serum from Platelet
Rich Plasma + Washed
Normal Platelets
Serum from Platelet







TABLE VIII Experiment 8 Appendix B, p.5.
The effect of washing on the ability of platelets to
react with serum VM factor.
To 0.2 ml active normal serum was added 0.2 ml washed test
platelet suspension and the presence or absence of viscous
metamorphosis recorded
Presence or Absence of Viscous tetame mhoeis
Number
of Platelet Suspensjion
Washings 1 2 3 4 I 6 ? 8
1 + •f + + ♦ + * +
2 + + + + + +
3 - + + + ♦ +
k - + «■» + •f 4- +
5 + mm + ± - + +
6 mm - mm - ± - + ±
7 - mm mm mm - _ - -
8 - • - - mm mm -
9 - - - - - - mm mm
10 mm - - - - - mm -
+ <» VM evolving within 1 minute
+ » VM evolving within 5 minutes
- » No Vffi after 10 minutes
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Ely varying the density of platelet suspensions "by doubling
dilution, it was possible to determine approximately the number
of platelets per cu.mm, that must be present before the
phenomenon of agglutination can take place. Again fresh
normal serum was used to induce platelet agglutination
(Experiment^ Appendix S") •
The results obtained show that at least 60,000 platelets/
eu.ram. must be present before normal VM can take place (Table
DC).
These observations agree with those made when unaltered
native plasma, prepared from thrombocytopenic blood,waft allow»<
to clot.
The Morphology of VM Induced by Fresh Serum
The rate and sequence of VM induced by fresh normal sera
in washed platelets was identical to that seen in normal
clotting platelet rich plasma. Unlike that induced in
platelet rich native or recalcified citrate plasma, or by
thrombin, no fibrin formed in relation to the platelet clumps.
The 'balloon' forms developed 20-30 minutes after the start
of the reaction and they were dark grey in colour as
illustrated in Figs. 16 and 17.
The VM Activity of Serum derived from Blood with Specific.
Acquired, or Congenital Defects of Known Coaftulation Factors
Bergsagel (195$) has suggested that the factor in serum
responsible for inducing VM in washed platelets was the same
as his intermediate product of thromboplastin formation. This
TABLE IX Experiment $ Appendix B, p.jj.
The minimum platelet density for normal viscous
metamorphosis.
To 0.2 ml each concentration of platelets was added 0.2 ml
fresh normal serum and the mixture incubated at 37 C for 10
minutes and the presence or absence of normal VM observed.
Final Density of









latter factor was, lis thought, produced by the interaction of
antihaenophilie globulin, Christmas factor and calcium. If
his theory were correct serum derived from blood deficient in
antihaemophilic globulin or Christmas factor should contain
little or no intermediate product and be unable to induce
normal VM in normal washed platelets. This assumption would
also be true if any other coagulation factor -was responsible
far serum VM.
Therefore serum derived from the blood of patients with
specific congenital or acquired coagulation defects was
examined for its ability to produce VM in suspensions of
washed normal platelet® (Experiment 10, Appendix 8)U)
Serum was prepared from cases of haemophilia, Christmas
disease, factor V deficiency, induced factor VH deficiency,
thrombocytopenia, Von Willebraad*a disease and Rosenthal's
syndrom© (P.T.A. deficiency). In parallel the ability of
platelets derived from these cases to react with normal serum
was determined to seo if platelets themselves sight be
insensitive to serum VM (Experiment 10).
The factor in serum responsible for VM was present in
serum derived from blood deficient in antihaemophilic
globulin, Christmas factor, factors V or VH or P.T.A., and
all these samples appeared to show normal activity
(Table X). The platelets derived from these patients with
these specific defects reacted normally to fresh normal serum.
TABLE X Experiment 10 Appendix B, p. $
(a) The presence of VM activity in sora derived from
blood with known congenital or acquired coagulation defects.
(b) The ability of platelet suspensions from duplicate

















































0 - It was impossible to mala suitable platelet suspensions
from these oases.
5k -
Thus serum VM factor did not seem to "be dependant on the
presence of any of these factors in the blood from which it
had been derived nor did these results appear to confirm
Bergsagel's hypothesis. The sera tested, however, were
derived from olotted blood in which the various factors
required for fibrin formation must have been generated, even
if slowly, Under the experimental conditions, used to
prepare the sera for testing, it is possible that Bergsagel's
intermediate product might have been generated slowly, even
in the presence of severe plasma factor defects and, by the
tine the sera were tested, be present in sufficient quantity
to induce VM in washed platelets.
Thus, while the present experimental results do not
appear to support Bergsagel's views, it is impossible to
refute his hypothesis on this evidence alone.
Serum VM Factor and Thrombin
Wright & Minot (1917) and Bergsagel (1956) concluded
that the platelet agglutinating factor in serum was not due
to thrombin. However, Stefamini & Silverberg (1951) thought
that platelets, when added to serum, were capable of generating
thrombin from the residual prothrombin in the serup^which, in
turn, could produce agglutination of the platelets.
Thrombin is defined as that fraction of blood, which,
when added to fibrinogen will convert it to fibrin (Biggs &
Macfarlane 1953). Therefore, if thrombin is present in fresh
serum or is generated in serum by the addition of washed
- 55 -
platelets, it should he capable of converting fibrinogen to
Appendix
fibrin (Experiment This experiment did not confirm the
belief that the VM activity of fresh serum was due to the
presenoe of residual thrombin, nor was it possible to show
that any thrombin was generated in fresh serum when washed
platelets, either alone or together with calcium, were added.
(Table XI).
Complement and Serum VM of Platelets
It has been determined in Chapter IV that physiological
VM does not require or fix Complement. As it was by no
means certain that VM produced in washed platelets by serum
was the result of the same mechanism as that observed in
platelet rich native plasma, it was important to discover
whether or not Complement was utilised during serum VM.
The titre of natural Complement in normal serum was
compared before and after it has been used to induce VM in
washed platelets, (Experiment 12. Appendix B )**/)•
Ho significant reduction in the titre of Complement in serum
was detected after it had induced VM. Therefore, it can be
assumed that complement Is not utilised during serum VM of
platelets. (Table XII).
Properties of the VM Factor in Serum
In order to determine the physical properties of the
platelet agglutinating factor in serum, fresh serum of proven
potency was re-tested after exposure to heat, absorption with
inorganic salts, after the addition of certain anticoagulants
TA33LB XI Experiment 11 Appendix B, p.7»
The relationship of eervua VM factor to thrombin.
Test mixtures rerc added, to a solution of mire fibrinogen and
incubated together at 3VC. The presence or absence of
fibrin formation was recorded at varying intervals.
Presence or Absence of Fibrin
Test Mixture Incubation Time in Mins,
5 30 60 120 2k0
Fibrinogen 0.2 ml


















m/40 CaCl2 0.2 ml.
Fibrinogen 0.2 ml
▼
Active Serum 0.2 ml. - - mm - -
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and after differential absorption with platelets and red cells
!
(Experiment 13. Appendix .
Serum VM factor was found to have certain well defined
properties (Table XIII). It is unstable cm storage at room
temperature, all the activity having disappeared within 24
hours, It is only partially destroyed by heating to 56°C for
30 minutes, being still capable of inducing agglutination but
not VM- It was completely destroyed by treating at the same
temperature for 1 hour. This agrees with the findings of
Wright & Minot (1917)I Stefanini & Silverberg (1951). The
factor is adsorbed by barium sulphate and aluminium hydroxide
gel and is inactivated by sodium citrate, oxalate and disodium
versene. Calcium is obviously essential for the action of
this factor, as the ability of the serum to produce VI, when
destroyed by citrate or oxalate, is restored by the addition
of calcium. Heparin destroyed the action of this factor while
thrombodym and soya bean trypsin inhibitor did not. These
actions of heparin and thrombodym were the exact opposite of
those obtained whan these anticoagulants are added to platelet
rich native plasma. (See Table II and p. 44 ). This factor
is apparently consumed or adsorbed during VM and can be
removed by dialysis against normal saline for 18 hours.
Isolation of the Serum Factor responsible for VM
In order to isolate the factor responsible for VM,
globulin, ammonium sulphate and phosphate fractions of activet
fresh serum were made and the resultant fractions were assayed
TABLE XIII Experiment 13 Appendix B, p. 8.
The physical properties of serum VM factor.
0.2 ml active serum Before and after various treatment was
added to 0.2 ml washed normal platelet suspension together
with 0.1 ml addition. The presence or absence of normal























































for their ability to produce VI in washed platelets,
(Experiment 14. Appendix B.Juo). The results are recorded
in Table XIV.
The Euglobulin fraction showed an increased activity
towards normal platelets. The retention of activity in this
fraction craves that the active factor is either a protein or; '
. •• ... . .
closely associated with protein.
Both the ammonium sulphate and phosphate fractions from
active serum showed no demonstrable activity against platelets.
As these inactive fractions were all dialysed against citrate-
• •• ■ • • * .v.*. - ■
saline for 24 hours it was possible that all or part of the
active fraction was dialysable. It has been shown (p. 5~65
that active serum dialysed against saline overnight also lost
'
its activity. It is well recognised that calcium can be
dialysed from serum and, as calcium is essential for serum
indaoed VI, calcium was added to the various protein
fractions obtained. In all instances it failed to restore
activity against platelets.
These observations suggest that the active fraction in
serum is made up of a protein associated with a dialysable
faction that doee aot appear to he oaleiem. The serum
factor responsible for VI was very unstable on storage unless
the serum was frozen at -12°C (Table xi»l). Therefore it
cannot be excluded that the apparent loss of activity, during
dialysis or salt fractionation or both, was not due to this
■
instability rather than to the removal of a dialysable fraction.
QUI©
Wl 3SO4 O jp ro
1i«I
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The experiments recorded in this chapter may he summarised
as follows:
(1) The activity of serosa VM factor is not influenced by
the number of platelets in the hlood from which it is derived.
(2) Before serum can induce VM, an optimum density of
platelets must he present and a co-factor must exist on the
surface of these platelets*
(3) This property of serum does not appear to he dependent
on A.H.G., Christmas factor, factors VII or Rosenthal's factor
(P.T.A.) in the hlood from whioh it is derived, 'ifor can this
action of serum he identified with thrombin. It cannot he
excluded that an intermediate product of thromboplastin might
he responsible for VM in all sera, both normal and abnormal,
(4) The serum faotor is unstable on storage, destroyed
by heat, inactivated by barium sulphate and aluminium hydroxide,
inactivated by decalcifying salts and heparin but not by
neodymnium or soya bean trypsin inhibitor, consumed during VM,
present in the globulin fraction but not in salt fractions of
active serum.
These findings agreed in many respects with those of Wright
& Minot (1917)* They found that in their experiments, the serum
from platelet-rich plasma was more aotive than that from platelet-
free but, on the other hand, they found that the serum from
thrombocytopenic blood was active - a finding confirmed in this
Chapter, They also denied that this faotor was consumed on the
addition of platelets. This latter discrepancy may have been
due to their failure to add a sufficient quantity of platelets
to absorb all VM factors.
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CHAFTEB VI
Viscous Metamorphosis and intormediate Promote of
Blood Coagulation (Including ThromMnj
Bergsaaal'a Intermediate Product of Thromboplastin
Fgraation
As has alreacly teen discussed, Bergsagel, ■addle t lying to
unravel the initial stages of "blood ooagulation, produced
# experimentally a factor capable of inducing VI in washed
platelets (Bergsagel 1956). This h© produced by incubating
a mixture of pig A. H. G., aged serum and calcium, and he
thought it to be an intermediate product of intrinsic thrombo¬
plastin formation.
If Ms hypothesis were correct, it would follow that VM
should not take place normally in patients with haemophilia
or Christmas disease.
As the experiments performed in the previous chapter©
did not confirm this it was thought to be worth while to
repeat Bergsagel's experiments.
Antihemophilic globulin derived from pig plasma (Bidwell
1955b), calcium and various aged sera were incubated together
for 20 minutes and samples of the mixture then tested for
their ability to produce VM in washed normal platelet
suspensions (Experiment 15. Appendix B, p. 13),
The results of this experiment suggested that Bergsagel1©
supposition was partially correct but it appeared that any
TABLE TV Experiment 15 Appendix B, p,i3.
The composition of Bergsagel's VM factor.
Pig A.H.G. (1 mgm/ml) 0.1 ml + 10*0 CaCl. 0,1 ml + addition
0.1 ml were incubated together for 20 minutes at 37 c and then
0.2 ml of the mixture added to 0.2 ml x2 washed platelets and
the presence or absence of viscous metamorphosis recorded
after incubation at 37 C for 5 Bins.
Incubation
Mixture Nature of Addition
Presence or Absence
of VM of Washed
Platelets
Pig A. H. 0. Saline
Saline 1/5 aged normal serum <•»
Saline Saline
Pig A.H.G. 1/5 aged normal serum
M 1/5 aged Christmas serum •f
M 1/5 aged haemophilia serum ♦
a 1/5 aged factor VII
deficient serum
♦




n 1/5 aged P.T.A. deficient
serum
♦
M H.T. Normal serum 56°C for
1 hour
M BaSO^ absorbed normal
serum
H.T. m Heat treated
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aged sera could replace normal aged sera (Table 3SV). The
absence of Christmas factor or factor VII from the serum
component of the mixture did not influence the results* This
was at variance with Bergsagel's findings (Bergsagei 1955).
These experiments differed from Bargsagel's in one important
feature, namely, the omission of buffer from the incubation
mixtures, Borgs&gel added 0.4 ml Imidazole buffer to his
mixt-ores, thus producing a twofold dilution of all the
components. This, it was felt, might produce false negative
results simply by reason of dilution. The serum factor that
was active in these mixtures was destroyed by heating to 56°C
for 1 hour and by barium sulphate adsorption.
The Properties of Bergsagel«s Faotoy
The properties of the VM factor generated in the above
mixtures were determined (Experiment 16* Appendix B,b.13). The
results ere recorded in Table XVI.
When these properties are compared with those of serum
VM factor (Table XIIl) they are similar with one important
exception? the VI faotor in the present experiments did not
require the presence of calcium for its activity.
f
... „
During the incubation of these mixtures of A.E.G., serum
and calcium, a fibrin clot formed before the twenty minute
period had elapsed. This must have originated from the
fibrinogen contaminating the pig A.H.G. concentrate (Bidwell
1955b) and, if this were so, it followed that thrombin must
have been generated in the incubation mixture. Whether the
latter was derived from residual prothrombin in the serum
TABLE XVI Experiment 16 Appendix B, p.13
The properties of Bergsagel's VM factor.
0,2 ml of the incubation mixture (I.M.) (Pig A.H.G., Serum,
Calcium) was added to 0.2 ml x2 washed normal platelets to¬
gether with 0.1 ml addition and the presence or absence of




I.M. Saline 0.85$ ♦
» Sodium Citrate 1,<?$ +




H Heparin 5 u/ml mm
W Thrombodym 2.5$ *





I.M. A1(0H)3 absorbed H -








I.M. Stored 2k hrs.
loom Temp.
W -




fraotion ox from prothrombin Contaminating the animal A.H.0,
was uncertain.
Bergsagel (1955a) also noted this phenomenon but, as he
did not think that thrombin could induce VM in platelets, he
ignored it.
Thrombin and Platelet VM
The effect of thrombin on platelets has been the subject
of controversy for many years. The evidence of the main
protagonists has been described in Chapter I.
The Aotion of Thrombin on Washed Platelets
Bergsagel'8 whole hypothesis on the ability of inter-
• ■*' - -'' • • ■ ■
mediate products of thromboplastin formation to induce VM in
•
. • • - • • * - • • " 6 - •«
washed platelets depended on his assumption that thrombin
could not produce similar changes# He considered that the
results of some workers could be explained by their use of
bovine thrombin, which he considered produced platelet
clumping by virtue of a non-specific interspecies reaction
or by its content of unsuspected intermediate products of
blood ooagulation.
Commercial thrombin is usually bovine in type and jin thxs
country, commercial thrombin (law*s Topical) is made by
absorbing prothrombin from oxalate bovine plasma with barium
sulphate* The prothrombin is ©luted from the barium powder
by washing with sodium citrate and the eluate is converted
to thrombin by the addition of calcium and lung thrombo¬
plastin. After dialysis the activity is preserved by
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lyophilisation. This process produces an extract which,
having definite thrombin activity, is probably contaminated
by other coagulation factors.
Human thrombin, prepared by the method of Biggs &
Maofarlane (1953) by precipitation from plasma at pH 5*3, is
relatively pure, although it cannot be excluded that it also
contains certain unspecified contaminants.
Thrombin and Washed Human Platelets
Bergsagel's experiments were repeated using identical
methods and his findings were confirmed (Experiment 17*
Appendix B/ but morphologically the changes induced by bovine
thrombin were those of simple platelet agglutination and the
typical changes of VM did not take plaoe (Table XVII).
The Effect of Human Thrombin on Platelet Rich Plasma
When human thrombin was added to normal platelet rich
citrate plasma fibrin was formed rapidly. When strong
concentrations (10-20 units/ml) were used, no platelet
changes took place before fibrin formation occurred but
minimal concentrations (0.5 - 2 units/ml), Just adequate for
the conversion of fibrinogen to fibrin, induced rapid
platelet VM at an appreciable interval before fibrin appeared.
The ability of varying anticoagulants to modify this
reaction was studied (Experiment 18. Appendix $ p. 14).These
results showed that this phenomenon was apparent in platelet
rich oxalate and citrate plasma but not in platelet rich
versene plasma. The addition of heparin, even in small
TABLE XVII Experiment 17 Appendix B, p.1^.
The effect of thrombin on gashed normal human platelets.
Thrombin 20 u/ml 0.2
platelets (x2) togeth
presence or absence o
5 tnins. incubation at
ml was added to norn




I ml, and the
>sis observed after















concentrations, completely Inhibited this reaction, but
leodyranium (3-sulpho-iso niootinat®) and soya bean trypsin
inhibitor did not (Table XVIII).
The pattern of results, obtained with the latter three
anticoagulants, was similar to that seen when they were added
to fresh serum (see Table XIII). Unlike serum VM the effect
of thrombin on platelets was not neutralised by sodium citrate
or sodium oxalate, and therefore calcium did not appear to be
necessary for this reaction. These properties were similar
to those found when Bergsagel's Intermediate Product was tested.
The inability of human thrombin to induce VM in platelet rich
versene plasma was probably due to the 'heparinoid* or anti-
thrombin action of this anticoagulant (Zucker 1954I
Triartaphyllopoulos, Quick & Greenwalt 1935)•
The lorgholofiy of VMJndaoea hy Thrombin
The platelet changes were similar to those described in
Chapter II but, like those in reoalcified platelet rich plasma,
the 'balloon-like' swellings produced, after fibrin formed,
were dark grey in colour. The latter change was fully
developed five minutes after fibrin formed and the entire
reaction took place more rapidly than that observed in platelet
rich native or recaloified citrate plasma (Pig. 18).
Thrombin VM Co-Factor
As human thrombin had no effect on washed platelets
separated from their plasma(but did induce VI in platelet rich
plasm, it appeared reasonable to suppose that some co-factor
TABLE XVin Experiment 18 Appendix B, p. 14
The effect of certain anticoagulants on thrombin
induced VM
0.4 ml human thrombin (1 u/ml) was added to 0.5 ml platelet
rich plasma together with 0,1 ml addition and the presence





















TABLE XIX Experiment 19 Appendix B, p.15
The ability of thrombin to promote VM in abnormal
platelet rich plasma.
To 0*5 ml platelet rich citrate
thrombin (1 u/ml) and the presen<
prior to fibrin formation was re<
plasma was added 0.4 ml
3© or absence of VM evolving
sorded.
Nature of Platelet Rich
Citrate Plasma
Presence or Absence of VM















(Phase contrast x 5500)
Yisoous Metamorphosis
Thrombin induosd viscous metamorphosis in platelet-rich
oitrate plasma* The typical platelet fusion and lysis has
occurred. The peripheral •balloons• are dark grey in
colour (oompare Figs. 8, 9» 10 and 16).
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must exist in the plasm which was essential for the action of
thrombin on the platelets. This co-factor could have been
one of the existing and reoognised coagulation factors.
Human thrombin was therefore added to platelet rioh
citrated plasma prepared from cases with specific coagulation
defects (Experiment 19. Appendix B/ (Table XDC).
In every instance platelet VM wae induced and therefore
the thrombin VM co-factor could not be A. H, G., Christmas
factor, factors V or VH or P.T.A.
It was still possible that prothrombin, fibrinogen, or
some other as yet undertermined plasma or serum factor might
have co-factor activity. Thrombin was therefore added to a
series of mixtures of washed platelets and plasma, serum,
barium sulphate adsorbed plasma and pure fibrinogen
P.15).
(Experiment 20. Appendix "Sf. (Table XX).
These results showed that purified fibrinogen had oo-factor
activity but the plasma fibrinogen did not (Table XX). Thus
either these two fibrinogens were different or purified
fibrinogen contained some other factor not present in freshly-
prepared platelet free citrate plasma.
Animal A.H.S. and Thrombin Co-faotor Activity
These preparations, made from pig and bovine blood,
(Bidwell 1955 a & b), contain a large amount of fibrinogen and
are prepared by a similar method to that used to separate
purified fibrinogen from plasma.
TABLE XX Experiment 20 Appendix B, p,15«
The nature of thrombin VM co-factor.
0.1 ml human thrombin (7 u/ml) was added to 0,2j. ml washed
normal platelets + 0.1 ml addition, and the presence or













N kged serum -
n Pure Fibrinogen +
Therefore these were tested for co-factor activity by a
Similar system to that used in the previous experiment.
They too were found to have thrombin VM oo-factor activity.
Thi. result suggested that either ealt fractionation confer,
co-factor activity on human or animal fibrinogen or that
concentrated JUH.G. together with fibrinogen contained some
other factor not present in high spun platelet-free plasma.
Platelet Factors and Thrombin Go-factor Activity
Both the purified fibrinogen and the animal A.H.G.
.
concentrates were prepared from platelet rich oitrated plasma;
the human fibrinogen from stored blood bottle plasma and the
animal preparations from platelet rich citrated pig or bovine
.
blood.
Therefore thrombin co-factor activity might arise from the
platelets or some breakdown products thereof. Extracts of
human platelets were therefore prepared before and after
washing and tested for their co-factor activity. (Experiment
21. Appendix: B, p. 16),
These results do suggest that thrombin co-factor activity
is in fact related to the platelets in some way (Table XXX).
Whatever the factor, it is removed instantly from the platelets
by washing, and thus it is unlikely that it is one of the known
platelet coagulation factors which are extractable from well-
washed platelet suspensions (Ware et al 1948; Creveld &
Paulssen 1951 & 1952; Deutsoh et al 1955). If this view
were correct, it was thought likely that thrombin co-factor
TAEIE XXI Experiment 21 Appendix B, p. 16.
Thrombin VM co-factor activity in platelet extracts.
Platelets were separated from normal plasma and protein
extracts made (1) immediately and (2) after washing three
times in normal saline. 0.1 ml of these extracts was tested
for VM co-factox* activity, human thrombin 0.1 ml (7 u/ml)
and (x2) washed normal human platelets (0.4 ml) being used as
the test system.














material could be released from platelets into plasma on
storage. Such a mechanism has "been suggested by Bounameaux
(1955) who has found platelets lost their ability to react
with thrombin on storage in saline.
Washed platelets were added together with thrombin to
high spun glass-stored plasma (blood hank plasma) in order to
determine whether this, unlike high spun fresh plasma,
contained VI factor (Experiment 22. Appendix "8, p.17 ).
This experiment confirmed that thrombin oo~factor is a
substance closely related to the platelets (Table XXIl). Its
exact nature has still to b© determined and its properties must
be more fully elucidated before it can be decided whether it
is the same as that described by other workers (Luscher 19565
Bounameaux 1957 b).
It has been assumed during all these experiments that
the human thrombin used was pure and that the morphological
platelet changes were due to the direct action of thrombin.
This assumption has been made by other workers (Luscher 1956?
Bounameaux 1957b)s but, while these thrombin extracts are
thought to be pure, it cannot be excluded thai those extracts
used in the present experiments, and those of other workers,
did not contain some other- as yet unidentified, coagulation
factors which might be responsible for platelet VM rather
than thrombin,.
Summarv
The experiments described i this chapter have shown that
(1) Thrombin can induce VM in platelets and requires a
TABLE XXII Experiment 22 Appendix B, p. 17.
The relationship of thrombin VM co-factor activity to
platelets.
0.1 ml high spun platelet-free fresh plasma and high-spun
platelet-free stored plasma were in turn added to a mixture
of human thrombin 0.1 ml (7 u/ml) and 0.4 ml washed normal
human platelets. The presence or absence of VM evolving




















co-factor for this action?
(2) this co-factor is probably derived from tha blood
platelets:
(3) artificial coagulation systems containing animal
A.H.G., serum and calcium can generate a factor
which will induce VM in washed platelets. Those
........
mixtures can generate thrombin and it is probable
that this, and not any other intermediate product
of blood coagulation, is responsible for inducing
VM in platelets. The fact that animal A.E.G.
has co-factor activity supports this contention.
.■ ' 1 , ' i 1' 'v ' X' " '
It is convenient at this stage to compare the factors
'
which inhibit or prevent 7M. in each of the three experimental
systems so far described (Table XXIII),
The variations in these results will be discussed in
Chapter VIII,
TABLE XXIII
A comparison of viscous metamorphosis in the three
Systems used experimentally to study this phenomenon.






































The effect of added anticoagulants can he compared
Sodium Citrate 3.8$ +
Sodium Oxalate 1.34$ - - +
Disodium Versene 4«5$ - -
Heparin 1 u/ml + - -
Thrombodym 0.15$ - + +
Soya Bean Trypsin + + +
Inhibitor 1 Egc/ml
Typical morphology ♦ + +
Co-factor required 0 ♦
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CHAFE® VII
Platelet Agglutination or Viscous Metamorphosis
By Other Factors Which Directly Influence
Blood Coagulation
Several factors have Been described which, when added to
blood, will accelerate the speed of coagulation. The
action of the majority has been explained satisfactorily but
their influence on the platelets has not been defined. She
evolution of techniques to determine whether they had any
direct actios on platelets was rendered difficult by the fact
that platelets undergo rapid VM in normal unaccelerated blood
coagulation. Therefore, in some instances, it has been
possible only to determine whether these factors can
agglutinate or produce VM of platelets suspended in plasma or
separated from plasma as washed suspensions.
Lister (lS6j>) was the first to stress that contact with a
foreign surface was an essential feature of blood coagulation.
In all experiments to study in vitro blood coagulation, glass
surface plays an important role and it is recognised that
blood clotted in glass does so much more rapidly than when
clotted in tubes coated with paraffin or silicone (Jaquas,
Fidlar, Felsted & MacLonaid 19^6). The role of platelets
in this phenomenon has been the subject of controversy. It
has been established that, if platelets are removed carefully




contact with glass (Jaquas at al 1946? Paton, War® &
Seegers 1948).
Losner, 'aylor & MacDonald (1942) considered t t t
effect of foreign surfaces on "blood coagulation was
of the platelets and that an inactive precursor ea&sted in
blood which, on activation by glass contact, had thrombo-
plastic activity. This view was supported by Jaques et al
(1946) and Hartmau, lonley & Lalley (1949)* who noted that
platelet free plasma took longer to clot in silicone than in
glass and that increasing the glass surface shortened the
clotting time of plasma regardless of the platelet concen¬
tration » Hartman et al (1949) also showed that glass
shortened the clotting time of plasma more'effeotively than
the addition of glass macerated platelets. If cephalin was
substituted for platelets the clotting time of plasma was
still shortened by glass contact (Ferguson 1953)* Thus the
phenomenon of 'glass* contact would appear to have no direct
effect on the platelets. Yet if blood is allowed to clot
slowly in siliconed glass, the resultant serum is rich in
prothrombin. Similarly the level of serum prothrombin is
high in glass clotted platelet free plasma. These findings
do suggest that both 'surface' contact and platelets are
essential for normal prothrombin consumption and that they





The mechanism of glass 'contact1 has been the subject of
muoh speculation. Oortner & Briggs (1928) suggested that
as glass had a negative Zeta-potential of 30 millivolts, and
the same glass coated with paraffin had a sero Zeta-potential,
the action of a glass surface could be due to the absorption
of positively charged particles on to glass, thus selectively
concentrating some blood constituent on that surface. A
similar hypothesis baaed on electrical charges was advanced by
Pickering (1928) and was revived by Wood, Horan and Sheppard
and Wright in 1950. Pickering considered that the wetting
of the glass by blood was sufficient to produce changes of
electrical charge sufficient to inaugurate blood coagulation.
These hypotheses are supported by the easily observed fact
that fibrin always appears first in the blood or plasma in
immediate contact with the glass surface,
Fiala & Both (1953) considered that glass removed an
inhibitor from the plasma and so allowed coagulation to proceed
more rapidly. They also thought that surface had no effect
on the platelets themselves. Margolis (195*0 revived the
suggestion that an active substance is liberated at the glass-
plasma interface and afterwards destroyed by an antagonist.
The actual level of activity under any given contact con¬
ditions would therefore depend on a dynamic equilibrium
between these two. In his experiments he found that contact
aotivity was independent of the number of platelets present,
but a few platelets had to be present before the activity
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promoted by the glas3 contact could bo measured (Kargolis 1957,
Contact with glass will produce clot promoting effect in
plasma, artificially rendered platelet free, and from which
A.H.G., Christmas factor, factors V and VII and fibrinogen had
boon removed (Shafrir & Do Vries 1956).
Blood platelets have been shown to adhere readily to
glass. This property, apparently independent of tho blood
coagulation mechanism, has been extensively studied by Wright
(1941, 1942, 1944, 1945, 1946 and 1951), Weiner, Zeltmacher,
Reich & Shapiro (1943), loolten & Vroman (1949), Moolton,
Vrosaan & Vroman (1949) end Stavitsky (1953)* All these
workers have studied the adhesiveness of platelets in platelet
rich plasma derived from both normal volunteers and patients
with varying diseases. These plasma were rendered
incoagulable by varying anticoagulants.
This property of platelets to adhere to glass would
appear therefore, to be independent of their ability to under¬
go VM as, in these experiments, calcium ions were not found
to be essential for platelet adhesion to glass.
The Effect of Glass Surface on Viscous Metamorphosis in
Rative Plasma
As the effect of 'glass' contact on the phenomenon of
platelet VM has never been specifically observed, it was
thought to be a worth while investigation. If glass contact
were to have any direct effect on platelets, it was possible
that platelets might undergo VM more readily in a glass tube
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than in a tube with a siliconed surface. Therefore duplicate
samples of the same platelet rich native plasma obtained from
both normal and abnormal blood, were allowed to clot at 37°C
in glass and siliooned tubes of identical size and the
relationship of VM to fibrin formation observed as in
Experiment t. (Experiment 23* Appendix B, p. 18).
The results showed that glass contact did not accelerate
VM, but a siliooned surface, as would be expected, delayed
fibrin formation* This latter phenomenon was even more
accentuated in haemophilia and Christmas disease* (Table XXXV).
The Effect of Glass Surface on the Ability of Serum to
Induce Viscous Metamorphoses
The variation in the ability of normal sera derived from
clotted samples of whole blood, to induce VM was difficult to
explain* It has been shown that the numbers of platelets
in the original blood did not influence this activity (p.
It was possible that this difference might b© the result of
variation in the amount of glass contact on the donor blood
received prior to clotting.
Therefore sera were prepared from native and recalcified
citrate plasma, clotted in glass or in siliconed glass tubes
of identioal size, and their ability to produce VM determined*
In addition the effect of increasing the area of glass in
contact with the plasma was observed. (Experiment 2k*
Appendix B, p.18 ).
TABLE XXIV Experiment 23 Appendix B, P» -jg
The effect of foreign surfaces on viscous metamorphosis
in platelet rich normal and abnormal native plasma.
Duplicate samples of platelet rich native plasma (C.5 ml)
were added to glass or siliccned tubes of identical size. The
onset of viscous metamorphosis and fibrin formation were
observed and the time sequence recorded.
Glass Tube Siliccned Tube











1 12 230 13 359
2 110 265 120 268
5 20 226 10 236
4 30 315 35 483
Haemophilia
5 15 525 15 1080
6 16 375 30 1210
7 25 1815 25 5400+
Christmas
Disease
8 28 460 60 1083
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Glass contact was found to enhance the ability of senna
to induce VM in normal washed platelets. This increased
VM activity in the sera could also be measured by the
increased speed at which the platelets underwent VM. (Table XXV).
Glass Surface and Thrombin Viscous Metamorphosis
The effect of thrombin on normal platelet rich citrate
plasma was compared in glass and siliconed tubes of identical
siae. Ho significant difference was a parent between the
two systems. This result was not surprising in view of the
already rapid reaction produced by thrombin.
Glass Surface and Platelet Suspensions
In tests to measure platelet behaviour, such as platelet
agglutination, it has become usual to use platelet suspensions
in their own plasma,or in a synthetic medium,and to handle the
blood and platelets entirely in paraffined or siliconed
containers. Stefaaini & Dameshek (1953) claimed that glass
contact would decrease the yield of platelets or produce
non-specific agglutination, and it was decided to find out
whether either of their claims were true.
First it was decided to determine whether the total
number of platelets in platelet rich plasma or in washed
platelet suspensions was decreased on storage in glass at
room temperature when compared with identical samples stored
in siliconed tubes at similar temperatures (Experiment 25
Appendix B, p. 19 )•
TABLE XXV Experiment 24 Appendix B, p. 18
The effect of foreign surface on the activity of VM
factor in serum.
Platelet free samples of normal native and recalcified citrate
plasma were allowed to clot after contact with various areas
of glass and silicone! glass at 3/ C. The serum obtained
was tested for VM activity against x2 washed normal platelets.
Titre of VM Factor
Type of Surface
Source of Serum










A significant decrease of the platelet Count occurred
when "both platelet rich citrate and versene plasma were in
contact with glass hut not when they were in contact with
silicone (Table XXVI). Ho drop in the platelet count
occurred whan washed platelets were exposed to glass.
This suggested that the platelets did adhere to the glass
surface or ware destroyed by virtue of some factor in the
plasm or on the platelet surface that could be removed by
washing.
The morphological changes induced in platelets by glass
contact were observed by phase contrase microscopy. Platelet
rich citrated plasma and washed platelets were added to glass
and siliconed tubes and agitated continuously for 1 hour at
room temperature. To increase the area of contact an eq.ual
volume of glass and siliconed beads were added to duplicate
tubes and similarly agitated (Experiment 26. Appendix B, p. 19
Glass contact was capable of inducing agglutination of
many of the platelets and even produced lysis (Table XXVII).
These alterations in platelet morphology were observed only
in platelet rich plasma. The rartial lysis in the washed
platelet suspensions was thought to be the result of
mechanical trauma as even silicone coated beads were capable
of producing this change.
Again these observations suggest that it is a plasma
factor that is activated by glans. This, in turn, was able
to induce mild platelet agglutination, similar to that
).
I
TABLE XXVI Bsperiaent 25 Appendix B, p#
The effect of fox'afen surface contact on norsal buraan
platelet suspensions.
1 tel mounts of acre*! platelet rich dirated ml verses©
plasm sad a nashod suspension of noraal platelets war©
placed in glass or silioonod tubes and agitated by rotation
once evsiy >* 5 seconds for 2 hours. Platelet counts were



















TABLB OTI Experiment 26 Appendix B, p.19.
The effect of foreign surfaces on the morphology of
normal human platelet suspensions.
1 ml amounts of platelet rich normal human plasma and a x2
•washed sus-oansion of normal human platelets were added to
glass and silicone! tubes and glass tubes containing glass
and silicone! "beads respectively. All were agitated for
1 hour by rotation once every 3*5 seconds. The morpho¬






























illustrated to Figs. 12 and 13« Yhis agglutination to no
way simulates the platelet change to VM. While it is
admitted that platelets do adhere to glass, the present
observations do suggest that glass contact may lyae com of
the platelets and therefore any drop to the platelet numbers
to suspensions to contest with glass may not he a true measure
of platelet adhesiveness.
.
These findings do confirm the general impression that
glass is injurious to platelets and that, in all experiments
involving Isolation of platelets or agglutination of pla elets,
ailiooned glass wear should always he used. Yet contact
must he gxces before any significant change takes place to
the platelets and transient glass contact, such as the
accidental use of a glass Pasteur pipette, is unlikely to
damage platelets or produce false agglutination.
H*
Stefaatoi (1955) suggested that air to the form of
hubbies or the blood-air interface might also damage platelets.
Air wee therefore bubbled continuously through platelet
rich versene plasma and a washed platelet suspension to
ailiconed tubes. The platelet suspensions were prepared as
described to Appendix A, p. 13. In neither sample was there
toy evidence of platelet agglutination or lysis.
?'.etal
The contact effect of a stainless steel surface on the
clotting time of whole blood has been studied by Hose & Broida
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(1954). ^hay found that, while not as innocuous as silicone,
it had not the same activating effect as glass and that its
accelerating effect on "blood coagulation was not improved by
silicon!ng.
As many authorities have advocated coating stainless
steel needles with silicone before collecting blood for the
preparation of platelet suspensions, it was important to
determine whether stainless steel had any effect on platelets.
Therefore platelet rich versene plasma and washed platelet
suspensions were agitated continuously for 2 hours in
stainless steel containers (Appendix A, p. 13)*
Ho morphological changes in the platelets of either
preparation could be found. Thus it does not appear to be
essential to silicone stainless steel needles before
collecting blood for the preparation of platelet suspensions.
Venepuncture Technique and Tissue Thromboplastin
Any worker in the field of blood coagulation is well
aware that a faulty venepuncture will shorten the coagulation
%
time of normal and abnormal whole blood. It has been known
for many years that tissue juices accelerate blood coagulation
due to their content of tissue thromboplastin? the latter,
together with factors V and VII, activates the conversion of
prothrombin to thrombin (Bigg® & Maofarlane 1953? Ackroyd
1956). Faulty venepuncture technique may introduce
significant quantities of tissue juice and therefore thrombo¬
plastin into the syringe along with blood and so accelerate
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the coagulation of the blood by rapid activation of prothrombin
(Alexander 1955)* Aynaud (1911a) suggested that tissue juices
might provoke platelet agglutination and lysis and Wright &
Minot (1917) thought that a faulty venepuncture might produce
morphologically normal platelet suspensions which were inert and
quite unable to undergo VM. Yet few workers have stressed
the importance of venepuncture technique when describing
methods for preparing platelet suspensions from whole blood.
In the course of the present investigations several
hundred venepunctures have been made in order to prepare the
platelet suspensions and it was obvious that there was no
factor which would destroy platelets more rapidly than the
faulty venepuncture. Attempts to suck blood into a syringe
whose needle is buried in tissue, produces no visible volume
of fluid. But if the vein is then punctured and blood
allowed to enter the syringe, it is common to find that the
low spun 'native' citrate or veraene plasma from such blood
contains no viable platelets but only fragments of broken
or lysed platelets. These fragments are quite incapable of
undergoing agglutination or VM and it is possible that Wright
& Minot (1917) considered these inert fragments were
platelets.
It has not been possible to determine whether the
platelets undergo rapid VM before they are destroyed, as no
intermediate stage with large platelet dumps has been seen.
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Either the plasm obtained, from a venepuncture contains normal
platelets or completely lysed platelets.
Tissue juice would therefore appear to contain a potent
platelet lysin or VM promoting factor which was capable of
breaking up the majority of the platelets before the blood
could be added to an anticoagulant.
Tissue Extracts and Platelet Visoous Metamorphosis
Tissue thromboplastin is probably made up of several
factors whoa® synergistic action measures the activity of any
given tissue juice. Therefore it was possible that certain
preparations might be capable of acting on platelets while
others would not.
Preparations of brain prepared by differing methods, but
of known thromboplastlc activity, were added to platelet
suspensions and the presence or absence of accelerated VM
or platelet agglutination was observed (Experiment 21, Appendix B, p. 20).'
I
These fractions of human brain were found to have no
action whatever on platelets either in plasma or as a washed
suspension, nor did they appear to cause VM before the
formation of fibrin when adds4 together with calolui% to
platelet rich citrated plasma. (Table XXVIII)
Vascular Endothelium and Platelet Agglutination
.
It is probable that vascular endothelium, when damaged,
may not only present a foreign surface to the blood stream and
so induce intravascular VII, but may, by releasing some factor,
be capable of directly or indirectly promoting VM (loskam 195^)-
TABLE XXVTIT Experiment 27 Appendix!, p. 20
The effect of tissue thromboplastin on platelet
viscous metamorphosis.
To 0*4 ml of normal platelet rich citrate plasma or a washed
normal platelet suspension was added 0.2 ml thromboplastin
(brain extract) together with 0.2 ml of addition and the
presence or absence of accelerated or normal VM observed.
Type of
Thromboplastin

























In all instances where calcium was added together with
brain extract tc platelet rich plasma no VM was observed
before fibrin formed. Fibrin formation was accelerated in
the presence of the saline and acetone extracts of human
brain.
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Chance observation of vascular endothelial cells is blood
films surrounded by dense masses of agglutinated platelets
has supported this latter theory (personal observation).
Crude saline extracts of macerated human and rabbit aortic
endothelium were prepared to determine whether they could
induce agglutination, lysis or VM of platelets when added to
platelet rich plasma or wasted platelet suspensions^ with and
without the addition of calcium. Reither of these extracts
had any obvious effect on these platelet suspensions and they
did not accelerate VM.
Russell' s Viper Venom ma shown by Macfarlane & Bamett
(1934) to have a thromboplastin-like action of unparalleled
power and required calcium for its full effect. Even when
diluted many million times this coagulant action was still
present, The presence of either platelets or lipoid in the
plasma was essential for this action.
The direct effect of Russell's Viper Venom on platelets
was studied by observing the effect of adding undiluted and
diluted venom to platelet rich plasma and x2 washed platelets
(Experiment 23. A pondix B, p. 20 ). The venom was obtained
as commercial "Stypven" (Burroughs Wellcome).
Russell's Viper Venom (Stypven 1/10,000) was capable of
inducing agglutination of platelets both in plasma and as
washed platelets in suspension (Table XXIX), Only platelet
agglutination was observed and no platelet VM or platelet
lysis took place. Dilution of the venom destroyed this
TABLE XXIX Experiment 28 Appendix B, p. 20
The effect of adding Russell • a Viper Venom to normal
platelet suspensions*
Russell's Viper Venom (Stypven B & W) 0.2 ml was added to
platelet rich citrated human plasma or a washed suspension












*Stypven* diluent - -
Russell's Viper Venom produced platelet agglutination
and not viscous metamorphosis.
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ability to agglutinate platelets and the commercial solvent
supplied with the dried venom had, by itself, no effect on
the platelets. Thus Russell's Viper Venom appears to he
capable of inducing agglutination but not VM or lysis of
platelets* This is thought to be a non-specific reaction
unrelated to the thromboblastio activity of the venom.
The apparent destructive action of tissue juices on the
platelets in blood would not appear to be related to the
../v
thromboplastio component of the tissues, but to some an yet
unidentified platelet lysin.
Moolton, Vroman, Vroman & Goodman (1949) and Moolten
(1953) suggested that there is a lipoid factor other than
thromboplastin present in tissue fat, as well as in lymph
nodes, spleen and egg yolk, which is capable of accelerating
platelet agglutination and adhesiveness. This they named
•Thrombocytesin'.
Further experimental work is required to see if this
lipoid agent can be isolated from fat and whether it will
in faot accelerate platelet VM.
fofttelet Bjrtyacts and, Platelet Agglutination
It has already been shown in Chapter VI, p. 65"that
platelet extracts have no direct effect on either washed
platelets or on platelet rich plasma.
Chylqmlcra ,ffid„Platelet Agglutination
Following the intake of a fatty meal the blood contains
numerous chylomicra or small fat particles. This is
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©specially marked in males who seem less capable of clearing
chyloaicra from their plasma than females. This increase of
fat has been shown by Fullerton, Davie & Anastasopoulos (1953)
and Poole (1955) to decrease the clotting time of plasma,
probably by virtue of the phosphatidyl ethanolaisine fraction
(Robinson & Poole 195^)* It was possible that this excess
fat might alter platelets in some way. Therefore platelet
morphology was observed both in platelet rich plasma rich in
chylomicra and in washed platelet suspensions prepared from
such plasma. Ho significant variation from normal was
apparent in either preparation. This has confirmed the
previous observations of Loughiy & Cole (1954) who found
that fat particles did not cause non-specific platelet
agglutination.
Red Blood Cells and Platelet Arj£ut ligation
This phenomenon will be discussed in Part II of this
thesis.
Platelet Agglutination and Animal Antihaemophilic Globulin
Ho discussion on platelet agglutination would be complete
without describing the dramatic platelet agglutination induced
in human platelets by animal preparations of antihaemophilio
globulin.
Bidwell (1955 a & b) successfully produced concentrated
antihaemophilio globulin from bovine and pig blood for the
treatment of the haemorrhagio complications of haemophilia.
This material is preoipitated by selective concentrations of
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phosphates from fresh citrate plasm, dialysed and subsequently
preserved by lyophilisation. The A, H.G. is concentrated
during this process and the activity per gramme of dried
protein is equal to approximately 20 litres whole plasma.
It is, however, far from pure and contains fibrinogen and
probably trace amounts of prothrombin. The bovine A.H.G.
fraction, when originally administered to humans by
laefarlane, Biggs and Bidwell (1954) was found to be capable
of Inducing massive agglutination of human platelets in vitro.
Furthermore, parenteral administration of this material to
a case of haemophilia produced acute thrombocytopenia in the
recipient. The platelet count returned to normal levels
within a few hours however.
Pig A.H.G. has not been found to have this effect
(Macfarlane, Kallam, Witts, Bidwell, Biggs, Fraenkel, Honey
& Taylor, WS7.)
It was decided to reassess this property of bovine
antihaemophilic globulin against human platelets in the systemB
used in this series of experiments, namely platelet rich citrate
plasma and a washed suspension of platelets.
Varying concentrations of the bovine and pig A.H.G.
fractions were tested. It was arbitrarily decided to
measure the concentration of the material in mgms. of dried
protein. This contained active A.H.G. but this activity
varied from batch to batoh and can only be measured by
specific assay (Biggs, Eveling & Biohards 1955). The use of
a given weight of dried protein is not therefore any measure
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Appendix B, p,2l)»
of A. H.G. activity (Experiment 29y? • fhe results are recorded
in Table XXX.
Platelet agglutination, in eveiy instance when it
occurred, was well established within 2 minutes,
The reaction with the bovine concentrate was so rapid
and intense that it was difficult to distinguish from
normal platelet VS. The platelets, however, retained their
identity, no fusion appeared to occur between the individual
platelets end no granules were released. It was interesting
to find that although the pig A.H.G, fraction did not appear
'
to have any thrombocytopenic effect in vivo, it did
agglutinate human platelets when used in a concentration ten
times greater than that of bovine A.H.G, (Table XXX),
As it was possible that these heterologous animal plasma
fractions might contain a concentrated physiological platelet
agglutinin, their activity was tested against both their own
platelets and platelets derived from other animals (Experiment
30. Appendix B, p. 21 ).
jAjj. ,
In none of these other platelet suspensions was there any
evidence of platelet agglutination (Table XXXI), The direct
specific agglutination of human platelets by bovine and pig
•7. ■ ■ , • »? ■
A.H.G. would seem to represent an interspecies reaction and
was not an example of the action of a concentrated physio¬
logical platelet agglutinin. Other examples of interspecies
platelet agglutinins have been described by Mushett, Eelssaer,
Veiner, ffakashima & Collett (1953), and the ability of bovine
TABLE XXX Experiment 29 Appendix B, p.21
Animal satihaemophilie globulin concentrates and human
platelets.
0.2 ml amounts of pig and bovine A.H.G, (Bidwell 1949 a & b)
were added to 0.5 ml amounts of normal platelet rich oitrated
human plasiua or a washed suspension of normal human platelets
and incubated at 3 ( c for 15 mins. Any alteration in the































Platelets underwent agglutination only and did not
undergo the typical changes of viscous metamorphosis.
TABLE XXXI Experiment 30 Appendix B, p.21
The effect of animal antihaemophilic globulin on other
heterologous platelet suspensions.
Equal volumes of animal A.H.G. and heterologous platelet rich
plasma were mixed in tubes and incubated at 37 0 for 5 mins.

















A.H.Q. to agglutinate human platelets non-speoifically
supports Bergsagel1 a suggestion that the action of bovine
thrombin on washed platelets might also be a measure of an
interspecies reaction (Bergsagel 1956). (See also p. 6Z).
The clinical implications of this non-specific agglutination
of human platelets by bovine A.H.G. has been discussed
elsewhere (Macfarlane, Biggs & Bxdwell 1954? Macfarlane,
Mallam, Witts, Bidwell, Biggs, Fraenhel, Honey & Taylor 1957).
Sisamaqy
1. Viscous metamorphosis of platelets in native plasma
appears to be independent of glass contact.
2. The activity of serum VM faotor is increased by glass
contact.
3. Platelets were damaged by glass contact but this
must be gross before any significant change occurred.
4. Air and metal surface contact did not appear to have
any deleterious effect on platelets.
5. Faulty venepuncture technique invariably prevents
the satisfactory separation of platelets from blood.
6. Tissue thromboplastin and vascular endothelial
extracts have been shown to have no deleterious effects on
platelets.
7. Eussell's Viper Venom in concentrated form will
agglutinate platelets but this property does not appear to be
connected with its thromboplastic properties.
8. Platelets separated from plasm rich, in fat or
cbylomiora are not apparently different from those from
fat-free plasma.
9, Both heterologous hovine and pig aatihaeaophilio
globulin oonoentrates were capable of producing agglutination
of human platelets. They had no action on platelets separated
from other heterologous species. Their action is thought to




Those experiments hav© established that, in certain
experimental systems, it is possible to study, in vitro, the
typical changes of platelet viscous raetamorphosis (Vl), and
the properties of the factor or factors responsible for
producing this phenomenon.
Early attempts to visualise VM as it evolved in standard
Biorosoopio preparations, were found to b© unsatisfactory.
■The production of a thin film of platelets by the pressure of
the coverslip inhibited all movement and by preventing
collision between individual platelets, stopped all platelet
©lumping. Therefor-© the method of agitating the platelets
in suspension in small test tubes was adopted for the study of
platelet VM, and the detailed morphological changes studied by
the esamination of serial samples by phase contrast microscopy.
This method was thought to be justified, as when
platelets start to clump and undergo VM in vivo, following dam¬
age to the vessel wall, they are travelling rapidly in the
blood stream and are able to collide with each other and the
damaged tissue. Thus this method approached the normal
physiological process more closely than any other.
By using this technique it has been possible to
demonstrate a reproducible sequence of platelet changes in
normal blood and to compare these with those occurring in the
blood derived from patients with specific coagulation defects,
The morphological appearances of normal VM described and
illustrated (Chapter II) were defined by studying serial
samples of the varying experimental systems by phase contrast
microscopy, either immediately or after fixation in formalin.
The typical changes seen when native plasma clotted
could be reproduced exactly in recaloified platelet rich
citrate plasma, in platelet rich citrated plasma by the
addition of thrombin, or in washed platelet suspensions by
fresh serum.
The clumping of the platelets, their fusion by adherence
of their pseudopodia, the release of granules, and the sub¬
sequent formation of granular masses in which the indivi¬
duality of the original platelets has disappeared, constitute
the typical changes of VM (Pigs, f to it).
The striking changes that later develop in these masses
after they are enmeshed in fibrin may or may not be part of
VM (Pigs. 9, 10, 16 and 17). Bergsagel (1^6) thought that
these characteristic changes, with 'balloon* formation at the
periphery of the clumps, were part of VM. However, this
change is not peculiar to the platelets alone and has been
shown to ocour in phase contrast studies of malignant cells,
granular leucocytes and megakaryocytes (Zollinger 1948*
Bessis 1949 & 1956). Zollinger considered that this change,
which he oalled 'potocytosis', represented a change of the
cytoplasmic gel to a sol and the resultant intake of fluid by
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the cell produced the observed swelling. He thought that
cells in secretory glands produced their secretion in a
similar way. If his interpretation of this change is correct,
these •balloons' may represent a process of secretion of some
factor by the platelets at the periphery of these clumps.
If such secretion does occur, it is unlikely that •potooytosis'
has any ifluenoe on blood clotting for it does not develop
until several minutes after fibrin has appeared and persists
unchanged for at least 2 hours,
Bessis (1956), has claimed that potocytosis can be
produced at will, by applying pressure over the cells under
observation. Such pressure must always be present in phase
contrast ^reparations of platelets as, unless they are spread
out on the microscope slide, clear definition of these cells
is impossible. Bessis (1954) further has illustrated poto¬
cytosis occurring in a wide variety of cells. Examples
taken from his personal studies are reproduced in Figs. 19 &
20 for comparison with those changes observed in the platelets.
These illustrate 'potooytosis' occurring in a megakaryocyte
and a neutrophil leucocyte. These, together with the
observation that similar changes can be observed in malignant
cells (Zollinger 1948| Humble, Jayne & Pulvertaft 1956),
suggests that this interesting cellular change is of little
significance in platelet physiology and may represent cellular
death, accelerated by the nature of the microscopic preparation.
The intriguing differences in the 'colour' of the balloons
Megacaryocytc granuleux dont on devine a peine le noyau' "
k aire tie la cellule. On constate la formation de nombreuses i':nU';,ie
plasmiques dont quelques-unes se sont detachees ct flottent dans J





Potooytosis in a megakaryocyte.
auaa 39
Potocytosis in a neutrophil leucooyte.
(Figures 19 and 20 are reproduced in this thesis hy kind
permission of Dr. M, Bessie and Masson et Cie., Paris.)
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observed in native plasma and those in recalcified citrate
plasma or thrombin dotted plasma are difficult to interpret.
They are probably the result of variations in optical density
of the 'balloons* or, what is more likely, of the plasma in
which they are suspended. It is unknown whether this
variation is of any importance.
Several workers have observed that, as VM occurs, the
platelets release granular material which they thought
represented the active component essential for blood coagulation
(Tait & Burke 19265 Bergsagel 1956). In both normal and
abnormal plasma the platelets were observed to release their
granules early in the sequence of VM and, within one minute
of the platelets first clumping, granules could be seen in the
plasma undergoing active Brownian movement. It is thought that
these granules represent that fraction of platelets essential
for plasma thromboplastin formation and thus VM must occur
before normal thromboplastin generation can take place.
While the experiments on platelet rich native plasma
have clearly shown that VM takes place and is,in fact,fully
developed by the time fibrin appears, Mann, Hum & Mathieson
(1949) and Brkelens (1956) have denied that any alteration
in platelet morphology takes place in clotting blood until
fibrin has formed. Basing their conclusions on the con¬
tinuous microscopic observations of clotting blood, they have
failed to recognise the vital function of platelet movement
in the process of VM.
The present experiments have shown that at least two
factors are capable of inducing the full sequence of VM
prior to fibrin formation.
The first and manifestly the most important is that which
produces VM within seconds of the blood being shad from the
body. The tine sequences and the morphological changes
observed suggest that VM is one of the earliest changes of
blood coagulation, and as it evolves in the presence of severe
defects of antihaemophilic globulin, Christmas factor,
and factors V and VII, it is probably independent of these
factors. If this is so, VM must precede the initial
interaction of these factors to form intrinsic plasma
thromboplastin.
In Rosenthal1s syndrome (Rosenthal et a1 1955)» where
there is an apparent deficiency of yet another plasma factor
(Plasma Thrombopiastin Antecedent, P.T.A.) the sequence of VM
differed from that observed in other syndromes. In the blood
derived from three cases of this syndrome, VI did not occur
until just prior to fibrin formation. This suggested that
P.T.A. is in some way essential for the normal sequence of VI
in the initial stages of blood coagulation. Whether it acts
on the platelets directly or first reacts with another factor
before producing VM is uncertain.
The Bagemsa factor described by Ratnoff et al (1955) W
also play a part in the initial stages of blood ooagulation
but the exact relationship of this factor to Rosenthal's
factor and VM is still unknown.
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The comparison of VM in normal plasma in glass and siliconed
tubes demonstrated that VI evolved normally, irrespective of
surface, while the formation of fibrin was delayed in the
ailiconed tubes. Thus glass contact, so essential for normal
blood coagulation in vitro, did not appear to influence
platelet VM, but did accelerate fibrin formation. The
dramatic effect of an inroerfect venepuncture on the platelets
did suggest that some non-haematogenous factor such, as tissue
juice or damaged vascular endothelium may instigate or
accelerate VX, Variation in the amount of this, as yet,
hypothetical factor would provide a convenient explanation for
the observed variation® in the time of onset end the intensity
of the reaction in normals. Whether such tissue factors are
in any way related to the effect of glass contact is still
uncertain.
While VI appears to be independent of A.H.G. in its
initial stages, it was noted tha| in moderate or severe
'
haemophilia, after heparin administration and in the presence
of a circulating anticoagulant, a qualitative difference from
the normal existed. In nil these groups the platelets
©lumped as in the normal and granules were released. Fibrin
formation was markedly delayed in these cases, and the platelet
clumps broke down and virtually disappeared before fibrin
formed. This did not occur in Christinas disease, congenital
factor V deficiency or induced factor VII deficiency. As
heparin and the circulating anticoagulant probably inhibited
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the formation of thromboplastin by preventing the utilisation
of A.H.G. (Hougi® 1955? Douglas 195*0 it is not surprising
that the same phenomena wore present in these oases as in
moderate or severe haemophilia. Thus A.H.G., while not
essential for the initiation of VM, would appear to confer
stability on the clumps.
Controversy has existed for many years on the behaviour
of platelets in haemophilia and It was at one time suggested
that the defect in haemophilia was inherent in the platelets
themselves (linot & Lee 1916). Many workers have claimed
that either the platelets in haemophilia were more stable or
dumped more slowly than in normal blood (Stubel 1914?
Howell & Cekeda 1926? Tocantins 1938? Wright 1946). Yet
other observers have specifically stated that they could
detect no variation of platelet behaviour from the normal in
haemophilia (Wright & linot 1917? Patek & Stetson 1936?
Fiala & Both 1953? Dluum IJJJ; Serf Inceraan 1956). Wright
<& ffiiaot (1917) did remark, however, that while VM appeared
normal they noted a probable defect of "cytoplasmic integrity"
in the clumps.
It cannot be said that the platelet abnormalities in
haemophilia,reported in this thesis, are an explanation for
these widely divergent views, but they do agree with Wright
& Minot's (1917) observation. It is possible that opposing
views might be formulated on platelet VM in haemophilia, if
the platelets were examined at different intervals during the
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proeess of clotting.
The occurrence of platelet VM in those cases with severe
defects of A.H.G. or Christmas factor, provided evidence to
refute the hypothesis that thrombin is the only factor
capable of producing VM (Quick 19515 Quick & Hussey 1952}
.7 5 • 'UM i '' IvoT .
Stefanini 1951; Luscher 1956} Bounsmeaux 1955)* is
inconceivable that any thrombin could be generated in such
cases within seconds of the start of coagulation (see Table I).
The failure of heparin, a potent anti-throabin, when used
in weak concentrations just capable of preventing fibrin
formation, to prevent VM confirms the results of Baranovsky
& Quick (1943) and eleo Jurgens & Braunsteiner (1950) and
provides evidence to negate the hypothesis that VM in the
early stages of blood coagulation is always due to trace
amounts of thrombin. It also tends to confirm the
assumption that platelet VM in native plasma is identical to
that seen in a damaged blood vessel in vivo as Best, Cowan
& Maclean (1938), Solaadt & Best (1940) and Zucker (1947)
have siaaeiy shown that, while heparin in large concentrations
inhibited all platelet VI in damaged vessels or in artificial
arteriovenous stmts, it would not, when used in small
concentrations.
Calcium is essential for normal VM, although only trace
amounts, insufficient for normal fibrin formation need be
present *
Soya bean trypsin inhibitor, a known inhibitor of active
94 -
thromboplastin (Macfarlaoe 1947) did- not inhibit VM. Con¬
versely Thrombo&yrr. (Heodyamium J-sulpho-iso-niootinate) in
large concentrations sufficient to inhibit or delay fibrin
formation also inhibited VM. The anticoagulant action of
this drug has been described by Hunter & Walker (1956), who
found that this drug inhibited Christmas factor and factor X
and, in large doses, A.E.G. They did suggest its action might
an
lie ir</antimetabolite action on calcium and, if correct, this
could explain its inhibitory effect on VM.
It has not yet been established whether this drug has
any effect on the P.T.A. factor of Rosenthal.
In native plasma derived fx'oia cases of idiopathic
thrombocytopenic purpura and in artificial thrombocytopenic
platelets must be present in a density of at least 60,000/cu.raa.
further in relation to the mechanism of haecnstasis.
While it appeared unlikely that thrombin influenced
platelets in the early stages of blood coagulation, it was
found that human thrombin, prepared by the method of Biggs &
Maofarlane (1953) oould, in faot, induce platelet VM when
added to platelet rich plasma. This could only be seen when
small amounts of thrombin were added as the rapid formation
of fibrin obscured the platelet reaction when large
concentrations were used. Whan small concentrations of
before VM can evolve normally
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thrombin (0.5 u/ml) were added, VM evolved very rapidly
developing approximately 60 seconds prior to fibrin formation
■
and, after the fibrin had appeared, the subsequent evolution
of VK was quicker than that seen in normal plasma. This
rapid sequence suggested that in normal physiological
coagulation thrombin say induce platelet VM, but only at a
stage just prior to fibrin formation. This finding agreed
with the observation that VM was apparently accented in
clotting platelet rich plasma just prior to the fibrin
appearing. Human thrombin, while capable of inducing VM in
platelet rich -plasm., had no influence on washed platelets.
Its VI activity was therefore dependent on a co-factor in
the plasma or adsorbed onto the platelets. It has been shown
that this could not bo P.T.A., A.H.G., Christmas factor,
factors V or V3H, prothrombin or normal fibrinogen, but that
it did appear to be some factor, as yet undetermined, loosely
bound to the platelets themselves and easily separable from
the latter by crashing or storage in vitro. Bouaameaux (19570
has suggested that this thrombin co-factor is not one factor
but a complex mixture consisting of glucose, phosphate, ester
phosphates of glucose and fructose. This opinion still has
to be confirmed but his observations on the behaviour of this
complex co-factor do not agree completely with the present
observations.
The changes induced by bovine thrombin on washed plate¬
lets appear to be those of simple agglutination rather than
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typical VM| a finding which supports Bergsagel's (1956) view
that this was an example of a non-specific interspecies
reaction.
fhe experiments discussed in Chapter VI have suggested
that the factor which Bergsagel (1956) claimed to he capable
of inducing VI in washed platelets was not, as he thought, an
intermediate product of thromboplastin formation, but thrombin.
The mixtures used by Bergsagel in his experiments were capable
of generating thrombin prior to the addition of platelets.
This opinion does depend on the assumption that his materials
also contained co-factor activity as he used washed platelets
as his indicator. That pig A.H.G. doss have this activity
has been shown on p. <>4- The physical properties of the VM
factor generated in similar experiments were similar to those
of thrombin and thus provided further evidence in support of
this opinion.
The factor in fresh serum which is capable of inducing
VM in washed platelets in many ways resembles thrombin*
Like thrombin the serum VM factor is inhibited by heparin
even in small doses, but not by Thrombodym or soya bean
trypsin inhibitor. Unlike thrombin serum VM factor did
require calcium before it could act and it could induce VI in
washed platelets. Stefanini & Silverberg (1951) and Luacher
(1956) have suggested that whan platelets are added to fresh
serum the unoonsumed prothrombin is converted to thrombin
which in turn induces VM in the platelets. Attempts to
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Attempts to demonstrate this generated thrombin by the
addition of fibrinogen to platelet-serum mixtures failed
completely* If this VM property of serum was due to trace
amounts of thrombin, insufficient to clot pure fibrinogen, it
is difficult to see how this could be proved. Thrombin oan
only be defined as that substance which will convert
fibrinogen to fibrin. To assume any other activity must be
pure hypothesis until the biochemical nature of thrombin can
be determined.
The activity of the VM factor in serum was not influenced
by the absence of P.T.A., A.H.G., Christmas factor, factors
V and VII from the blood from which it was derived} similarly
the number of platelets in the donor blood did not influence
its activity. The amount of glass contact imposed on the
original blood or plasma prior to clotting did, however,
influence the VM activity of serum.
By using the ability of fresh normal serum to induce VM
in platelets it was possible to show that platelets derived
from eases of haemophilia, Christmas disease, P.T.A.
deficiency (Rosenthal's syndrome), congenital factor V
deficiency and acquired factor VII deficiency were capable of
normal VM.
While it has bees assumed for the purpose of these
experiments that the human thrombin used in these experiments
is pure, it is by no means certain that this is so. The
method used to separate it from plasma by primary precipitation
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of the prothrombin carrying fraction, rocalcifioation, sub¬
sequent precipitation by acetone and elution of the thrombin by
saline may not be spooific and it is remotely possible that
such preparations may contain some contaminant which, by
itself, is capable of inducing VI in platelet rich plasma.
Therefore the VM which follows the addition of thrombin may
only be incidental to the ability of the material to convert
fibrinogen to fibrin. This doubt cannot be removed until
further experiments have more clearly elucidated the nature
of the VM factors in the inital stages of coagulation or in
serum.
It would be convenient to find a theory which would
reconcile the differences in the factors influencing VM in
the three systems examined in these experiments (Table XXIII).
These differences, however, cannot be explained in terms of
modern theory, and it must be assumed that three separate
factors may induce VM in platelets either before or after the
blood clots. It is reasonable to propose that during blood
coagulation platelets would appear to undergo VM in the
initial stages by the action of a factor which may be either
P.T.A. or a factor produced by disruption of extravascular or
vascular tissue or both. This process releases the platelet
thromboplastie component, which, reacting with A.E.G.,
Christmas factor and calcium, forms an intermediate product
which, reacting with faotors V and X, forms active thrombo¬
plastin! this converts prothrombin to thrombin. The latter
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then, would appear to augment the action of the primary
factors and accelerate the process of VI in those platelets
which until this time have net become involved. This
theoretical sequence does fit in with the observed morpho¬
logical evolution of Vtt. The apparent accentuation of the
reaction just prior to fibrin formation in cases with P.T.A.
deficiency and haemophilia, would strongly support this
secondary effect of thrombin. Once the blood has clotted the
latter
expressed serum oan further promote VM. This/function,
while apparently of rather academic interest in 'in vitro'
studies, may play a most important role in intravascular
haemostasia and thrombosis. The ability of fresh serum to
promote VM, may explain why serum can rapidly clot platelet
rich citrate plasma and the observed power of serum to
induce intravascular thrombosis when injected intravenously
(Wessler 1953).
Perhaps the most significant finding in these experiments
has been the definite interval that was observed to elapse
between the development of definite VM and fibrin formation.
This interval, especially marked in severe haemophilia and
Christmas disease, in the presence of a circulating anti¬
coagulant, and following the administration of heparin, may
even be significant in normals.
From the many'in vivo' studies it is almost certain that
platelet VM plays an important role in the mechanism of
haemostasia. When a vessel is damaged or partially cut the
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platelets accumulate over the damaged section within seconds
of the wound being inflicted or form a plug around and in the
breach in the wall. The factor or factors responsible for
this rapid reaction on the part of the platelets have still to
be determined.
If the blood flow in the vessel is maintained it has been
noted that no fibrin forms around these platelet masses. But
fibrin formation say occur if the blood flow ceases hy virtue
of vaso-cnnstfiction or complete occlusion of the vessel by
the platelet mass.
The fact that platelet thrombi can form without fibrin
formation was first noted by Eberth & Sohimmelbuech (1888),
and the observed interval between VM and fibrin formation may
provide an explanation for this phenomenon. As it is thought
that the platelet products, necessary for thromboplastin
formation, are released early in the sequence of VM, to take
cart in a time-oonsuming reaction with A.H.G., Christmas
factor, calcium and factor V, it is not unreasonable to
suppose that, if blood is still flowing past the platelet
mass, the Platelet products can be washed away or diluted
before they oan react with these other factors. Thus the
platelet mans may be left in situ, being reinforced as other
platelets collide with it, but without any fibrin formation
around it. Theoretically a thin layer of fibrin may form on
the surface of the platelet mass where escaping products tend
to be concentrated, or in the interstices of the olunrp. If
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the Mood becomes static in the vessel or by extravasation,
no such dilution factor will apply and the platelet products
will react with the other coagulation factors in situ and
fibrin will be formed. Admitted hypothetical, this theory
does agree with the views of those workers who have observed
the mechanism of haemostasia in animals and humans.
If true for normal blood, this interval between VM and
fibrin formation is even more significant in those cases
where a defect of one coagulation factor has significantly
delayed fibrin formation and so prolonged the interval. In
Bevere haemophilia and Christmas disease, tire difference
from normal is so marked that it must play some part in the
defective haemostasia in these syndromes. In both> normal
primary haemostasia appears to follow trauma, but after &
variable interval, severe secondary haemorrhage may occur and
persist for days and even weeks. The following theory can be
advanced to explain this not uncommon occurrence. The
platelets,undergoing VM in the initial stages of dotting,
form a haemostatic plug and release both their coagulation
products and vaso-constrictiva agents? thus the initial flow
of blood from the vessels is stemmed. At present it is un¬
known how long tleplatelet mass or vaso-constriot 1 ex; may persist
in humans, but it is entirely possible that one or other may
had
disappear before the platelet products have/time to react with
the defective coagulation system to form reinforcing fibrin.
It is even possible that in severe haemophilia and Christmas
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diseaseffibrin formation may be delayed or imperfectly formed
in static or extravasated blood. If this is so, the failure
of the immediate haemostatic mechanism unsupported by normal
fibrin formation will allow profuse secondary haemorrhage to
occur. Why the process of platelet agglutination and vaso¬
constriction cannot be repeated, and so stop this secondary
blood loss, is unknown. Yet, if Margolis'(195?) observations
of the effect of glass contact on blood coagulation are
applicable to damaged tissue surfaces, it is probable that the
effect of the latter is also capable of exhaustion and thus
has only a transient effect on the blood coagulation,
The apparent instability of the platelet clumps in
haemophilia blood may provide an explanation for the observed
clinical differences between Christmas disease and haemophilia.
In the former, a virtual complete absence of Christmas factor
is not usually accompanied by such a severe haemostatic defect
as that seen in classical haemophilia where no antihaemophilic
globulin can be determined, The total ^bsence of VIS in
thrombocytopenic blood was supported by the experimental
observation that at least 60,000 platelets must be present
before normal VM can occur (Chapter :V ). The haemorrhagie
tendency associated with thrombocytopenia cannot be due
solely to this failure of VI as, in some patients with very
few circulating platelets,no haemostatic defect can be
determined. (Chuipliui 11, y. )li
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Again it must b© stressed that this analysis of the
aeehaniara of haemostasis in the light of the experimental
results of this thesis, is purely hypothetical, hut it cannot
be denied that it has provided an explanation for some of the
discrepancies encountered in studies of normal and abnormal
haemostasis*
With this knowledge it is intended to carry out further
research to determine whether these assumptions can be sub¬
stantiated by in vivo studies. Such an investigation will
necessitate employing histological as well as vital studies
in both experimental animals and huaans. So far, orthodox
histological techniques have failed to differentiate fibrin
from viscous metamorphosed platelets. As can be seen from
the illustrations of platelet changes in VM in Chapter II,
this is not entirely surprising, as it is difficult to
recognise the platelets as such once they have clumped. Thus
the solution of this problem must await the development of
new techniques or the adaptation of established methods.
The influence of glass contact on platelets is difficult
to assess. Proa published experimental work it is obvious
that glass contact will quantitatively accelerate normal
blood coagulation and that some degree of glass contact is
essential for what is accepted as normal 'in vitro' ooagula-
tioa. While glass does not seem to have this aotioo by
virtue of damaging platelets, but rather by activating some
plasma component, there is no doubt that glass contact will
damage platelets* These cells will adhere to glass when
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when suspended in their own plasma and will in fact agglutinate
when exposed to a large area of glass for a long period. They
do not, however, undergo the typical B©quenoe of VM.
While VM in platelet rich native plasma appeared to he
independent of glass contact, evolving normally in siliooned
tubes, it cannot he denied that the bloods examined may have
received soma oontact during the process of collection prior
to testing. This contact oould not have "been due to glass
hut it is possible that damaged tissues may have similar
properties to glass surfaces.
The observed increased activity of the serum VM factor by
glass contact does suggest that this factor could he the
actual 'contact factor' as described by Margolis (195?' and
Shafrir & 35e Vries (1956) • This supposition is strengthened
by the failure to relate this serum VM faotor to any known
coagulation faotor.
Contact with air or a stainless steel surface did not
appear to have any deleterious effects on the platelets.
lo factor oould damage platelets more dramatically than
bad venepuncture technique. Whether this is due to some as
yet undetermined tissue platelet lysin or was simply an
expression of accelerated coagulation by tissue thrombo¬
plastin has not been decided. Experimentally tissue thrombo¬
plastin had little or no effect on the platelets either
during coagulation or when added to platelet suspensions.
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The effect of Russell's Viper Venom, a potent thrombo¬
plastin, must be assumed to be an esample of non-specific
platelet agglutination rather than an expression of the
coagulant activity of this material.
The ability of both bovine and pig A.H.G, to agglutinate
platelets, while apparently irrelevant to the present problem,
provides yet another example of non-specific platelet
agglutination. The recording of these observations is worth
while, however, as they do emphasise the dangers of using
heterologous proteins in blood coagulation research,
especially where platelet systems are being employed. It is
of interest that this effect appears to be peculiar to human
platelets only, although not all animal platelet suspensions
have been examined.
The experiments so far recorded and discussed have
provided information of value to the understanding of normal
blood coagulation and haemostasia. They have also clarified
the original problem that presented while trying to demon¬
strate platelet agglutinating factors, other than those
concerned in the process of blood coagulation, in the blood of
patients with idiopathic thrombocytopenic purpura.
Thus it is now possible to proceed to the second part of
this thesis which constitutes an investigation into the
validity of the many claims to have demonstrated platelet
agglutinating factors in the blood of patients with




A Brief Historical Review of the Pathogenesis of
Thrombocytopenic Purpura ■with Special Reference
to the Theory of Immune Mechanisms
Cutaneous purpura has "been recognised since the 15th
century hut Werlhof (1776) is, by custom, credited with the
first description of the clinical appearances of idiopathic
or essential purpura. He called the syndrome "morbus
maculcsus haemorragicus" to describe the association of
cutaneous purpura with epistaxes and monorrhagia. But it was
not until the last two decades of the 1Jth century that
platelets were recognised as separate cellular elements of the
circulating blood and were found to be reduced in number in
certain types of purpura (Krause, 1883; Benys, 1887; Hayem,
1895).
The classical clinical features and laboratory findings
of idiopathic thrombocytopenic purpura were described fully
by Duke (1912) and these remain unchanged to-day.
Once Bizzozero's (1632) belief that platelets were
separate elements of the circulating blood, and not fragments
of broken down leucocytes or red cells (Howell, 1391), pre¬
cursors of the latter (Hayem,1878), or precipitate plasma
proteins (Boxmee, and their origin from the mega-
kaayocytes was accepted (Wright, 1910), theories began to be
propounded to explain why the platelets disappeared from the
circulation in thrombocytopenic purpura.
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The thrombocytopenia, with associated purpura, that
accompanied the destruction of the marrow and the megakaryo¬
cytes by poisons or by replacement with neoplastic, leukaemia
or fibrous tissue, has been easily understood and accepted
(Minot, 1917)* On the other hand, the idiopathic or
essential variety of thrombocytopenic purpura, appearing
suddenly and either disappearing spontaneously, or persisting
for months or even years, had attracted experimental workers
and the theorists for many years.
The recognition that immune mechanisms might be a partial
or oomplete explanation for this syndrome is not as modern as
the present literature would lead the reader to believe.
As long ago as 1896, Hayem, in one of his excellent
papers on platelets ("les hematoblasts") described "la
penetration dans le sang d'une substance alterant les heraato-
blasts et les precipitants, Ce sont les hematoblasts alteras
qui rounds en amas, seraient la cause dss hemorragies et
mieux dea infarctus hemoiragiques". He did not qualify this
remarkably prophetic statement but the standard of Hayem's
observations was so high that it is probable this wrj the
result of experimental observation. Thus he mp/t have been
the first to describe a platelet agglutinin.
Very rapidly it was found that, if an animal was injected
with platelets derived from a heterologous species, antisera
could be prepared which would agglutinate the platelets of
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immunising species (Marino, 1905). Anti-human platelet
serum produced in rabbits was capable of agglutinating and
lysing human platelets, even when diluted (Cole, 1907). It
would agglutinate human red cells only when used undiluted
and this differential agglutination tended to confirm
Bixaosp&ro's hypothesis of platelet individuality from other
cells of the blood. Similar antisara were found to be
capable of producing the full clinical picture of purpura
as well as thrombocytopenia (Ledingfaam, 1914) Ledingham &
Bedson, 1915) bee & Robertson, 1916$ Leonard & Falconer,
1941), Their action was specific for the platelets of the
speoies used to immunise the antisera donor animals. Lee
& Robertson (1916) noted that normal sera,which did not contain
any antibodies, were also capable of inducing transient
thrombocytopenia but never purpura, when injected into animals
of a heterologous species.
Bedson (1921, 1922) reported a series of Important
experiments in which he showed that, while purpura always
accompanied the thrombocytopenia induced by heterologous anti¬
platelet sera, it did not appear if the thrombocytopenia was
induced by mechanical methods (intravenous injection of 0.5$
agar in serum). Hum he injected anti-red oell serum prior
to depleting the animal of platelets by agar-sexum, purpura
developed. Thus he demonstrated in animals what has so often
been observed clinically in humans, namely, that thrombocytopenia
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can be present without concomitant purpura developing.
Splenectomy was found to protect animals from the effect of
anti-platelet sera (Bedson, 1924) but Elliot and Whipple (1940)
found that abnormal capillary fragility could still be
demonstrated if very large doses of platelet destroying
antisera were given to aplenectomised animals.
At this time, experimental work started in Japan by
Katsura (1923, 1924), showed that non-thrombocytopenic purpura
could be induced by heterologous antisera prepared against
vascular endothelium. This 3erum, however, when used along
with anti-platelet sera, enhanced the effect of the latter
in the
and produced severe thrombocytopenia/animals. By Complement
fixation he thought that he could demonstrate that platelets
and vascular endothelium shared at least one common antigen.
These observations were unknown to the Western world until
Clark & Jacobs (1950) translated the original papers and
confirmed the Japanese observations.
Tocantins (1936a) has stressed the ability of anti-
platelet sera to produce a rapid fall of the blood platelet
.
level within minutes of injection. The platelet count
returned to normal levels within a few hours. Leonard &
Falconer (1941) felt that the concomitant purpura was found•mm. %m
only when the platelet count dropped rapidly and not if the
thrombocytopenia developed slowly.
■
This growing realisation that thrombocytopenia alone
not explain all the manifestations of idiopathic purpura led
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others to stress that capillary damage must play an important
role in the pathogenesis of purpura (Bedson, 1922; Tidy, 1926j
Elliot & Whippfe, 1940? Robson, 1949; Clark & Jacobs, 1950).
Altered capillary function in thrombocytopenic syndromes was
noted by Macfarlane (1941)«
It is surprising that those experiments did not stimulate
a more rapid enquiry into the occurrence of platelet
agglutinating or lytic factors in the blood of cases of
icfepathic thrombocyte ->enlc purpura in humans. Lee &
Hobertson (1916) did think of the possibility but obtained
negative results in the one case they examined.
%
One explanation for this may have been the preoccupation
of other workers in the role of the spleen in this syndrome.
Following the reported success of splenectomy in the treat¬
ment of idiopathic thrombocytopenic purpura (Kaznelson, 1916;
Hess, 19171 %ers, Maingot & Gordon, 1926), many believed
that the spleen generated a humoral faotor capable of
destroying platelets or inhibiting their formation from
megakaryocytes (Minot, 191?J Wiseman, Loan & Wilson, 1940?
Lameshek & Miller, 1946)»
The isolation of a factor from the spleens of
thrombocytopenic patients, capable of inducing thrombocytopenia
when injected into experimental animals, strengthened the
beliefs of these workers. This was named 'Thrombocykopen*
by Troland & Lee (1938) and Otenasek & Lee (l94l)i Their
findings were confirmed by Torrioli & PudcLu (1938) and
- 111 -
Hobson & Witts (1940), but both groups remarked that the
method of extraction was all important as normal splenic
extracts were also capable of this action. Torrioll et al
(1938) thought that the main action of these extracts was to
if . ■ • - ' •• ' r • TH.' •!.
damage the megakaryocytes. A further possible function of
the spleen was advanced by Hblloway & Blackford (1924) and
Wiseman, Doan & Wilson (1940) who, in a comparative study of
platelet counts in the splenic artery and vein, noted that the
count was lower in the vain. This led them to propose that
selective "sequestration" of the platelets occurred in the
spleen and that any over-activity would lead to thrombocyto¬
penia. This sequestration theory has been denied by
Stefaaiil, Chatterjea, Dameshek, Welch & Swenson (1952), but
Bell & Alton (1955) have again claimed to have shown selective
sequestration of platelets by the spleen in cases of idio¬
pathic thrombocytopenia# but not in normals.
Accordingly two concepts of pathogenesis developed.
One assumed that increased platelet destruction constituted
the main basic defect while the other supported defective
production. The observation that anti-platelet sera also
produced morphological changes in the megakaryocytes and so
might influence the manufacture and release of platelets
& Stewart
unified the two theories (Tocanting 1939? Pisciotta,
StefanirS, & Dameshek, 1953) • The unique common antigenicity
of the megakaryocytes and the platelets has been confirmed by
the use of fluorescein labelled anti-platelet serum (Humphrey,
1955).
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The modern, era of research Into the role of immune
mechanisms in the pathogenesis of idiopathic thrombocytopenic
purpura was stimulated hy Evans & Duane (1949) who drew
attention to the not infrequent finding of low blood platelet
levels in cases of acquired haemolytic anaemia where anti-red
blood cell antibodies were demonstrable in the circulating
blood of the affected patient. The natural history of these
casesf they stressed, was very similar to that of idiopathic
thrombocytopenic purpura and they postulated that the latter
syndrome could be the result of a similar mechanism. They
proceeded to confirm their hypothesis by demonstrating
platelet agglutinating agents in the blood of oases of
thrombocytopenia (Ivans, Takahashi, Duane, Payne & Liu, 1951)
Almost simultaneously Aekroyd reported that, when he addedfche drug
l
Sedoraid to the blood derived from patients with Sedormid
induced thrombocytopenic ourpura, he was able to show in vitro
platelet agglutination and lysis and, by similar means,
inhibit all clot retraction after clotting had occurred
(Ackroyd, 1949 a, b, c). He was also able to show that
Complement was fixed during this reaction and that this
occurred only in the presence of the specific drug Sedormid'
(Ackroyd, 1951 )• These findings demonstrated clearly an
immune mechanism in drug induced purpura and supported the
Evans-Duane hypothesis.
Further supporting evidenoe was rapidly produced by
transfusion studies in cases of idiopathic thrombocytopenic
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purpura. It has ba<» establish*'* that the natural survival
time of the platelet lood varied between 5 and 9
days when studied in vivo by radio isotope techniques (Ode11,
Tausche, Puxth, 1954, 19551 Leeksma & Cohen, 1955, 1956).
Survival was shorter by 2 - 3 &ays if the platelets were
removed from the body, tagged with the isotope, and retransfused
(Odell et al, 1954, 1955). polycythemic platelet rich
I
blood was transfused by a direct method using a siliooned
'
5,.tv" )]' . .. ;•; *; \.: \, ; »f/ ■
syringe into patients with various foims of thrombocytopenia,
it was possible to raise the platelet count to 90,000/cu.mm.
and normalise the haemostatic function as measured by the
bleeding time, prothrombin consumption index, and vascular
fragility. These platelets survived for 4-6 days in
secondary thrombocytop«nia but in idiopathic thrombocytopenic
purpura, especially the acute variety, they only survived for
30 mins. - 24 hours, indicating a destructive process existed
(Hirsoh & Gardener, 1951,1952? Stefanini, Chatterjea,
Dameshek, Zannos & Santiago, 1952j Sprague, Harrington,
Lang© & Shapleigh, 1952).
The apparently dangerous experiment of transfusing blood
from cases of idiopathic thrombocytopenic purpura into normals
produced dramatic falls in the platelet counts of the
recipients and, in some, overt purpura. This induced
thrombocytopenia persisted for several days (Harrington,
Minnich, Boilingsworth & Moore, 1951). In a further series
of 35 cases, Harrington and his co-workers demonstrated that
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they were able to indue© thrombocytopenia in normals by
injecting blood from 16 separate cases of idiopathic
thrombocytopenic purpura (Harrington, Sprague, Mirmieh, Moore,
Aulvin & Dubach, 1953). Identical results were obtained
using the blood of two such cases following a return of their
platelet counts to normal after successful splenectomy.
Harrington* s observations were confirmed by Stefaninj
Dameshek, Chatterjea, Adelson & Mednicoff (1953)» and
Kissemeyer Uielsen (1953b).
These findings were parallel with those obtained
! I
following the injection of heterologous anti-platelet serum
in animals and therefore provided strong evidence that idio¬
pathic thrombocytopenic purpura was due to the presence of a
circulating anti-platelet factor in the blood.
This apparently irrefutable evidence has been somewhat
modified by the observations of Stefanini & Chatterjea (1952),
who claimed that normal blood or plasma when transfused into
normals could induce transient thrombocytopenia. Purpura,
however, did not result. Serum they found produced a more
sustained reaction. Further, Krevans & Jackson (1955) found
that, if large volumes of stored blood, were transfused rapidly
into normals, thrombocytopenia and even purpura, together with
impairment of haemostatic function, would ensue. Both series
stated that splenectomised normals reacted in a similar
fashion. Also, it was shown that exchange transfusion of
the newborn induced thrombocytopenia (Stefanin, Mednicoff,
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Salmon & Campbell, 195M Desforges & O'Connel, 1955)* A
somewhat confusing observation was made by Wilson, Eiseraan
& Cbanoe (1952) who claimed that when they repeated
Harrington* s experiments the induced thrombocytopenia was
apparent in the recipient only when they measured the platelet
count by the indirect method of Bameshek (1932) (numbers of
platelets assessed by comparison with the total number of
red cells/cu.mm, of blood) and not when they used direct
methods (directly counting the platelets, after lysis of red
cells, in a counting chamber). The significance of their
findings is obscure and they have not been confirmed. The
most likely e:cplanation for this post transfusion thrombocyto¬
penia would appear to be the diluting effect of transfused
stored blood and the non survival of the donors platelets in
the recipients circulation. Thus these findings do not
necessarily detract from the importance of Harrington*s
findings.
Stefaniii, Dameshek & Adalson (1952) observed that, if
repeated transfusions of fresh blood were given to
thrombocytopenia patients with aplastic anaemia, the survival
time of the transfused platelets in the recipient's blood
became shorter and the clinical improvement less obvious
after each transfusion. On the assumption that these
repeated transfusions might have induced the formation of a
platelet agglutinin in the recipient, blood from eleven
patients who had received multiple transfusions were tested
I
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"but in only one was a platelet agglutinin found. A similar
decrease of the beneficial effect of repeated platelet trans¬
fusions was reported by -liraoh &> Gardener (1952) who also felt
that platelets administered by transfusion might be antigenic.
Both Harrington and Stefanini and their co-workers found
further evidence to suggest that repeated platelet or whole
blood transfusions were antigenic and had produced platelet
agglutinins in the recipients (Harrington et al, 1953?
Stefanini, Plitman, Dameshek, Chatterjea & Mednicoff, 1953).
Simultaneously with these observations, Sprague, Harrington,
Langs & Shapleigh (1952) and Harrington et al (1953) were
able to demonstrate that platelet agglutinins could be demon¬
strated in the blood of cases suffering from, idiopathic
thrombocytopenia. fhese experiments together with early-
observations of Evans et al (1949 & 1952) stimulated other
workers to explore this field and to report the presence of
platelet agglutinins in similar patients (Stefanini,
Chatterjea & Adelson, 1992- Bausset, Belafontaine k
Pleuriot, 19525 Miesoher, Vanotti, Couchand k Hemmeler, 19521
Holthenius, Hborweg & Van Loghem, 1953? Bausset, 1954?
Verstraete k Vandenbroucke, 1955? Weinreiob, 1955j 1956).
One isolated case was desoribed by Stefanini and his
cc-workers which is worth more detailed analysis (Stefanini,
Dameshek, Chatterjea, Adelson & Kednicoff, 1953). In this
Case they were able to demonstrate a powerful platelet
agglutinin with a tit re of 1/2048 by direct agglutination
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tests. When "blood from this patient was transfused into a
noraial individual* not only did it produce severe thrombocyto¬
penia in the recipient which persisted for 12 days, but a
measurable agglutinin could be detected in the recipient's
blood. This agglutinin disappeared only as the platelet
count returned to normal. The megakaryocytes in the marrow
of the normal recipient were also damaged and the platelets
gave a positive direct reaction when tested with anti-human
globulin serum (Coomb's Test) (see p. It&). A study of the
physical properties of the platelet agglutinin revealed that
it was a relatively well defined factor. One unusual pro¬
perty was the absorption or neutralisation of this agglutinin
by guinea-pig kidney. This property is peculiar to Forssman
or heterophil antibody and? although Forsaman type antibodies
have been detected in the sera of patients with idiopathic
or secondary thrombocytopenic purpura in a titre higher than
that found in normal sera (Stefanini & Adelson, 1952)* these
sera, unlike the case of Stefanini ©t al (1953)» did not
agglutinate human platelets (Adelson & Stefaniis, 1952).
Electrophoretic separation showed that this high-titre
a^slutinin was apparently in the beta-2 globulin fraction
(Stefanini et al, 1953) yet the platelet agglutinin or lysin
detected by Tullis (1953$M956) appeared to be confined to
the gamma globulin fraction as did the antibody measured by
Stefanini on an earlier series (Stefanini, Chatterjea &
Adelson, 1952 b)
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Tullis claimed that ha was able to detect a platelet
lysin in the sera from patients with idiopathic thrombocyto¬
penia. He was able to demonstrate a fall in the non-
agglutinated platelet count after incubation of a mixture of
patient's serum and normal washed platelets. His claim has
received support from Bes3is & Tabuis (1955) Also were
able to show platelet lysins in the presence of Complement in
blood from cases of idiopathic thrombocytopenia.
All these series, using differing techniques, show
considerable variation in the number of cases of idiopathic
thrombocytopenic purpura in which platelet agglutinins could
be detected and in thei* distribution of positive tests
between acute and chronic varieties. The techniques used
and the distribution of positive results are summarised in
Table XXXII, at the end of this chapter.
The failure of the direct platelet agglutination test
te detect agglutinins in every case prompted other workers
to explore other techniques in the quest of a more sensitive
and reliable method for detecting anti-platelet factors in
blood of cases of idiopetbic thrombocytopenic purpura.
The adaptation of the Coomb's test (Coombs, Mourant &
Eace, 1945) to this problem was an obvious step. This test
was devised to detect incomplete or non-agglutinating immune
anti-red cell antibodies lodged on the surface of red cells.
As these antibodies were globulins, the addition of anti-human
globulin rabbit serum, agglutinated these red cells. It
«• 1t$ *•*
was probable that if immune antibodies existed in the blood
of patients with idiopathio thrombocytopen!o purpura, some
might be incomplete and coat the platelets without producing
agglutination, and therefore might be demonstrable only by
using Coombs' technique. Fluckiger, Hassig & Kollar (1953)
found that, in 5 cases of idiopathic thrombocytopenic purpura
where no platelet agglutinins could be demonstrated by-
direct agglutination techniques, 3 positive direct Coombs'
tests were obtained when anti-human globulin serum was added
to washed suspensions of the patient's platelets. Con¬
siderable doubt was thrown on their results by Sauer & Van
Leghorn(1954) who tested 47 cases of idiopathic thrombocyto¬
penic purpura usang this technique with completely negative
results. Bausset & Malinvaud (1954) found that certain
anti-human globulin sera would agglutinate all platelet
suspensions, normal and otherwise. To add to the confusion,
Ifelken & Gureviteh (1956) have claimed that in 2 cases of
acquired haemolytio anaemia due to immune antibodies, the
Coombs' test was positive with both the red cells and the
platelets. Both oases, however, had normal platelet counts
and did not show any abnormal bleeding tendency.
The indirect Coombs' test, used to detect the presence
of an incomplete antibody in serum has been adapted by
Jaeger-Draefsel, Weigman & Van Loghem (1956$- to test the sara
from cases of idiopathic thrombocytopenic purpura with
apparently encouraging results. Preliminaiy incubation of
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these sera with normal human platelets was performed to
allow any non-agglutinating anti-platelet factor in the sera
to coat the platelets. The subsequent addition of anti-
human globulin serum to these platelets proved that such
antibodies were present in many of these sera.
Moulinier (1955) proposed a further modification of the
indirect Coombs' test by comparing the titres of residual activity in
anti-human globulin serum after exposure to platelets
sensitised by preliminary incubation with serum from cases
of idiopathic thrombocytopenic purpura and normal serum.
He claimed that this was a far more sensitive technique
than the classical indirect Coombs' technique.
Kissemeyer Hdelsen (1953a) devised an ingenious
technique for measuring anti-platelet factors, based on a
modification of Boyden's tannio-acid-red cell-protein
indicator for measuring anti-protein sera (Boyden, 1951).
After first incubating washed human red cells with tannic
aoid,he exposed them to a human platelet protein extract
which was absorbed onto the tanned red oell surface.
These coated red cells were added to test sera and, if the
former were agglutinated, these sera we e throught to
contain anti-platelet antibodies. This technique gave
reproducible results with anti-human platelet rabbit serum
and suggestive results with sera derived from some cases of
idiopathic thrombocytopenic purpura. This technique was
adopted by other workers who supported Kissemeyer H&flsen's
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claims (Sauer & Van Loghem, 1954, 1955I Vandenbroucke &
Verstraete, 1955;). Pauasetfc 1955)r
Ackroyd (1955a) however, reported dissatisfaction with
this technique and Bausset, achieving a partial volte-face,
now claims that this technique, far from measuring platelet
antibodies, appears to detect son® unknown substance released
from fibrin after fibrinolysis has occurred (Dausset,
Bergerot-Blondel & Paraf, 195®)»
Dausset (1953) and Hicola, Bosti, & Zangaglia (1955)
attempted to determine whether Complement was fined when serin
from cases of idiopathic thrombocytopenic purpura were incu¬
bated with normal platelets but, in both series, entirely
negative results were obtained.
Jamra, Be Angelis, Vorrastro & Coelho (1953) devised a
technique to measure platelet lysins similar to that used by
Tullls (I953k*& 1956) but instead of counting the number of
non-agglutinated platelets before and after exposure to
test sera, these workers estimated the packed platelet volume
(thrombocrit). They claimed that they were able to show a
drop of 50$ in the volume of platelets, after exposure to
serum from one case of thrombocytopenia. Holthenius,
Koorweg, Van Logbem (1953) found what they considered to be
platelet agglutination promoting factors, in serum of certain
cases of thrombocytopenic purpura. They found that when
they added test serum from 3 cases of purpura to anti-human
platelet rabbit sera the titre of the latter was increased
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by 100 - 500$. Of their J oases only one was thrombocyto¬
penic. They rightly considered that this phenomenon of
agglutination promotion was analogous to that measured by
the Differential Agglutination Test used in the diagnosis of
cases of rheumatoid arthritis (Rose, Ragan, Pearce, & Lipman
1948)* Yet another technique to demonstrate anti-platelet
factors in certain sera has been suggested by Moulinier &
Mesnier, (1954)» They first prepared a lipoid extract of
platelets with alcohol, ether, and chloroform which, when
added to a suspension of micro crystals of cholesterol,
provided sensitised particles that eould be agglutinated by
certain sera from a mixed group of patients with thrombocytopenia
but not by normal sera. So far there has been no con¬
firmation of the efficacy of this test.
Before completing this survey it is necessary to con¬
sider two further aspects of thrombocytopenic purpura which
provide further support for Evans* hypothesis of immune
'
■ *
mechanisms in idiopathic thrombocytopenia.
It has already been shown how Aokroyd*s work (Ackxoyd,
1949 a, b, c, & 1951» 1952, 1954) provided ma^or advance in
our understanding of the pathogenesis of thrombocytopenic
purpura and it is desirable to consider his work in more
detail. He demonstrated in vitro the probable mechanism of
platelet destruction in the blood of patients recovering
from thrombocytopenic purpura induced by tire drug; 'Sedormid* -
allyl-isopropyl-acetyl carbamide). He found that plasma or
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serum from such. patients could, in the presence of both
SedormidL and Complement, produce agglutination and lysis of
"both t he patient fs and normal platelets. Further, when the
patient's platelet rich plasma was clotted in the presence
of Sedormid, clot retraction was completely inhibited. Ho
such reaction took place if normal serum or plasma was
substituted for the patient's, or if the patient's serum
plasma was added to platelets in the absence of 'Sedormid'.
He further found that Complement was fixed when platelet
lysis was induced by the patient's serum in conjunction with
Sedormid and that this reaction was specific (Aclcroyd, 1951)»
■
■■
These observations suggested that Sedorraid mist unite
with the patient's platelets and, acting as hapten*,
confer antigenic properties upon them so that they will
stimulate the formation of a platelet agglutinin or lysin
in the patient's blood. These antibodies will react with
the platelet drug complex and induced thrombocytopenia. On
ceasing the administration of the drag, the antigenic complex
disappears and the mechanism of platelet destruction can no
longer operate (Ackroyd, 1955a).
Acfcroyd's hypothesis has been confirmed in other cases
where drugs have caused thrombocytopenic purpura.
Quinine Grandjean 1948. Bolton & Young 1953
Quinidine Bolton <fc Young 1953, Barkhsm &
Tooantins 1954, Bigelow & Desforges
Hapten - a substance, itself non-antigenic, which can,
when combined with a protein, confer specific antigenicity
on that pintein.
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1952, Larson 1953, Harrington 1954,
Bolton & Bameshek 1956, Bolton 1956*
Sulphamesathine Bolton & Young 1953
Antazoline Ackroyd 1955b.
Dormisone Stefanini 1954
Paraminosalicylic Wursel and Maycock 1953*
Acid
Thrombocytopenic purpura may be caused by a large vari
of drugs apart from those already quoted. A very full list
of these has been given both by Ackroyd (1955e) and
Stefanini 4b Barasshek (1955) and any further review here would
be superfluous. Although, in many of these instances, in
vitro sensitivity tests by Aokroyd* s methods have not bean
performed it is probable that the underlying mechanism is the
same in all.
Idiopathic thrombocytopenic purpura may develop
in the newborn ohild and such oases have boon the subject of
several excellent reviews. Robson & Davidson (1950)
reviewed the literature of this oondition in relation to
maternal purpura in pregnancy. In their series all the
mothers of the affected neonates were or had been
thrombocytopenic. A similar review by Epstein, Losner,
Cobbey & Davidson (1950) stressed the relatively high,
neonatal mortality and morbidity of this oondition although
transient and self limiting in the child.
suddenly
Other cases of neonatal thrombocytopenia have been
reported by Akerren & Rhinand (1950), Driere (1951), Stening
(1953)» Harrington et al (1953) Morris (1954), Sauer & Van
Lo^iem (1955) and Peterson & Larson (1954), Vandenbroi#^ &
Verstraete (1955), and Stefanini & Dameshek (1955)* Many
of these examples suggested that a humoral factor or antibody
was transferred through the placenta from the thrombocytopenic
mother to the child producing t1 rombocytopenia of variable
duration and, in some cases, it was possible to determine
that a specific antiplatelet factor did exist in the mother's
and baby's serum. Both Harrington and Stefanini have
stated thai* if no platelet antibody can be found in the blood
of a thrombocytopenic mother, the child will not be affected
(Ske/anini, Kadnicoff- & Plitman, 1954; Harrington, Minnich
& Art'-•■sira., 1956). Harrington and co-workers (Harrington ®t
al, 1953) together with Stening, (1953), Morris (1954),
Sauer & Van Logbem,(1955)> Stefanini, Mednicoff & Plitman
(1954), Stefanini & Dameshek (1955) and Tullis (1956) have
drawn attention to neonatal thrombocytopenia appearing in
the children of & normal mother who had never shown any evidence
of thrombocytopenia or purpura. This combination suggested
that the mother must have become immunised to the baby's
platelets due to their having an antigenic structure different
from her own, a state of affairs analagous to the red cell
Ehesus factor incompatibility in haemolytic disease of the
newborn. In this group antibodies have been found in the
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mother*s blood which, selectively agglutinate the father's
platelets and those of certain other normals but not the
'
mother's platelets (Harrington et al. 1953? Harrington 1954).
'
Sauer & Van Leghorn (1955) found that using Kissemeyer Nielsen's
technique, that serum from normal mothers might contain some
anti-platelet factor which would induce agglutination of tanned
red cells coated with platelet protein made from the mother's
own platelets. In view of the apparent non-specificity of the
technique used in these experiments, no importance can be
attached to this finding.
The analogy between neonatal thrombocytopenic purpura in
children of normal mothers and haemolytic disease of the newborn,
due to red cell group incompatibility, has supported other
claims: to have demonstrated a platelet group structure separate
from that of red cells. (Harrington et al* 1955? Stefanini et
al. 1955b).
If it be accepted that specifio anti-platelet antibodies
exist which are capable of destroying or damaging the platelets in
certain cases of idiopathic thrombocytopenia and other related
conditions, the majority of these must be agglutinins or lysins
and more than one type must exist.
They may be defined as follows:
1. Allergic anti-platelet agglutinins or lysins found in
cases of drug or toxic thrombocytopenic purpura.
2. Anti-platelet pan-agglutinins or lysins oapable of
agglutinating or lysing not only the patient's own platelets
but also those derived from normal donors.
- 127 -
3* Anti-platelet auto-agglutinins or lysina which agglutinate
or lyse the patient's platelets only and have no effect on
suspensions of normal platelets.
4. Anti-platelet iso-aggluiinins or lysins which agglutinate
or lyse certain normal platelet suspensions hut not those
of the patient.
These terras will he used in the discussion to follow.
This review has summarised the evidence that has been
produced in support of the Evans hypothesis. It is obvious
that the major, difficulty confronting workers in this field
has been the establishment of suitable techniques for demon¬
strating anti-platelet factors in blood. Platelets will
clump under the influence of certain blood coagulation and
non-specific factors. Some workers have failed to recognise
these pitfalls and their experimental findings must be
discarded. Therefore, to confirm or refute these many claimf,
it was essential to make a personal survey of this problem
using a technique which allowed for the presence of



















































































































































































































































































































































































































































































































































































































































































































































































la the previous ohapters the behaviour of platelets
during the sequence of blood coagulation has been analysed in
three separate experimental systems. The agents which
produced viscous metamorphosis (Vll) in these systems showed
definite differences from one another, and although no one
factor was common to all, it was possible to determine how the
factors responsible for platelet VM could be destroyed or
neutralised. Similarly, certain factors were found to
produce non-specific platelet agglutination and these must
be avoided if platelet agglutination is to be studied in vitro|
Any platelet clumping that occurs in a system, in which both
coagulation and non-specific factors have been excluded, must
be a measure of yet another form of platelet agglutination.
In Chapter IX the claims of other workers to be able to
demonstrate a platelet agglutination faotor in the blood of
certain oases with thrombocytopenia, have been described.
Preliminary experiments by the author using some of these
methods showed that their, apparently satisfactory, results
could not be repeated. Therefore a platelet agglutination
test was designed which excluded these coagulation and non-
speoific platelet agglutinating factors.
Platelet Agglutination Teat. (The detailed technique is given
in Appendix A, p.14)»
129 -
Preparation of Platalat Suspensions
Platelets suspended in their own plasma have been shown
to be more readily affected by any change in their environment
and to be much more sensitive to residual amounts of coagula¬
tion factors. When separated from their plasma, and all
traces of the latter removed by repeated washing, they became
store resistant to environmental change. Moreover, well
washed platelets were found to be resistant to serum viscous
metamorphosing factors (fable VIII). Therefore it was
decided to use washed normal platelet suspensions as the
indicator in the platelet agglutination test. Achard &,
Aynaud (1908b) and Tocaatins (193$) have claimed that the
addition of many agents, foreign to the blood, will produce
non-specific agglutination. They oited gelatin, peptone,
egg albumen, egg lecithin, gum arabio, and colloidal arsenic
as examples, and stressed that the one feature ooaaaon to all
was their colloidal nature. Therefore any materials used in
the separation, washing, or resuspension of blood platelets
had first to be examined in order that any, which might produce
non-specific platelet agglutination,be excluded.
The Effect of Anticoagulant on Platelets
First, it was essential to decide the optimum anti¬
coagulant for the preparation of adequate platelet suspensions.
Sodium citrate, sodium oxalate, disodium vereene, and heparin
have all been used for the isolation of intact platelets from
the blood. The criterion of the most suitable anticoagulant
- 130
was decided arbitrarily as that which weald allow the
platelets to stay suspended in their own plasma, without
agglutination or lysis, for 13 hours at 37° (Experiment 31,
Appendix B, p. 22 )•
Only dissodiusa versene (disodiun ethylene diamine tetra-
acetic acid) met with this criterion (Table XXXIIl). This
powerful calcium-binding salt has strong affinity for divalent
ions and has proved to be the best anticoagulant for the
preservation of platelets (Proescher 195t). Further, it is
widely cited as the coagulant of choice for the preparation
of platelet concentrates for intravenous transfusions (Dillard,
brooder & CronJsdte 1951)*
Tfta Separation of Plate,^sta from tfre Plasm?
The platelets were separated from their plasma by high
speed centrifugation and resuspended in various isotonic salt
solutions. This process was repeated three times in order to
remove all traces of plasma from the platelets. Various iso¬
tonic solutions were assayed for their suitability as platelet
washing fluids (Experiment 32. Appendix S, p. 22 )♦ After
the platelets had been washed three times, and resuspended in
the same fluid, they were examined for the presence or absence
of platelet agglutination (Table XXXIV).
The best solution was found to be dextrose-acetate-saline
(MS), as recommended by Tullis (1953a). lot only did this
solution provide an agglutinate-free suspension of platelets
but the morphology of the surviving platelets was better than
TABLE XXXIII Experiment 31 Appendix B, p^2
The effect of varying anticoagulants on the stability
of platelet suspensions.
Samples of platelet rich plasma collected in varying anti¬
coagulant mixtures were incubated for 18 hours at 37 C in









Sodium Citrate 3.8$ 1 part to ♦ m
9 parts blood
Sodium Oxalate 1,34$ 1 part to «e» +
9 parts blood
Pisodium 4»5$ 1 Part to * mm
Versene 33 Parts blood
Heparin 10 u/ml ++ <*
TABLE XXXIV Experiment 32 Appendix B, p. 22
The optimum medium for washing platelets free from
plasma.
Platelets were separate




d fcom platelet rich 'Vs
bed three times in the i
finally resuspended in





Isotonic Salt Solution Platelet Agglutination Platelet lysis
0.85$ Saline ± *
O.855S Citrate Saline -
5# Glucose in 0.85$
Saline
± -











pH 7.3 with Glyoxa-
line Buffer
± **
+ m denotes definite agglutination or lysis
+ * denotes occasional platelet clumps
- « unaltered platelet morphology
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when other solutions sere employed. Further, the platelets
resuspended easily in this medium and thus were washed more
efficiently.
The pi of these isotonic solutions was found to be an
important factor in the prevention of non-specific agglutination.
Whenever the pK of these washing solutions fell below 6.0,
non-specific agglutination took place immediately. This
reaction was even more intense when the pE was less than 5«5«
Baiaing the pE above neutrality to pi 8.5 did net alter the
platelets in any way.
These observations agreed with those- of Tccantins (1938)
and Harrington (1954) who both reported that lowering the pS
would produce platelet agglutination. The latter considered
that if the pi fell below 6.6, non-specific agglutination
might occur.
la an attempt to nullify this factor, isotonic glyosaline
buffer was added to MS solution in the proportion of on©
part of buffer to nine parts MS. This resulted in a solution
of pH 7.1 which should not have induced any platelet changes.
Unfortunately, when used to wash platelets, this buffer - MS
solution - was found to prodtxee partial platelet agglutination.
This impasse was circumvented by using freshly made distilled
water to prepare each batch of MS. Small batches of MS
were made up and used within one week, the pH being checked
prior to each experiment. With these precautions, the pH
was maintained above 6.8.
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Media for the Suspension of Platelets
The platelets, having been separated from their plasma
and washed, had to be suspended in some suitable medium before
addition to test serum for a fixed period of Incubation. It
«v
was essential that the suspending medium did not promote non¬
specific agglutination during this period of inoubaticn and
so various suspending media were examined (Experiment 33.
Appendix B, p.23 ). The only suitable media were MS, 2$
gelatine in MS, and 1$ disodium vsrsene in saline (Table XXXV).
The 7$ concentration of gelatine in MS conferred stability
on the platelet suspensions whereas "Jp gelatine provoked
definite agglutination.
Red c?U,a, Flatlet Agglutination
During the course of these experiments, it was observed
that, if platelet rich plasma,containing an appreciable number
of red cells in suspension, was oentrifuged at high speed, the
platelets agglutinated or, in combination with the red cells,
formed mixed agglutinates. These agglutinates were resistant
to resuspension even after repeated washing. That the red
cells alone were implicated in this phenomenon was shown by
selectively packing platelets and white cells together in
plasma. Heither the platelets or white blood cells showed
any evidence of agglutination and could be resuspended easily.
To define the conditions under which this red cell-
platelet agglutination phenomenon occurred, various experi¬
mental mixtures were examined.
TABLE XXXV Experiment 33 Appendix B, p. 23
A suitable medium for preserving platelets in
suspension.
Normal human platelets were separated from versene plasma
and washed three times in &extrcse-aoetate-saline. Then
they were resuepended in the following and platelet morpho¬
logy observed after the suspension had stood in siliooned
tubes at varying temperatures for 3 hours.
Suspending Media
(Concentration)




37°c Room Temp. 4°C
Saline 0.85$ ♦ + «•»




Glucose 5$ ± - ■m






2$ Gelatine in DAS - - 0







Egg Albumin •M- ++ +
Human Fibrinogen ± -
0 a No observation ++ - Strang platelet agglutination
+ » Definite platelet ± • Occasional platelet clumps
agglutination
- m No agglutination
- 1j>3
Platelets and red cells obtained by differential centri-
fugation from the same blood were washed separately in MS and,
after each washing, the equal volumes of washed platelets red
cells were raised and forced together by high speed centri-
fugation. The presence or absence of platelet or mixed
agglutination was then observed by phase contrast microscopy
(Experiment 34- Appendix B, p. 24 )
Only when platelets and red cells are packed together
in plasma did this platelet or mixed red cell platelet
agglutination take place. lashing either series of cells
inhibited the phenomenon (Table XXXVI). Therefore some
factor must be removed easily from the red cell or platelet
surface by washing.
The individual supernatants fro® the first washing of
both platelets and red cells were re-added to washed platelet-
red cell mixtures in an attempt to restore the agglutination
phenomenon. Neither separately nor in combination could
these saline ©luates of these cells restore their ability to
agglutinate.
In a further attempt to unravel this problem, washed
red calls were added to platelet rich plasmaafter exposure to
tiypsin or incomplete immune anti-Shesus antibody of known
potency in an attempt to restore the ability of these washed
red cells to promote this phenomenon (Experiment 35. Appendix
B, p. 25 )•
TABLE XXXVI Experiment 34 Appendix B, p.24
The effect of washing on the platelet red cell
agglutination phenomenon.
Before and after washing a mixture of platelets and red cells
were packed together by oentrifugation and then resuspended.
The presence or absence of platelet or mixed agglutination
was recorded.
Normal Platelets
Presence or Absence of Platelet or mixed
Platelet-Red Cell Agglutination
10# Red Blood Cells
In Plasma Wash 1 Wash 2 Wash 3
In Plasma ++ em - -
Wash "1 - - - •
Wash 2 - me - •
Wash 3 - — - -
 
TABUS XXXVII Experiment 35 Appendix B, p. 25
The effect of trypsin and incomplete antibodies on
platelet red oell agglutination.
0.5 ml of a 10/S suspension of modified red cells were added
to 0.5 ml platelet-rich plasma or 0.5 ml once washed plate¬
lets in D.A.S. Bed Cells and platelets were packed together
by high speed centrifugation, resuspended, and the presence
of platelet or mixed red cell-platelet agglutination recorded.
Modified Rod Cells











Whatever the explanation, the practical importance of
this observation is clear. It non-specific agglutination of
platelet suspensions is to be avoided, all but trace amounts
of red cells must be removed from the platelet rich plasma
before platelets can be separated successfully from plasm by
high speed centrifugatian.
Bacteria and Platelet A^lutination
Aynaud (1911b) noted that when certain bacteria were
added to platelet rich plasma, platelet agglutination took
place* In the present experiments, accidental bacterial
contamination of stored platelet suspensions or test sera
resulted invariably in marked non-specific platelet clumping.
Therefore all anticoagulant solutions used in these experiments
and platelet washing solutions were sterilised prior to use
and all sera were separated and stored in sterile universal
containers at -15°C.
Preparation of Test Sera
Serum, unaltered by anticoagulants, is, in the experience
of the majority of serologists, a far more reliable agent for
demonstrating immune reactions than plasma, and has been used,
with certain exceptions, in all the experiments to be
described. As unaltered fresh serum contains a factor
capable of inducing VM in washed platelets (Chapter V), it
was nscessaxy to destroy this property of serum. The addition
of decalcifying anticoagulants was the simplest method
available (Table Xin), but this would not only dilute the
serum but restore it to a state identical to that existing
* -
in plasma. Therefore tto exclude all residual coagulation
factors, the test sera were treated as follows?
(a) the serum was 'aged' by standing at 37°C ia contact
with the original clot;
(b) the serum was heat treated at 56°C for 1 hour. This
was found to be essential for complete destruction of
the serum VI factor* (Table XIII). This treatment
destroyed Complement completely and therefore platelet
lysis was not expected to occur in the test used in
this series*
(o) finally, the serum was adsorbed by barium sulphate
powder.
Any one of these methods was, by itself, capable of
destroying the ability of the serum to induce VI in washed
platelets, but was not able to destroy the ability of serum
to produce mild agglutination after prolonged incubation with
platelets.
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Platelet Agglutination in Normals
)
Before it could "be determined that any acquired immune
platelet agglutinating factors existed in the sera from cases
of idiopathic thrombocytopenic purpura and other related
syndromes, it was important to determine whether any similar
factors could he found in sera prepared from normal blood.
forfe
Ther©^Platelet Agglutination Tests were performed using blood
from forty normal subjects.
Bonsai healthy ®als and female volunteers were selected
at random from the medical and technical staffs of the United
Oxford Hospitals and tested in groups of ten. The red cell
blood group structure of all these donors was determined
(Table XXXVIII). Bene of these normals had received any
blood transfusions nor had any of the females been pregnant.
Thus it could be assumed that none cf the sera prepared from
these normals contained any immune auto- or iso-agglutinins.
Washed platelet suspensions were prepared from 10 normals and
added to treated sera frcsa the same 10 persons so that every
platelet suspension was tested against ©vary serum, involving
100 tests in all (Experiment 36. Appendix B, p. 26 ). The
results of the first one hundred test3 are recorded in Pig. 21.
This experiment was repeated at random 10 times until
1000 individual platelet agglutination tests had been
performed (Experiment 36. Appendix B, p. 26 ), using
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POSITIVE AGGLUTINATION
I | NEGATIVE AGGLUTINATION
fhe results of 100 platelet agglutination tests performed
"by mixing 10 normal sera with 10 normal platelet suspensions
in all possible combinations.
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platelet-serum combinations were tested by necessity several
times and not all the 1600 possible combinations were examined*
A summary of the tea experiments is given in Pig, 22#
A surprisingly high incidenoe of positive results was
found in this survey. In 1000 tests, 72 positive
agglutination tests were found and it was apparent that
certain platelet suspensions were more readily agglutinated
by normal sera than others. This su^ested platelets might
be divisible into groups akin to red blood cell groups or
that they had a separate group structure of their own.
Platelet Groups
That platelet groups might exist had been suggested by
Toda (1923)» Harrington et al (1953)* Stefanini, Plitman,
Dameshek, Chatterjea & Mednicoff (1953)* These workers
found that there was no evidence of any inter-relationship
between possible platelet groups and the ABO system of red
blood cell groups. However, Gurevitoh & lelken (1954* 1955a,
& b), Mourean & Andre (195#)* and Dausset et al (1954)
claimed that platelets did in fact carry the same ABO antigen
as their corresponding red cells.
Platelets and the ABO Blood Group System
It was decided to analyse the results illustrated in
Fig. 22 to see if there was any evidence of A & B red cell
antigens on the platelets, or alternatively whether any other
platelet group pattern could be determined, and so determine
which of the above claims was correct.
PLATELETS
1 2 3 4 5 6 7 8 9 10 1112 13 1415 16 17 18 19 202122232425262728293031323334353637383940
■ POSITIVE AGGLUTINATION Hi NEGATIVE AGGLUTINATION □ NOT TESTED
the results of 1000 platelet agglutination tests
performed on samples of normal blood. This figure incor¬
porates the results of ten experiments involving random
mixtures of normal sera and suspensions of normal platelets
prepared from blood derived from 40 normal donors.
US -
Table XXXtflU demonstrates the distribution of ABO and
Rhesus groups in the 40 normal donors used In these tests.
The remaining red cell group structure was known only in 29
individuals, but this number was sufficient to give samples of
sufficient numbers for reliable analysis.
The J2 positive results were analysed into groups
according to the known group structure of the red colls of the
donor from which the serum and platelets were derived
(Table XXXIl). From this analysis the numbers of positive
results appeared to vazy according tc the ABO and Rhesus
groups of the blood froir which the platelets were derived.
Therefore, it appeared to be possible that the platelets did
cany the ABO and Rhesus antigens. If this were so, it
would be expected that all the platelets which had been
cross-matched with sera of incompatible ABO groups should be
agglutinated. The results were therefore re-analysed in
term of compatible and incompatible ABO groups (Table XL)
Far from all the incompatible combinations being
agglutinated only 14*19$ save positive results. Tills figure
was higher, however, than that obtained from compatible
groups. Statistical analysis of these differences
(Appendix D, p. 2 ) showed that P equalled less than 0 01:.
Therefore this difference was significant and unlikely to be
due to chance.
But, although these results were suggestive, the hypo¬
thesis that platelets contained the ABO group antigens was
Tatolejfojx
Analysis of positive platelet agglutination Tests (Fig 22)
and other
in terms of the ABO/groups of platelet donor blood and serum

































































































































































Kell ) Insufficient variation of these groups among the
Lutheran) donors rendered any analysis impossible.























































Determination of ABO Platelet Groups by Specific Antisera
In a further attempt to confirm or refute this hypothesis,
washed suspensions of platelets* derived from "blood of known
ABO group, were specifically tested against sera containing
anti A and B iso-agglutinins of known potency (Experiment 37,
Appendix B, p.27).
These specific agglutinins agglutinated only some of the
platelets which possibly contained A and B antigens (fable XLl).
They did not agglutinate platelets from Group 0 or from A or B
group blood derived from persons who were non-secretors of
A and B substance in their saliva. (These were selected from
those normals with red cell sub group Lea+ who are known to be
non-secreiors of blood group substance (Race & Sanger 1954))*
Etarther, only high titre sera and not routine blood grouping
sera gave reliable results.
These observations suggested that either the amount or
concentration of A and B antigen on the platelets was
considerably less than their corresponding red cells, or if the
platelets from non—secretors of A and B substance could not be
agglutinated, the A and B antigenicity of platelets might
be due to A and B substance adsorbed by the platelets from the
circulating blood.
If this latter hypothesis was correct, it might be
possible to dislodge this adsorbed material by repeated
washing of the platelets (Experiment 38. Appendix B, p.28).
Table tt.t Bxrreriment 37 (Appendix B, p.27 )
To determine the presence or absenoe of A & B antigens in
platelets.
Washed platelet suspensions ware prepared from donors of known
red cell group and added to an e<iual volume of Anti A and Anti
B grouping sera. After incubation the presence or absence of





Anti A Anti B
Low Titre Sera

























High Titre Serum Anti A substance
Anti B substance
Babbit sera
Titr»(Anti A v. Group A red cells) 1/5120 (v. Group A
platelets) 1/6%
(Anti B v* Group B red cells) 1/1560 (v. Group 1
platelets) 1/32
Low Titre Serum National Blood Transfusion serum (routine
issue)
Titre (Anti A v. Group A red cells) 1/256 (v. Group A ,
piste lets)* l/2~ or nil ,
(Anti B v. Group B red cells) l/l28 (v. Group B
platelets) 1/1 or nil.
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After 10 washes, however, platelets from Group A and B
secretors could still he agglutinated "by their respective high.
■
titre antisera (Table XIJ. A).
Eixed Bed Cell Platelet Agglutination Test
fhis problem was eventually decided "by utilising the
method described by Coombs & Bedford (1955) for determining the
... . . . .. ... . . , ... • . . ;
: ■ .
antigenicity of platelets. This they called the •mixed red-
cell-platelst agglutination test'.
They evolved this test after they had also decided that
the demonstration of the A and B antigens on platelets was
not so straight forward as other workers had suggested. Ihey
claimed that if platelets and red cells shared the sac©
antigenic structure they would show a definite pattern of
mixed agglutination in the presence of the appropriate antibody.
If they did not share the antigen, either the red cells or the
platelets might agglutinate separately, but never together.
The mixed red cell Platelet agglutination they illustrated
as demonstrating a specific appearance peculiar to their test.
The test was divided into two stages. The first
involved preliminary incubation of the test platelet
suspension with specific antisera. The platelets were then
separated from the antisera by washing and red cells of known
antigenicity were now added to the platelets and any-
potential mired agglutination provoked by centrifugation of
the mixture for a short period (Experiment 39* Appendix B, p.»).
gable
xLIA E^rlmant ^ (Appendix B, p.gg )
To determine whether platelets carry adsorbed A or B
substance on their surface.
Platelet suspensions were prepared from blood of known ABO
blood group and repeatedly washed. After each washing the
platelet suspensions were exposed to an equal volume of high

























































Their test was applied to confirm or refute the hypothesis
that Group A or B non secretors did not carry A and B antigen
on their platelets.
The results obtained (Table XLIl) proved conclusively
that A and B antigens were present on the red oells
irrespective of whether the donor was a secretor or non
seoretor of blood group substance.
In conclusion, human platelets were found to share the
ABO blood group system with their corresponding red cells.
It is difficult to reconcile this conclusion with the
small proportion of positive ABO incompatible cross
agglutination tests. Yet this finding is not surprising in
view of the inability of specific anti A and B sera to
agglutinate all platelet suspensions containing the opposite
antigen.
Platelet Groups other than the ABO System
Rirther study of Table XXXU showed two unexpected
results.
Platelets derived from blood of group A and B cross
matched with serum derived from group A or B blood
respectively, and therefore compatible with the AB antigens,
were agglutinated more frequently than platelets dsrived from
Group 0 blood.
Furthermore, platelets derived from blood whose red
cells were Hiesua positive agglutinated more readily than
those derived from She sua negative donors. These differences
Table XLH Experiment 39 (Appendix B, p. 28 )
Mixed Bed Cell-Platelet Agglutination Test (Coombs &
Bedford, 1955) to confirm the presence of A or B antigens
in platelets*
Washed platelet suspensions (x 3) prepared from donors of
known blood groug were incubated with Anti A or Anti B sera
for 1 hour at 3? C. The platelets were then separated from
the sera, washed x 2, and added to an equal volume of group
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A (Hon Seoreior) Anti AAnti B
- ++ w#
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were significant , as with on© degree of freedom, the values
for P were <0.01 and <0,05 respectively (Appendix B, p. 3 )J
Platelets and Porssman Antigen
The fact that Group A and B platelets are more readily-
agglutinated than Group 0 platelets suggested that the former
mi^it cany an antigen, unrelated to Group 0 blood, which
reacted with an agglutinating antibody present in normal
serum. The Porssman antigen has been found to be associated
with the A antigen (K&bat 1956) and, as some normal sera do
contain Forssraan antibody, experiments were performed to
determine whether human platelets carried the Forssman antigen.
It had been previously claimed by Crus & Faro (1954) and
Hicols, Bosti & Zangaglia (1956) that, while cat, rabbit, dog,
goat, sheep, guinea pig and horse platelets cany the Forssman
antigen, human platelets did not do so. Their experiments,
however, did not define any blood group separation of human
platelets and therefore a further investigation was indicated.
A modification of the mixed red cell-platelet agglutination
technique described by Coombs et al was used.
Potent Forssman antibody was prepared by immunising a
rabbit with successive intravenous and intra-peritoneal
injections of sheep red cells, (Experiment 40. Appendix B, p.30)»
The anti-serum, both before and after adsorption with
guinea pig kidney (to selectively adsorb the Forssman antibody
(Wilson & Miles 1946)), was tested for its ability to promote
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mixed red cell-platelet agglutination by the method of
Coombs & Bedford (1955)* Using sheep red cells as the test
antigen no mixed red oell-platelet agglutination was obtained
with anti-Forssman sera and therefore neither Group A nor
Group B platelets appeared to carry the Forssman antigens
(fable XLIII).
Platelets and the Rhesus, Antigen
fhe difference in the number of positive platelet
agglutination tests obtained, when suspensions of platelets
were prepared from bloods whose Rhesus groups were positive or
negative (measured by the presence or absence of the D antigen)
was significant. The value for P was less than. 0.05
(Appendix D, p. 3 ). Such a value is usually considered to be
significant in biological research, but Bace & Sanger (t$54)
require a value for P of less than 0.01 before they consider
any results obtained in a survey of the incidence of blood
groups, to be worthy of farther investigation. Further, as
none of the platelet donors used in these tests had received
blood transfusions nor had been pregnant, the normal sera
should not have contained immune Rhesus iso-agglut iniris. As
anti-Rhesus antibodies are never found as naturally occurring
agglutinins, it is unlikely that these results were due to the
presence of the Rhesus antigen on the platelets.
However, in order to confirm this view, the mixed red
cell-platelet agglutination technique of Coombs et al (1955)
was adapted to determine whether the Rhesus antigen detected
on the platelets (Experiment 41. Appendix B, p. M).
Table XLEtlExperiment 40 (Appendix B, p.40 )
Mixed Bed Cell-Platelet Agglutination Test to detect the
presence of Forssman antigen in platelets
Washed platelet suspensions (x 3) prepared from donors of
known ABO blood groups were incubated with rabbit serum
containing Forssman antibody (1) rabbit serum from which
Forssman antibody had been removed by specific absorption
with guinea pig kidney (2) for 1 hour at 37 c« The platelets
were then separated from the sera, washed and added to
suspensions of sheep red cells (Forssman antigen) and human
red cells (no Forssman antigen) and the presence or absence












































As no positive results were observed (Table XUV), it was
reasonable to assume that the Rhesus antigen D was not carried
on human blood platelets* Ho studies were made to determine
the presence of the other sub groups of the Rhesus factor,
i.e* B.E., c.d.e. as these were not considered to be relevant
to the present investigation. Ashurst, Bedford & Coombs
(1956) have also found that the Rhesus 3) is not present on
platelets and in addition showed that the antigens C.E. and 0
were not carried by platelets.
^at^ets and Other Red Cell Bl<x?4 Group?
3a Table XXXIX the analysis of positive agglutination
tests applied to other blood group antigens, i.e. M.H.P.S.,
Kell, Duffy and Lewis, did not reveal any other significant
differences in the percentage of positive results obtained.
These results did not exclude the presence of any of these
antigens on the platelets but, as this survey had been made
to detaitnine the incidence of positive platelet agglutination
tests in normal blood, their influence on these tests was
obviously negligible and any further investigation was not
I • .......
considered to be necessary.
It has recently been claimed that the platelets do cany
antigens other than those of the ABO group (Ashurst et al 1956).
They found evidence which showed that the platelets carried
the M and N and Tj a antigens in parallel with the red cells
of their donor blood. This is an important advance in this
field of research and further experiments must be performed
TABLE XLIV Experiment 41 Appendix B, p. 31.
Human platelets and the Rhesus antigen.
Washed platelet suspensions prepared from Group 0 Rhesus + and
Rhesus ~ve donors sere incubated with specific anti-Rhesus
serum (incomplete anti-D). The platelets were separated and
added to an equal volume of sensitised Group 0 Rehsus + and
Rhesus -78 red blood cells together with one volume of anti-
human globulin rabbit serum.
Red cell group of
platelet donor




Sensitised human red blood
cells
GRhf Oith-
0 Eh+ Anti D «•»
0 Bh+ Anti 33 • «N»
0 Rh- Anti B - «§*
0 Rh- Anti 33 -
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to determine whether these findings have any practical
significance in terms of platelet agglutination tests and
platelet transfusions.
Platelets and Individual Platelet C-ro^pg
These experiments have shown that apart from tlae ABO
antigens, no other known red cell blood group appears to
influence platelet agglutination. (Ho analysis has been
possible in terras of the antigen T^a as this group had not
been determined on the red cells of any of the 40 donors used
... ■.
. ■... «...
in these tests). If the positive results, due to ABO
incompatibility between the platelets and serum, were excluded,
a significant number of positive platelet agglutination tests
still remained (Table XL). These might be due to the
presence of a separate platelet group system and the presence
of naturally occurring platelet iso-agglutinins in normal
serum. Alternatively, if the latter assumption was not made,
these could represent false positive results due to inadequacies
of the technique.
On the .assumption that platelet groups might exist, the
positive results, unexplainable in terms of ABO incompatibility,
were subdivided into the following categories»
(1) Platelet suspensions which were not agglutinated
by any serum and whose corresponding serum did
not agglutinate any other platelet suspensions.
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(2) Platelst suspensions which wore never agglutinated
"out whose corresponding serum did agglutinate
other platelet suspensions.
(3) Platelet suspensions which were agglutinated hut
whose corresponding serum did not agglutinate
other platelet suspensions.
(4) Platelet suspensions which were agglutinated and
who33 corresponding serum agglutinated other
,4) platelet suspensions.
• <
These subdivisions wax* mada from data obtained from
Jig. 22, which is summarised in Table XLV.
In the fourth group listed above it was obvious that if
naturally occurring iso-agglutinins existed that the serum
of any number of this group must not be able to agglutinate
another member of the same group. With this limitation in
mind, it was found to be necessary to split this fourth
category into two separate groups (Table XLVl),
The platelets having been subdivided into five separate
groups, it was possible to suggest a theoretical pbenotype
and genotype for each platelet groups and determine a
percentage incidence for each group. The letters XI Z and 0
were used to designate these groups (Table XLVi).
The technique used in arriving at these conclusions was
essentially similar to that used hy Landsteiner (1900) when he
discovered the existence of the ASO blood group system in
human blood.
TABLE XLV
An analysis of positive platelet agglutination tests
unexplained in terns of ABO incompatibility. (Data derived
























































































































































The evidence provided by these experiments allowed this
theoretical platelet group structure to he evolved hut, by
itself, this was insufficient evidence to base a definite
group structure. As Race & Sanger (1954) have suggested,
further elucidation of any blood group system may be obtained
by preparing appropriate antisera in animals# Therefore, two
rabbits were immunised by serial intravenous injections of
platelet suspensions derived from donor© whose theoretical
platelet groups were o and Z. Antisera from those animals
were then tested against platelet suspensions from 20 normal
donors selected at random to see if any selective cross
agglutination could be demonstrated (Experiment 42- Appendix
B, p. 32). Both sera, however, agglutinated all 20 platelet
suspensions while sera from normal non-dssaunised rabbits had no
such agglutinating powers (Table XLVIl).
This did not confirm the subdivisions made in Table XLVI
as, if the results had been as expected, the rabbit receiving
the Croup o platelet suspensions, should not have produced any
antibody while the other receiving the Croup Z platelet
suspension, should have only been able to agglutinate 9 of the
suspensions tested (namely those suspensions included in
Group Z and YZ).
This oast considerable doubt on the existence of
separate platelet groups, but it is possible that these anti-
human platelet rabbit sera may have contained a non-specific



















































































































platelet factors in the blood of thrombocytopenic patients
(p«//S") and that neonatal thrombocytopenia can occur in
children of healthy nonthrombocytopenic mothers who have
specific platelet iso-agglutinins in their blood (p. /!$% do
provide otroog ovidmo. to support thl. bypothoaio of eoparato
platelet groups. While this clinical evidence suggests that
separate platelet groups do exist, it has been impossible, so
far, to provide iirrefutable serological proof of their
existence.
Whatever the implications of this work, one practical
fact emerged. If sera from a wide series of cases were to be
examined for platelet agglutinating factors, the platelet
suspensions should be derived either from ABO compatible blood,
or from Group 0 blood alone. Therefore in the tests to be
described in the following chapter, platelet suspensions were
prepared from Group 0 red cell donors, irrespective of the
group of the blood from which the test serum was derived.
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CHAPTER XII
Platelet Agglutination In Thrombocytopenic
and Hon-Thrcrnboeytopenic Purpura.
Serum was obtained from oases with both thrombocytopenic
and non-thrembocytcpenic purpura and from any case where in
vivo platelet agglutination might provide an explanation for
the signs and symptoms. The test was performed in every case
as detailed in Appendix A, p.14. Each serum was tested against
at least four platelet suspensions derived from Group 0 blood
■
and if positive, the titre of the agglutinating factor was
determined against one of the platelet suspensions aggl
in the initial test.
A positive result was recorded if the test serum
agglutinated at least two separate suspensions of platelets
(Appendix A, p.16 )• When using platelets derived from
Group 0 blood, 2.55p of normal sera gave positive results,
and therefore this criterion of a positive result reduced the
probability of a false positive result. The sera from 73
cases were tested against normal platelet suspensions and 29
of them gave positive results. An analysis of these positive
results was made in order to determine in what types of cases
positive tests occurred (Table XLVHl).
The relevant details of all 73 cases have been summarised
in Table LV and summaries of the Cfis© hj, s*trO x*i©s in
Appendix C.
Table XLVIT
Distribution of Positive Agglutination Tests
















Secondary Thrombocytopenia 8 1
Drug Thrombocytopenic Purpura 4 2
Neonatal Thrombocytopenic
Purpura 5 4












Percentage of positive results =* 41.85$




















Percentage of positive results » 33-3$
- War
The results have been analysed under the following
headings
(1) The incidence of positive agglutination tests la cases
of thrombocytopenia and in those with normal platelet
counts.
(2) The incidence of positive tests in the several types of
thrombocytopenia.
(3) The incidence of splenomegaly in those cases with
positive tests as compared with those with negative
tests.
(4) The relationship of blood transfusion or pregnancy to
the positive agglutination tests.
(5) The relationship of positive agglutination tests to
therapy (steroid administration and splenectomy).
These positive tests were a measure of the power of serum
derived from these oases to agglutinate normal platelet
suspensions and, if the agents responsible were acquired
immune agglutinins, they must have been, by definition,
iso-agglutinins. The ability of the sera to agglutinate
platelets derived from the same blood (auto-agglutinins)
was only tested in those eases with normal platelet counts,
as it was found to be impossible to prepare satisfactory
suspensions of platelets from the blood derived from cases of
thrombocytopenia, even when using large quantities of blood.
The platelets from thrombocytopenic individuals did not
resuspend satisfactorily when separated from their plasma, a
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fact which in retrospect may b® significant (see p.19$)•
This difficulty was also encountered by Holthemius et al (1953) -
However, if a case with thrombocytopenia is found to have a
platelet agglutinating faotor in the blood that will agglu¬
tinate platelet suspensions derived from normals, it is not
unreasonable to suppose that it must also be capable of
producing agglutination of the platelets, and consequent
thrombocytopenia in the blood from which it was derived.
I. The Incidence of Positive Agglutination Tests in
Thrombocytopenic and lon-Thrombocytopenio Purpura.
An analysis of all the tests performed showed that the
proportion of positive results was the same whatever the
platelet count. TABLE XLIX
Type of Case number Positive Hegativ©
Tested Agglutination Agglutination
Tests Tests
Thrombocytopenic 55 23 32
Hon-thrombocytopenio 18 6 12
An analysis of these results (Appendix D, p. if. ) shows that
P is greater than 0,7 and therefore there was no significant
variation between these two groups.
II. The Incidence of Positive Tests in Different Types
of Thrombocytopenia
Acute and Chronic Thrombocytopenic Purpura
Table XLVIII illustrates clearly that a higher
percentage of positive results occurred in chronic idiopathic
thrombocytopenia than in the group of acute idiopathic
- 153
thrombocytopenia, (Gases with, symptoms of more than 6 months
were olassified as chronic). These results, however, agree
with those of Sauer & Van Loghem (1954) and Stefanini (1955&)
who also determined a higher Incidence of positive tests in
cases of long duration.
Among those cases classified as chronic thrombocytopenic
purpura are four cases which, clinical^, were considered to be
examples of hypersplenlsm. All had anaemia, leucopenia, and
thrombocytopenia secondary to splenomegally of unspecified
aetiology. As the cause of the splenomegaly and the pan¬
cytopenia wo-S unknown, and the duration of the illness was
prolonged, they were thought to justify this grouping.
Seoondary Thrombocytopenia
In secondary thrombocytopenia due to replacement of bone
marrow with secondary malignant tumour deposits or due to
uncontrolled proliferation of the constituent cello, only one
case was found to have positive agjutination test (Case 46).
Drug Induced Thrombocytopenic Purpura
Several cases were encountered in which a drug or other
toxic agent may have been responsible for reducing the plate¬
let count and induoing purpura.
.
In two, the offending drug was ascertained by in vitro
platelet agglutination tests and the sensitivity confirmed
after the platelet count had returned to normal on withdrawal
of the drug therapy. The techniques used are desoribed in
Appendix A, p.16. Case 36 showed definite sensitivity to
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sulphamezathine and, what was more interesting, showed a
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definite cross sensitivity reaction with other members of the
sulphonasoid© group. The purpura apparently resulted from the
administration of sulphamezathine "button in vitro testingt
positive results were obtained with sulpbathiazole and
sulphanilamide as well as aulphasezathine. This was
surprising in view of the definite specificity of the
chemically related drugs Quinine and Quinidine in 'in vitro'
tests when one or other of these drugs has "been implicated
as the causal agent in thrombocytopenic purpura (Bolton &
Young 19531 Bolton 1956).
Gase 35 showed a definite sensitivity to the antihi
drug 'Histantin* (Cblorocyolaaine Sferdroehloride) which was
"being administered along with Carhr:; tal and Codeine. This
provided yet another example of an antihistamine preparation
which is capable of inducing thrombocytopenia, previous
and Harrington, Eianich & Arimura (1956) (Benadryl). Two
further cases were placed in this group although in both
Instances they were not confirmed by in vitro testing.
In Case 38» a definite episode of thrombocytopenia was
induced by skin testing with Johnston's Furniture Polish.
The nature of this preparation rendered it impossible to
perform any in vitro tests.
*
In Case 37* thrombocytopenia, associated with severe
agranulocytosis, was induced by uncontrolled administration of
examples having bean cited by Ackroyd (1955b) (Antazoline),
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methyl thiouraoil. Blood from this ca3e gave entirely
negative in vitro tests for platelet sensitivity to this drug.
On withdrawal of the drug, the whit© cell and platelet count
returned to normal levels. fhe bone marrow biopsy in this
case showed narked toxic changes with maturation arrest of
myelopoesis, megaloid exyrthropoesis and apparent absence of
megakaryocytes. Thus this may not have been an example of an
immune reaction but rather of toxic depression of marrow
activity hy the drug. Drugs of the thiouracil group have
rarely been implicated as instigators of thrombocytopenia
(Moore 1946).
In three other cases symptoms associated with
thrombocytopenia have followed the recent administration of
drugs (Quinine, Aspirin, Phenacetia, Camphor, Codeine,
Benzocaine, Cocaine, Penicillin) but in none of these did
in vitro tests confirm any definite association between the
drug in question and platelet sensitivity. As none of these
cases recovered spontaneously following withdrawal of these
drugs, they were grouped as cases of Idiopathic thrombocytopenia
according to the duration of the thrombocytopenia.
Farther cases of nonthrombocytopenic purpura associated
/
with drug therapy will be considered under the nonthrombo¬
cytopenic group.
Keonatal Thrombocytopenia. (Cases 30, 31, 32, 33, 34).
Five oases of neonatal thrombocytopenia were encountered
in infants in the first few days of life. All these
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children showed, either purpura or soma other evidence of
spontaneous haemorrhage associated with thrombocytopenia.
In none could any evidence of ABO or Rhesus Incompatibility
be proved. Three combinations of thrombocytopenia in
pregnancy have been described (see p. 12.5).
(1) The occurrence of thrombocytopenia in both
mother and child!
(2) Thrombocytopenia in the mother but a normal ohild5
(5) Informal mother with a thrombocytopenic child.
All five cases tested fell into the third group. Pour
of the mothers had never at any time shown any abnormal bleeding
tendency nor were they ever found to be thrombocytopenic.
One mother (Case 51) developed a transient purpuric rash at
58 weeks of pregnancy. This was confined to her waist and
disappeared in 2 days but at no time was she found to be
thrombocytopenic. In four, a platelet agglutinating factor
could be demonstrated in the mother's serum. In three cases
this factor did not agglutinate the mother's own platelets but
only those of other normals including, in the two instances
tested, their husband's. These cases were therefore typioal
examples of this group.
The fourth case gave unusual results, in that although
the mother appeared to be entirely normal, her serum agglu¬
tinated her own platelets, as well as her husband's and those
of normals. This was observed twioe following the delivery
of two successively affected ohlldren (Case 3k)*
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In the fifth case (Case 33)» no agglutinating factor
oould be demonstrated in the mother's serum although. the
child was definitely thrcfoibocytopenie. The thrombocytopenia
in this child, however, was very short lived (1 week) unlike
that seen in the other 4 cases, where it persisted for
"between 6-8 weeks. In three cases, where a platelet
agglutinating factor was present in the mother's serum, the
first-born child had been affected, although none of the
mothers had had previous miscarriages or blood transfusions.
If this syndrome is, as suggested, the result of the mother
acquiring a specific immune platelet agglutinin, the exact
method of sonsitisation is difficult to explain. In the
analogous state, due to red blood cell Shesua factor
incompatibility between mother and ohild, the mother requires
the stimulus of at least one previous pregnancy, miscarriage,
or blood transfusion# before she will produce specific immune
antibodies. Therefore first-born children are virtually never
affected unless the mother has had a previous miscarriage or
received an incompatible blood transfusion. In cases where
ABO incompatibility between mother and child has resulted in
haeomlytio disease of the newborn, first-bora infants are
frequently affected. In such cases the naturally occurring
antibody in the mother's blood is stimulated rapidly by the
foreign, foetal blood group antigens and, following trans¬
placental transfer, may produce haemolysis of the red cells
in the first-bora ohild (lollinson 1951).
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If the analogy of platelet group incompatibility is to he
sustained as an explanation for cases of neonatal thrombo¬
cytopenia arising in first-born children of normal mothers,
it must be assumed that the mothers of these cases had had
naturally occurring platelet antibodies in their blood, which
were raised to abnormally high levels by the stimulus of the
foetal foreign platelet antigen. On transplacental transfer,
this antibody had, in turn, damaged or destroyed the foetal
platelets and in some instances, provoked purpura. Therefore
it is not unreasonable to suppose that the mothers of these
thrombocytopenic first-born children, by virtue of having
naturally occurring platelet antibodies, destroyed the
platelets in their children as these antibodies rose to very
high titres.
The duration and behaviour of the thrombocytopenia in
the infants closely simulates that seen in Erythroblastosis
Tbetalis said the common duration of the thrombocytopenia
(5-6 weeks) agrees closely with the half life of immune
globulin, namely 20 - 50 days (fullis 1956). The presence
of an *in vitro* platelet agglutinating factor in the serum
of one mother (Case %) cannot be explained by any current
theory. Although this was capable of agglutinating the
mother's own platelets in vitro, it had not produced any
thrombocytopenia or otherwise damaged her platelets.
Thus, while certain discrepancies were found in this
series of cases whiok did not confirm the accepted theories of
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the pathogenesis of neonatal thrombocytopenia, they provided
insufficient evidence to justify any radical change of opinion*
The demonstration of a platelet agglutination factor in the
blood of a pregnant mother may be of practical importance and
the implications of a positive finding in these oases will be
further discussed on p. 2.00.
Defibrination Syndroms of Premanoy
Two cases in whom a sever© lack cf fibrinogen, compli¬
cating the terminal stages of pregnancy, were discovered to be
also severely thrombocytopenic. In Case 49» the prolonged
carrying of a dead foetus in utero provoked a severe
haemorrhagic state in the mother, which, when found to be
associated with marked thrombocytopenia, was originally
thought to be acute idiopathic thrombocytopenic purpura. On
subsequent examination the lack of fibrinogen was discovered
and adequate therapy with fibrinogen produced a dramatic
improvement in the patient's condition and a cessation of all
haemorrhage. The platelet count, however, did not return to
normal for 10 days.
In the second (Case 43), a concealed accidental haemorrhage
provoked defibrination and severs thrombocytopenia. Again
fibrinogen therapy improved the baemorrhagic state without
producing a rise in the platelet count. The latter returned
to normal 5 days later.
In neither ease oould any platelet agglutinating factor
0% demonstrated in the serum obtained before or after the
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administration of fibrinogen.
The pathogenesis of this syndrome is generally accented
to he due to massive release of tissue thromboplastin from the
placenta or deoidua into the systemic circulation with
resultant intravascular fibrin formation and depletion of the
total blood fibrinogen (Schneider 1955)* Presumably the
platelets become involved in this mechanism and are depleted
during the in vivo ooagulaticm of the blood by undergoing VM
by becoming entrapped by the fibrin as it forms. Therefore,
at present, there is no evidence that any specific platelet
agglutinating factor, other than those which may produce VM
during intravascular coagulation, exist a in these syndrome®.
Acquired Idiopathio Baeaolytlc Anaemia and Thrombocytopenia
In two instances thrombocytopenia and haemorrhagic
signs had arisen in oases of acquired baecxjlytio anaemia of
long standing. In both oases the red blood cells were found
to be coated with incomplete antibodies by the direct Coombs
test.
Only in one oass (Case 51) could any platelet agglutinating
factor be demonstrated and that disappeared from the blood
following 1 week's Prednisone therapy.
The positive agglutination test obtained in this case
may well have been the result of multiple blood transfusions.
This patient, besides having a non-specific red cell agglutinin
of the cold antibody type, had an immme iso-agglutinin
against S+ red oells, her own red cells being S-. Platelets
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from donors, whose red cell group was S-, were agglutinated "by
serum from this case as well as platelets from S+ donors, thus
the platelet agglutinating factor was not related to this
specific antibody.
The second case (Case 50) in spite of having a positive
Direct Coombs Test on his red cells did not have any
demonstrable platelet agglutinating factor. The serum tested
■ - - 7~ ■ - '■
was prepared before the start of successful steroid therapy.
ZZ £ . .. r . . V.
Ho specific red-cell group antibody was detected In this case.
This combination of haetaolytic anaemia and thrombo¬
cytopenia originally led Evans & Duane (1949) to revive the
'
concept of an immune mechanism in idiopathic thrombocytopenia.
That such a mechanism existed was confirmed in one of these
oases, where an aotive platelet agglutinating factor was
demonstrable against several platelet suspensions. Ho valid
explanation can be offered for the failure to demonstrate a
platelet agglutinating factor in Case 50.
Hon-Thrombooytopanio Purpura
Eighteen oases of purpura or unexplained abnormal bleeding
.
tendency were encountered in which the presence of in vivo
platelet agglutination might have provided a rational explana¬
tion for the observed olinieal state. The platelet count was
never found to be other than within normal limits in these
cases. It Is impossible to exclude that transient thrombo-
oytopenic did not exist for a very short time in these oases,
and that during this phase, purpura or other haemorrhagie
J*
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manifestations may haw occurred. Aokroyd (1952) found that
■when he administered a test dose of a drug to a patient with
established sensitivity to that particular drug, the peripheral
platelet count fell to very low levels within 2 hours.
Similarly, the administration of bovine antihaoraophi1ic globulin
to patients with haemophilia will induce thrombocytopenia
within a similar time and the platelet count returns to normal
levels within a few hours (Macfarlane, Biggs & Bi&well 1954).
Earlier studies by Achard & Aynaud (1908 a, b & c) showed
that similar transient episodes of thrombocytopenia could b©
induced in experimental animals by the intravenous injection
cases of
of gelatin® or peptone. So it is possible that many/so-called
non-throrabocytcpenic purpuras would have been found to be
thrombocytopenic if examined at the appropriate time.
Henoch Schonlein Purpura
Four oases of non-throuabocytopenic purpura were
encountered which were clinically considered to be examples
of the Henoch Schonlein group. lo positive platelet
agglutination testa were found in any of these cases.
Cryoglobulinaeiaic Purpura
Three cases of sever© purpura associated with
cryoglobulinaemia were encountered, of which two were
thrombocytopenic. In all three, the abnormal protein fraction
or cryoglobulin could be demonstrated in abnormal amounts by
its property of spontaneous flooculation at room temperature
J
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or at 4°C. All three cases appeared to fall into the group
of essential cryoglobulinaesia described by Lemer & Watson
'
(1947), Waldenstrom (1952). The cryoglobulins were in
each case discovered in the plasma or serum of these patients
and were not associated with other abnormal proteins.
(Macroglobulins or a high gamma-globulin fraction). In no




Platelet agglutination tests were positive in all these
cases at those tenerpatures which allowed the cryoglobulins to
spontaneously precipitate namely room temperature and 4°C. If
the serum and added platelets were kept at 37°® eo
agglutination occurred.
This, therefore, would appear to be an expression of non¬
specific platelet agglutination associated with the spontaneous
precipitation of the cryoglobulin fraction of the serum
2 _
proteins, rather than a measure of any specific platelet
agglutinating factor. It is of interest to know that such
platelet agglutination may occur in these cases as the
cryo-protein precipitates. The severe purpura, skin
ulceration and Raynaud's phenomenon,that these cases may
develop on exposure to cold (Waldenstrom 1952), may be due
to a similar mechanism taking place with the blood vessels
in vivo.
... . . ....
Acute Dis-^minated lupus Erythematosus
Two oases of this syndrome were encountered where the
• 164 -
elinical diagnosis was confirmed by in vitro demonstration of
the Lupus Erythematosus cell phenomenon. In neither ease
— .
could any platelet agglutinating factor he demonstrated.
Positive agglutination tests have, however, heen reported
in this syndrome by Harrington ©t al (1956).
Unspecified Hon-Tfrrombooytopenlo Purpura
In the assorted series of cases which were grouped as
unspecified nonthrombocytopenic purpura, four cases were
found to have platelet agglutinating substances in their sera.
In all four the sex's contained factors capable of agglutinating
both the patient's own platelets and those of normals.
Case 64 had received multiple transfusions of compatible
blood to replace blood lost par rectum in an acute
exacerbation of ulcerative colitis. Following one trans-
fusion of 2 pints of blood she developed localised purpura
on the anterior chest wall and shoulder. On testing a
platelet agglutinating factor was found to be present in her
blood which agglutinated both her own platelets and those of
normal donors. Her platelet count was always normal and,
examined
when tested- 3 weeks later, the platelet agglutinating factor
oould not be demonstrated.
Case 58 had received over 100 blood transfusions for
unexplained gastrointestinal haemorrhage and although he was
never found to be thrombocytopenic or to have purpura, his'
•• • - • • ■ •
blood oontained a platelet agglutinating factor against his
own platelets and those of certain normals.
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The36 oases were probably examples of a platelet
agglutinin developing as a result of repeated blood transfusions*
The relationship of blood transfusion to platelet agglutinating
factors will be discussed further on page I TO,
Case 65 developed purpura following a reaction to the
administration of several pints of human albumin intravenously*
He too was found to have a weak platelet agglutinating factor
in his serum which agglutinated both his own platelets with
those of normals. This reaction oould be enhanced by the
addition of reconstituted dried human albumin (Lister
Institute) but not by a preparation of his own albumin pre¬
pared two weeks after his last transfusion of albumin
(Experiment 44- Appendix B p.55*) As in previous oases, no
drop in the platelet count was ever demonstrated.
The latter case appeared to be an example of a reaction
to human albumin whioh had acquired antigenic properties in
this particular case and had stimulated a platelet
agglutinating factor. The observation that the patient's own
albumin,freshly prepared,di^ not provoke a similar reaction in
vitro suggested that either the human albumin had been
denatured during the process of preservation or that it
contained some other unspecified antigenic material common to
both the transfused albumin and the albumin used to prepare
Solutions for in vitro testing* The mechanism of antibody
production, in this case, may have been similar to that
suggested by Ackroyd in drug purpura. Alternatively, an
unrelated antigen-antibody reaction may have produced transient
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thrombocytopenia and purpura as suggested by Hoigne,
Grossman & Stork (1955) <uad Miescher & Straesal© (1956).
In one isolated example (Case 72) a powerful platelet
agglutinating factor was discovered in the serum of a case
convalescent from acute virus pneumonia. This had entirely
disappeared three weeks later. Again no purpura or
thrombocytopenia was aver discovered.
On four occasions cases have been submitted for
investigation following the appearance of purpura during a
oourse of multiple drug therapy or following the isolated
administration of one specific drug. Hone of these cases
were thrombocytopenic nor could sensitivity to these drugs be
demonstrated in vitro by the techniques described in
Appendix A, . The pathogenesis of these purpuric
episodes was never satisfactorily determined.
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CHAPTER XHI
^he Significance of the Positive Agglutination Test
in Throntacytopenia
The Relationship of Positive Agglutination Testa to
Splenomegaly
It has "been often suggested that any platelet agglutina¬
ting factor might induce thrombocytopenia by accelerating the
destruction of platelets by the spleen. Conversely the role
of the spleen might be to produce the agglutinating factor
which either damages the platelets of the psripheral blood or
inhibits their formation from the megakaryocytes in the marrow
(Troland & Lee 1938f Dameshek & Miller 1946).
Whatever the explanation, the results obtained in this
series of tests were analysed to see if there was any
specific correlation between positive agglutination tests and
splenomegaly (Table L).
TABLE L
Platelet Agglutination Tests and Splenomegaly.
Positive Tests negative Tests
Hormal spleens 15 35
Enlarged spleens 9 11
Statistical analysis (Appendix D, p. 4 ) showed that P was
greater than 0.30 and therefore the difference between these
groups was not significant and wa3 most likely due to chance.
i © .
P3,a,telet Agglutination Tests and Response to Therapy
In Throabocyfcopenic Purpura
It has always been hoped that the platelet agglutination
tests would he of value in assessing prognosis or response
to therapy in cases of thrombocytopenia, and, in several series
of cases, analyses of results have been made to decide whether
cases with positive tests had responded more favourably to
therapy than those with negative tests*. Harrington (1554)
claimed that this was true in relation to splenectomy* In
Ms series of cases he found that those cases of thrombo¬
cytopenia with positive tests responded more favourable to
splenectomy. His opinion was supported by Bernard & lathe
(1955)• But Stefanini (1955) in an analysis of his series
denied this association, as did Tullis (1956)*
Although the present series of cases is smaller than
those of other workers, an analysis of the response to
therapy and positive platelet agglutination tests was thought
to be worth while. 22 oases with thrombocytopenia received
steroid therapy. 12 showed a complete or partial response
and 10 showed no response. (Table Li).
TABLE LI
Steroid Therapy
Platelet Agglutination Total lumber Beeponse negative
Test Response
Positive 7 4 3
negative 15 8 7
Inspection of theso results showed that the differences were
unlikely to achieve significance (Appendix D, p. 5 )•'
•, ... .. .. .m; I
Therefore these results did suggest that a positive platelet
agglutination test provided no guide to the response to steroid
therapy in thrombocytopenic syndromes.
TABLE LH
Splenectomy
12 cases had their spleens removed. 7 responded and 5
showed a complete or partial return to normal.
Platelet Agglutination Test hespouse Ho Basponse
Positive k 2
negative 3 3
One further case died immediately after splenectomy
before the effect of the operation could "be assessed.
Again, inspection of the results in Table LII show that
the differences between these groups were unlikely to achieve
significance (Appendix 3>, p. 5), and therefore, a positive
agglutination test was no guide to the outcome of splenectomy
in cases of thrombocytopenic purpura.
The Relationship of Blood Transfusions and Pregnancy
It has been stated by Harrington (1955) that previous
pregnancy or blood transfusion may themselves produce a
platelet agglutinating factor in the blood and thus induce
thrombocytopenia. Certainly in cases of secondary thrombo-
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cytopenia, blood or platelet transfusions have been shown to
do thisf and subsequent platelet transfusions have become , as
a result, progressively loss beneficial.
It has been shown ('fable XLVTIl) in this present series,
that more positive agglutination tests occurred in the ohronio
or long standing cases of thrombocytopenia and it was
possible that blood transfusion given to combat the
haemorrhagic tendency in long standing thrombocytopenic
'
purpura, or to correct anaemia, might have provoked a platelet
agglutinating factor, thus preventing a spontaneous remission.
Thb present series of cases have been analysed to
determine whether either previous blood transfusion or preg¬
nancy were more common in those cases with positive
agglutination tests than those with negative tests (fable
LUI A & B). Statistical analyses of these results showed
that the differences between the groups in these two surveys
were not significant (Appendix B, p.6). Therefore neither
pregnancy nor blood transfusion appear to be capable of
producing a platelet agglutinating factor. This does not
exclude that they may be the stimulus in certain individual
cases and, as has been already discussed, multiple transfusions
may have been responsible for the appearance of a platelet




Blood Transfusion and Platelet Agglutination
Platelet Agglutination Test




Blood Transfusion 19 29
TABLE LXXX B
Pregnancy and Platelet Agglutination Tests
Platelet Agglutination Test
Positive Tests Negative Tests
Previous Pregnancy 15 14
Never Pregnant 14 30
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Physical Properties of the Platelet Agglutinating Factor
The properties of the platelet agglutinating factor
found in certain oases cf this series were compared with
those of the factor found in fresh sera which could induce
agglutination and VM in washed platelets. A high titre serum
(Case 8) was selected for testing. Initially it was treated
"by heat and absorption with barium sulphate as all the sera
in this series. The continued ability of this serum to
induce platelet agglutination after various treatments,
additions, and fractionations was observed (Table LIV).
These observations showed that the platelet agglutinating
factor had certain well defined properties which separated it
from the known blood coagulation factors remaining in fresh
serum after clotting (Compare Table XIII).
(1) This factor resists heating at 56°C for 1 hour but is
destroyed by heating at 65°C for 15 minutes.
(2) It is relatively stable on storage and may be preserved
for long periods at -15°C,
(3) The agglutinating power was partially inhibited by the
decalcifying salts sodium oxalate and disodium versene,
but not by trisodium citrate.
(4) The factor is adsorbed from the serum by concentrated
i . v
platelets but not by red cells or white blood cells.
Insufficient serum was available to see if any selective
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adsorption took place when using a large number of
separate platelet suspensions. This, if it had been
possible, might have given further information as to
the ooourrence of platelet groups.
(5) The 33-50$ ammonium sulphate fraction of the serum, but
no other fraction, retained the original agglutinating
factor.
(6) She Euglobulin fraction of serum did not show any
activity.
TABLE LIV Experiment 42 Appendix B, p. 32
The physical properties of platelet agglutinating factor
(1) 0.2 ml serum containing proven platelet agglutinating factor was
added to 0.2 ml washed platelet suspension together with 0.1 ml addition.
(2) 0.2 ml serum was treated by various adsorbents or anticoagulants
before adding to 0.2 ml washed platelet suspension. Both systems were
then incubated for 2 hours at 31 C and then the presenoe or absence of
platelet agglutination recorded^ In each instance the serum was used
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Alternative Techniques for Demonstrating Anti-
j, Platelet Fug-tors Li Dloou
Complement Fixation Test (Appendix A, p.21).
A large number of techniques have been described which
were thought to measure either a platelet agglutinating
factor, or other anti-platelet factors, in the blood obtained
from certain patients with idiopathic thrombocytopenic
purpura. It has been assumed by nearly every worker in
this field of immuno-haematology that these factors are
immune antibodies, the majority being specific platelet
agglutinins,
Tullis (1953 & 1956) and Bessis & Tabuis (1955) hava
claimed that certain of these antibodies were lysine and
required Complement for their action. The platelet-
agglutination technique used in the present series of tests
would not be expected to demonstrate such platelet lysine, as
the sera were inactivated, and their Complement destroyed
before testing. If platelet lysine requiring Complement
were present in these sera, it was possible that their
presence could be demonstrated by their power to utilise or
fix Complement as they reacted with platelets. Therefore
a Complement fixation test was designed in an attempt to
demonstrate these specific platelet lysine in the hope that
-175
such a test might provide a more sensitive method for
detecting anti-platelet factors in blood or serum
(Appendix A, p. 21 ) *
It has been shown in Chapter 17 that whan fresh serum
induces VM in platelets, Complement is not fixed or consumed.
Therefore any change of Complement levels in serum whan
mixed with platelets would he a significant finding and might
he a measure of a specific platelet lysin.
Washed normal platelet suspensions were used as the
antigen and Complement was provided in the form of guinea pig
serum. The human serum to he tested was inactivated to
destroy its natural Complement prior to incubation with
platelets. The antigen, Complement, and test serum were
incubated together for a fixed period. Than the platelets
have been removed, the tit re of residual Complement was
determined. This titre was compared with that of control
mixtures.
This technique was preferred to more orthodox methods
as the platelet suspensions used as antigen showed varying
anti-complementary activity, presumably due to trace amounts
of adsorbed disodium versene, used as the anticoagulant to
facilitate the separation of the platelets from the blood.
This anticoagulant removes magnesium as well as calcium from
the blood and thus inhibits the ability of Complement to
react with the haemolytic system. (Mayer, Croft & Gray 1948).
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(Sheep red blood cells sensitised
by haeiaolytic serum)
Complement fixed by reaction of platelet lysin with platelets
and therefore no haemolysis of sheep cells oan occur.
Hegative Result
Antigen Inactivated Serum
Platelets No platelet lysin
Complement not fixed by serum antigen reaction and is
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Either the serum or platelets used in the test system
my destroy Complement partially or completely, and therefore
haemolysis is inhibited correspondingly.
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20 of the sera tested In the previous series, including 5
sera which gave positive agglutination tests, were tested,
along with 20 normal sera, for their ability to fix Complement
when incubated with platelets. In addition, sera from two
rabbits containing potent anti-human platelet agglutinins and
lysina were tested along with two samples of normal rabbit
serum (Appendix A, p.23).
In this test none of the twenty human sera showed any
evidence of fixing Complement in the presence of normal human
platelets, whereas both the anti-human platelet rabbit sera
were able to fix Complement as they reacted with human platelets*
These findings confirm those of De Ricola, Rosti & Zangaglla
(1955) and Stefaafni (1955*0 and Introzzia it De llicola (1956).
Mixed Bed Cell Platelet Agglutination Test for the Detection
of Antibodies to Human Platelets
(Coombs, Maries & Bedford 1956) * (Appendix A, p. 24).
Following the successful use of this technique to confirm
the ABO antigens on platelets it was decided to determine
whether the sera, encountered in this series and which gave
positive direct agglutination test, would also give positive
results with the above technique. 2 sera with high titres
1/8 and 1/32 respectively were tested together with 2 normal
sera. All the sera were heat inactivated and barium sulphate
absorbed as for the direct agglutination test.
The sera were first incubated as for the platelet
agglutination test with a suspension of washed normal human
platelets and incubated for 1 hour at 37°c» The platelets
were then washed, resuspended and an equal volume of Group 0






































purpura. His claims were supported try- the results of
Verstraete and Vandenhroucke (1955)j and Bauer & Van Loghem (1954)•
11 of the sera in this present series, together with
10 normal sera, were tested using this technique.
While the occasional positive results were obtained,
this was also true of the normal controls. Furthermore,
while tanned red cells by themselves did not spontaneously
agglutinate, when combined with platelet protein, they showed
partial agglutination.
In the author*s experience, the differences between test
and controls were often negligible, and, even when present,
were not sufficiently convincing to support the continued use
of this technique. Further, it has recently been shown that
this technique is probably not a measure of a specific anti¬
platelet factor but that it would seem to demonstrate a
breakdown product of fibrin following fibrinolysis (Pausset et
al 195^; Jaeger-Braafsel, Weigman, Fabius & Van Loghem 1956a).
This unknown factor was present in large amounts in the blood
from cases with cirrhosis of the liver, but is also found in
oases of I.T.P. The exact significance of these latter
observations is still obscure. Also, it is difficult to
define what is present in the platelet protein solution or "extras
I •' ' ' v< :J .•«. . . v *'• " '• ' ••• ' • ■.
that is united with the tanned red cells. This is obtained by
breaking up the platelets by repeated freezing and thawing,
and after spinning off the platelet debris the supernatant is used
as the "platelet extract". Such extracts contain a multi¬
plicity of varying protein coagulation factors (Creveld et al
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1952
1951/1 Ware, Fahey & Seagers 1948| Seegers 1956j Rounameaux
.
1957a), and it is impossible to ensure that successive
extracts are the same and contain the ap-oropriate antigens.
Cooabfe' Test (Coombs, Mourant & Race 1945)-
Kelther the direct or indirect Coombs' technique have
been used in the present series of experiments as, on
preliminary testing, it was found that anti-human-globulin
rabbit sera agglutinated all the washed suspensions of human
platelets tested.
This result was not unexpected as it was known that
platelets carried absorbed globulin as Factor V on their
surface (Hjort, Rapj/aport & Owren 1955)♦ This cannot be
removed by repeated washing. Also Bounameaux (195l£ has
shown that A.E.G., factor VII, Christmas factor and prothrombin,
all known globulins, may adhere to the platelet surface.
Theoretically, therefore, anti-human globulin serum
added to human platelet suspensions should provoke
agglutination or be neutralised. However, in view cf the
recent claims by SSoulinier (1955)» daeger-Draafsel et al (195^>)
arid Helicon & Gurevltch (1956), it would seem that these
assumptions may have been erroneous and that this technique
should be reinvestigated kore fully.
Platelet Agglutination by "Mothcde d1agitation" of Dausaet
(Appendix A, p. 20 ).
Dausset (1954) suggested that, if a mixture of ths sera
to be tested for the presence of platelet agglutinins was
19 6b
- 182
continuously agitated with the platelets the sensitivity of
the agglutination reaction was enhanced. He used platelet-
rich plasma as his indicator* and the test serum was exposed
to heat at 56°C for 15 minutes prior to testing. A mixture
of these was then agitated on a Kline shaker for 30 minutes
and the presence or absenoe of agglutination determined.
During the present investigations* several sera, both
normal and from patients with thrombocytopenic purpura, were
tested by this method but extremely unsatisfactory results
were obtained. Control normal and test sera produced
intermittently fibrin clots in the platelet-rich plasma and
platelet clumps ware formed by both normal and control sera.
These clumps appeared morphologically to consist of platelets





II is impossible to consider the role of platelet
agglutination in oases of idiopathic thrombocytopenic purpura
(ITP) without some misgiving. Seven years have elapsed since
Evans & Duane (1949) opened this new era of research hy¬
postulat ing the existence of an immune mechanism in such cases,
and it must he freely- admitted that, to date, there is no
reliable technique which will give consistent results other
than in the hands of its originator. In addition, many-
earlier claims to have demonstrated anti-platelet factors in
ITP cannot be accepted,on grounds of inadequate technique.
In spite of Stefanini's and Silverberg's (1951) warning that
heat treatment of the test serum (56° for 30 mins.) did not
entirely remove the non-specific platelet agglutinating effect
v
of normal serum, several workers, notably Dausset (1954) and
Bausset & Malinvaud (1954) ignored this observation, and
continued to use only heat treated seium (56° for 15 mins.)
in their tests. In their original work on this subject,
Dausset and his co-workers claimed to have demonstrated
positive agglutination tests in 13?P using serum whioh had not
even been heat treated. They supported their results by a
series of pictures which obviously demonstrated platelet VM
and not simple agglutination (see Chapter II) (Dausset et al
1952).
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The earlier claims by KisseraeyerrUielsen (1953a) and others to
have detected specific anti-platelet factors in blood by use
of the tanned red blood cell-platelet-protein agglutination
teet have also not been confirmed (Dausset et al 1956).
However, the results from the main American centres of
research (Harrington 19541 Stefanini 1955b? Tullis 1956)
oaanot be criticised on grounds of technique. All these
series measured direct agglutination or lysis of platelets.
Although Tullis did add serum in a 1/32 dilution to his test
system in order to provide Complement, it is unlikBly that
it had any effect on the platelets when used in such dilutions.
Their results, together with the present series, do
demonstrate that in the blood of certain cases of thrombo¬
cytopenic and nonthrombocytopenic purpura there exists a
factor or factors, which can be shown to be detrimental to
platelets in vitro, and which do not appear to be related to
any known factor involved in the blood coagulation or
Complement systems.
Why this factor is not found in every case is a matter for
conjecture. Several opinions have been advanced, all of which
are, at present, purely hypothetical. It may be that, in the
group of idiopathic purpuras, we are dealing with a protean
series of disorders in which only one type is oaused by
circulating anti-platelet factors. Alternatively, several
types of anti-platelet factors may be present, only some of
which are demonstrable by direot platelet agglutination
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testa. This concept has been supported by the recent work
of Jaeger-Draafsel et al (1956b) who claimed that they were
able to demonstrate both direct platelet agglutinating factors
and incomplete or non-agglutinating factors* the latter being
capable of attaching themselves to the platelets without
producing their agglutination. A further tenable hypothesis
is that cases with negative platelet agglutination tests are
those in which all the anti-platelet factors have been con¬
sumed during the 'in vitro* platelet destruction.
The techniques may be faulty where normal platelets are
used to detect anti-platelet factors. It may be that only
the platelets derived from the blood of affected cases carry
the appropriate antigen or antigens. The difficulties of
isolating platelets from patients with thrombocytopenia
tends to preclude the design of a reliable technique to
demonstrate this concept in vitro.
The platelet agglutination test, described in this thesis,
has been shown, in the study of incompatible combinations of
sera and platelets carrying A, B, 0, blood group antigens, to
be relatively insensitive. It is quite possible that either
this technique Iras detected platelet agglutinating factors only
whan they have been present in strong concentrations, or the
normal platelet suspensions may have been rendered unagglutin-
able by the process of washing. This latter explanation is
a complete antithesis to the observation that platelets, both
in whole blood and in washed suspensions, tend to agglutinate
at the slightest provocation.
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fhis somewhat critical appraisal of the problem does not
include the earlier work "by Marino (19®5)♦ Ledingham (1914) end
Robertson & Lee (1917) and Be&son (1921 & 1922) and others
. . .... ...... ....
using heterologous anti-platelet sera, nor the work of Ackroyd
(1949 a, b, c, 1951, 1952 & 1954) on drug induced purpura, In
both examples, platelet agglutination could be demonstrated in
vitro with ease, and there was no doubt that agglutination, so
produced, was distinct from platelet VM.
The present experimental work has confirmed that human
platelets carry the A and B antigens in common with the red
cells of the same blood. This has supported the claims of
Gurevitoh & Uelken (1954, 1955) and Coombs & Bedford (1956)
and others and settled the controversy created by Toda (1925)#
Harrington et al (1953) and Stefanini et al (1953b) who failed
to recognise this fact. The claims of the latter workers to
have demonstrated platelet groups separate from the red cell
groups have received some support from the present experiments
performed on normal blood but, as has already been discussed,
these results, when analysed, were too ill defined to sub¬
stantiate the claims of these workers* A strong argument
for the existence for separate platelet groups has been
presented by those cases of neonatal or congenital thrombo¬
cytopenic purpura arising in infants bom of normal mothers.
While most of these cases apparently occur in children cf
thrombocytopenic mothers, the former group are being
- 187 -
ancountered more frequently, no doubt due to an increasing
awareness of the condition, and if platelet counts were done
more frequently in cases of haemorrhagic disease of the
newborh, it is possible that even more cases would be
found. The analogy to ABO and Rhesus incompatibility of
the red oells and baemolytic disease of the newborn has been
convinoing, but in the present series of 5 cases this hypo¬
thesis has not been wholly confirmed. In 3 cases, where the
mothers had never been transfused or had miscarriages, it was
reasonable to accept that the first pregnancies had resulted
in affected children. This, together with the ability of
the mother's serum in Case 34 to agglutinate in vitro, not
only her own platelets, but those of her husband and of normal
persona, casts some doubt on the validity of the platelet-group
hypothesis. This mother was never found to be thrombocytopenic.
The lack of immunising stimulus oan be explained If the
presence of naturally occurring platelet group antibodies is
accepted,as discussed on page /S9. Then, if the foetus carried
a foreign platelet antigen, the mother's naturally occurring
platelet agglutinin might be increased in strength so that it
would be capable of destroying the foetal platelets, if
trane-placental transfer ware to ooour at term.
It has not been possible to oonfizta the antigenic
structures detailed in Table XLVI by transfusion studies in
cases of thrombocytopenia. Specific platelet transfueionr
have only been indicated clinically on one occasion, and
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in a case with a negative platelet agglutination test.
Further, platelet transfusions can he antigenic and their
indiscriminate experimental use might well have prejudiced the
henefioial effect of a subsequent platelet transfusion
required to control intractable haemorrhage. Disappointingly,
heterologous anti-human platelet sera did not provide any
confirmation of the distribution of platelet group (p.148).
Further experimental work with similar heterologous serum and
selective cross absorption of sera containing potent platelet
agglutinins, by varying platelet suspensions, may confirm the
presence of separate platelet groups. At present, the evidence,
though suggestive, is extremely tenuous.
If this hypothesis of separate platelet groups is
unacceptable, the occurrence of positive agglutination tests
in normals, unexplainable in terms of ABO incompatibility
between platelets and sera, can only be an expression of the
inadequacy of the platelet agglutination technique and must
represent false positive results.
Perhaps the strongest support for the existence of anti¬
platelet factors in thrombocytopenic purpura, lies in the
transfusion experiments described by Harrington et al (1951)
and Sprague et al (1952). The fact that blood from
certain thrombocytopenic patients was oapable of inducing
thrombocytopenia and even purpura when transfused into normal
recipients, strongly supported the idea that these bloods con¬
tain anti-platelet antibodies. This property of blood from
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cases of HP can be reproduced by the intravenous adminis¬
tration of fresh serum (Stefanini & Chatterjea 1952), and it
would appear that thrombocytopenic blood may differ from
normal blood, in that when it is transfused, it behaves as
fresh serum and may induce thrombocytopenia by some, as yet
undetermined, coagulant activity rather than by any platelet
antibody content.
The present series of experiments did demonstrate a
platelet agglutinating factor in the sera from certain cases
of thrombocytopenic and nonthrombocytopenic purpura and
related syndromes. Whatever the nature of this agglutinating
factor it is qjui*® certain that its properties are distinct
from those of the platelet agglutinating or viscous metamor¬
phosing factors in normal fresh serum. Serum derived from
thrombocytopenic blood cannot, however, be considered normal
aid apart fro® the large amount of unoonsuraed prothrombin
present (Quick & Favre-Gilly 1949) other residual platelet
viscous metamorphosing factors may be present. The aging,
heat, and adsorption process, adopted to treat the sera in
these cases before testing, ruled out the possibility of
existing thrombin, thrombin generated from prothrombin by the
addition of platelets to the serum, or any other knotm serum
factor, being the platelet agglutinating factor. The unidenti¬
fied viscous metamorphosing factor, responsible for the initial
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agglutination of platelets in blood coagulation described in
Chapters 111 and 17 of this thesis, taay not be utilised
completely as thrombocytopenic blood clots. It has been
impossible to discover whether this factor is neutralised by
heat, or barium sulphate absorption, in the native plasma
system used to demonstrate its existence. Therefore it cannot
be ruled out that uaoonsumed amounts of this factor may be
present in serum derived from oases of thrombocytopenia and,
unaffected by heat or barium sulphate absorption, be capable
of producing platelet agglutination in the test mixtures. If,
however, the positive tests were due to unconsumed amounts of
this or any other VM factor, they should have been obtained
with every serum derived from thrombocytopenic blood. This
was certainly not so, and the sera which gave positive result
produced platelet agglutination and not, if I interpret the
change correctly, VM.
It has been assumed by nearly every worker that they
were measuring a specific platelet antibody in the form of an
agglutinin or lysin and those who have considered alternatives
have also concluded that this was so (Stefanini et al 1953a?
fullis 1956). Both these workers based their conclusions on
-------
platelet agglutinin or lysin was adsorbed specifically by
platelets and not by red cells and was present in the globulin
component of the blood proteins. But, as serum platelet VM
factor is absorbed specifically by platelets and is related
I - 191 -
to the globulin fraction* albeit different from, that containing
the platelet agglutinating factor (see fables XIV and UV)}
these criteria would appear to be insufficient evidence upon
which to decide that the platelet agglutinating factor, in
thrombocytopenic blood, is a specific platelet antibody.
Although other techniques of established value in
serology have been applied to this problem, they have been less
.
■ ' ' • ' ■ •• ■ • ' • • <• - ,
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reliable than direct platelet agglutination techniques.
Coombs, Marks & Bedford (195^)» using a modification of their
original mired erythrocyte-platelet agglutination technique
were not able to demonstrate positive results in thrombocyte-
panic purpura while strong positive results were obtained
with potent anti-human platelet rabbit sera. They suggested
tentatively that perhaps the platelet agglutinating factor
found in certain cases of thrombocytopenic purpura was not
'
an antibody. This, as they state, is a serious conclusion
in view of all the published results on this subject, et the
so many conflicting results obtained in the search for these
so-called antibodies, and the protean nature of the latter,
tend to suggest that this dissenting opinion may be sustained.
If not an antibody or a coagulation factor, seme other
explanation must be offered for the presence of these platelet
agglutinating factors. These must be largely hypothetical,
but nevertheless of value.
It has been dalmed that alteration in the platelet
surrounding may induce non-specific platelet agglutination by
disturbing their equilibrium (Achard & Aynaud 1908 a, b, c, and
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Tooantlns 1938). They cited a wide variety of agents
capable of this actions egg albumin? gelatin, guia arabic, egg
lecithin, collokdal arsenic and peptone, mid Achard & Aynaud
(1908c) drew attention to their cannon colloidal nature.
Starlinger & Sametniok (1927) considered that platelets
could he agglutinated hy any increase in the negatively
charged proteins (fibrinogen and globulin fractions). These, hy
lowering the electric charge of the platelets, themselves
negatively charged (starlinger et al 19271 Wright 19511
Bigelow & Desforges 1953) allowed them to approach more
closely to one another and agglutinate. This action
Wright (1951) considered, was due to these proteins being
hydxophilic colloids, capable of reducing surface chars® by
modifying the position adsorbed water on the cell surface.
It is possible that such non-specific altaratiomsoof the
blood might induce platelet agglutination in vivo or in vitro
and could explain some of the observed phenomena.
Within the past 2 years two original communications from
Switzerland have suggested yet a farther explanation. Boigne,
Grossman & Stork (1955) have described bow they were able to
demonstrate a fall in the platelet count in patients in whom
they provoked an antigen-antibody reaction. They farther
claimed that they could also demonstrate this phenomenon in
vitro with associated platelet agglutination. 3?hat such a
mechanism exists has been demonstrated experimentally in
rabbits (liecher & Straessle 1956). ^y using radioactive
tracer techniques these workers were able to demonstrate that
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soluble antigen-antibody complexes in the blood stream become
firmly fixed to the platelets. Si one instance strong
platelet agglutination was provoked when such a reaction vms
induced experimentally, The factors controlling the
presence of agglutination appear to be, the nature of the
antigen, the antibody,and the ratio of one to the other.
This latter factor was also stressed by Hoigne ©t al (1955)
who found that platelet agglutination only occurred in vitro
when an optimum concentration of antigen has been achieved
and this lay within a very narrow rango. These observations
are important and the critical ratio of antigen-antibcdy may
explain some of the observed variation in experimental work
in cases of thrombocytopenia. It is hi$ily probable that
such a mechanism existed in Case 65 where apparent sensitivity
to human albumen could be demonstrated by in vitro platelet
agglutination. Certain features of this hypothesis are
Kisdlar to these suggested by Ackroyd (1955*) to explain the
mechanism in drug sensitisation purpura. For this vary
reason further experimental work on similar lines to Hoigne
©t al (1955) and Miescher et al (1956) may be fruitful. If
such a mechanism does exist in ITP it is probable that in
vitro platelet agglutination tests nay be a measure of free
unbound antigen antibody complex. If, however, the soluble
antigen-antibody complex has been bound completely to the
platelets while provoking agglutination' in vivo', no platelet
agglutination phenomenon would be demonstrable in'vitrd.
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This might explain the negative results obtained in this and
other series,and!t would be unlikely that such a mechanism could
be demonstrated other than by direct platelet agglutination
tests or by the use of anti-human globulin serum (Coombs et a]
1945)«
If either of these hypotheses (i.e. abnormal amounts of
normal proteins or an antigen-antibody complex) be accepted,
even tentatively, as an explanation of the pathogenesis of
ITP, some explanation must be offered for their presence,
Stefanini (1955a) has suggested that viruses, bacteria, or
drugs may alter normal protein synthesis in such a way that
the abnormal or abnormal amounts of certain protein fractions
may be produced which will behave as "antibodies". A gross
example of such a 'dyaproteinaemia' is illustrated by the
three oases with cryoglobulinaemia (Cases 52, 53 & 54)
encountered in the present series and may be by the one case
of virus pneumonia (Case 72)# An antigen-antibody reaction
might result from action of viruses, bacteria or drugs on
the platelets, bestowing antigenic properties on these cells by
altering their structure, or, akin to Ackxoyd's hypothesis
conferring antigenic powers on the platelet by acting as
haptens. The resultant antibodies would, when formed, react
with the appropriate antigen, damage the platelets, and so
induce thrombocytopenia. If this is so, in vitro tests
only give reliable results when the patient*s platelets and
not normal plat lets are used as the 'antigenic' material.




Stefanini 195^)• These workers have claimed that they were
able to modify rabbit platelet suspensions in vitro, with drugs,
bacteria, and viruses, so that when the^former were re-injected
into the donor rabbit, it appeared to become imnunised against
its own modified platelets (auto-immunisation) in some instances.
; j
Alternatively viruses, bacteria, drugs or proteins,
antigenic in their own right, may attach themselves to the
platelets and, on reacting with their own specific antibodies,
provoke platelet agglutination and even lysis both In vivo'and
'in vitro.'
That bacteria or other particulate matter may unite with
i i
the platelets has been claimed by Aynaud (1911b), Tocantins
(1938) and Bloom, Gustavsen & Swenson (1955)* Aynaud (1911b)
claimed that bacteria by themselves, directly agglutinated
platelets in dog and rabbit blood. This, he olaimed, was by
virtue of their altering the physico-chemical equilibrium of
the blood. The factors involved in maintaining this physico-
chemical equilibrium have still to be defined.
There is abundant evidence that virus diseases are often
accompanied by thrombocytopenia (Hayem & Bensaude 1901 -
smallpozj Aohroyd 1949&- rubella? Motulsky 1953 - influenzal
Jorgensen 1953 - glandular feveri Belber, Davies & Epstein
1954 - cat scratch disease! Moesohlin, Siegenthaler, Gasser
& Haseig 1954 - virus pneumonia? Hudson, Weinstein & Chang
1956 - measles) and indefinite febrile Illnesses are
quite frequently encountered immediately prior to the onset of
196 -
thrombocytopenic purpura (Robaon 1954).
If it be acoepted that anti-platelet agglutinins or
lysine exist in the blood of thrombocytopenic and certain
non-thrombocytopenic purpuras, it is necessaiy to consider
how they produce thrombocytopenia or purpura. fhey may
induce thrombocytopenia by destructi on of the circulating
platelets in the blood by either lysing the platelets or by
altering them in such a way that they are phagocytosed by
circulating monocytes (Bessie & Tabuis 1954) or by the
reticulo-endothelial system (Bedson 1926), Alternatively it
has been suggested by fooantins & Stewart ^-1939) and Pisciottd
et al (1953) that they may act directly on the megakaryocytes
preventing the normal maturation of the cells and platelet
production. Their action could^of course^be a summation of
these two actions.
The role of the spleen is still controversial. It is
assumed by many that by virtue of its content of reticulo¬
endothelial cells it will destroy the platelets damaged by
circulating platelet antibodies and thus when the spleen is
removed the platelets may return to normal levels. Yet
other oi-gans contain reticulo-endothelial elements and these
should be capable of taking over the phagocytic action of the
spleen. In those cases in the present series where the
platelet agglutination test was performed after successful
splenectomy, the agglutinin had either disappeared or the titne
had fallen. This suggested that the role of the spleen in
197 *
thrombocytopeniC purpura might wall be the production of the
platelet agglutinating factor with or without concomitant
platelet destruction in the organ. This view, of course,
reverte to the original hypothesis of Troland & Lee (1938). It
received some support from the observation of Stefanini
(1955b) who claimed to have isolated platelet agglutinins
from the spleen of cases where agglutinins were detected in
the blood. As he admits, however, this finding might
represent merely a saturation of the tissues by the agglutinatng
factors.
As has already been discussed in the introduction to
Part I of this thesis, thrombocytopenia per se, does not
explain the occurrence of purpura and other spontaneous
haemorrhages in these cases and it is attractive to speculate
whether the anti-platelet fbotors might have some simultaneous
action on the blood vessels themselves. This they might do^
CLnd
as Hayem (1896) suggested by producing blockageAinfarction of
small vessels by the agglutinated platelet masses. Alter¬
natively, if Clark & Jacob's (1950) hypothesis is sustained,
it is possible that vascular endothelium, sharing a common
antigen with the platelets, may be damaged as the
thrombocytopenia is induced.
This discussion of the nature of the platelet agglutinating
factor and the pathogenesis of ITP has bean rich in specu¬
lation, but it has served to show that this subject is far
from being decided as the modem literature has tended to
suggest and it has provided several important hypotheses
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upon which future research may be based,
Whatever the explanation of the pathogenesis of the
idiopathic thrombocytopenic syndrome, it is possible that all
these mechanisms may be involved and if so, it is futile to
aspect one standard technique to demonstrate all theso factor®.
It may well be necessary to use a battery of investigations
in order to determine the pathogenesis of any one case of
thrombocytopenic purpura.
Lastly it is necessary to ascertain whether the knowledge
gleaned from this 4and other series of observations,has pro-
vided the clinician with anything other than a rather ill-
defined academic explanation for the pathogenesis of certain
cases of thrombocytopenic and non-thrombocytopenic purpura.
The present series describes the results obtained using
one particular test to examine the blood from 73 cases of
purpura, and related syndromes, encountered in general
hospital practice in a period of two years. The technique
used, while not difficult, required careful control and is not
yet suitable for use as a routine test. To prepare, on every
occasion, satisfactory suspensions of platelets, siliconed
glassware, and large and multiple specimens of normal blood,
is time-consuming, and not every laboratory staff is willing
to provide the multiple specimens of blood required. It
must be stressed that the use of control samples from so-oalled
normal patients, may bo misleading. In addition, as in so
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many other laboratory testa, it is difficult to maintain a
satisfactory standard and adequate controls. Unless the
technique is being used at frequent intervals, it is doubtful
whether the results obtained can provide information that may
modify clinical judgement of a given case. One exception is
in those cases of possible drug purpura where a platelet
agglutination test may, together with other tests, pinpoint
the offending drug (Case 35)* $he general trend towards a
higher number of positive tests in chronic thrombocytopenic
purpura does suggest that a positive result obtained in the
early stages of the disease may indicate that a spontaneous
remission will not occur. The present series has not con¬
firmed that cases with a positive agglutination test have a
more favourable response to splenectomy than those with
negative results, nor do the results suggest that any fore¬
cast can be made in respect of the response to steroid
therapy. Thus, clinical judgement must still be the
criteria for the selection of therapy in cases of thrombo¬
cytopenia of whatever cause,
A positive result in any given case would, on theoretical
grounds, suggest that platelet or fresh blood transfusions
would be valueless as immediate destruction of the transfused
platelets should take place. Again, however, it would not
•» 300
appear to "be justified to withhold such therapy because of a
positive agglutination test in the recipient. Platelet
transfusions are usually reserved for the control of intract¬
able spontaneous haemorrhage which is endangering life and,
in suoh instances, may improve haemostatic function without
any apparent survival of transfused platelets. Further
platelet transfusion may provoke a spontaneous remission in
the thrombocytopenic recipient (Stefaniai, Chatterjea,
Dameshek, Zannos & Santiago 1952? Creveld, Paulasen & Bartels
1953).
In neonatal thrombocytopenia encountered in children of
normal mothers, the finding of a platelet agglutinating
factor in the mother* s serum my provide evidence upon which
to base prognosis both in relation to the existing case and
to future children. A negative finding would suggest that
some other factor such as infection or congenital marrow
aplasia might be present (Stefaniai & hameshek 1955). It is,
however, by no means certain that it is correct, on the basis
of this test, to give an unfavourable prognosis in regard to
the incidence of thrombocytopenia purpura in subsequent
children, luck a prognosis was given in one case in the
present series, and the subsequent child was, as predicted,
thrombocytopenic. However, the fallacies of the test are
such that this advice might have been misleading. Conversely,
a positive result suoh as obtained in Cases 30 and 34 does
indicate that subsequent pregnancies should be carefully
• 201
observed and deliverer performed in a hospital centre equipped
for providing fresh platelet transfusion.
Therefore, essept in these quoted instances, the
platelet agglutination test does not appear to help the
clinician towards a differential diagnosis in cases of
thrombocytopenic or non-thrombocytopenic purpura, nor does it
aid him in his decision as to the therapy or the prognosis
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The study of immune reactions involving blood platelets
has been complicated by the ability of these cells to undergo
clumping and lysis during the normal physiological process of
blood coagulation. This change is similar to the sequence
of agglutination and lysis which cells undergo when acted
upon by specific immune antibodies and therefore it was of
paramount importance to separate these two phenomena. Many
workers have tried to circumvent this problem by evolving
techniques to detect anti-platelet immune antibodies that did
not necessitate the measurement of platelet agglutination.
These, while apparently giving reliable results in the hands
of their originators, have tended to be unreliable in the
hands of other workers. Platelet agglutination techniques
seem to provide more reproducible results.
The factor or factors that control physiological platelet
agglutination during the sequence of blood coagulation have
been the subject of controversy, and a fuller understanding
of these factors had to be reached before any analysis of the
results of other workers could be made, or a suitable technique
evolved, for measuring immune platelet agglutination. The
experimental results detailed in Part 1 of this thesis have
advanced our understanding of physiological viscous
metamorphosis (VM). The latter would appear to be an
- 203 -
important feature of "blood coaxial-ion as it is the first
visible change that takes place in shed blood and precedes
fibrin formation by approximately two minutes. During VM
the platelets would appear to release granular material which
is thought to supply their contribution to intrinsic plasma
thromboplastin generation.
It is the belief of many workers that thrombin, and
thrombin alone, is always responsible for Tin. Purified
human thrombin has been shorn in Chapter V to bo capable of
producing VM in the presence of a labile co-factor attached
to the surface of the platelets. Bounameaux (1957 a & b) and
Luaoher (1957) have evolved an attractive hypothesis, based
on the observed concentration of coagulation factors on the
surface of the platelets. They believe that coagulation
starts on the surface of the platelet, as in whole blood, and
that trace amounts of thrombin are generated rapidly on this
surface which will induce the full sequence of VM in platelets
long before fibrin appears. If this is true, in severe
haemophilia and Christmas disease, the plat-lets are probably
as deficient in antihaemophilie globulin or Christmas factor
as the surrounding plasma. Therefor® it is unlikely that
thrombin could be generated rapidly on their platelet surfaces.
However, during the experiments performed on platelet-rioh
native plasma obtained from severely affected oases of
haemophilia and Christmas disease, VM took place within minutes
of the blood commencing to clot. In addition, heparin, a
potent anti-thrombin, also failed to inhibit this early VM
*20!f *
except when used in high concentrations. Thus the
Bounameauxs-Luscher hypothesis cannot he sustained.
This property of thrombin is dependent on the assumption
that the human thrombin used in these experiments was
functionally pure. It is by no means certain that this was
so, for it cannot be ruled out that this thrombin does not
contain other factors which might be capable of producing VM
independently from the conversion of fibrinogen to fibrin by
thrombin itself. The factor in fresh serum, which will
induce VM in washed platelet suspensions, has still to be
Identified, but it was not shown to be thrombin. It could
be the same as the intermediate product of thromboplastin
formation, as suggested by Bergsagel (1956), and this latter
factor could also be present as a contaminant in the 'pure*
human thrombin used in these experiments,
Bergsagel (1956) considered that VM was induced by an
intermediate product of thromboplastin formation which was
the result of an interaction between antihaemophilie globulin
and Christmas factor and calcium. He did not think thrombin
had amy action in the platelets. If this were correct, VM
should not take place in clotting platelet-rich plasma derived
from cases of haemophilia or Christmas disease. The present
experiments have shown clearly that this was not so, and
therefore Bergsagel1s hypothesis could not be confirmed.
Repetition of Bergsagel's experiments has suggested that
the VM factor in his mixtures was thrombin, but it cannot be
- £05-
excluded that the thrombin converted fibrinogen to fibrin,
incidental to the VM, and that Bergsagel' 3 observations were
the result of yet another, as yet undetermined, VM factor,
similar or identical to that responsible for the produet ion
of VM by serum or in the initial stages of blood coagulation.
This study of VM, and the factors which control its
evolution, have tended to complicate rather than simplify the
problem of differentiating immune platelet agglutinins from
those involved in the blood coagulation process, but it has
been possible to demonstrate that the morphological appearances
of VI are different from those of immune platelet agglutina-
tion. From the experimental data obtained during this study
of the behaviour of platelets in blood coagulation, it was
possible to decide upon a technique to measure platelet
agglutinating factors, which excluded all known coagulation and
non-specific factors which might produce platelet dumping.
Whether other VM factors might exist which, although not
present in normal serum, might be found in serum derived
from thrombooytopenic blood, but if this were so, all sera
prepared fro® thrombocytopenic blood should be capable of
inducing platelet olumping after appropriate treatment to
exclude known VM factors. This was not found to be the case.
1 ' '
to order to ootoblioh -other this ttooretlooUy o^toom
platelet agglutination test was of practical use, a series of
tests using normal sera was performed. Platelet suspensions
i v-v V ;
were prepared from the sane normal donors as the sera, and, by
cross agglutinating these sera with the platelet suspensions
in groups of ten, it was possible to observe whether normal
- 206 *
sera could agglutinate normal platelet suspensions. This
exercise provided a great deal of useful information, as a
surprisingly high number of positive results were obtained.
Certain platelet suspensions were more readily agglutinated
than others, and this suggested that some group structure
existed on the platelets.
Using specific anti-A and B sera, it was confirmed that
A and B antigens of the red blood cells were shared by the
platelets. Yet only very high titre sera were capable of
provoking direct agglutination and not all platelet suspensions
from group A and B donors could be so agglutinated. This
failure to agglutinate appeared to be confined to those
platelet suspensions from group A and B donors who were non-
secretors of A and B substance. This led to the conclusion
that the A and B antigenicity of platelets might be due to
A and B substance from the plasma on to the platelet surface,
but this hypothesis was not confirmed by the mixed red cell-
"v
platelet agglutination technique devised by Coombs & Bedford
(1955)* This showed clearly that the non-secretors, as well
as secretors of A and B substance, carried the A and B antigens
on theix* platelets. After excluding those positive
agglutination tests which oould be explained in terms of ABO
incompatibility, a significant number of positive results
still remained. The Rhesus antigen D and the Porssman antigen
were not found to be present in the platafets and there was no
evidence that any other known red cell antigen was shared by
- 207 -
■the platelets. Therefore it was considered that these
remaining positive results might represent a separate platelet
group system, or were simply false positive results. A
theoretical platelet group structure was composed from these
cross agglutination experiments, hut it has not heen possible
to confirm this serologically or by transfusion studies.
When sera were prepared from patients with thrombocyto¬
penic and non-thromboeytopenic purpura and related conditions,
and tested by the platelet agglutination test, a much higher
I
incidence of positive results was obtained than when normal
sera were used. The distribution of the results was somewhat
haphazard, but there was a higher incidence of positive
results in those sera from oases of long standing thrombo¬
cytopenic purpura and from the mothers of infants with
neonatal thrombocytopenia than in other groups. These
results were not thought to be a measure of a physiological
VM factor, as morphologically this platelet agglutination
was similar to that produced by immune sera. Therefore it
was possible that these positive agglutination reactions
could be a measure of immune platelet agglutinins and so a
confirmation of the hypothesis of immune mechanisms in the
pathogenesis of thrombocytopenic purpura.
Why positive results should not be found in all cases of
'
idiopathic thrombocytopenia and why certain other techniques
have failed to give reproducible results, remains a mystery.
Various explanations have been discussed in the previous
chapter and it must be concluded that more experimental work
must be performed before these problems can he answered.
- 208 „
Disappointinglyi an analysis of positive results
obtained in these cases did not appear to offer any advance in
our knowledge of the pathogenesis of these conditions, nor
provide any guide as to appropriate therapy. The platelet
agglutination test may assist in assessing the prognosis of
an individual case and this is especially true for cases of
neonatal thrombocytopenic purpura.
To summarise, this thesis has established:-*
(1) that two types of platelet agglutination exist,
namely physiological agglutination or VM, and immune
agglutination, and that these may be differentiated morpho¬
logically:
(2) that VM of platelets is an essential feature of
the sequence of blood coagulation and that during this process
the platelets release material essential for thromboplastin
formation!
(3) that while thrombin does appear to be capable of
promoting typical VM, it is not the only factor that can do
so. At least two others must exist, one in the initial
stages of the sequence of blood coagulation requiring the
presence of Rosenthal's factor (P.T.A.), the other in fresh
serum}
(k) that it is possible to destroy or neutralise all the
VM properties in a given serum. Therefore, if this serum
will then produce platelet clumping, the latter must represent
some process, other than VM|
- 209
(5) that platelets do carry the ABO antigens according
to the red cell group of the original bloodf
(6) that a theoretical platelet group structure can he
devisedj
(7) that sera derived from oertain cases of idiopathic
thrombocytopenic purpura do contain platelet agglutinating
factors, hut it has still to he demonstrated beyond all
possible doubt that these are specific platelet immune
antibodies. Alternative explanations for the existence of
these factors have been discussed.
Therefore this thesis has established its original purpose,
namely to study viscous metamorphosis and platelet agglutina¬
tion in order that the techniques of other workers could be
analysed and a test devised to measure platelet agglutinating
factors, other than those concerned in the sequence of blood
coagulation, in normal and abnormal blood.
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APPENDIX A
REAGENTS AND TECHNICAL METHODS
Qlasa Washing?
All glassware used in the experimental work described in
this thesis was cleaned as follows:
Tubes and pipettes were given a preliminary wash using
warm tap water oontaining a few drops of detergent ('Teepol* -
Shell) to remove any residual plasma, serum, whole blood, or
other proteinaceous material.
Following this preliminary wash, the glassware was rinsed
in clean tap water and then stored prior to bulk washing.
Bulk washing of tubes and glass containers, other than
pipettes, was carried out by boiling the glassware in dis¬
tilled water containing a small amount of 'Brylyana' (George
T. Qtixa for 15 minutes. The glass was then washed
thoroughly inff/1000 hydrochloric acid and rinsed thoroughly
in several changes of tap water. Final rinsing was performed
in distilled water and the glassware dried at 37°c»
Pipettes were washed in several changes of tap water
and distilled water by suction. A final rinse with acetone
eradicated all traces of moisture.
When glassware was unusually dirty it was immersed for
at least 24 hours in concentrated chromic acid (3.6 ml.
saturated sodium diohromate in 96.4 ml. concentrated
sulphuric acid).
Preparation of Sillooned Glassware
Clean glass surfaces were siliconed by the application
of a varnish silicone, SS, 1107 (Midland Silioones Ltd.)
diluted to 5$ in carbon tetrachloride*
The glass containers or pipettes to be siliooned were
filled completely with diluted silicone. The silicone was
then discarded into ite original container and excess silicon
allowed to drain onto filter paper. The siliooned glassware
was first dried at room temperature and then baked in a hot
air oven for 1 hour at 100®C, This process produoed a
perfect non-water wettable surface.
All glassware was resiliconed each time it was used.
The siliooned glassware must be handled separately from
ordinary glassware used for coagulation or biochemical
This is due to the property of silicones to spread and coat
all surfaces such as sinks, washing brushes and other glass¬
ware. This was found to be true for the present type of
varnished silicone. One sink, test tube brushes and
rinsing buckets should be reserved for siliooned glassware
only.
Anticoagulants
Trisodium Citrate (Aaalar) 3.8$ w/v.
9 ml. of venous blood was added to 1 ml. sodium citrate
and mixed thoroughly.
Sodium Oxalate (Anala?) 1,34$ w/v.
9 ml. venous "blood was added to 1 ml. sodium oxalate and
mixed thoroughly,
Pisodium Verssne (•Sequestrene* j Bisodiua-ethylene
diamine tatra-acetic acid). (d. Light & Co., Colnbrook, Backs).
4.5$ Vv isotonic.
9.7 »1. venous blood was added to 0,3 ml.' disodium
veraene and mixed thoroughly.
Heparin (Boots Ltd.)
Ampoule 5>000 u/ral.
This was diluted in normal saline to obtain the
concentrations defined in experiments (Appendix B).
'Jhroffibodvm fHeodymnium 3-sulpbo-iso nicotinate).
2.5$ solution in ampoules. Auer Laboratories, Berlin.
Dilutions were mad© in isotonic saline.
Soya Bean Trypsin Inhibitor (Pure Crystalline; Kunitz 1945)
was provided for experimental use by Dr. R.G. Maefarlane.
Calcium Chloride (Analar)
Molar CaCl2 contains 1 gramme molecular weight or 111
gms/litre.
Anhydrous CaClg was dissolved in water to give solutions
of strengths m/10, m/20, M/40. As only approximately 65$ of
this anhydrous salt goes into solution, the solution was
made up to give more than the desired strength and the Cl-
oontent titrated with standard silver nitrate. From the
calculated concentration of CaCl2 appropriate dilutions were
made to give the exact Molar strength required.
Barium Sulphate
X-ray barium sulphate was washed prior to use as a
I
plasma or serum absorbent. Failure to do this resulted in a
fine opalescence persisting in the serum or plasma following
absorption whioh in turn led to widespread inaccuracies in
subsequent experiments.
1 lb. x-ray barium sulphate was therefore added to 2
litres 0.005M trisodium citrate and the mixture stirred
thoroughly. After being allowed to sediment for 5 hours at
room temperature, the opalescent supernatant was removed and
the sedimented barium sulphate resuspended in a further 2
litres of 0.005M sodium citrate. After 5 hours the
opalescent supernatant was removed and the residual sediment
filtered through coarse filter paper (Whatman No. 3). fhe
precipitate was dried in the hot air oven for 8 hours at
100°C, ground into a fine powder in a pestle and mortar,
redried, reground, and stored for use in a glass bottle.
For optimum absorption of prothrombin, Christmas factor
and factor VII, this washed powder was used in the proportion
of 200 mgms. barium sulphate/milli-litre of oxalate plasma or
serum. (Barium sulphate will not absorb these factors from
citrate plasma). After allowing the powder to stay in
suspension in the plasma or serum for 15 minutes at room
temperature, it was removed by high speed centrifugation
(3600 g for 15 mins.). The absorbed plasma or serum was
pipetted off, taking care not to resuspend the barium.
Aluminium Hydroxide Gel was mad® accordicg to the method of
Biggs & Macfarlaae (1953)•
For absorption of plasm or serum 0.1 ml. gel was added
to 0.9 ml. plasma or serum, mixed thoroughly and allowed to
stand for 3 minutes at 37°C. The aluminium hydroxide was
removed "by high speed centrifhgation at 3®00 g for 15
The supernatant plasma or serum was pipetted off.
Imidazole Buffer (Marts & Owen 1940)
1.72 go. Imidazole was dissolved in 90 ml. l/lO BC1 and
diluted with water to 100 ml.
Citrate Saline (0,85$)
0.85$ saline containing 0.00751 trisodium citrate
Dextrose Acetate Saline (MS) (Tullis 1953b)
This fluid, used for washing platelets free from plasma,
was made up as follows!
L-Dextrose 5 gms.
Sodium acetate 0.2 gms, (CHyCOOSTa^HgO).
Sodium ohloride 0,8 gas.
Fresh distilled water to 100 ml.
This solution was sterilised in small volumes by
autoclaving for 10 minutes at 15 lbs. per square inch.
It was found convenient to sterilise and store this
balanced salt solution in 20 ml. amounts and to disoard any
unused solution after each experiment as contamination
frequently occurred when the bottle was opened.
Gelatine (Davis Sparkling Granulated Gelatin. Davis
Gelatine Ltd., 29 Mitre Street, London, E.C.3.)
This was dissolved into warmed MS to make 2 or 5$
solutions w/v.
These were provided by Dr. E. Bidwell. They were
prepared by the methods described by her in 1955- (Bidwell
1955a & b). Ih the present experiments the strength of any-
given solution is expressed as might of protein/ml. This was
not a true expression of the actual antihaernophillo globulin
(A.H.G.) activity of any batch but provided a convenient
method of experimental ooraparisGn of one species concentrate
with another. The lyophilised concentrates were dissolved
in an appropriate volume of distilled water. Any subsequent
dilutions were sad© with isotonic saline.
Human Thrombin
This was prepared from human plasma using the method of
Biggs & Macfarlane (1953).
The strength of thrombin in the final lyophilised
extract was 23 thrombin units/mga. For every mgm. of
thrombin 1 ml. distilled water was added to reconstitute the
the thrombin into solution (23 u/ml). Any further dilutions
were made with isotonic saline.
Human Fibrinogen was prepared according to the method of
Jagues (1943)- (Quoted by Biggs & Macfarlans 1953* P.3A?).
Bovine Thrombin. Maw's Topioal, 200 u/ml. This was dissolved
in the provided diluent and diluted for use in 0.85$ saline.
glass Contact
Small glass ballotin i, 0.1 rasa. In diameter, were acid
washed in dilute hydrochloric acid and subsequently washed
jeIO in distilled water.
>y tH .v- - , "f y . V-■ yy, ^ - i ... i . • .
In order to augment glass contact surface experimentally,
m equal volume of glass ballotinae was added to 1 ml amounts
of platelet suspension, plasma, or whole blood,
Siliconed Glass Beads were siliconed as ordinary glass tubes
(see Appendix A, p. Z> ).
Brain Extracts
Saline Extract of Brain
fhe meninges were removed from & normal human brain and
both cerebral hemispheres less cerebellum, pons and medulla
were emulsified in 1500 ml. 0.35$ saline in a *Waring Blender'.
Acetone Extract of Brain was prepared by the method of
Biggs and Macfarlane (1953).
Chloroform Extract of Brain was prepared by the method of
Ball & Alton (1954)«
Russell's Vieer Venom. ('Siypven'. Burroughs Wellcome Ltd.).
fhe lyophilised extract was dissolved in the solvent
provided and subsequent dilutions made with isotonic saline.
Zeo Carb. 215 (Fermutit)
Cation ion exchange resin .100 rages, of this rosin were
added tc each 1 ml. serum and allowed to act for 60 minutes at
room temperature. Such sera was found to contain 0,9 - 1.3 mgra.
calcium/100 ml, and to have a pH of 5.4 - 5*3 (Doran pH meter)
after adsorption for this period*
jg££ was dataradaed by using tba Boran Electric pH rsatar.
Bough dstarndnatiais mx& mM using B.D.B. universal indicator.
It was found convenient to add 1 drop ef tost solution to
1 drop indicator on a white til# Which had "been thoroughly
. • '• ' • •" * '• -
washed in neutral distilled water bafemhand.
I '• ; "■■ V''; '•! - • ■ > • •' ' ': •; '• 1! * <■ • '•' '■ : : ; • '
agUM nmtm
©#1 s&» of platelets mm Added to 1 ad. 13$ neutralised
salt formalin. After 5 -tauten the platelets were spun down
at 3600 g.and the supernatant fixative rawveft. The
platelets war® resuspesded in 0.2 nl Isotonic dextrose ecet&ta-
saliae for oicrosoopic eawataatim.
Cofijratrt ,^oyyfi<gg
The morphological changes of platelet viscous oet&mrphosis
and agglutination mm observed in every instance by phase
contrast sicroaeepy* fbr routine aorphological study, a
Cooke, Tropica, & 3is» phase contrast Microscope was used
using X200, 73tOO and X950 salifications. The light source
was conventional unfiltered direct illumination from a CT3
lamp*
% *
This Irs performed either using the above microscope or
a Zeiss Phase Contract Microscope (access tc the latter was
granted by Br. Pirie of the Nuffield Bye Laboratory).
Photographs war® taken using 35 film in a reflex Pwfctiflex
camera*
Kodak 'Rekordat* microfilm was used and developed in
fine grain developer (Promicrol - May & Baker). Developing
time 12 ruins, at 68°C, l!his allowed 50$ more developing
• v ' " """ '
time in order to achieve adequate contrast in the negative.
The films rere fired, washed and dried by conventional
methods, Kodak 'Recordat* is ideal film for 55 mm. photo¬
micrography as its very fin© grain allows good enlargements
to he produced.
Enlargements were made on Kodak single weight glossy
hroiaide paper.
Developer. Johnston© Universal diluted as for bromide
paper. Fixation using 'Amfix*.
(The prints, used as illustrations in this thesis,were printed
by Mr. A.M. Blackwood of the Department of Anatomy, University
of Oxford, froia negatives provided by myself).
The Method Used, to Btu3y the, Morphological Changes of Platele-jf
Viscous Metamorphosis and Agglutination
As these changes evolved in the experimental systems
used in their study, 3©rial samples were removed and either
examined immediately or fixed (Appendix A, p. S ) for
subsequent study.
A drop of either preparation was added to thoroughly
cleaned glass slides and covered with a elean ccverslip. In
order to obtain satisfactory phase contrast the field to be
examined had to be thin and all movement inhibited. This
was achieved by inverting the slide plus plasma and ooverslip
onto filter paper and applying firm press-ore for 10 seconds
with a clean cloth on the under surface of the slide. Excess
plasm was expressed onto the filter paper. The preparation
was now placed, coverslip uppermost, on the microscope stage
and examined. If prolonged examination was required the
preparation was sealed with a vase1 lne-paraffln wax mixture.
Phase contrast microscopy (Appendix A, p. 8 ) was used both
for visual said photographic study of these changes.
Relative Centrifugal Force or g was determined according to
the following formulat
S 03% )2 H * revolutions per minute
R « radius of centrifuge head
(spindle to centre cf bucket)
in cms.
Platelet; Counts
These ware performed by the method of Brecher & CronkiteI . , • • ■ *•+
(1950) using 1$ ammonium oxalate as diluent.
A 1/20 dilution of capillary or venous blood, platelet
rich plasma or washed platelet suspension was made using the
above diluent.
An improved leubauer counting chamber was filled with
the diluted platelet suspension and the number of platelets
in 16© squares each l/j+00 of a square mm., counted using
either direct microscopy or, in all experimental work, phase
contrast microscopy. The depth of the counted area was 0,1
Romaa! range 2-300,OOO/cu.mm.
Bleeding flutes were performed "by ihemethod of Ivy (Biggs &
Maofarlane 1953) • Normal - up to 5 minutes.
Occasional bleeding times on patients under the caro of
the Nuffield Medical Unit were performed by Duke's method
(Duke 1912).
Capillary fragility was estimated by the application of a
sphygmomanometer cuff around the upper arm at a pressure of
90 mm* of mercury for 5 minutes. After releasing the
pressure the number of fresh petechias appearing in 1 minute
in an area 6 cms. in diameter over the anteoubital fossa
were counted. Abnormal capillary fragility was considered
to exist if more than 10 fresh petochiae were present in this
area
Whole Blood Clotting fino was performed "by the method of Lee
& White (1913)* Normal - up to 10 reinutes.
Prothrombin Consumption Index was derived from the results of
the method of Merskey (1950). Normal 0 - 20$. (Originally
0 - 40$).
■
ffhromboplaatin Generation Test was performed as described by
Biggs & Douglas (1953)• Test plasma or serum fractions were
compared with normal controls in each instance.
Platelet Bjch Native Plasm
Venous blood was obtained using a 30 ml. silicone! or
paraffin oiled syringe and clean No. 1 stainless steel needle,
A rapid clean venepuncture was essential.
fine "blood was added immediately to cooled siliconed
tubes and cooled rapidly "by immersion of tlio tube into
melting C3eushed ice contained in a thermos flask* Ho anti¬
coagulant was added at any stage* After 5 minutes cooling,
the cooled blood was transferred to a refrigerated centrifuge
previously cooled to 0°C. The red cells were separated by
spinning at 11,00 g for 10 minutes at 0°C and the platelet rick
supernatant plasma transferred to a further cooled siliconed
centrifuge tube in crushed ieej a siliconed pipette was used
for transfer.
Platelet-Prae Hatyre Hagaa,
fbe whole blood was obtained as above and transferred to
the refrigerated centrifuge. fo free the plasm from all but
the occasional platelet the blood was spun at 20,000 g for
15 minutes at 0°C in a siliconed high speed centrifuge tube.
The platelet-free native plasma was transferred to a further
siliconed tube in crushed ice.
It was also possible by this method to obtain native
plasma free of chylomicra. These minute fat particles rise
to the surface on high speed centrifugation. On cessation
of centrifugation, the infranatant plasma is removed rapidly
before the fat resuspaada in the plasma.
Both platelet rich and platelet-free native plasma
remained unclotted for several hours if kept at Q°C.
A13
Native Plasma
Both platelet-rich and platelst-free native plasma would
Clot when added to glass tubes at 37°C. The clotting tirao
of platelet free plasma was prolonged.,
Platelet-Rich Citrate Plasma
Venous blood was obtained using a rarafftn oiled or
siliconed syringe and No. 1 stainless steel needle.
9 ml. venous blood was added to 1 ml. 3*8$ sodium citrate
in a siMooned centrifuge tube and mired thoroughly, Uha
decalcified blood was centrifuged at 1400 g for 15 minutes
at room temperature and the platelet-rich plasma separated
and placed in a siliconed tube.
Platelet-Rich Oxalate and Pisodiua Versene Plasma
These were prepared in a similar manner to platelet-rich
citrated plasma.
(a) 9 ml. venous blood was added to 1 ml 1.3?)-$ sodium oxalate
(b) 9.7 ml. venous blood was added to 0.3 ml 4.5$ disodium
versene.
Siliconed glass was used throughout.
Washed Platelet Suspensions
Platelets were separated from platelet rich disodium
versene plasma in a siliconed conical centrifuge tube by-
spinning at 42)0 g for 15 minutes. The platelets were
packed into a button at the bottom of the tube and the
supernatant plasma pipetted off. The final traces of plasma
wax's removed by inverting the tube on filter paper for
Aik
5 Eiiititoa. A Tilvsm of \n%siixi»$ fluid (aerfceoas aoetate
•aline 3. 5 unless otherwise stated) equal to half tte
original voluo® of platm was added to the platelets^ and the
latter raauspon&od "by agitation. further c^trifustian at
42 X g for 15 milsitae repacked the platelets a«d the miner-
n&iant m»Mn$ fluid was discarded,
fhie prcoess was repeated until the desire rurter of
UMBhtttftft had teen yerforsad,
11.10 platelets were rseua 'er^ad finally in a eruffieient
volume of sal in© or deatroae-ftcstate-iialiiis to produce a final
platelet density cf 200-300tQCO platelets /cu.ss,
Active Sorsol (see Chapter 2V). (Active VI ftetor)
PlriteloterSofe native s&sosei prepared aa on p,
was alleged to ©lot at and fbllcMtaer tte appearafflce of
fibrin was incubated for 2 hours at 37°C t© destroy any
uauaed ttosrahiiu ffca fibrin was sesasved and ©stressed
seotoiioally In order that all sen®, we aapcaasad fsara tte
olot. fhia ©eras was tested for its ability to induce VM
in maad wasted platelet#.
A test sttspsasion of waoted platelets wa.g pwoarad from
normal blood. The platelets wore wanted x3 in dextrose**
aoatatu-selins (Appendix A, p. 5 5 and the final msuspension
m£b ix\ de^roco-tM^oto-^alino containing 2$ grlstine
(Appendix A, p. 6 )*
feat Saras ### prepared from whole blood derived from the oaae
to "bo investigated. 10 - 20 ml. venous blood was collected
into sterile universal containers and stored at 37°C for
18 hours. The serum was separated and, either tested
immediately, or stored at -15°0 before testing. On the day
of testing the serum was heated to 56°C for 1 hour in a
thermostatically controlled water bath. Then each sample
was absorbed with barium sulphate powder to remove all
residual prothrombin, together with Christmas factor and
factor VII. The powder was added in the proportion of 200
ragas/ml serum and was allowed to act for 15 minutes at room
temperature. The barium powder was removed by centrifuging
*2.
at XOQ g for 15 minutes.
h&ltV rv <1*i
o* ....
0,2 ml. treated test serum was added to 0,2 ml washed
ft
normal platelet suspension and incubated at 37 c for 2 hours.
The contents of each tube was then examined for the presence
or absence of platelet agglutination by phase contrast micro¬
scopy. It was found that any longer inoubatioa would produce
non-speeifio agglutination. Thus, if it was inconvenient
to read the results at the end of the initial period of
incubation, the tubes were plaoed in the refrigerator at
0-4°C. At this temperature the gelatine set solid and
preserved the platelets in their agglutinated or non-
agglutinated state. The tubes were reincubated at 37°C for
15 minutes prior to reading the results.
Sera for testing were stored until at least 3 samples
were available and each serum was tested against four
separate suspensions of normal platelets* In addition at
least one normal control seium was tested against the same
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tests the final results
























Possible Sensitivity to Drugs
in Cases of Thrombocytopenic Purpura
In eases of thrombocytopenia, where it was suspected that
drug sensitivity played a part in the aetiology of platelet
destruction, blood was tested in vitro using the following
techniques.
Platelet Agglutination Test.
The patient's serum was tested as in the conventional
agglutination test with the exception of the addition of a
solution of the suspected, drug in O.t ml. amounts.
In patients whose platelet count had returned to normal
following withdrawal of the drug, the following tests were
also performed.
(1) Rapid Platelet Agglutination Test
To 0,5 ml. platelet rich versene plasma was added 0.1 ml
of a solution of the suspected drug. The mixture was in¬
cubated at 37°C for 60 minutes* The presence or absence of
platelet agglutination was then determined. Control
samples of normal platelet-rich versene plasma plus drug or
saline and patients platelet-rioh versene plasma and saline
were also tested. If drug sensitivity existed strong
agglutination developed within 15 minutes.
(2) Clot Retraction Test
1 ml. amounts of the patient's rich plasma were added to
1 ml. IS/40 calcium chloride together with 0.1 ml. of a
solution of the suspected drug. The plasma was allowed to
clot at 37°C and incubated for 1 hour at that temperature.
The degree of clot retraction was then recorded as normal
or inhibited. It was apparent that if dot retraction were
inhibited due to drug sensitivity, it was inhibited completely
Control normal platelet-rich plasma was tested in parallel.
In all these experiments test drugs were mads up in solution
to give a final concentration of 10 mgas/ml. If partially
insoluble, each drug was made up as a saturated solution and




Certain drugs, whan dissolved in solution, wore acid in
reaction, Thasa acid solutions were capable of agglutinating
both washed platelet suspensions and platelets in versene
plasma non-specifically, Porther, they inhibited clot
retraction in reealcified platelet-rich plasma. When these
acid solutions were encountered, the drug was redissolved in
dextrose acetate saline containing an equal volume of buffered
Imidazole buffer (pH 7»3» Appendix A, p. 5 )•
non-specific platelet agglutination resulting from the
'
addition of this buffer (p. 151 ) could be ignored in these
- ■-.*
tests where a positive result was accompanied by gross
platelet agglutination.
Tanned Bed Call-Platelet Protein Agglutination Test
(Kissmeyer Nielsen 1953)
Red Cells.
Human group 0 erythrocytes free from platelets were
obtained from defibrinated normal blood. These cells were
washed three times in 0,85% saline and resuspended in 0,85%
saline (buffered to pH 7.2 with phosphate buffer) to give a
2,5% concentration of cells.
Tannic Acid Treatment of Bed Blood Cells
One volume of this red cell suspension was added to one
volume of tannic acid (B.D.H. 1/40,000 w/v in fresh 0.85$
saline). The mixture was incubated at 37°C for 10 minutes
and the red cells separated from the tannic acid solution by
centrifugation and washed once in buffered saline (pH 7*2).
The red cells were resuspended finally in 0,85$ saline in a
2$ concentration.
Antigenic Extract (Platelet Protein)
Platelets were separated from platelet rich citrate
plasma and resuspended in 0,85$ saline (glass tubes were used
instead of siliconed tubes). The final resuspension of
platelets was made in 0.85$ and frozen at -20°C and thawed.
The process was repeated three times and the platelet debris
removed by spinning at 42 00 g for 15 minutes, The super¬
natant was used as the 'antigenic extract'.
Combination of Tamed Red Ceils with Platelet Protein
One volume of a 2.0$ suspension of tanned red cells was
added to one volume of protein extract and one volume of
phosphate buffer to give a pE of 5,4*
The mixture was allowed to stand for 30 minutes at room
temperature. Then the red cells were separated by
centrifugation and washed twice in normal rabbit serum diluted
1/100 in 0,85$ saline. The final resuspension of these red
cells was made in 1/400 normal rabbit 30rum to give a 1$
concentration.
Test Serum was inactivated at 5€°C for 30 minutes,
*£S*
Doubling dilutions of 0,1 ml volumes of test sera were
made in saline and 0,1 ml. 1$ tanned-platelet protein red
oells was added to each dilution.
The mixtures were incubated at room temperature for
2 hours and then stored at 0 - if°C for 18 hours or overnight,
The presence of absence of red coll agglutination was then
determined microscopically.
Controls
(1) Tanned-platelet-protein red cells + normal serum.
(2) lorraal untreated red cells + test serum.
(3) Tamed normal red cells + test serum.
Platelet Agfdutinatjon Test 'Methods d'agitation'
(Dausset 1954)
Platelet-rich versene normal plasma was prepared as
described in Appendix A, p. _
Serun from the patient or control was heated at 5^0C for
30 minutes.
Test
1 ml. test serum was added to 0.1 ml platelet-rich normal
versene plasma contained in a ailiconed glass tube. The
mixture was agitated in a Kahn shaker for 30 minutes at 3?°C.
Aliquot samples were then removed and observed by phase
oontrast microscopy.
The presence or absence of alternations in platelet
morphology wore recorded.
In Bausset's original paper he stated that he added 10 ml
test serum to 0.5 nil platelet rich plasma. These volumes
were found to be excessive and the above concentration of
platelets produced an optimum density for microscopic
examination.
Complement Fixation Test for Platelet Antibodies
Antigen. A three times washed suspension of normal
platelets was prepared from platelet-rich versene plasma as
described on p.13.0a final r©suspension the platelets were
resuspended in the least diluent to give a concentration of
500,000/OU*EBB.
Test Serum from patients, normals, or rabbits was
heated at 5<>0C for 30 minutes to inactivate natural
'Complement'.
Complement was provided as fresh guinea pig serum used
undiluted.
Haemolytio System
Sheep red blood cells separated from oxalated blood were
washed x3 in saline and following the final wash the red cells
.
were packed by centrifUging at 800 g for 20 minutes.
0.75 ®1» packed red ceils were added to 25 ml» saline to
give a 3$ suspension.
0,13 ml. haemolytic serum was diluted in 25 ml. saline.
Equal volumes of the 3$ sheep cell suspension and
haemolytic serum were mixed and incubated at 37°0 for 20
minutes and used on the day of preparation only.
To detect the presence or absence of Complement, 2
volumes of this suspension were added to 1 volume of each
test mixture.





0.5 ml. test serum was added to 0.1 ml. platelet
Each tub© was then spun at high speed to remove all platelets
and 0.2 ml. of the supernatant was diluted -§■ and ;§- and,in
doubling dilutions of these, to a titre of 1/512.
To each dilution was added 0.4 ml. of the haemolytio
system and after incubation at 37°C for 30 minutes the titre
of residual Complement was determined as described in
Appendix B, p. 4.
. ,
The following control mixtures were tested in parallel*
Control (1). Test Serum 0.5 ml.
M (2) Complement 0.1 ml.
Saline 0.6 ml.
" (3) Saline 0.5 ml.
Platelet Suspension 0.1 ml.
Complement 0.1 ml.
" (4) Test Serum 0.5 ml.
Complement 0.1 ml.
Saline 0.1 ml.
« (5) Serum 0.5 ml.
Mixtures 3 and 4 were designed to measure any anti-
Complementary activity on the part of the platelets or serum.
Mixtures 2 and 5 gave a control for a comparison of
the amount of Complement consumed in the actual test mixture.
Saline 0.2 ml
Complement 0.1 ml.
fashed human red cells 0.1 ml.
In all examples where human sara tested in this system
no Complement was found to he fixed by the seroia-platelet
mixtures.
When rabbit antisera containing a high titre of human
platelet agglutinin were tested, Complement was fixed, there
being no residual Complement left following incubation of the
test mixture. Control mixtures contained residual
Complement,
The results of such an experiment is illustrated below.
Mixture Tltre of Residual Complement







Suspensions of washed normal human platelets were
prepared as on p^|.l3.To 0,1 ml. of these suspensions were
added 0,1 ml, amounts of anti-human globulin sera diluted
l/2, 1/10, and 1/100. The mixtures were incubated for
30 minutes at 37°G and the platelet suspension examined
by phase contrast microscopy.
A24
Mixed Bed Cell Platelet A^lutinatlon Test




A washed suspension of normal human platelets was pre¬
pared as described in Appendix A pJ3 fro® Group 0 donors.
Test Sera from nomale and patients with apparent
platelet agglutinins were treated by heating at 5^°" for
30 minutes only.
Sensitised Bed Blood Cells
Bed blood cells were separated from venous blood samples
from Group 0 Rhesus positive donors. These cells were
washed three times in dextrose acetate saline solution (DAS)
and finally resuspended in a 2$ solution in DAS.
To 1 ml, of these cells was added 1 ml. of a 1/10
dilution of anti Rhesus serum (anti D) containing an incomplete ~
non-agglutinating antibody, (supplied by Br. M.M. Pickles).
The mixture was incubated for 1 hour at 37°C. The sensitised
red cells were then separated by centrifuging and washed x3
in DAS.
Anti-human Globulin Rabbit Serum (diluted 1/10) was
supplied by Dr. M.M. Pickles.
Test
3 drops of platelet suspension were added to 3 drops of
each test sera and the mixture incubated for 1 hour at 37°C.
The platelets were then deposited by oentrifuging at
2800 g for 5 minutes. The supernatant fluid was removed and
the platelets in each tube washed three times in DAS and
finally resuspended in 1 drop MS. fo each tube was added on#
drop eensitised red blood cells and one drop diluted anti-
human globulin sera.
The mixtures were centrifuged at 2800 g for 2 minutes
and the platelet-red cell mixture resuspended.
Each tube was examined by phase contrast microscopy for




Purpose, To study the relationship of platelet viscous
metamorphosis to fibrin formation in normal and abnormal
plasma.
Method
Platelet-rich native plasma was prepared as described in
Appendix Af p.11, from normal blood and from blood derived
from patients with known specific congenital or aoquired
coagulation defects.
In every instance 30 ml. syringes and Ho, 1 stainless
steel needles were used in order to standardise experimental
conditions,
0.5 ml. amounts of platelet-rich plasias were allowed to
clot at 37°C in glass tubes of uniform diarister, while being
agitated continuously. This agitation promoted platelet VI
and the onset of this phenomenon was recorded in relation
to the time the platelet-rich native plasma was added to glass
tubes at 37°0 and to the appearance of fibrin. The results
are recorded in Table I.
Experiment 2
Purpose. To study the effect of various anticoagulants
on platelet VM in normal platelet-rich native plasma*
Method
The following anticoagulants were added in 0.5 ml,
normal
to 0.5 ml. amounts of platelet-rich/native plasma to
give final concentrations as defined in fable 22. The
influence of these agents in VII was recorded (fable n).
Sodium citrate
Sodium oxalate
Bisodium verseae I see Atroendix Af
lfeparta < md 3
fhrombodyro
Soya bean trypsin inhibitor
Experiment 3
Purpose. fo decide the role of calcium in VM,
Method
Platelet-rich citrate, oxalate and disodium versene
plasma were prepared as described in Appendix A, p.13*
0.5 ml. of each type of platelet-rich plasma was added
to 0,5 ml. M/hO calcium chloride, fhe tubes were agitated
at 37°C and the time of onset of VI and fibrin formation
recorded in relation to the addition of calcium. flie
results are recorded in fable in.
Experiment 4
Purpose, fo determine the optimal Ca4+ strength for
platelet VM.
Method
0,5 ml, platelet-rich citrated plasma was added to 0.5 ml.
samples of m/40 CaClg solutions diluted in doubling dilutions
to give final concentrations as defined in fable IV. Each
mixture was agitated at 37°G and the time of onset of VM re¬
corded. fhe presence or absence of fibrin was observed
after 30 minutes' incubation. fhe results are recorded in
Table IV.
Experiment 5
Purpose. To compare th@ sequence of VI in normal
platelet-rich native plasma and in normal platelet-rich,
reealoified plasma,
mm
Venous "blood was obtained from 5 normal volunteers and
both platelet-rich native plasma and platelet-rich citrate
plasma prepared according to the methods detailed in
Appendix A, p. 13.
To 0,5 ml. platelet-rich native plasma was added 0.5 ml
0,855S saline and to 0.5 ml, platelet-rioh citrate plasma was
added 0,5 si. &/40 CaCl,,. Both specimens were allowed to
clot at 37°c in glass tubes of identical else and the onset
of VM and fibrin formation observed^and the times from the
onset of clotting An both-samples were recorded (Table V).
Experiment 6
Purpose. To determine the relationship of Complement to
platelet VM.
Method
Both platelet-rioh and platelet-free samples of native
plasma were obtained from both normal and abnormal plasma
(Appendix A, pp. 11 & 12 and Table VI).
1 ml. amounts of both platelot-rieh and platelet-free
native plasmas were allowed to olot at 37°C in glass tubes of
identioal size. After the formation of fibrin the clotted
plasma was incubated for 1 hour at 37°C, The fibrin was then
removed and the resultant serum titrated for its content of
residual Corrrnl aman+..
This titre was estimated by malting doubling dilutions of
sera diluted ■§• and in normal saline. To each dilution was
added 2 volumes of 1.5$ suspension of sensitised sheep cells.
(Appendix A, p.21). After 50 minutes* incubation at 37°0
'
■ ' ■ ' •
the tubes were spun at 11*00 g for 5 minutes and the percentage
haemolysis determined in each tube. 0.5 ml. of each super¬
natant was diluted to k*5 ml. with 0.01*$ ammonia. The degree
of haemolysis in each tube was deteitoined using the M.E.C.
grey wedge photometer. 100$ haemolysis standard was pre¬
pared by adding 2 volumes of sensitised sheep cells to
1 volume distilled water, 0$ standard contained distilled
water only.
Experiment 7
Purpose. To determine the effect of platelet numbers
on the activity of serum VM factor,
Method
Hatelet-rioh and platelet-free samples of normal native
plasma were prepared as described in Appendix A, pp. 11 St 12,
and 1 sal. samples were allowed to clot in glass tubes of
identical size at 37°0. fbllowing the formation of fibrin
the clotted plasma was incubated for 1 hour at 37°C to destroy
thrombin. Its ability to induce VM in twice-washed normal
platelets was assayed by titrating the activity in doubling
dilutions of sera. 0.2 ml. serum was added to 0,2 ml. of a
twice-washed platelet suspension prepared as in Appendix A,
p.13. Tubes of identical size were used for all experiments.
The mixture was agitated at 37°C and a positive result was
B5
recorded if typical W. had developed within 60 seconds of the
test sera being added to the platelets,
The litres of VM activity in the sera derived from
platelet -rich and platelet-free plasma are recorded in
Table VII.
Experiment 8
Purpose. To establish the effect of washing cm the ability
of platelets to react with serum VM factor.
MM
......
Platelet-rich veraene plasm was prepared from 8 separate
samples of normal blood as in Appendix A, p.13.
The platelets in each sample were separated from the
plasma and washed repeatedly in dextrose acetate saline
(Appendix A, p.5) • After each washing 0.1 ml. platelet
suspension was added to a tube containing 0.1 ml. active
•
>
- • • • '• - • • • - -
normal serum prepared as in Appendix A, p.14.
*
The tubes were agitated at 37°c and the onset of typical
"
VM in 60 seconds recorded (Table VUl). To ensure that the
platelet suspensions were net successively diluted with each





Purpose. To establish the minimum platelet density for
normal VM.
*fethod
A twice-washed normal platelet suspension was prepared
ftom platelet-rich versene plasma (Appendix A» p.13). A
series of doubling dilutions of this platelet suspension was
made in MS and the total number of platelets/cu.mm. in each
suspension determined by the method of Brecher & Cronkite (1950)
(Appendix A, p.10). To 0.2 ml. of each dilution of this
platelet suspension was added 0.2 ml. active normal serum and
the mixture agitated at 37°C. The presence or absence of
typical VM after 1C minutes was recorded (Table IX) following
both naked eye observation and phase contrast raiorosoopy.
Experiment 10
Pux-pose - To assess the VI activity of certain abnornal
sera and to observe the ability of platelets derived from
blood with known coagulation defects, to undergo typical VM
when exposed to normal active sera.
Method
(i) Sera ware prepared from platelet-rich samples of normal
and abnormal plasma (Appendiat A, p. 14) derived from blood with
known congenital or acquired deficiencies of specific coagu¬
lation factors (see Table X). 0,2 ml. amounts of these sera
were added to 0.2 ml. amounts of a twice-washed normal
platelet suspension (Appendix A, p. 13 ) &nd the presence or
absence of typical VM was observed after the mixture had been
agitated at 37°c for 60 seconds.
The results are recorded in Table X.
(ii) Twice-washed platelet suspensions were prepared from
platelet-rich versene plasma derived from patients with specific
oongenital or acquired coagulation defects (see Table X), The
method used was identical to that described for the preparation
of normal washed platelet suspensions (Appendix A, p.13)* To
0.2 ml. of these varying suspensions was added 0.2 ml. normal
active serum and the presence or absence of typical VM was
"
" "" '■ - '• •
observed after the tube had been agitated at 37°C for 60
seoonda.
,
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Thrombin may be defined as that substance which converts
fibrinogen to fibrin.
Therefore to disoover whether serum VM factor was related
to existing or generated thrombin in serum-platelet mixtures,
0.2 ml. additions were made to 0.2 ml. amounts of normal active
serum and human fibrinogen as defined in Table XI. These
mixtures were incubated for varying periods and the presence
or absence of fibrin recorded.
The results of these experiments are recorded in Table XI.
Human fibrinogen )
) see Appendix A, p.6.
Human Thrombin )
Experiment ,J2
Purpose. To determine the relationship of Complement
to serum induced VM.
Method
Samples of 5 fresh active normal sera were tested for
their Complement activity before and after exposure to normal
twice-washed, platelet suspension (Appendix A, p.13)* 0*5 ml.
of each serum was added to 0.5 ml. MS containing a 2$
suspension of washed human red cells, and was incubated at 37°C
for 10 minut3S$(B). 0.5 ml. of each serum was added to 0.5 ml*
platelet suspension and after agitation at 37°C for 10 minutes
typical VM evolved. The platelet masses were then removed "by
■- ■ „■ ■' ;
centrifuging at 1i*0Q g. for 15 minutes (A).
The titrs of residual Complement in each sample of serum
was determined both in the control and test sera as in
Experiment 6 (Appendix E, p.3), The results are recorded in
Table XII.
Experiment 13
Purpose. To determine the properties of the viscous
metamorphosing factor in serum.
Method
0.2 ml. active normal serum was added to 0.2 ml. of a
twice-washed normal platelet suspension, before and after
varying treatments, or together with 0,1 ml. of additions.
Serum Tr-eatoent
Heat treatment. 0.2 ml. amounts of serum were added to
tubes and placed in a 56°C water bath for 30 or 60 minutes
prior to testing.
Absorption with Aluminium Hydroxide gel (Al(0H), and
Barium Sulphate Powder (BaSOj)
1 ml* amounts of sera were absorbed with these inerganio
,
salts as detailed in Appendix A, pp. 4 and 5.
Zeojgarb. (Appendix A, p.7)*
100 mgms. cation ion exchange resin was added to 1 ml,
active normal serum and allowed to act for 10 minutes at 37°C.
Platelet-Absorbed Serum
0.5 ml. active normal serum was added to 0,2 ml. packed
twice-washed platelets (Appendix A, p. 13). The latter were
resuspended in the serum and after agitation at 37°C for
15 minutes the platelet masses were spun off at 1400 g for
15 minutes. 0.2 ml. of the supernatant serum was added to
3.2 ml. twice-washed platelet suspension and any residual VM
activity determined.
Bed Cell Absorbed Serum
Active normal serum was absorbed with twice-washed human
red cells substituted for platelets.
Pjalvsed Serum
5 ml. fresh active normal serum was placed in a bag of
dialysing membrane and dialysed overnight (18 hours) against
3 litres 0.85$ saline at 0°C.
Following removal from the dialysis bag the serum was
tested for VM activity.
Storage Active normal sera were stored in glass uaiveraj
containers (i) at room temperature for 24 hours, (ii) at -12°C
for 24 hours and (iii) at -12°C for 7 days. The residual VM
activity was then determined.
Additions






Soya bean trypsin inhibitor 5 rngt^ml
have been described in Appendix A, p.xirb .
B10
The results of these experiments are recorded in Table XHI.
Experiment 14
Purpose. To concentrate serum VM factor.
Method
Active fresh normal serum was prepared as detailed in
Appendix A, p.14« Its ability to induce typical VM in washed
normal platelets was confirmed. Prom this serum various
protein extracts were prepared and their ability to induce VM
in washed platelets observed.
Globulin Fraction
2 ml. of active serum was added to 18 ml. of distilled
water which had been acidified by carbon dioxide gas.
After the mixture had stood 15 minutes at room tempe-i. ature
the precipitate obtained was separated by centrifugation and
washed once in acidified distilled water.
The precipitate was dissolved in 1 ml, 0.35$ saline and
the pH adjusted to 7.0 by 1$ ammonium carbonate,
0.2 ml. of this extract was added to 0.2 ml. of a
suspension of washed platelets and following agitation at
37°c» the presence or absence of typloal VM observed. The
results are recorded in Table XIV.
Ammonium Sulphate Fractions
10 ml. active serum was added to 10 ml. 50$ saturated
ammonium sulphate. The precipitate obtained was separated
by oentrifugation (0-25$ ammonium sulphate fraction), and
the clear supernatant removed.
To 10.mi. of this supernatant was added a farther 10 ml.
50$ saturated assaonium sulphate. Again the precipitate
obtained was separated (25 • 33$ ammonium sulphate fraction)
and the supernatant removed.
To 10 ml# of the second supernatant was added 1 gm.
ammonium sulphate. The third and last precipitate was
separated (33 » 50$ ammonium sulphate fraction) and the
supernatant discarded,
a
All three precipitates were dissolved separately in 5 ml.
amounts of 0,85$ saline and each solution dialysed in dialysis
• • ! ......
bags against 0.85$ citrate saline at 0 - 4eG.
The volumes of the resultant dialysed fractions were
adjusted to 10 ml, with 0.85$ saline. 0,2 ml. samples of
each dialysate were tested for their ability to induce VM in
suspensions of washed human platelets.
The results are recorded in fable XIV.
Phosphate Fractionation
Volumes of JM phosphate solution were added to 5 ml.
samples of active normal serum to give final concentrations
of 1.0K, 1.5M and 2.CM of phosphate.
The phosphate was made up as follows:
K, H-PO, 817.O gms.
ICOH d 4 168.0 gas.
Distilled water to 2 litres.









5 5 5 1.0
5 2.5 7.5 1.5
K
J 0 10 2.0
fh.3 precipitates obtained with each concentration of
phosphate were separated by eentrifiigation at 3400 g. for
30 rain-ate3, fhe infra- or supernatant was removed and
discarded.
Each precipitate was dissolved in 0.85$ saline and
dialysed overnight against 0.85$ saline at 4°0.
The ability of each dialysed solution to induce VM in
suspensions of washed normal platelets was assessed,
fhe results are recorded in fable XIV.
Experiment 15
Purpose. fo confirm the composition of Bsrgsagel*s VM
factor (Bergsagel 1956).
Method
An incubation mixture was made of pig ant ihaetaophilie
globulin (1 rago protein/ml) O.f ml. together with 0.1 ml.
U/40 calcium chloride and 0.1 sal. addition.
The additions were composed of 1/5 dilutions of varying
?iged sera derived from patients with known specific
coagulation defects and normal heat treated and "barium
sulphate absorbed serum.
After incubation of these mixtures for 20 minutes at
|. . •: '-r . • *• 0 "v .... ■ » • •••- •
37°c> 0,2 ml. samples of the varying test incubation mixture®
were tested for their ability to induce typical VM in 0,2 ml*
of a twice-washed human platelet suspension (Appendix A, p.13)«
The results are recorded in Table XV.
iixoerirnent 16
i ii i mini * tiimi
j
Purpose. To define the properties of Bergs&gel'a VM
factor.
An incubation mixture was prepared, consisting of 1 ml.
amounts pig antihaomophilie globulin, aged normal serum and
diluted 1/5 in saline M/40.
After incubation for 20 minutes at 37°C, 0.2 ml# of the
incubation mixture was added to 0.2 ml. twice-washed normal
platelet suspension before and after certain treatment or the
addition of certain anticoagulants (0.1 ml.).
The incubation mixture was beat treated, absorbed with
aluminium hydroxide gel, barium sulphate powder, platelets and
red cells, and stored as in Experiment 13.
Additions of various anticoagulants were made in strengths
as defined in Experiment 13*
The results are recorded in Table XVI.
Experiment 17
Purpose* fo observe the effect of thrombin on washed
normal human platelets.
Method
Human thrombin was prepared as detailed by Biggs &
Macfarlane (1953)*
Bovine thrombin. Maws Topical Thrombin 200 u/ml. was
used*
0*2 ml. volumes of both human and bovine thrombins, in a
concentration of 20 u/ml, were added to 0.2 ml. twice-washed
suspensions of normal human platelets (Appendix A, p. 13)
together with 0.2 ml. of addition. Glass tubes of identical
ft
size were used and the mixtures agitated at 37 C for 15 minutes.
Any alteration in the morphology of the platelet sus¬
pensions was observed by phase contrast microscopy.
The results are recorded in Table XVII.
Experiment 18
Purpose. To observe the effect of certain anticoagulants





0.4 ml. human thrombin, diluted to a strength of 1 u/ml.,
.
was added to 0.5 ml. platelet rich citrate, oxalate, or
versene plasma together with 0.1 ml, 0.85$ saline, Altej>-
natively, an identical amount of thrombin was added to 0.5 ml.
platelet-rich citrate plasma together with 0.1 ml. of varying
anticoagulants (heparin 10 u/ml.j thrombodyn 2.5$} soya bean
trypsin inhibitor 10 mgm/ml.). In each instance the presence
'
or absence of typical VI occurring at least 1 minute before
fibrin foxidation was recorded.
The results are shown in Table XVIH.
Experiment 19
Purpose. To decide the ability of human thrombin to
promote VM in abnormal platelet-rich plasma.
Method
Platelet-rich citrate plasma (Appendix A, pt3) was pre¬
pared from patients with known specific congenital or acquired
coagulation defects. To 0.5 ml. of each sample was added 0.4
ml. of human thrombin and the presence or absence of typical
! I '
VM,developing 60 seconds prior to fibrin formation,recorded.
The results are detailed in Table XIX,
Experiment 20
Purpose. To determine the nature of thrombin VM co-factor.
I
Method
As it has been shown that human thrombin has no action on
washed human platelets, it was possible to test any material
for co-factor activity by addition to a mixture of human
B16
thrombin and washed human platelets (Chapter V).
0.1 ml. human thrombin (7 u/ml.) was added to 0.4 ml.
washed platelets together with 0,1 ml, addition.
The additions were
(i) saline 0.85&
(ii) high spun platelet-free oitrated normal plasma)
(iii) normal platelet-free oxalate plasma absorbed with
barium sulphate)
(iv) aged serum (24 hours storage at 37°C5 ot 7 days at
room temperature)
(v) pure human fibrinogen (Appendix A, p.6).
The presence or absence of typical VM, evolving at least
$0 seconds prior to fibrin formation, was observed.
The results are recorded in Table XX.
Purpose. To test for thrombin co-factor activity in
platelet extracts.
Method
Human platelets were separated from normal platelet-rich
oltrate plasma by high speed centrifugation. To one sample was
added 2 ml. distilled waiter and the suspension frozen solid in
an ioe salt mixture. This was then thawed rapidly at 37°C.
The freeze-thawing was repeated x3 and the platelet debris
removed by spinning at 20,000 g for 15 minutes. The super¬
natant was tested for oo-factor aotivity.
of platelet-rich or
Platelets separated from a second sample* were washed x3
in normal saline before being resuspended in distilled water
rate plasm
and exposed to the process of extraction. The platelet debris
was again separated and the supernatant tested for co-factor
activity.
0,1 ml, of both extracts was added to 0,4 ml, of a sua-
pension of twice-washed normal human platelets together with
0,1 ml. of thrombin (7 u/ml.). The presence or absence of
typical platelet VM evolving within 60 seconds of the addition
of thrombin was observed.
The results are recorded in Table XXI.
Experiment ffi
Purpose. To decide the relationship of thrombin VM
co-factor activity to platelets.
Method
High spun platelet-free oitrated plasma was prepared from
(1) a fresh specimen of blood collected into acid citrate
dextrose (disodium citrate 2 gm., dextrose 3 gm., water to
120 ml.).
(2) Stored blood collected into A.C.D, 21 days prior to testing
and stored at 4°C.
0,1 ml, samples of these plasma were added to 0,4 ml, of
a suspension of x2 washed normal human platelets together with
0,1 ml, human thrombin (? u/ml.).
The presence or absence of typical VM evolving within
60 seconds of the addition of thrombin was observed.
The results are recorded in Table XXII,
Experiment 23
Purpose, To observe, the effect of foreign surfaces on VM
in platelet-rich normal and abnormal native plasma.
Method
Platelet-rich native plasma was prepared as in Experiment
from normal and abnormal plasma. 0.5 ml. samples of each
plasma were allowed to olot either in glass or siliconed tubes
of identical size at 37°c# and the time of onset of VM and
the appearance of fibrin compared. The tubas were agitated
as the plasma was allowed to olot.
The results are recorded in Table XXIV.
PurposeTo observe the effect of foreign surface on the
activity of VM factor in serum.
Method
1 ml. platelet-free samples of normal native and reoalcif:
citrate plasma were allowed to olot at 37°E after contact
with varying areas of glass and siliconed glass. The tubes
were of identical size but the area of glass was increased by
the addition of 1 ml. amounts of glass ballotini to one sample
of each plasma.
Following fibrin formation the tubes were incubated for
2 hours at 37°C to destroy thrombin. The fibrin was removed
and the VM activity of the resultant sera assayed by titration.
Doubling dilutions of each sera were made and 0.2 ml. of




The bighestdiiution of serum«which could produce typical V*
of the washed platelets within 60 seconds was recorded as the
strength of the VM factor.
The results are detailed in Table XXV.
Experiment
Purpose. To define the effect of glass surface contact
cm normal human platelet suspensions.
MM
Suspensions of normal human platelets were prepared as
followss
(1) Platelet-rich citrate plasma )
(2) rt M versene plasma ) Appendix A
(3) x2 washed suspension of platelets )
1 ml. samples of each suspension were agitated both in
.
glass and siliooned tubes by rotation once every 3*3 seconds
for 2 hours at room temperature.
The number of platelets /eu.mm. in eaoh suspension was
counted before and after agitation using the direct technique
of Breoher & Cronkite (Appendix A, p. 10). and phase contrast microscopy.
The results are recorded in Table XXVI.
Purpose. To observe the effect of foreign surfaces on
the morphology of normal human platelet suspensions.
Method
1 ml. samples of human platelet-rich citrate plasma and
a x2 washed suspension of normal human platelets were added to
glass and siliconed tubes containing glass and siliconed
beads respectively. All tubes were agitated for 1 hour at
room temperature by rotation once every 3*5 seconds.
The morphological changes observed by phase contrast
microscopy are recorded in Table XXVII.
Experiment 27
Purpose. To observe the effect of tissue thromboplastins
on platelet VM.
Method
0.2 ml. amounts of tissue thromboplastin in the form of
brain extracts prepared as detailed in Appendix A} p.?•> were
added to 0.4 ml. normal platelet-rich citrated plasma, or
0.4 ml. of a twice-washed normal platelet suspension. To each
tube was added 0.2 ml. of addition in the form of saline or
M/40 calcium chloride.
The morphology of any platelet changes were observed
both microscopically and macroscopically. The results are
recorded in Table XXVIII.
Experiment 28
fcV .. .... ^ f
Purpose. To observe the effect of adding Russell's Viper
Venom to normal platelet suspensions.
Method
0.2 ml. Russell's Viper Venom ('Stypven' Burroughs
Wellcome Ltd), was added in varying dilutions to 0,4 ml. normal
platelet-rioh citrate plasma or 0.4 ml, of a twice-washed
suspension of normal human platelets, 'Stypven' represents
viper venom in & 1/10,000 dilution! therefore when used
undiluted this material is tabulated at this dilution
(Table XXIX).
Platelet changes were observed by phase contrast
microscopy. The results are recorded in Table XXIX.
Experiment 29
Purpose. To determine the effect of animal antihemophilic
globulin concentrates on human platelets.
Method
Pig and bovine antihaemophilic globulin concentrates
were prepared in varying strengths as defined in Appendix A,
p.6., and in Table XXX.
0,2 ml. amounts of these concentrates were added to
both a normal platelet-rich citrate plasma and a twice-
washed suspension of normal platelets. The mixtures were
incubated at 37°C for 15 minutes. Any alterations in
platelet morphology were observed by phase contrast microscopy.
The results are recorded in Table XXX.
Experiment 50
Purpose. To observe the effects of animal antihaemophilic
globulin on other heterologous platelet suspensions.
Method
Platelet-rich citrate plasma was obtained from venous
blood derived from a pig, cow, rat, guinea pig, rabbit,
mouse, oat, and dog.
0.2 ml. volumes of each of these plasmas were added to
0.2 ml, of either pig or bovine A.H.G. (see Experiment 29),
(10 mgms/ml.). The mixtures were incubated at 57°C for
B22
15 minutes and any alterations in platelet morphology
observed by phase contrast microscopy.
The results are recorded in Table XXXI,
Experiment 31
Purpose. To study the effect of varying anticoagulants
on the stability of platelet suspensions.
Method
Samples of venous blood were added to the following
anticoagulants in slliooned tubeai
Tri-sodium citrate (3-8$) 1 part to 9 parts blood.
Sodium oxalate (1.34$) 1 Part to 9 parts blood.
Disodium versene (i*»5$) 1 P&rfc to 33 parte blood.
Heparin (10 u/ml» blood).
Platelet rich plasma was prepared from each sample and
incubated in silicone! tubes at 37°C for 18 hours. Any
alteration of platelets morphology was observed and recorded
in Table XXXIII.
Experiment 3?
Purpose. To decide the optimum medium for washing
platelets free from plasma.
Method
Platelets were separated from 5 rale, platelet-rich
versene plasma and cashed three times as described in





5$ glucose in 0,85$ saline
5$ gluoose
Dextrose acetate saline. Appendix A, p.5«
Dextrose acetate saline (buffered to pH 7*3 with an
vol.glyoxallne buffer).
1$ disodium versene in saline.
After these washings each sample of platelets was re-
suspended in 1 ml. volumes of their respective washing
solutions. Any alteration in platelet morphology was
observed and recorded in Table XXXIV.
equal
Purpose. To determine a suitable medium for preserving
I
platelets in suspension.
• •' 1 "• "V 1' . 'V-V ' ' :'i ■ I: • .• •
Method
Platelets were separated from 2 ml. platelet-rich versene
plasma and washed three times in dextrose acetate saline
(Appendix A, p. 13). Finally they were resuspended in 0.6 ml.
volumes of the following solutions and 0.2 ml. volumes of each
suspension incubated in siliconed tubes at 37°C> room
temperature and 4°C respectively for 3 hours.
Saline 0.8555
Citrate saline 0.85$
1$ Disodium versene in 0.8555 saline
/ Glucose 555
m
5$ Glucose in 0.85$ saline
Dextrose acetate Saline (Appendix A, p. 5)
2$ Gelatin in DAS
5$Gelatte in 0.85$ saline
20$ bovine albumen
Human albumen 5$ (Lister Institute)
%g albumen 10$ in 0.85$ saline (v/v)
Human fibrinogen (100 ta&m/iH 0,85$ saline)
A«y platelet agghctfaation that had resulted from this
process was recorded.
The results are presented in Table XXXV.
Experiment 34
Purpose. To observe the effect of washing on the
platalet-red-oell agglutination phenomenon.
Method
Korea! venous blood from Group 0 Rhesus positive donors
was collected into disodium versene and the platelet rich
plasm separated (Appendix A, p. 13)
0,2 ml. samples of a 10$ suspension of red blood cells in
plasma and in saline, after one, two and three washes, was
added to 4 separate 0*2 ml, samples of platelet-rich plasma.
All k samples were spun at 3600 g for 5 minutes and reaus -sanded
by tapping. The presence or absence of platelet or mixed
platelet-red oell agglutination was observed in each tube.
This experiment was repeated adding red cells to platelet
suspensions after they had been washed one, two or three
times. Again, each mixture was oentrifuged , resuspended
and the presence of platelet or mixed platelet-red dbll
agglutination observed.
The results are recorded in Table XXXVI.
Experiment 35
Purpose. To study the effect of trypsin and incomplete
antibodies on platelet red cell agglutination.
Method
Hormal red blood cells were separated from Group 0
Rhesus positive donors and washed three times in normal
saline. The cells weremodified either by the use of trypsin
or by sensitising with antiserum containing an incomplete
anti-Rhesus (anti-D) antibody.
Trypsinised Red Blood Cells
A solution of trypsin (30 mgms/ml) was diluted 1/10 and
1 ml. added to 1 ml. packed washed red blood cells. The
mixture was incubated for 30 minutes at 37°C. The red oells
were then separated by centrifugation, washed three times
in dextrose-acetate-saline (DAS) solution and finally resus¬
pended in DAS to give a 10$ suspension.
Sensitised Red Blood Cells were prepared as for the
mixed red cell platelet agglutination test (Appendix A, p.2k).
The sensitised oells were resuspended to give a final
concentration of 10$ red blood cells in MS.
0.2 ml. trypsinised or sensitised red blood cells were
added to 0.2 ml, platelet rioh versene plasma. The mixture
was centrifuged at 3600 g for 5 minutes and gently resus¬
pended by tapping.
The presence or absence of platelet or mixed platelet
32<5
'sr-k.; >v'. : %i: r
red cell agglutination was observed in each tube.
i
The results are recorded in Table XXXVII.
Experiment 36
Purpose. To define the incidence of positive platelet
agglutination tests in normals.
'
- •''' ••---• • ■ '
. I
Method
Ten normal human donors, of known red blood cell group
structure, each donated venous blood. This was allowed to
olot in glass tubes at 37°c and aged at 37°C overnight. On
the nest day a further 9*7 ml. of venous blood was removed
from the same donors and transferred to siliconed centrifuge
tubes containing 0.3 ml. disodium versene.
Serum and platelet suspensions were prepared from each
donor as defined for the platelet agglutination test
(Appendix A, p. 14) •
0.2 ml* of each serum was added to 0.2 ml. of each
platelet suspension in a siliconed tube* In all, 100
mixtures were made so that every serum sample was matched
with every platelet suspension. The mixtures were incubatec.
for 2 hours at 37°C and the presence or absence of immune
platelet agglutination observed in each of the 100 samples.
The results of the first hundred test are recorded in
Figure 21 • The identification number of each donor can be
interpreted in terms of red cell group structure by reference
to Table XXXVIII.
Similar series of cross agglutination experiments were
performed using similar groups of 10 normal donors selected
at random until 1000 platelet agglutination testa bad "been
performed,
The results of these 1000 tests, involving 40 separate
donors, axe recorded in Figure 22.
Experiment 57
Purpose. To determine the presence of A and B antigen
on platelets.
Method
Suspensions of three times washed normal platelet
suspensions were prepared from "blood derived from donors
whose red blood cells ABO group had been determined
previously.
Specific antisera of two types were available.
(a) titre serum. Anti A and Anti B serum derived
from rabbits immunised against specific Group A or B substance
(supplied by Br. M.M. Pickles)
(b) Low titre serum. Anti A and Anti B human blood
grouping serum (National Blood Transfusion Service).
Both types of serum were heat treated at 56°C for 60
minutes and absorbed with barium sulphate powder before
addition to platelet suspensions (see Appendix A, p.4)«
0.2 ml. undiluted specific anti~A and anti-B sera were
added to 0,2 ml. of each washed platelet suspension g^d the
mixtures incubated for 2 hours at 37°C.
The presence or absence of immune platelet agglutination
r
in each sample was observed by phase contrast microscopy.
The results are recorded in Table XLI.
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The titres of both the high titre and low tltra anti-A
aiid B sera were determined, after heat treatment and absorption
with barium sulphate powder, by addition of 0.2 ml. samples to
equal volumes of washed suspensions of washed red cells or
platelets derived from donors of known ABO group.
The high, titre serum was titrated by doubling dilutions
of a 1/10 dilution in 0,85$ saline; the low titre serum by
doubling dilutions of this serum.
The results are recorded at the foot of Table XLI.
Experiment 58
Purpose. To determine whether platelets carry adsorbed
A or B substance on their surface.
Method
Platelet suspensions were prepared from platelet-rich
versene plasma derived from donors of known A and 3 red cell
groups and washed repeatedly (Appendix A, p.13). After
each wash 0.1 ml. of each platelet suspension was added to
0,1 ml. of high titre anti-A or anti-B sorum (Experiment 37)•
In all, the platelets were washed ten time3. The mixtures
were ineubated for 2 hours at 37°C and the presence or
absence of platelet agglutination observed by phase contrast
microscopy.
The results are recorded in Table XLI A.
Experiment 59
Purpose. To confirm the existence of ABO platelet
groups by the mixed red cell platelet agglutination test
(Coombs & Bedford 1955)*
Method
Washed platelet suspensions were prepared as detailed in
Appendix A, p.13» from donors of known ABO blood and secretor
state, and the final concentration of each suspension was
adjusted to give a density of approximately 500,000 platelets
/ou.mm.
Antl-A and Anti-B grouping serum. Low tit re (National
Blood Transfusion) specific antisera.
Red blood cells from Group 0, A and B donors were washecl
three times in dextrose acetate saline solution (DAS) and
finally resuspended to give a •§$ solution.
Teat
6 drops of both antisera were added to 6 drops of each
platelet suspension and the mixtures incubated for 1 hour at
room temperature. The platelets were separated by centri-
fuging at 2300 g for 10 minutes and, the supernatant having
been removed, washed twice in MS. The platelets were
finally resuspended in k drops MS.
1 drop of sensitised platelets was added to 1 drop of
samples of suspensions of Group 0, A and B cells in MS.
The mixtures were spun at 2?00 g for 2 minutes,
resuspended and observed by phase contrast microscopy.
The presence or absence of mixed red cell platelet
agglutination was recorded and the results are presented in
Table XLII
Experiment hO
Purpose. To detect the presence of Forssman antigen in
platelets.
Method
Washed platelet suspensions ware prepared as in
Experiment 38.
Specific Forssraan antiserum was prepared in rabbits,
fashed suspensions of sheep x*ed blood ceils were
injected aa 1 ml. amounts of packed red cells,both intra¬
venously and intraperitoneally,at weekly intervals for 3
weeks. 1 week after the last injection the rabbit was bled
and serum separated. One sample of serum was absorbed with
an equal volume of a suspension of macerated guinea pig
kidney for 1 hour at 37°C to remove specific Forssman antibody
'litre of antiserum (unabsorbed) again sheep red
oells - l/l02k-
Titre of antiserum (absorbed) against sheep red
cells -1/32
The antiserum, both absorbed and unabsorbed, was used
after diluting 1/64 to exclude the non-specific heterophil
agglutinin.
Bed blood cell suspensions.
A thrice washed suspension of sheep red blood cells was
resuspended finally in MS to give a -£$> suspension. A
control suspension of human Group 0 red blood cells was also
prepared as in Experiment 39*
Test
"J
6 drops of each. platelet suspension were added to 6 drop
samples of both unabsorbed and absorbed antiserum. The
mixtures were incubated for 1 hour at 37°C.
The platelets were separated, washed and resuspended in
■
MS as in Experiment 39*
t drop sensitised platelets was added to a suspension
of either sheep or human red blood cells* The mixtures were
spun at 2800 g for 2 minutes, resuspended and the presence or
absence of mixed red cell-platelet agglutination observed by-
phase contrast microscopy.
The results are recorded in Table XLIII.
Experiment 41
Purpose. To decide whether human nlatelsts earried the
Bhesus antigen.
Method
Washed platelet suspensions were prepared (Appendix A,
p.13) from known Group Rhesus positive and negative donors
as in Experiment 38.
Specific Anti-Rhesus Antiserum (incomplete Anti-D),
Supplied by Dr. M.M. Pickles.
Sensitised Red Cell Suspensions. Red blood cell
suspensions were made from both Ihesus positive and negative
donors and washed three times in DAS. The cells were
sensitised as described in Appendix A, p.2kt and again washed
three times in DAS.
Anti-human Globulin Rabbit Serum was supplied by
Dr. M.M. Pickles and used in a dilution of l/lO.
Test
6 drops of each platelet suspension was added to 6 drops
incomplete anti-Rhesus (snti-D) antiserum. The mixtures
were incubated at 37°C for 1 hour,
6 drops of each red cell suspension were similarly
sensitised with incomplete anti-D antieera. Both platelets
and red cells were separated from the antisera and washed
three times in MS,
1 drop of sensitised platelets was added to 1 drop sen¬
sitised red cells together with 1 drop anti-human globulin
serum,
The mixtures were incubated at 37°0 for 30 minutes
before centrifuging at 2800 g for 2 minutes. The red cell-
platelet mixture was resuspended and the presence or absence
of mixed red cell-platelet agglutination observed.
The results are recorded in Table XLIV.
Experiment 42
Purpose, To study the effect of Group specific anti-
human platelet rabbit serum on normal platelet suspensions.
Method
Two rabbits were given infections of thrice washed
human platelet suspensions prepared from donors whose
theoretical platelet group had been provisionally determined
(Table XLVl). Three intravenous and intraperitoneal
thrice-
infections of 1 ml, /cashed human platelets were given at
weekly intervals. 10 days after the last injection the
rabbits were bled and their sera separated fcr testing. In
parallel sera were prepared from normal rabbits.
Both antibody containing and normal sera were treated
as defined in the platelet agglutination test (Appendix A, p.14)
lashed suspensions of platelets were prepared from normal
human donors of known theoretical platelet group structure
(Appendix A, p. 13). 0.2 ml. test and normal sera were
added to 0,2 ml. of each platelet suspension and the
mixtures incubated for 30 minutes at 37^0. The presence
or absence of platelet agglutination was observed by phase
contrast microscopy.
The results are recorded in Table XLVH.
Experiment 4^
Purpose. To determine the physical properties of the
platelet agglutinating factor*,
Method
Serum, containing an apparent specific platelet
agglutinin in high titre, was prepared from 50 ml* blood
derived from a case of idiopathic thrombocytopenia and
allowed to age at 37°0 fox* 18 hours.
This serum was treated in various ways or exposed to
varying additions (Table UV), and then retested for its
ability to produce typical immune agglutination in normal
platelets. Each sample, irrespective of the treatment that
it had been given, was exposed to heat (56°C) and barium
sulphate absorption as in the platelet agglutination test
(Appendix A, p. ). 0,2 ml, of the treated serum was
added to a suspension of thrice washed normal platelets in
MS and incubated at 37°C for 2 hours.
The presence or absence of immune platelet agglutination
was recorded in Table LIV.
Heat treated serum
1 ml. of serum was heated at 65°C for 15 minutes.
Qjalvaed serum
5 ml. of test serum was lialysed against 0,85$ saline
for 18 hours at 4°C.
Platelet absorbed serum
0*5 ml. serum, previously heated at 5^°C for 60 minutes
and absorbed with barium sulphate powder, was added to 0.5 ml.
of packed, thrice washed, normal platelets and the platelets
resuspended in this serum. The mixture was incubated at
at 4300 g for 30 minutes. The supernatant serum was xete
for its ability to induce typical immune agglutination in
washed platelets.
Bed cell absorbed serum
The procedure detailed above was repeated using 0.5 ml.
packed^ thrice washed red blood cells.
Ammonium sulphate fractionation
Three fractions of serum were prepared by ammonium
sulphate precipitation as described in Experiment 14.
Euglobuljn fraction was prepared as described in
Experiment 14.
Other procedures are detailed in Table LIV.
37°C for 2 hours and the platelets separated by centrifugaiion
See Appendix C, Case 65» and Chapter XII ?• 145.
Preparation of Patient's Human Albumen
36 ml, of tha patient's venous blood was added to 4 ml*
3*8$ sodium citrate,
30 ml, high spun plasma was obtained and to this was
added 30 ml* saturated ammonium sulphate (to give a 50$
saturated solution).
This was allowed to stand for 1 hour at 0-4^0, and the
precipitate was separated by centrifuging at 6,800 g for
15 minutes at 15°C*
The supernatant was removed and to this was added 10,3 gms.
ammonium sulphate to give a saturated solution according to
the formula-
V m volume supernatant (30 ml.)
X ■ weight of ammonium sulphate to be added.
This solution was allowed to stand for 1 hour at Q-4JC
and spun at 6800 g for 20 minutes at 4°C. The precipitate
floated to the top and the infranatsni was carefully removed.
The precipitate was dissolved in 0*85$ saline and
dialysed against 0,85$ at 4°0 for 13 hours.
The pH of the dialysed fluid was adjusted to pH 7*0
using 1$ ammonl m carbonate.
The concentrat ion of albumen was found to be 0,78 gme$
(Dr. E. Bidwell).
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In vitro piatslet agglutination tests and clot retraction
inhibition testa were performed as for drug sensitivity tests
(Appendix A, p.16 ) using test and control albumen solutions
in the above concentration instead of solutions of drugs.
Solutions of Human Albumen (Meter) 0.7%%
* " Human Albumen (American) 0.7$$
M " Bovine Albumen 0.78$
* • II.B. Albumen 0.78$
***w , - •
were used in each test system.
fha results are described in the case history (Case 65)
(Appendix C).
APPENDIX C.
SUMMARIES OP CLINICAL AND LABORATORY FINDINGS IN
73 CASES OP THROMBOCYTOPENIC PURPURA AND RELATE®
CONDITIONS.
All these eases have been interviewed by
myself and in many instanoes histories were obtained
and laboratory investigations were carried out
personally. On those cases under the care of
Professor L.J". Witts, Laboratory Investigations wi
(Haemoglobin, bleeding time (Duke 1912) Capillary
Fragility, Platelet Count (Dameshok 1932) and Sternal
biopsy)
marrow/were performed in the laboratories of his unit.
1* D*S.(Female) aged 57• This lady had bruised easily
all her life but 2 months prior to admission to hospital
she developed a sore throat. This was associated with an
increased tendency to bruise. It was not apparently
spontaneous but followed trivial trauma. She was found
to be thrombocytopenic 10,000/cu.mm. and was placed on
cortisone and then prednisolone therapy as an out patient,
but her bruising persisted.
On admission to hospital physical examination
revealed numerous resolving bruises over chest, arms and
legs. There was no splenomegaly.
Laboratory Investigations. Hb. 104$ -15.4 ;;ms.$.
Platelets 10,000/cu.mm. Capillary fragility was increased.
Platelet agglutination teat - negative. Marrow biopsy -
megakaryocytes plentiful. Further steroid therapy
produced no improvement and was discontinued.
This patient was discharged under observation and
splenectomy may be performed shortly.
Previous Blood Transfusion - nil. Previous
Pregnancy - nil.
Summary* Acute idiopathic thrombocytopenic
purpura in a female aged 57•
thrombocytopenia (19,100/cu.mm
Ho cause was discovered for this acute episode. She
responded to parenteral penicillin therapy and, following
blood transfusion, there was a spontaneous return of her
blood picture to normal. In 1954 she was delivered of a
normal male child and there were no complications. ghe
developed monorrhagia following this confinement. In
January 1955 she suddenly started to bruise spontaneously
and had mild epistaxes. Physical examination revealed
that the spleen was enlarged. Again she was anaemic and
thrombocytopenic but her white count was normal. The
Bone marrow was hypoplastic but megakaryocytes were present.
The blooding time and capillary fragility were abnormal.
Cortisone therapy produced a clinical improvement and the
platelet count returned slowly to normal. This remission
lasted 2 months but she again relapsed with acute
thrombocytopenia and spontaneous bruising and purpura.
Splenectomy was performed in June 1956 with a dramatic
return of platelet count to normal and complete clinical
2. G.P.(Female) aged 22. This girl was first seen
in 1949 when she had an acute
recovery.
She is now fit and well with a normal blood
picture (December 1956).
Platelet Agglutination Teste - positive Jan 1955«
Ho titre recorded. Negative Oct 1956(Post splenectomy).
Previous Blood Transfusions - 2. Previous
Pregnancy - 1.
Summary. Chronic idiopathic thrombocytopenia
presenting originally as a case of Hypersplenism with
thrombocytopenia.
3. K.O.(Mala) 14. This boy suffered from recurrent
episodes of spontaneous purpura, epistaxes and bruising
sine© the age of 3« Repeated examinations have always
revealed a thrombocytopenia 10~3Q,000/cu.mia., a prolonged
bleeding time - usually 15* (Ivy) and abnormal capillary
fragility. The spleen has never been enlarged.
Harrow biopsy showed numerous megakaryocytes in
an active normoblastic marrow. Platelet agglutination
has been positive (if) on the two occasion® it has been
tested.
Splenectomy has been refused by the Boy's parents
and steroid therapy has not been given.
Previous Transfusions - nil.
Summary. Chronic idiopathic thrombocytopenia in a
boy aged 14.
4. B.P.(Female) aged 28. This young lady was
admitted to hospital in January 1955 because of a sudden
onset of purpura and bruising of 5 days duration.
Physical examination showed that the purpura was
confined to her legs and chest and there were occasional
bruises on her legs. The spleen was not enlarged and
no other abnormality was detected. She had been taking
dextro-araphetamine because of increasing obesity hut
had had none for 1 month prior to the onset of the purpura.
Laboratory investigations. Hb. 88$ 13«0 <P»$*
White cell count 5,600/ou.tasa. Platelets were too few to
count. The bleeding time was prolonged (15* + Ivy) and
the capillary fragility was abnormal. Platelet agglutin¬
ation teat was negative. Sternal marrow biopsy showed a
hyperplastic marrow with abundant megakaryocytes.
Cortisone therapy produced an immediate remission
with a rise in the platelet count to normal level with
10 days* (Platelets 310,000/cu.mm.). This therapy was
maintained for 2 months and, as the remission had been
maintained,the dose was tailed off and therapy stopped.
There had been no occurrence of purpura or bruising
18 months later.
Previous Blood Transfusion - nil. Previous
Pregnancy - nil*
Diaraaosla. Acute thrombocytopenic purpura in a girl aged 28.
3. R.F. (Female) 32. This woman has had episodes of
spontaneous bruising for several years. Because of gross
obesity she has been attending hospital and it was
observed in 1953 that there was a purpuric rash involving
one shoulder. Physical examination revealed no
abnormality apart from gross obesity and splenomegaly.
Laboratory investigation revealed that she was then
thrombocytopenic 40,000/cu.mra., the bleeding time being
15' + (ivy) and capillary fragility was increased.
She has been seen at frequent intervals since this
episode, but although she still continued to bruise, no
episodes of spontaneous purpura occurred. Her platelet
count fluctuated, being normal at one time, 200,000 - 500,000,
with normal bleeding time and tourniquet test and markedly
abnormal the next (too few to count).
In January 1956 she was seen because of a
recurrence of her purpura. Platelets 25,000/cu.mm.
B.T. 15* + (Ivy), capillary fragility - abnormal. Platelet
agglutination test was positive
She was placed on the waiting list for steroid
therapy but to date has refused to come into hospital.
Previous Blood (Transfusions - nil. Previous
Pregnancies - 2.
Summary. Recurrent chronic thrombocytopenia in a
female aged 52.
6. P.V.(Male) JO. fhia man was admitted to hospital
following the sudden onset of widespread purpura, epistaxes,
and gum haemorrhages 2 days previously. For the previous
2 years he had taken "Anadine" tablets for recurrent
headaches. (Anadine tab * Aspirin gr. 3> Phenacetin gr. 3,
Caffeine gr. Quinine gr. l/l2.) Immediately prior
to the onset of spontaneous haemorrhages he took 8 tablets
but had had none for the 12 days prior to admission.
Physical examination revealed a widespread
petechial rash on the trunk and legs and ther© were
several blood blisters in the mouth. The spleen was not
palpable.
Laboratory investigations. Hb. 114$. 16.9
White cell count 10,400/eu.mm. Platelets - too few to
count. Bleeding time 15* + (Duke). Capillary fragility -
not recorded. Marrow Biopsy - Megakaryocytes were
plentiful. Platelet agglutination test - negative. In
vitro tests for aspirin, phenacetin, caffeine and quinine
sensitivity were negative. (Clot Retraction and Modified
Platelet agglutination test see Appendix A p.) Mo skin
tests were performed and no trial dose of quinine was given.
Cortisone therapy was given and there was
immediate improvement in his haemostatic mechanism in that
his bleeding time returned to normal. His platelet
count did not rise at first but slowly climbed to normal
in 2 months. The improvement was maintained following
withdrawal of the steroid therapy.
Previous Blood Transfusions - ail.
Summary, Acute thrombocytopenic purpura in a
male aged 30. This may have been provoked by quinine
sulphate but in vitro laboratory tests did not confirm
this.
7» D.S.(Female) aged 60. This woman had been
dyspnoeic for many years and during the past 2 years had
complained of retro-sternal pain when she stooped or
lay flat. 7 months before admission she developed a black
eye spontaneously. This resolved but 2 months later she
had a spontaneous nose bleed and bruises appeared on her
arms.
Laboratory investigation at this time revealed
a marked thrombocytopenia 9,000/cu.taza. and a bleeding time
of 25 minutes (Horton General Hospital, Banbury).
1 month later she had a further nose bleed and was
admitted to hospital for investigation. She had been
taking no drugs over this period. PhyBioal examination
revealed an obese old woman with purpura over the chest
and multiple bruises of her arms and legs. Two sub¬
mucosal haemorrhages were present on the palate. The
spleen was not palpable. Ho other abnormality was
discovered.
Laboratory Investigations. Hb. 11.5gn$.
White cell count 5»030/cu.ram. Platelets 37»000/<m.raa*
Bleeding time 11*>0" (Luke).
Coombs test negative. Platelet agglutination
to a titre of 1/4»
test - positive j . X-ray examination showed the spleen
was enlarged X 4 normal. Marrow biopsy showed that
megakaryocytes were present. Ho other abnormality was
detected.
In view of her history no therapy was given.
3 months later her purpura and bruising still persisted
and had become more severe. Splenectomy was advised but
has not been performed to date.
Previous Blood Transfusions - nil. Previous
Pregnancies + <iaui«liiui uml.irisuj.
Summary. Chronic thrombocytopenic purpura in
a female aged 60*
8. I.B.(Female) aged 59* This lady had a radium
menopause at the age of 44 for monorrhagia. She
subsequently was well until the age of 58 when she began
to feel vaguely unwell. Paring the 6 months prior to
admission she developed an increasing anaemia and had
bruised excessively. This culminated in the development
of a purpuric rash on her limbs. She had taken no drugs
apart from barbiturates.
On admission physical examination showed that
31*,
she was normal apart from anaemia, Kb./ 4.6 g.% with marked
thrombocytopenia (7,000/cu.ram) and an unexplained
reticulocytosis 18.2$. The peripheral blood and marrow
showed marked iron deficiency changes. There was
increased red cell activity in the taarrow and Megakaryocytes
were frequent. The changes were those of an haetaolytic
anaemia with thrombocytopenia. All investigations to
determine the aetiology of the haeraolytic process did not
reveal aay specific cause but the platelet agglutination
test was strongly positive to a titre of l/32.
Prednisone therapy induced a remission in her
thrombocytopenia but she relapsed immediately it was
stopped. Splenectomy was performed with immediate
clinical and baematological improvement and on discharge
2 weeks after splenectomy her platelet count was 858,000/cu.j
and her Hb. 92$ (13«5 Reticulocytes 0.6*. Platelet
agglutination test - post splenoctosgy ♦ l/l6. (1 week).
Biagaosi®. Chronic Idiopathic thrombocytopenic
purpura with associated haeraolytic anaemia responding to
splonaeto&ty.
Proviouss Blood Transfusion * 1. Previous
Pregnancy ♦
9* L.8 .(Male) aged 52. This aan was originally
seen in 1953 with exilarged cervical lymph nodes at first
presumed to be tuberculous.
In 1954 ths- lymph nodes in the left side of his
neck were removed surgically and the histological picture
was suggestive of Hodgfcias disease (lymphadexiema)•
Radiotherapy produced an immediate regression in the aiae
of his lymph nodes.
6 months later he was admitted to hospital with &
generalised pan^qytopania. layaical examination revealed
enlaTiiOd lymph nodes in the cervical and axillary regions.
Both the liver and spleen were enlarged. Ho other
significant abnormality was discovered. There was a
persistent pyrexia.
Laboratory investigations. Mb. t*8$ 7*1 gaw.^
Whit© Blood cells 1,509/eu.mm.(neutrophils lOSO/cu.ssa)
"latolets 5?.,000/cu.E»m. E.S.R. IP m/hour. Sternal marrow
biopsy revealed a hypoplastic normoblastic marrow. The
produce or absence of wegtfzaryocytea was not recorded.
Tubercle bacilli were isolated from the urine which
contained occasional pus cells.
Plassa proteins. Total 5*0 Albumen 2*9 gas$.
Streptomycin and P.A.3. therapy were given Wifc a oooci
clinical response and the patient became afebrile but the
pancytopenia persisted.
Whan seen in October, 195®, Platelet agglutination
test was negative.
Previous Blood Transfusion + 1
Smsaary. Pancytopenia with thrombocytopenia
associated with splenomegaly due to lymphadenoraa.
Addendum.
Splenectomy was performed in February 1956 with
a slow but definite response both clinically and
haematologically. Platelets 407j000/cu.5nm. 10 months later
he slowly relapsed and his pancytopenia was again present
(Platelets 5»000/cu.®u). Platelet agglutination teat
at this time was negative. Histological examination of
the Spleen did not decide the exact pathology in this man;
the changes were
caao.—It was/not typical of lymphadenotaa.
10. W.W.(l£ale) aged 35- man was admitted to
hospital as an emergency following a haeiaatemesia and
melaena. Previous history was negativecpart from beri-beri,
amoebic dysentry and malaria while a Japanese P.O.'A'.
On admission he did not appear to have lost much
blood. His blood pressure was normal and his haemoglobin
was 8C$ (11.8 gms$). Haematocrit 3He was confused and
maniacal but no localising C.H.S. signs were elicited.
Laboratorv inveat igation showed mailed thrombocytopenia
6U,000/cu.mm.^although the bleeding time and capillary
fragility were normal. All tests of coagulation function
were normal. lone marrow 'biopsy revealed a hyperplastic
normoblastic marrow with, abundant megakaryocytes. X-ray
examination could not exclude the presence of a duodenal
ulcer, but no definite ulcer was demonstrated. Platelet
ag'lutiriation teat was positive l/k- Ha continued to
have occult blood in the stools and splenomegaly developed.
The thrombocytopenia persisted but he did not
develop any purpura or bruising. He continued, however,
to have occult blood in his stools, 6 months later he was
readmitted for dental treatment and his thrombocytopenia
was still present (Platelets 12,000/cu.mia.) The bleeding
time was prolonged 11* (ivy) and capillary fragility was
abnormal. Again the platelet agglutination test was
positive l/k»
1 year after the first episode he had had no
recurrence of his gastro-intestinal bleeding nor had he had
any other haemorrhagic episode. His thrombocytopenia
and splenomegally still persisted. At no time had this
man any specific therapy for his thrombocytopenia.
Previous Blood Transfusion i 1.
Summary. Chronic Idiopathic Thrombocytopenia in
a male aged 35.
11. N.C.(Female) aged 24* The woman has suffered
from purpura and spontaneous bruising since the age of 8.
The attacks have been intermittent and in between the
attacks she has been perfectly normal apart from
monorrhagia since the menarche. Her present attack was
of 5 months duration and was associated with widespread
purpura and bruising.
Physical examination revealed no abnormality
apart from the purpura.
Laboratory Investigations. There was an iron deficiency
anaemia. Hb. 68$ (lft.1 g*s$). Platelet count was
14,000/eu.sm. and the bleeding time was prolonged 15' +(lvy).
Clotting time and prothrombin time (Quick) was normal.
Coomb's test negative(on red blood collet Sternal marrow
showed megakaxyocytic hyperplasia. Platelet agglutination
test was positive to a titre of
As she wished to start a family, splenectomy
was advised but has not yet been carried out.
Ho Previous Blood Transfusions. No previous
pregnancies.
Diagnosis. Recurrent chronic idiopathic
thrombocytopenia.
12. S.A.(Female) aged 10. This child had had
persistent thrombocytopenia with an abnormal tendency to
bruise for 2 years and there was a severe haemorrhage
following the extraction of one tooth. There were no
epistaxes, haematuria or evidence of gastro-intestinal
haemorrhage.
When seen in the Radcliffe Infirmary in April 1956
no physical abnormality was detected apart from bruises on
the right leg. The spleen was not enlarged.
Her bleeding time was prolonged 15« + (ivy) and her
capillary fragility was increased. The platelets were
too few to count. In view of her approaching monarch©,
splenectomy was performed with immediate clinical and
haeinatological return to normal.
Platelet agglutination tests both pre and post
splenectomy were negative.
So Previous Blood Transfusions.
Diagnosis. Chronic idiopathic thrombocytopenia
in a child aged 10.
13. E.H.(Female) aged 61. In 1944 this woman noticed
that numerous spontaneous bruises were appearing on the
legs and trunk and she had recurrent epistaxes. These
were found to be associated with thrombocytopenia which
responded dramatically to immediate splenectoE*/(Birmingham).
In 1953 there was an isolated short-lived recurrence of
the sponteneous bruising and purpura together with mild
epistaxes. Laboratory tests showed she was again
thrombocytopenic.
2 years later there was a further recurrence of the
bruising, purpura and epistaxes. She had been taking no
drugs prior to this episode. She was admitted to the
Radcliffe Infirmary, Oxford where physical examination
revealed widespread purpura and bruising on the legs and
there were several blood blisters in her mouth. No other
abnormality was detected. The spleen was not enlarged.
Laboratory investigations. Hb. 100$. 14.8 gms.
White cell count 12,800/cu.jaa. Platelets 11,000/cu.mm.
Bone marrow biopsy i- Hyperplastic normoblastic marrow with
abundant megakaryocytes. Coomb's Test on red blood cello -
negative. Platelet agglutination test - negative.
Cortisone therapy produced a dramatic remission
within 1 week (platelets 334,000/cu.a®) This was maintained
following withdrawal of the drug.
One previous hlood transfusion. On© previous
pregnancy•
Summary. Eeeurrent chronic thrombocytopenic
purpura in a female aged 6l.
!-!"•"*v-JTglfc Ji ■ J':''
14. A.M.L (Male) aged 10. This boy was first seen
in July 1955 with a mild attack of mumps, associated with
widespread subcutaneous bruising, purpura and epiataxes,
which had been present for 1 week. He had been known to
bruise easily, following trauma, since the age of 5 but
apart from vary small nocturnal epistaxes he had not had
any other evidence of spontaneous haemorrhage.
Physical examination showed widespread confluent
bruises over both legs and numerous petechial haemorrhages
on the trunk. Both parotid glands were enlarged and
slightly tender and there appeared to be a slight ooze from
the left tonsil. There was no splenomegaly.
Laboratory investigations. Hb. 102$(l5«l gms$)
White cell count 6,800/cu.mm. Platelets were too few to
count. The bleeding time was 15' + (Ivy) and capillary
fragility was abnormal. Clot retraction was nil after
1 hour at 37°- Platelet agglutination test was positive
to a titre of The purpura and bruising persisted
together with thrombocytopenia following clinical recovery
from mumps and in view of his pending entry into boarding
school an immediate splenectoay was performed. This
produced a dramatic clinical improvement and the platelet
count, "bleeding time, capillary fragility and clot
retraction all "became normal within 25 days. This
improvement persisted and he was discharged . 3 months
later his clinical improvement had "been maintained hut
there was a mild thrombocytopenia (Platelets 90,0QQ/cu.nas).
The platelet agglutination test was still positive at this
time.
So previous blood transfusions.
Summary. Acute thrombocytopenic purpura in a
hoy aged 10.
15. E.P.(Female) aged 70. For the past year this
woman had had symptoms of anaemia, associated with
spontaneous bruising, purpura and recurrent epistaxes. Iron
therapy had produced no response. Blood transfusion was
given prior to her admission to Radcliffe Infirmary, Oxford.
On admission there was widespread purpura over
her arms, legs and front of chest and there were multiple
haemorrhagic blisters on the inner aspect of the cheeks and
lips. There was marked pallor and koilonyohia. The liver
was enlarged but the spleen was not palpable.
54*
Laboratory Investigations. Kb./'8.0 gms* Reticulo¬
cytes 6.2*. White cell count 1,900 (neutrophils 50q/gvl.mh)
Bleeding time 15* +(lvy). Platelets were too few to count.
J /'
Direct Coomb*s Test on red blood cells - negative. Platelet
agglutination test - negative. Sternal marrow was cellular
and normoblastic} nyelopoesis was depressed and no
megakaryocytes were seen. Stools persistently contained
occult blood. Steroid therapy (Prednisolone) produced
a rise in the number of white cells but the thrombocytopenia
and haemorrhagic state persisted. (Platelet 8,000/cu.mm.
B.T. 15* +.) Platelet transfusion improved the haeraorrhagic
state but did not produce any rise in the platelet count.
Spleaeotony was performed whioh produced an
immediate improvement in her haemorrhagic state. The
bleeding time fell to 8* and the spontaneous purpura and
bruising ceased. The platelet count rose to 8l,000/cu.mm.
but fell to levels varying between 17 & 58,000/cu.tam.
'
Unexplained bilateral supra-clavicular swellings
appeared soon after her admission. These were originally
thought to indicate a mediastinal haemorrhage but they did
regress with the improvement in her condition following
splenectomy.
One previous blood transfusion. Three previous
pregnancies.
Summary. Thrombocytopenic purpura due to a
probable idiopathic hypersplenism in a woman aged 70•
16. A.C.(lale) aged 9» This boy developed acute purpura
following a febrile illness of an unspecified nature. During
the febrile phase he was given 3 'John Bell* capsules which
contain quinine, camphor, aBpirin, phenacetin and phenol-
phthalein. The purpura persisted and, when he was seen in
Oxford 2 months later, he was markedly thrombocytopenic
(10,000/cu.iaa.) in spite of having received Prednisone therapy
for 1 month.
Laboratory investigation showed that his bleeding
time and capillary fragility were normal, but that clot
retraction was abnormal (35$ after 1 hrs. incubation at
37° G.) Physical examination revealed that the spleen
was enlarged. Splenectomy was advised if a further period
of 'Prednisone1 therapy produced no improvement.
Whan seen after a further 2 weeks' therapy
his condition had worsened. The bleeding time was 15* *»
capillary fragility was abnormal and the platelets were
too few to count. Direct platelet agglutination test on
both visits were negative.
In view of the purpura apparently following the
administration of drugs, he was tested for drug sensitivity
1 month after the drug had been withdrawn. There was no
evidence at that time of sensitivity to quinine, camphor,
aspirin or phenacatin as measured by platelet agglutination
tests and clot retractions (Aokroyd 1950) (See Appendix Ap).
Steroid therapy was stopped gradually and before splenectomy
could be performed he underwent a spontaneous remission with
complete clinical recovery. The platelet count and all
tests of haemostatic function returned to normal.
Bo previous blood transfusions.
Summary. Acute thrombocytopenic purpura in a
boy aged 9.
17. B.P.H.(Mole) aged 10» This boy had suffered from
spontaneous bruising and the occasional nose bleed for the
past year and was admitted to Stoke Mandevilla Hospital
following a sudden exacerbation of this bruising tendency
and the development of a widespread petechial rash.
Physical examination revealed widespread purpura and
numerous braises. The spleen was enlarged and the
platelet count was 60,000/cru.rara. He also at this time
had colicky central abdominal pain and passed altered blood
in his stools. 2 monbhslater he was readmitted following
a fall, bleeding continuously from nose and mouth. There
was also gross haematuria. The bleeding persisted and
Prednisolone therapy and repeated blood transfusions had no
beneficial effect.
Laboratory Investigation showed that his blood
platelet count was 36,000/eu.mra. Bone marrow biopsy showed
that numerous megakaryocytes were present. Splenectomy was
performed but the bleeding continued and the platelet
count did not rise above SOjOOC/cu.mm. Further Prednisolone
therapy produced no improvement and he was transferred to
the Badcliff® Infirmary, Oxford.
On admission, Physical examination showed that
there was widespread purpura and numerous bruises were
present over the trunk and lower limbs. A large blood
clot was present in the nasopharynx.
Laboratory Investigations, Hb. 105$. White cell
count 13,C00/cu.raa. Platelets - too few to count.
Capillary fragility abnormal. Tests of coagulation function
showed no other defect apart from thrombocytopenia.
Platelet agglutination test negative. The platelets
remained too few to count but large doses of Prednisolone
reduced his bleeding time and capillary fragility to
within normal limits. Spontaneous bruising also ceased.
In view of his poor response to steroid therapy the drug
was gradually withdrawn without any worsening of his
clinical condition. The platelet count remained
persistently low. No follow up notes are available.
One Previous blood transfusion.
Summary. Acute thrombocytopenic purpura in
boy aged 10.
18. R.L.(Male) aged 3k • This little boy was seen
as an outpatient with widespread purpura and bruising of
5 days duration, ^he onset had bean associated with a
febrile episode and stiff knee joints.
Physical examination revealed widespread purpura
and many bruises. There was no splenomegaly.
Laboratory examination. Hb. 92^ 13.6 Go. White
blood cells 7,000/cu.mia. Platelets 10,000/cu.ma, Bleeding
tin© 14,' (Ivy). Capillary Fragility abnormal. Platelet
agglutination test - negative. He was sent home to bed
and when seen 2 weelcs later the purpura and bruises were
disappearing and all laboratory investigations had returned
to normal. Platelets 570,OOC/eu.rass.
No Previous blood transfusion.
Summary. Acute thrombocytopenic purpura in a
boy aged 3 years with spontaneous recovery.
19. «T.W. (Male) aged 43. This man was admitted to
hospital for investigation of widespread purpura of sudden
onset.
For the past 2k years he had bruised easily and
during the past 2 years had had recurrent epistaxas and
blood blisters in the mouth.
3 years before he had Herpes Zoster of the
intercostal nerves. This was treated by Chlorampenicol
(12 gms. in 2 weeks). Otherwise he had been a perfectly
fit man.
Physical examination revealed widespread bruises
of arms and legs together with widespread purpura of lags,
arms, trunk and lips. The spleen was not enlarged,
115#
Labqralftsy Invest^Ipns. Hb./16.5 Gm/IQG ml.
W.B.C. 10,800/cu.am. Platelets too few to count. Bleeding
time (Ivy) 15* ♦, Clotting Time (Lee & White) 7 mins.
Coombs Test on red blood calls - negative. Capillary
Fragility - markedly increased. Marrow Biopsy - A cellular
normoblastic marrow. Megakaryocytes easily found.
Abdominal x-ray revealed mild splenomegalyi Platelet
agglutination test was positive to a titra of 1/S,
Cortisone therapy produced no shortening of his
bleeding tendency, or any rise in the platelet count. His
spontaneous purpura and epistaxes continued and became
gradually more severe. He was readmitted following the
sudden onset of a left facial palsy of upper motor neurone
type and severe sciatica. There was widespread purpura
and numerous sub-mucosal haemorrhages were present inside
the mouth. Again his bleeding time was prolonged(121 -
Duke) and the platelets were too few to count. Platelet
agglutination test was again positive 1/4.
In view of the severity of his symptoms
splenectomy was performed. There was a sudden copious
secondary haemorrhage post-operatively and the patient
died in spite of intensive transfusion of fresh blood.
At pest--mortem the peritoneal cavity was
filled with blood and blood clot which had come apparently
from the splenic pedicle. There was also evidence of an
old cerebral haemorrhage involving the left temporal lobe.
Bo previous blood transfusions.
Nummary. Chronic thrombocytopenic purpura in
a man aged 43.
20. D.S,(Female) aged 31. This woman had had a
bleeding tendency all her life. Severe haemorrhage
followed tooth extraction and monorrhagia has been present
since the monarch©. Her sister died at the age of 3
following tonsillectomy.
She was admitted to hospital for investigation
prior to multiple tooth extractions. Physical examination
revealed that there was purpura over the knees and elbow
and that the spleen was enlarged.
Laboratory Investigations showed that 3he was
anaemic, (Hb. 7.0 gms) with marked iron deficiency changes.
Bleeding time was prolonged 15' (Ivy) and there was a
thrombocytopenia (32,000/cu.ma.) The platelets present
showed numerous giant forms. In spite of the
thrombocytopenia, clot retraction, prothrombin consumption
and thromboplastin generation test (Patients platelets)
were normal. There the platelets in spite of being
decreased in number showed normal function. These unusual
. findings together with positive family history suggested
that this might be a case of a congenital functional platelet
defect rather than a typical ease of chronic idiopathic
thrombocytopenia.
Ho other members of the family were available for testing.
Platelet agglutination tests ware consistently
negative.
Tooth extraction was followed by severe
haemorrhage but this was controlled by splints and blood
transfusion.
Cortisone produced no remission.
Splenectomy was deferred in view of the strong
family history.
One Previous blood transfusion. One previous
pregnancy.
diagnosis. Chronic Thrombocytopenic Purpura
in a fomale aged 31.
21. S.B. (Female) aged 75. This old lady was
admitted to hospital because of spontaneous vitreous
haemorrhages in both eyes. Physical examination revealed
no other abnormality.
laboratory investigation showed that she was
thrombocytopenic (50,00C/cu.ma.) The bleeding time was
prolonged 151 ♦ (Ivy) and capillary fragility was
increased.
In view of her age and general condition she was
discharged home without further investigation or therapy.
Platelet agglutination test » negative.
Four Previous pregnancies. She had no memory
of previous blood transfusion.
diagnosis. Idiopathic Thrombocytopenia of
unknown duration.
22. E.T.(Female) aged 26. This young woman was
first seen at the age of 19 whan sho was complaining of
the sudden onset of spontaneous bruising and purpura.
At the same time she developed severe aenorrhagia.
Physical examination revealed no abnormality
apart from widespread purpura and bruising. There was
no splenomegaly.
laboratory Investigations. Hb. 74$. White cell
count 2,100/cu.am. Platelets 21,000/eu.mra. Bleeding time
39' (Ivy) Capillary fragility was increased.
Immediate splenectomy was performed but no
clinical or haematological improvement followed. Bom
marrow biopsy performed after splenectomy showed that the
marrow was hypoplastic and no megakaryocytes could be
found.
Becurrent purpura continued and menorrhagia
continued. In 1951 Cortisone therapy provoked a clinical
remission but the platelet count never rose above 40,000/
cu.mm. "gain the bone marrow biopsy slowed that no
megakaryocytes were present. For 4 years she was
completely symptom freo and during this time gave birth to
a full time normal male infant. 10 months ago all her
symptoms recurred.
Prednisone therapy provoked a further clinical
remission but again, there was no rise in her platelet
count. This remission lasted 5 months and then her
purpura, bruising and monorrhagia recurred but with
increased severity, necessitating admission for blood
transfusion. The monorrhagia was so severe that
hysterectomy was advised but deferred to allow her to have
a further pregnancy.
14,000/cu.mm. B.T. 15* + (Ivy). Capillary fragility
increased. Platelet agglutination test - negative.
One previous blood transfusion. One previous
pregnancy.
Summary. Chronic thrombocytopenic purpura in
a female aged 26.
23. E.F. (Female) aged 42. This woman was admitted
to a nursing home for hysterectomy. She had had
monorrhagia and intra-menstrual loss for 5 years. There
was no other history of any haemorrhagic tendency and she
never had had any purpura.
Physical examination revealed no abnormality.
The spleen was not enlarged.
Laboratory Investigation showed a mild
thrombocytopenia 109»000/cu.mo. Hb. 89$ (13.2 gms$).
Platelet agglutination test - positive to a tifre of b
The hysterectomy was performed and there were
no post-operative complications.
As this patient was a private patient no follow
up laboratory investigations were performed prior to her
discharge from the Nursing Home.
No previous blood transfusion. Two previous
pregnancies.
Summary. Mild thrombocytopenia with monorrhagia
in a female aged 42.
24# M.C. (Female) aged 51# This woman was first
seen in April 1956 when she complained of easy bruising
of her upper arms and legs for several weeks. Previously
she had been a fit woman.
Physical examination revealed no abnormality
apart from subcutaneous bruises. She was not anaemic
(Hb. 83$ 13.0 gras$) but there was a marked thrombocytopenia,
9,000/eu.mra. and the bleeding time vas prolonged (201 +
Duke) Sternal marrow showed megakaryocyte hyperplasia.
Prednisone therapy produced a dramatic remission clinically
and haematologically and the remission was maintained on
withdrawal of the drug after 8 weeks therapy.
When seen as an out patient 5 months later she
■was clinically well, and her platelet count was 251,000/cu.nm
Platelet agglutination tests were negative.
No previous blood transfusions. One previous
pregnancy.
Diagnosis. Acute idiopathic thrombocytopenic
purpura.
25. P.B.(Male) aged 13. This boy was first seen in
1953 whan he complained of increasing lassitude, breathless-
ness and an abnormal tendency to bruise spontaneously.
This tendency was accompanied by severe recurrent and
spontaneous epistaxes.
Physical examination revealed an enlarged spleen
and an apical systolic heart murmur. There was fine
purpura of the ankles, chest and buttocks.
Laboratory Investigations:- He was anaemic
there was a further recurrence of purpura associated
with clinical mumpsj the platelets were on this occasion
too few to count. Again there was a spontaneous remission.
In 1955t a further recurrence of purpura, associated with
epistaxes and haematuria and haematemesis necessitated
her admission to hospital. Again the platelets were too
few to count. Cortisone therapy was given but after 3 days
there was a fresh haoraateraesis associated with a convulsion.
As there was no improvement in her platelet count and the
bleeding time remained prolonged, Splenectomy was performed
although the spleen was normal in size. A Platelet
Agglutination Test performed just prior to splenectomy
was positive to a titra i.
Clinically she improved following the operation
but the platelet count did not rise.
The purpura, bruising and epistaxes recurred
2 months after the operation and the thrombocytopenia
persisted (0 - 30,000/cu.mm.), Her haemorrhagic state
has persisted and when last seen in September 1956 she
was covered with petechial haemorrhages but was otherwise
fit and well.
No bone marrow biopsy has been performed on this
child to date.
One previous blood transfusion.
Nummary. Recurrent ChronicIdiopathic
Thrombocytopenic purpura in a child aged 6.
27. C.M,S(Male) agedlS. This young man developed
a purpuric rash 1 week after he had had a sore throat.
Slight purpura and spontaneous bruising persisted in
spite of Cortisone therapy for 6 weeks. He had been
taking no drugs and had been perfectly fit previously.
6 months after the onset of his symptoms he was admitted
to the Radcliffe Infirmary, Oxford, for investigation.
Physical examination revealed spares purpura of
the legs and there were several blood blisters in the
mouth. Thar© was no splenomegaly.
laboratory investigations. Mb. 100$ 14.8 gms$.
White cell count 6,10G/cu«mm. Bleeding time 11* (duke).
Platelets 41,000/cu.mm. Capillary fragility was increased.
Bom marrow biopsy - megakaryocytes present. Direct
Coomb's Test on red blocd cells - negative. Platelet
agglutination teat was positive to a titre of i".
Splenectomy was performed with an immediate
clinical and haematological response, the platelet count
returning to normal levels, 512,000/cu.mm. in one week.
The bleeding time was 1'3G" (Duke). Platelet agglutination
test performed 2 weeks after splenectomy was still
positive -t;0 a titre of 1/2.
Mo previous blood transfusion.
Summary. Chronic thrombocytopenic purpura in a
male aged 18.
28. A.K. (Male) aged 50. This man, a painter, had
a sudden episode of widespread purpura for 5 days. It was
confined to both legs and abdomen. It was not painful or
itchy* The purpura faded leaving a fuiirfc brown staining.
He had been taking no drugs in the last 6 months and was
not exposed to lead containing paints.
Physical .Examination showed that apart from
tha fading purpura, this man was apparently healthy.
Laboratory investigation 7 days after the onset
of the attack, revealed that there was mild thrombocytopenia
(51,00C/cu.mia) but both the bleeding time and capillary
fragility were normal. Prctlirombin time (Quick) was
normal. He abnormal proteins were detected. Platelet
agglutination test was negative.
1 month later, this man was found to be normal
clinically and all laboratory investigations gave normal
results* There was no recurrence of the purpura in the
next 6 months. Ho further platelet counts performed.
!?o previous blood transfusion.
nummary. Acute Idiopathic Thrombocytopenic
Purpura in a man aged 50.
2BA, M.A. (Female) aged 57. This woman had had
recurrent purpura for at least 20 years. Initially
limited to her legs this purpura had spread first to the
trunk, then the anas and, eventually to her face. The
eruption of the purpuric haemorrhages had been proceeded
usually by small indurated swellings which, on rosolving,
left a small area of extravasated blood.
On admission there was symmetrical purpura over
legs and arms, and narked residual brown pigmentation over
both legs below the knees* No other physical abnormality
was noted. The spleen was not enlarged.
Laboratory Investigation. Hb. 90> (13.3 gms,>)
Platelets 4Q,000/eu.na« Coomb's test on red blood calls
negative. Marrow biopsy was hypocellular but megakaryo¬
cytes wore present in normal proportions. Platelet
agglutination test was negative.
No defect of in vitro blood coagulation was
detected. No abnormal proteins were found in the blood.
The platelets gradually climbed to normal levels
560,G00/eu.imn. in a period of 3 weeks following the
commencement of Cortisone therapy. Cortisone, was given
for 9 days only before she developed acute abdominal
discomfort and barium meal revealed equivocal signs of a
duodenal ulcer.
Although the platelet court returned to normal,
the purpura persisted. She was discharged on "Adranoxyl"
(Adrenochroma mono-semi carbazome) therapy and, when seen
3 months later, had improved clinically although the purpura
still recurred at intervals.
No previous blood transfusion. Previous
V «
pregnancy.
Summary. Chronic purpura in a female aged 57
associated with a definite episode of transient
thrombocytopenia.
29. G.D,(Female) aged 39. At the age of U this
woman had had a transient haematesesis which did not recur
until 1955 when she had a further severe haematemesis
necessitating, blood transfusion. The stools contained
altered blood. Between these episodes she had had vague
symptoms of indigestion with attacks of low back pain.
These ware not related to meals or improved by any medicine.
A doubtful duodenal ulcer was fovm& by x-ray. Incidentally
it was discovered she had a congenital heart lesion and it
was thought that this was an inter-atrial septal defect to
which she was well compensated. At this time her platelet
count was normal. Following transfusion there was no
recurrence of her haematemesis or pain.
It was observed at follow up examination 3 months
later that she had hyperextendable finger and elbow joints
and it was thought that she might be a case of Bhiar's
Danlos Syndrome, amine* woe cusposteel ■this nl^ht explain liei
'Symptoms*
Laboratory Investigation showed that she was also
thrombocytopenic 72jO0G/cu.mm, but her bleeding time and
capillary fragility were normal. Platelet agglutination
test at that time was negative. On subsequent examination
2 weeks later her platelet count was 190,000/cu.mm. and
the platelet agglutination test was again found to be
negative.
Investigation of her family showed that her brother
and her niece both appeared to be cases of hhler's Danlos
Syndrome. This confirmed the clinical diagnosis.
Comment. The only rational explanation that
can be offered for tills apparently transient thrombocyto¬
penia was that her one large blood transfusion had
stimulated a very weak platelet agglutinating agent^ not
demonstrable by in vitro testing.
One previous blood transfusion.
Mammary. Transient thrombocytopenia associated
with Ehler's Danlos Syndrome in a female aged 39.
30. Mrs. B. aged 27. Baby B. (male) was born on
26th December 1954 at hci.s* 3 weeks prematurely, and,at the
age of 5 days/ developed purpura of the legs. He was
found to bo thrombocytopenic on transfer to Gloucester
Royal Infirmary and received two blood transfusions. In
spite of this his platelets entirely disappeared by the
9th day. He died, aged 10 days, after numerous spontaneous
haemorrhages had occurred. Coomb's Test on red blood
cells was negative. Post~mort@a showed widespread purpuric
lesions with involvement of the brain. The mother and
father of this child were referred to Oxford for investigation
four months after the death of this child.
This had been the mother's third pregnancy. Sbm
had two girls aged 4 and 3. Both had been entirely
normal since birth. Ohe had been perfectly fit apart from
an attack of jaundice at the age of 17. Oha had never
bruised easily, had any purpura nor had experienced any
abnormal haemorrhages. There was no family history of
bleeding. She had been perfectly fit during the last
pregnancy and had had no purpura, the had never required
a blood transfusion. When examined 4 months later she was
found to be a normal healthy woman.
laboratory investigation:- Hb, 100$£ 14.8 gms/i>.
Platelets 212,000/cu.mm. Bleeding Time V 45" (ivy).
Capillary fragility - normal. Platelet agglutination test
showed that her serum agglutinated normal platelet
suspensions, suspensions of her husband's but not her own
platelets.
The father of the child was also entirely normal
and platelet agglutination tests on his serum were negative.
Supmarv. Neonatal thrombocytopenia causing death
at 10 days in the third child of a healthy mother.
31. Mrs. D. aged 24 and Baby. Baby D male, bora
at Amersham General Hospital, developed purpura in the
first day of life and on investigation, was found to be
thrombocytopenic.
When seen on the fifth day of life the child was
covered in purpura and echymoaes and was slightly jaundiced.
There was no splenomegaly.
Laboratory investigations. Hb. 105# (15.5 gras#)
Platelet count 10,000/cu.mm. Bleeding time 10* (Heal prick).
Coomb's test on red cells was negative. Platelet
agglutination test done on serum derived from the baby
was negative. The child continued to thrive but the
platelet count remained abnormally low until 6 weeks when
it returned to normal.
Mrs. D. This was this mother's first pregnancy.
She had never had any miscarriages or blood transfusions.
She was perfectly normal throughout the pregnancy
until at 33 weeks she developed a rash around her waist.
This was not seen by a Doctor but from the patient's
description this could have been purpura. It faded within
2 days and did not recur.
Physical examination revealed no abnormality and
there was no apparent splenomegaly.
laboratory investigation. Hb. &5% (12.6 gms;>)
Platelets 406,CXX)/cu.mm. Bleeding time 6' (Ivy). Capillary
fragility was increased. Platelet agglutination test
was positive when the mother's serum was added to normal
suspensions but not when added to suspensions of Iter own
platelets. The titre was only 1/1. No opportunity
presented to test the mother's serum, against her husband's
platelets.
Summary. Neonatal thrombocytopenic purpura
in the first-born child of an apparently healthy mother.
32. Mr3. A.S. aged 2$. This woman was delivered of
a full term male infant in 1952. This child, her first,
developed widespread bruising and purpura over arms, legs,
trunk and especially in the hands and feet at the age of
2 days. There was no previous history of illness, blood
transfusions or miscarriage and at no time had the mother
had any abnormal bleeding tendency or spontaneous purpura.
The baby showed no evidence of anaemia (Hb.l50/i
22.2 ffaajC) but his platelets ware too few to count.
Bleeding time 10*45" (Duke). Capillary fragility was
normal. Coomb's test on red blood cells was negative. The
mother'3 blood was found to contain a powerful platelet
agglutinin which agglutinated her husband's platelets, and
29 out of 30 normal platelet suspensions. It did not,
however, agglutinate her own platelets (Dr. R. Gillett).
The purpura and bruising resolved in 4 days and the
platelets returned to normal levels in 3 weeks. This baby
continued to thrive as any normal child and at the age of
3 years, was a perfectly noma! healthy sale child. There
was no recurrence of the purpura.
In 1955 Irs. A.S. "became pregnant for the second
time and was admitted to hospital due to mild toxaemia.
Labour was spontaneous and a full term male infant (5 lb.
11ir oz) was delivered. 2 days later the child vomittod
altered hlood and a few petechiae appeared on the buttocks.
Platelets were again found to be too few to count. Coomb*s
test on the baby's red blood cells was negative. Apart
from a slight ooze from the oord the child progressed
normally and fed well. The platelets did not show any rise
until 6 weeks after delivery (101,000/cu.ara.) and did not
return to normal until 8 weeks (402,OOO/'cu.am.). Bleeding
time and capillary fragility were found to be normal. The
mother's serum again contained a platelet agglutinating
factor against suspensions of her husband*0 platelets and
4 out of 5 suspensions of normal platelets. Her serum did
not agglutinate a suspension of her own platelets. At no
time during the pregnancy had the mother suffered from any
bleeding tendency or purpura.
Laboratory investigation of the mother showed no
evidence of thrombocytopenia (Platelets 454,000/ou.tms.).
Bleeding time (Ivy) 4* • Capillary fragility - normal*
Summary • ITeonatal thrombocytopenic purpura in the
second child of a normal healthy mother1. The first child
was also affected.
33. Mrs# G. aged 28, Baby G. aged 5 days. This full
tine male infant started to vomit on the 5th day of life and
it was noted that there was altered blood in the vomit.
No other physical abnormality was discovered.
laboratory investigation showed that the infant
was thrombocytopenic (62,0QQ/cu.raa.) There was no anaamia
and white cell count showed no significant abnormality#
The platelet count gradually returned to normal and was
187,0GQ/cu.rara. one week later. (12 days). There was no
further evidence of abnormal bleeding#
The child*s mo*'her (aged 28) was normal and
shewed no evidence of an abnormal blooding tendency.
Platelet count 336,000/cu.mni. This pregnancy, her second,
was „ every way.
Platelet Agglutination Test. The mother's serum
did not agglutinate the baby's platelets, her husband's
platelets or the platelets of 5 normals.
Summary. An unusual case of transient neonatal
thrombocytopenia in the first-born child of a normal healthy
mother.
34. Mrs. T. aged 24 and Baby T. Mrs. T. had always
been perfectly fit and 3 s years ago gave birth to a normal
full time male infant. In the first 2 weeks of life this
boy developed a purpuric rash and had several melaena
stools but in all other respects, was a normal child.
2 years later she was delivered of a 4 week premature male
infant. This infant rapidly developed bruises all over
the body and was transferred to hospital in Gloucester where
and this rash was considered to be toxic in nature and
probably provoked by the Codein Tablets. These tablets
ware stopped and Histantin therapy instituted. This brought
about a dramatic improvement in the rash but 1 month later
she developed widespread purpura ever the trunk and limbs
and her original papular rash reappeared; this time with
a haemorrhaglc element. The drugs were stopped and she was
sent to hospital for investigation 1 week later.
Physical examination showed that the purpura
was fading and no fresh lesions vera seen. She was a frail
old woman crippled by advanced rheumatoid arthritis involv¬
ing knees, hips, hands and elbows, but no other abnormality
was detected.
Laboratory Investigations. Hb,» 9*$ (24.4 gms^Q
Platelets 129»000/cu.mm. Bleeding time 8' (Ivy). Capillary
fragility - normal. Direct platelet agglutination tests
were positive when the patients serum was added to
suspensions of her own platelets and those of normals. It
was found that Histantin enhanced these results. When
histantin was added to the patient's platelet rich plasma
and this was allowed to clot, clot retraction was inhibited
completely. Nc such reaction took place when this drug
was added to clotting platelet rich normal plasma
(Appendix A p.16).Ho such reactions occurred when other
drugs were addeu under similar conditions, e.g. Carbrital
and Codeine. The former drug had been administered along
with the iiistanfein. Following withdrawal of the histantin
no further purpura appeared, and the platelet count
returned to normal levels.
No previous blood transfusions. Previous
Pregnancy.
Summary. Drug induced thrombocytopenic purpura.
36. F.H. (Male) aged 72. This patient developed
in infected haematocoele as the result of surgical
tapping of a right sided hydrocoele. Streptococcus
faecales was isolated from the cyst and sulphamezathin©
therapy given. After 1 week's therapy purpura appeared
on his left leg and 3 days later spread tohis right leg
and thigh. There was no splenomegaly.
Laboratory investigation showed that the Hb.,
white count and blood film were normal. Platelet count
was 3QfQ00/eu.m®. The bleeding time was normal but the
capillary fragility was increased. In vitro tests showed
that the patient's serum would agglutinate suspensions
of his own platelets and those of normals in the presence
of Sulphama zathine, Sulphathiazolo, and Sulphatriad to a
titre of 1/4* No reaction took place unless these
specific drugs were added. Further, these drugs were
capable of inhibiting normal clot retraction when added to
the patient's platelet rich plasma as it clotted. Control
systems using normal serum, normal platelet rich plasma
and other drugs gave entirely negative results (Appendix
A«P>t6).
Ivhen Sulphonamlde therapy was withdrawn the
petechial rash disappeared and the platelet count returned
to normal two weeks later.
Ho previous blood transfusion.
Summary. Drug induced thrombocytopenic purpura.
37. R.H. (Female) aged 24. This young woman was
admitted to hospital with an ulcerated throat associated
with severe agranulocytosis, (following the treatment of
clinical thryotoxicosis with methyl thiouracil for 1 year).
Through a misunderstanding her white cell count had not
been checked during this period.
Physical examination revealed ulcerated fauces
and both tonsils were covered with exudate. The spleen
was not enlarged.
Laboratory investigation. Hb. 90/t (13.3 gms/0
White cell count 2,00C/cu.mm. (Neutrophils 350/cu.mm.)
Platelets --33jOOO/cu.mm. Bleeding time 10' (Ivy).
Capillary fragility increased.
Marrow biopsy showed a definite maturation arrest
of myelopoesis at the myelocyte levels and transitional
megaloblastic change in the erythroid precursors.
Megakaryocytes were plentiful. Platelet agglutination
test » negative. When performed with the addition of
methyl thiouracil it again was negative. Leucocyte
agglutination test - equivocal. Clot Retract Inhibition
Tests were not performed on this patient.
Withdrawal of the drug was accompanied by a slow
return of the white blood cell count and the platelet count
to normal over a period of three weeks.
When seen 1 month after discharge from hospital
this patient was entirely normal.
No previous blood transfusion. One previous
pregnancy.
Summary. Drug induced thrombocytopenia ■■and a.
agranulocyto sis.
38m L.N. (Female) aged 56. This patient suffered
from a toxic dermatitis of hands and arms for tli3 past
5 years. This appeared to be associated with the use of
metal, floor or furniture polish.
Skin tests revealed a violent skin and systemic
reaction to Johnstone's Furniture Polish, and 1 week later
this patient developed spontaneous braising and purpura
of both legs below the knee.
laboratory Investigation. Platelet count
53»000/cu.mm. Bleeding time and capillary fragility ware
normal# Platelet agglutination test was negativa.
Further testing showed that the platelet count had returned
to normal one month later.
In view of the dramatic results of the skin
sensitivity tests it was not considered advisable to repeat
the reaction. In vitro drug sensitivity tests were not
practical in view of the nature of the sensitising agent
(Johnstone's Furniture Polish).
No previous blood transfusion. No previous
pregnancy.
Nummary. Thrombocytopenic purpura apparently
due to sensitivity to Furniture Polish.
39. 0.0.(Female) aged 59. This woman was originally
seen in 1952 with gastro-enteritis complicating cirrhosis
of the liver and, splenomegaly. In March 1956 she had a
severe haematamesis due to oesophageal varices. At this
time she was found to be thrombocytopenic (Platelets
25,000/cu.Etrn.) and platelet agglutination test was positive •
to a tltre of 1/2.
hospital with a 5 week history of congestive cardiac
failure. This had been sudden in onset and it was
suggested that he had had a "silent" coronary thrombosis.
Electrocardiographic traces showed no abnormality. He
rapidly went downhill after admission and a tentative
clinical diagnosis of periarteritis nodosa was made. He
suddenly, however, developed spontaneous purpura and nose
bleeds.
Physical examination at this time showed no
abnormality apart from scattered purpuric haemorrhages
over the trunk and limbs. There war, marked ankle and
sacral oedema and distended jugular veins. There was no
splenomegaly*
laboratory Investigations. lib. 66^ (9.8 gms/Q
Platelets 15,000/eu.mm. Bleeding time 15' + (Ivy).
Capillary fragility increased. Peripheral blood contained
numerous immature granulocytes and occasional 'blast* cells
together with occasional normoblasts. Platelet agglutin¬
ation test - negative. Bone marrow biopsy revealed that
normal marrow tissue was replaced by focal collections
of immature cells. The appearances of the cellular clumps
suggested that they were malignant tumour cells. Ho
further investigations were performed and the patient was
discharged without any primary neoplasm being located.
performed
Ho follow up examination has bee^ done to date.
No previous blood transfusions.
nummary. Secondary Thrombocytopenia due to
disseminated carcinomatosis.
42 D.H.(Female) agod 56. This woman was admitted
to hospital with a 6 months history of painless jaundice
associated with an increased bruising tendency.
Physical examination revealed hepato and spleno¬
megaly associated with deep jaundice.
Laboratory investigational Serum bilirubin 6.9 -
10.5 fflgms. Alkaline Phosphatase - 4 units (King Armstrong).
Plasma Proteins* Total 5.8 mgms/». Albumin 1.8 gmsyi.
Liver floculaticn tests - negative. Terminally became
positive. Prothrombin Ratio (Quick) 1.2 - 1.8. Kb, IS'i
(7.1 gms/i) lietics. 5.8$. Platelets 16,000/cu.mm. The
red cells were marked anisocytotic and showed many distorted
forms ("fragmentation"). Coomb's test on red blood cells -
negative. Platelet Agglutination Test - negative. Bone
marrow biopsy revealed a hyperplastic marrow containing
numerous smear cells whose exact nature was indeterminable.
Bed cell survival test (Ashy) showed shortened survivals
of normal cells when transfused into the patient.
Cortisone therapy promoted a temporary clinical
improvement but had no effect on the haemolytic process or
the thrombocytopenia. She rapidly relapsed and died in
coma.
Post-mortem examination revealed a diffuse
hepatic cirrhosis and associated with histiocytic medullary
reticulosis involving the liver, spleen, lymph nodes and
bone marrow.
Previous Blood Transfusion. Previous Pregnancy.
Diagnosis. Secondary Thrombocytopenia due to
Histiocytic iledullary Reticulosis in a female aged 56.
43. M.L.(Female) aged 17. Admitted to hospital
with a history of feeling unwell for 6-8 months. She
complained of headaches and was febrile on admission.
Temp. 103-104° F.
Physical examination. Enlarged inguinal and
cervical lymph nodes. Epleen enlarged. Small bilateral
pleural effusions. No other abnormality detected.
Radio-chromium survivafjpSMd increased haemolysis.
Lafopratoyy Iiprestlgatipn. Hb. 65% (9.6 gras/«).
W.B.C. 1400. Platelets 12,000/cu.mm. Platelet
agglutination test - negative. There was a persistent
Beticulocytosis. Sternal marrow. Hyperplastic normo¬
blastic marrow showing no evidence of leukaemia.
Megakaryocytes easily found. Coomb's Test on the red
blood cells was negative.
Treatment. Prednisolone produced a slight
improvement but she relapsei^Mlvaloping jaundice. I.N.H.
and Streptomycin produced remission of 10 days duration
but she again relapsed,and died 1 month after admission.
Post-mortem. Acute Hodgkins disease or
Histiocytic Medullary Reticulosis.
No previous blood transfusion. No previous
pregnancy.
Summary. Secondary Thrombocytopenia.
44. D.F, (Female) aged 49. This woman had a long
and involved illness lasting 3 years. She was first seen
in 1953 when she was found to have purpura associated with
thrombocytopenia and splenomegaly. 2 months later she
was found to have a spheroidal cell carcinoma of the left
breast and underwent radical mastectony.
The purpura, thrombocytopenia and splenomegaly
persisted and in 195-4 she commenced to have gastro -
intestinal haemorrhages with melaena. the was admitted
to hospital at intervals for investigation and treatment
of anaemia following intestinal haemorrhages.
In September 1955 a right axillary lymph nod©
was removed and found to be infiltrated with secondary
carcinoma. Repeated x-rays and marrow biopsies failed to
reveal any evidence of disseminated carcinomatosis* In
February 1956 a narrow biopsy revealed a megaloblastic
marrow which reverted to normoblastic maturation on
Vitamin B 22 therapy. Megakaryocytes were extremely scairty.
There was, however, no improvement of her persistent anaemia
or thrombocytopenia (50 - 7O,QQ0/cu,mm.)
Again in May 1956 her marrow showed megaloblastic
erythropoesis but on this occasion there was no response
to therapy with Vitamin B 12 Folic acid or Crude Liver
Extract.
Che was now severely anaemic, (Kb. 27/ 4 gms>)
leucopenic (1700/cu.mm.) and thrombocytopenic (70,000/cu.mm.)
Terminally she developed an unexplained eosinophilia.
She died in October 1956 and Post-mortem revealed
generalised carcinomatosis with secondary deposits in bone
marrow, lymph nodes and liver. The spleen was three times
larger than normal. (450 gms) but was not infiltrated with
tumour.
Platelet agglutination tests were persistently
negative,
f. « ■
Multiple Blood Transfusions, Previous
Pregnancies
diagnosis. Thrombocytopenic purpura secondary
to generalised carcinomatosis arising from a primary focus
in left breast,
-45, J»H. (Male) Aged 53, This man was perfectly fit
until 5 weeks before admission when he suddenly noticed
that he was bruising excessively after trivial trauma,
2 weeks later he had a severe epistsxis and at this time he
felt vaguely unwell.
On admission j^, had multiple subcutaneous bruises
and occasional crops of petechias on legs and feet. Apart
from slight liver enlargement and axillary lymph node
enlargement no other physical abnormality was found.
laboratory Investigation revealed that ha was
anaemic with thrombocytopenia (19,0G0/cu.ram) and a rising
white cell count, 15 - 33,000/cu.mm. His bleeding time
was prolonged (15' ♦) Ivy and capillary fragility was
increased. The peripheral blood film showed numerous
promyelocytes and myelocytes and marrow smears showed an
acute promyelocytie leukaemia. Megakaryocytes were absent.
Platelet agglutination test was negative.
There was no response to Prednisolone or 'Ityoleran'
therapy or to blood transfusion.
He died suddenly 2 weeks after admission and
post-mortem revealed a cerebral haemorrhage and tissue
and marrow changes consistent with acute myeloid leukaemia.
Ko Previous blood transfusion.
Diagnosis. Thrombocytopenia secondary tc acute
myeloid leukaemia.
46. A.H. (Female) aged 57# This woman was admitted
to hospital with a 1 year history of epigastric discomfort
after meals. This was accompanied by anorexia. For three
months there had been severe pain following meals and
during the 2 weeks prior to admission she had vomited after
every meal.
Laparotomy revealed generalised abdominal
carcinomatosis with the primary located in the stomach. The
spleen was enlarged but did not appear to be infiltrated
with neoplasm#
Laboratory Investigations. Hb. 103$ (15.2 gms$)
White blood cells 5,900. E.L.r. 3. Platelets 95,000/cu.mm.
Capillary fragility - increased. Platelet agglutination
test was positive to a titre of 3/1 on two occasions.
Do previous blood transfusion. Previous
pregnancies 2.
Summary. Thrombocytopenia secondary to
disseminated carcinomatosis in a female aged 57.
47# M.B. (Male) aged 67. This patient was admitted
in fully developed congestive cardiac failure with
associated peripheral gangrene of fingers and nose. There
was associated cutaneous purpura of both lower limbs. He
had complained of increasing dyspnoea and orthopnoea for
6 weeks prior to admission. His heart was enlarged and
there were systolic and diastolic aortic murmurs and a
faint mitral diastolic murmur.
Laboratory Investigation revealed that he was
thrombocytopenic (17,0G0/cu.rnm. ) As it was considered
that his peripheral gangrene might have been due to
recurrent platelet emboli, provoked by an immune platelet
agglutinin, platelet agglutination tests were performed.
These were, however, negative. His gangrenous tissue
demarcated and separated but in spite of therapy he
remained a state of congestive heart failure and died
4 months later after transfer to another hospital. Post¬
mortem revealed left ventricular hypertrophy with aortic
stenosis.
Ho record of previous blood transfusion.
Nummary. Thrombocytopenic purpura associated
with congestive cardiac failure and peripheral gangrene
in a male aged 67.
48. W.W. (Female) aged 40. This woman was admitted
to hospital following a severe ante parfcum haemorrhage.
It was noted that she had several cutaneous petechial
haemorrhages on the trunk arms and legs. She had had two
previous normal pregnancies and both children were normal.
On Physical Examination she was noted to be
excessively pale and her B.P. was recorded as BOjO .
Blood was removed for cross matching with fresh
donors and it was observed this did not clot in the tube
after 30 mins. Immediate laboratory investigation showed
a marked fibrinogen lack, accompanied by thrombocytopenia
pregnancy was uneventful and there was no evidence of
thrombocytopenia in the mother or baby.
2 Previous hlocd transfusions.
Summary. Thrombocytopenic purpura associated with
Acute defibrination syndrome of Pregnancy.
50. J.S. (i4ale) aged 67. This man had been perfectly
fit until 1955 when he developed a virus pneumonia from
which he apparently recovered. In June 1956 he was
admitted to Northampton General Hospital complaining of
giddiness, headaches, braathlessness. He had had one
sudden epistaxis one weak prior to admission.
Physical examination revealed ecchymotic
subcutaneous haemorrhages of the right hand and left arm.
The spleen was enlarged.
laboratory Investigations. Hb. 72$ (10.7 ga«£)
White cell count 23,300/cu.ram. Reticulocytes 14$. Normal
distribution. birect Coomb's Test (Patient's red cells) »
positive. Cold agglutinins l/l. Platelets 95,000/cu.ma.
Bleeding time - 3'10" (bufce). Platelet agglutination test -
motive. Bone Marrow biopsy. Active cellular marrow.
Megakaryocytes present.
Cortisone therapy restored his platelet count to
normal levels, but his haemolytic anaemia persisted. He
developed suddenly a Salmonella Typhi-raurium septicaemia
which necensitated cessation of steroid therapy. At no time
had he had any blood transfusions. He was discharged from
hospital and no follow up examination has been made to date.
Nummary. Thrombocytopenic purpura associated with
an acquired hasmolytie anaemia.
i'
51. G. (Female) aged 34. This woman was first seen in
1954 when she was found to have an acute hasmolytic anaemia,
due to an auto & iso cold agglutinin. Direct Coomb's Test
on the red blood calls was positive. A specific airti-t>
iso-agglutinin was presentj the patient's red cell group
being 8-
Physieal examination revealed no abnormality apart
from splenomegaly. the was treated by multiple blood
transfusions and cortisone without improvement.
In January 1955 as her anaemia persisted and
thrombocytopenia had developed (45»0GO/cu.mm) she had her
spleen removed. At this time she had had no spontaneous
haemorrhage. Again there was no improvement of her
haemolytic anaemia but her platelet count returned to
normal levels, 310,QOO/eu.mm.
In January 1957 she was readmitted to btofce
of
Mandeville Hospital, Aylesbury because /the sudden onset of
repeated and severe epistaxes arid intractable monorrhagia.
Laboratory Investigations. Hb. 49i (7.25 gms^)
Platelets 50,000/cu.mm. Letieulocytes 3.0/C. Bleeding time
15+ (Ivy). Direct Coomb's Test on red cells - positive.
Both the cold agglutinin and the antibody. Aati-S ware
still present. Platelet agglutination test was positive
against both platelets derived from 0+ and S-v© blood to a
titre ofi~. Prednisolone therapy produced a slow but
definite clinical improvement and her platelet count arid
bleeding time returned to normal limits. Lepeated blood
transfusions wore also given.
10 days after the start of the Prednisolone therapy
a repeat platelet agglutination test was negative.
There had been 3 previous pregnancies, (2 in 1948*
1 in 1954; all resulting in miscarriages at 20, 12 and 14
weeks respectively) prior to the onset of her hasraolytic
anaemia.
When last seen this patient had no spontaneous
bleeding and it was proposed to perform a hysterectomy.
huirtmary. Thrombocytopenic purpura associated
with an acquired haemolytic anaemia in a female aged 54.
52. N.E, (Female) aged 56. In March 1952 this patient
was seen, as an cut patient, complaining of dryness of the
mouth associated with swelling of the parotid gland and
vague rheumatic pains in muscles and joints of several
months duration. A diagnosis of Sjorgans syndrome was made
and her symptoms were partially improved by cortisone therapy.
2 months later she first noted purpura on her legs and this
became more pronounced until, in June 1955, she was admitted
to hospital for investigation. Physical examination revealed
purpura on the legs, abdomen and one arm. There was
marked residual brown staining as the purpura faded. There
was no splenomegaly.
Laboratory Investigations. Hb. 32% (12.1 gn$)
White cell count 5,000/cu.mm. E.S.R. 23 rain/hour.
Platelets 89,000/cu.mm. eternal marrow was normally
cellular and normoblastic. Megakaryocytes ware easily found.
Biochemical examination revealed a cryoglobulin in her
serum (0.6 gms%) Platelet agglutination test was negative
at 37°C but positive at 20°C and 4°C with associated
precipitation of cryoglobulins. The test was positive
when a suspension of the patient's own platelets were used.
X-rays and sternal narrow biopsy showed no evidence of
myelomatosis.
The purpura continued to appear while in hospital.
The platelet count fluctuated between 34,000 and 172,000/cu.nn.
Cortisone and 5-hydroxytryptomine creatinine sulphate
(Anteracvis) failed to improve her purpura.
Ko previous blood transfusions. One previous
pregnancy.
Diagnosis. Thrombocytopenia and purpura associated
with cryoglobulinaemia in ^organ's Dyndrone in a female
aged 56.
53. W.P. (Male) aged 49. This man was originally
admitted to hospital In 1953 with a 9 months history of
a purpuric rash on both legs and lower trunk of 6 months
duration. The purpura, when it faded, left marked brown
staining of the skin. Physical examination revealed no
abnormality apart from this purpura and staining.
Laboratory investigations all gave normal results
with the exception of the plasma proteins which showed an
excess of X globulin on electrophoresis. X-ray examination
revealed mild splenomegaly. eternal marrow showed a slight
increase in the number of small lymphocytes. No other
abnormality was detected. As no satisfactory explanation
could be offered for his purpura he was discharged from
hospital.
Fresh exacerbation of his purpura necessitated
his readmission to hospital in February 1954 when it was
discovered that he had an abnormal cryoglobulin in the
protein fraction of his blood (1.2 gms/), His E.S.R. was
5 ran/hour at KT. and 45 mm/hour at 37°C. He was never
thrombocytopenic but platelet agglutination test at that
time was positive (Dr. R. Gillett). At this time the
purpura was associated with mild thrombocytopenia (84»0G0/cu.mm)
In May 1955 he was readmitted because of a
cerebrovascular accident which had produced a loft hemiplegia.
The purpura persisted and a platelet agglutination test
performed at this time was negative when performed at 37°C.
At 20°C and 4°C marked platelet agglutination appeared to
take place along with a dense precipitate of the cryoglobulin
fraction. The test was positive when a suspension of the
patient's own platelets ware used.
This patient'® condition subsequently deteriorated
he
and when last heard of/was completely bed ridden due to
further cerebro vascular accidents and associated severe
hypertension. The purpura was now widespread and involved
hands and arms as well as both legs.
Ho previous blood transfusions.
Summary. Thrombocytopenia and purpura associated
with Egrential or Idiopathic czyoglobulinaemia in a male
aged 49.
54 W.L. (Male) aged 59. In 1947 this man had a
severe pneumonia treated by sulphonamides. A few months
later he developed purpura of both lower limbs below the knee.
This purpura appeared in successive crops and led eventually
to ulceration of the skin. Before these episodes of
purpura appeared, the patient felt a burning sensation,
and the attacks were exacerbated by cold. If he put
his hands or feet into hot water, they became covered with
purpura when withdrawn.
Numerous laboratory investigations failed to
detect any abnormality either kaesatologieally or
biochemically until in 1956 when he was admitted to
hospital for reinvestigation.
Physical examination shoved extensive purpura of
ankles, feet, legs, hands, forearms, and ears. This was
associated with narked brown staining of the skin. There
was no splenomegaly and no other physical abnormality was
detected.
Laboratory Investigations. Hb. 103/ (15.2 gas/)
W.B.C., 6,000/Cu.am. Normal distribution. Platelets
234,G0Q/cu.mm. Bleeding time 3'45* (Ivy). C.T. 7*45".
Tourniquet test - negative. E.s.R. 37°C - 55 mra/hr,
Room temp - 7 mra/hr. 0-4°C 1 mm/hr. Cryoglobulins
associated with the I globulin fraction of tire plasma
proteins were present at room temperature and in the cold.
Marrow biopsy revealed an entirely normal marrow. Platelet
agglutination test was negative at 37°C but positive at
room temperature. Cortisone therapy exacerbated his purpura
and so therapy was stopped. As no other therapy was
available he was discharged home.
No previous blood transfusion.
Summary. Purpura associated with Cryoglobulinaemia
in a male aged 59.
55. M.W. (Mala) aged 56. This man had developed
arthralgia of increasing severity over the 3 years prior to
admission to hospital in 195-4* This was diagnosed as
rheumatoid arthritis. Gold therapy was given with no
improvement in his condition. fie then developed widespread
"seborrhoeic dermatitis" which responded to treatment with
Phenergan. subsequently he complained of dysphagia and
recurrent sore throats. Immediately before admission he
developed bilateral pleurisy with increasing dyspnoea.
Physical examination revealed arthritis in knees,
elbows, wrists, shoulders aid fingers. There were bilateral
pleural effusions and the spleen and liver were enlarged.
It was also noted that he had a mask-like fades and the
texture of his skin was unduly hard. There was mild ankle
and sacral oedema.
febpffitqyy Iffyestigtttfofl?* Hb. 8% (12.9 gms/Q.
White cell count 8,500/cu.mm. Platelet count 254»00Q/cu.mm.
E.S.R. 95 mm/hour. Coomb1s Test - negative. Urine contained
numerous red cells and albumin (1.5 gms/24 hours).
Numerous lupus erythematosus cells ware found on
every preparation made of peripheral blood. These were also
found in smears made from the pleural exudates. Platelet
agglutination test was negative. Skin biopsy revealed
changes consistent with the diagnosis of scleroderma.
Cortisone therapy improved his arthritis and skin
changes and the number of L.E. cells decreased, but were
still present 12 months later while clinical remission.
I
was maintained by continual cortisone therapy.
No Previous blood transfusion.
Diagnosis. Acute disseminated lupus
Erythematosis in a male aged 56.
56. F.B. (Male) aged 59# This man, who had had
severe rheumatoid arthritis for 16 years, developed a
coneommitant renal lesion with albuminuria and hypertension
in 1953• Both his arthritis and renal lesions improved
dramatically on cortisone. Physical examination revealed
widespread rheumatoid arthritis affecting elbows, knees,
wrists, and hands. There was associated ankle and sacral
oedema. The spleen was enlarged. There was no evidence
of skin lesions and no other significant abnormality was
discovered. hapeated examinations for L.E. cells were
performed before a positive result was obtained in 1955.
laboratory investigations revealed a mild anaemia.
Hb. SO1/, (11.8 gms/»)« White cell count 9-10,000/cu.mm.
His E.B.B, was persistently high 90 - 107 mm/hour and has
remained high in spite of the clinical improvement obtained
with steroid therapy. Total Proteins 5-6 gma>, Albumin
1.6 grns/, Globulin 4*0 gms>. Blood uraa, 30 - 52 mgms/U
Platelet court /30,000/cu.mm. Coomb's Test - negative.
Platelet agglutination test - negative.
No previous blood transfusions.
Diagnosis. Probable acute disseminated lupus
erythematosus in a mala aged 59.
57# W.P. (Female) aged 54-. This woman had developed
a progressive lower motor neuroi® disease following a severe
fall 6 years previously. For some years she had noted she
was liable to bruise easily. 3 months before admission
to hospital this bruising became more marked and purpura
developed but she did not have any other evidence of
abnormal bleeding tendency. Apart fro:.: large doses of
Vitamin E she had taken no drugs in the past 6 months.
Physical examination showed purpura on the
anterior chest wall and there were numerous bruises on her
anas. There was no splenomegaly. There was wasting of
hand and thigh muscles and fibrillation of arm and thigh
muscles and the tongue. Upper limb reflexes were brisk g
the leg reflexes were depressed
but doproDocd in the lege and uhe right ankle jerk was
absent as were both plantar reflexes. There was no
sensory disturbances. There was no evidence of
telangiectasia.
Labppatqry inyegt^tiopp, Hb. 1(X$ (14.8 gas>)
White blood cells 5#6GG/cu.ima. Platelets 229>000/cu.mm.
Bleeding time 15' ♦ (Ivy) was prolonged on the first
examination but returned to normal within 2 weeks.
Capillary fragility was abnormal* All tests for coagulation
function were normal. Coomb's test and platelet agglutin¬
ation test were negative. It was decided that her bruising
and purpura were not connected with her atypical lower
motor neurone lesions.
Ho previous blood transfusion or pregnancy.
Summary. Hon-tlironbocytopenic purpura in a female
aged 54 associated with progressive lower motor neurone
disease.
58. R.H. (Male) aged 70. This man was fit 'until the
age of 52 when ha had a sudden melaena. This did not recur
until the aga of 59 and since then he has had virtually
continuous iselaena of unexplained origin# A partial
gastrectomy was performed 6 years ago and subsequently
he has had 3 laparotomies, all of which have not revealed
any cause for the persistent gastro-intestinal haemorrhage.
He has required multiple transfusions for anaemia secondary
to this blood loss# Cortisone and Adranoxyl therapy
produced no improvement. Ha was admitted to the Radcliffe
Infirmary in 1954- when he was found to have a prolonged
bleeding time 15* ♦ normal platelet count (405,000/cu.mm.)
and abnormal capillaries compatible with Von ftiliebrand's
syndrome, There was no family history of any haemorrhagic
diatheses, Ho other significant abnormality was detected.
There was no splenomegaly.
In June 1956 he was readmitted for further
investigation as he had had further severe intestinal
bleeding requiring blood transfusion, There had been no
purpura but there was excessive bruising. Up to this time
he had had over 100 blood transfusions.
Laboratory Investigations showed that he was
anaemic (lib, hU,L 6.5 gpS/Q Platelet count 309,000/cu.mm.
Bleeding time 9' + (Ivy). Reticulocytes 8.8/i Clotting time
5*15". Clot retraction - normal. Patient's platelets
generated thromboplastin normally and clot retraction was
normal. Capillary fragility was abnormal. Platelet 5 -
8
hydroxytryptamine was abnormally low (5ng/10 Platelets).
8
(Hormal 60ng/10 Platelets). In addition he was found to
have an acquired haemolytic anaemia with warit^ ^psC:^ff^ibody
(Coomb's test - positive).
Platelet agglutination tests revealed both auto-
agglutinins and specific platelet iso-agglutinin, which
agglutinated his own platelets and four out of six normal
platelet suspensions examined. This antibody was probably
the result of his repeated blood transfusions.
As it was felt that this man might be improved
by parenteral 5-hydroxytryptamins he was given daily
'Antemovis' (5-hydroxytryptamine - creatinine Sulphate).
As there was an apparent improvement in this man's condition,
this therapy was continued. While undergoing this treatment
this patient was transferred to the Boyal Infirmary,
Liverpool, and no follow up information has been supplied
to date.
('Anteraovis' for the treatment of this patient
was supplied by Vismara Therapeutic!, Como, Italy.).
Summary. Hon thrombocytopenic purpura with
gastrointestinal haemorrhage in a male aged 70.
59. J.T, (Female) aged 26. This young woman suddenly-
developed purpura of both legs below the knee 2 months before
she was admitted to hospital in 1953. Shortly afterwards
both her ankles started to swell at the and of the day.
This latter feature was associated with quite severe pain.
Almost simultaneously she developed acute abdominal pain
accompanied by diarrhoea but there was no blood seen in the
stools. Lhe had had her first child 6 months previously but
the pregnancy was entirely normal. There had been no
abnormal tendency to bruise.
Physical examination revealed both fading and fresh
purpura lesions of both logs and thighs. There was no
splenomegaly.
Laboratory investigations. Hb. 88$ (13.0 gras$)
Platelets 134-197,OGO/cu.mm. Bleeding time 3'15" (Ivy).
E.S.K. 40 m rn,/hr. Urine shewed mild albuminuria (95 mgms$)
with red cells but no casts were present.
Cortisone therapy improved both the purpura and
the albuminuria. Che was discharged on a maintenance dose
of Cortisone for 5 months. Her albuminuria gradually
V
increased and red cells were persistently present in the
urine but no casts were seen. Occasional crops of purpura
recurred on her legs. When readmitted her platelet
agglutination test was negative. The albuminuria gradually
became more severe -until she was passing 1 gm. pratein/lOGal
urine. The number of red cells present fluctuated from a
few to a large number. Her blood urea was never higher
than 53 ragm$.
The patient*e condition remains the same when
last seen in March 1957.
Ho previous blood transfusion. Previous pregnancy.
Mummarv. "Henoch Ochonlein" non thrombocytopenic
purpura in a female aged 26.
60, W.H. (Mala) aged 43. This man had been perfectly
well until 3 weeks before admission to hospital, when he
complained of a sore throat. 1C days later the throat
returned to normal but he developed a rash over his back,
arras, legs and buttocks. This was accompanied by painful
swelling of knees, elbow joints, and hands. To alleviate
the pain, he was in the habit of tailing Compound Codeine
Tablets.
On admission he was febrile, there was a
purpuric rash over his back, arms, legs and buttocks. On
examination no other physical abnormality was discovered.
He had persistent albuminuria, with microscopic
haematuria. '^here was no anaemia and the bene marrow
was norma! in appearance. Megakaryocytes were present.
Platelet count 2G5,GOG/eu.mm., bleeding time, clotting
time, prothrombin time wars normal.
Cortisone depressed the E.S.R. to 32 am/hr. but
the purpura and albuminuria persisted until discharge from
hospital. CldLn biopsy revealed a non-specific vasculitis
involving the dermal capillaries and small arterioles.
Platelet agglutination tests were negative.
There was no in vitro evidence of drug sensitivity to
Aspirin, Phenacetin or Codeine.
No Previous blood transfusion.
Summary. Henoch Scfaonlein Purpura in. a male
aged 43*
61. B. (Male) agad 65. This man was referred for
haematological investigation following the onset of wide¬
spread purpura of legs, arms and trunk of 1 weeks duration.
This was associated with recurrent episodes of acute
abdominal pain. He had never suffered from any other
form of spontaneous bleeding before and had been talcing no
drugs. He had been travelling extensively abroad and
had been flying a great deal.
Physical examination revealed no abnormality
apart from purpura.
Laboratory investigation. Kb. 112$ (16.6gras$).
Platelets 321,Q0C/cu.nn. Bleeding time 3* (Ivy). Capillary
fragility - increased. E.S.R. 10 mm/hr. platelet
agglutination test - negative. Urine contained albumin
and red cells. Ho casts were present.
No further history was available in this case as
the patient want abroad immediately after examination.
No previous blood transfusion.
Summary, Probable Henoch-Sehoniein purpura in
a male aged 65,
62. L.B, (Female) aged 77. This woman, a mild
diabetic not requiring insulin, was admitted to hospital
because of the sudden appearance of widespread purpura
associated with abdominal pain and vomiting, iter joints
were not involved.
Physical examination revealed a widespread purpura
over the feet, legs, thighs, buttocks, lower abdomen, arms,
breasts and shoulders. This was confhent in some areas.
No other significant abnormality was discovered and there
was no splenomegaly.
Laboratory investigations. Kb. 122$ (18.0 gms$).
White cell count 9,400/cu»raia. platelets 190-262,000/cu.ma.
Bleeding time and capillary fragility were normal. Platelet
agglutination test - negative.
The purpura continued to appear in crops affecting
the same areas as the initial outbreak.
64. E.W. (Female) aged 24. This young woman, who
had had sever© ulcerative colitis for on® year, was admitted
to hospital for the treatment and correction of anaemia
resulting from severe blood loss per rectum. SJ» received
five separata transfusions of compatible blood and following
the last transfusion she developed purpura of the skin over
the shoulders, arms, chest and back. She had had no other
reaction to the repeated transfusions. She had had on©
child previously.
Physical examination showed no abnormality apart
from the purpura. There was no enlargement of the spleen
on the day following the onset of purpura.
Laboratory investigations showed that there was
no evidence of thrombocytopenia 239>0GQ/cu.nm. Hb. 64/
(9.5 gm/) E.S.R. 96 am/W. Bleeding time -4' . Capillary-
fragility increased. Platelet agglutination tests showed
that she had both auto and isc platelet agglutinins to a
titre of 1/2. When retested 3 weeks later no demonstrable
platelet agglutinins were present.
The case notes of this case could not be found in
hospital records and no record was available of any reaction
to further blood transfusion.
Summary. Nonthrombocytopenic purpura following
blood transfusion in a woman aged 24.
65. M.D. (Male) aged 15. This boy was admitted to
hospital with a Type II Nephritis (Ellis) with gross oedema
and albuainaamia. There was severe hypo albuminaemia
(1-2 gms/) and in an attempt to restore the level to normal
Summary. Allergic Non-thrombocytoponic purpura
provoked by human albumen transfusions.
66. J,S* (Female) aged 49• This patient was referred
by her general practitioner for investigation of localised
purpura of sudden onset. This had appeared 1 week before
examination. This purpura had started suddenly and was
not itchy or painful. No particular exciting agent could
be traced. She had been talcing no drugs. Otherwise she
had no complaints, and physical examination revealed no
abnormality apart from fading purpura over the anterior
aspect of both legs.
Laboratory investigations showed that she was not
anaemic. Hb. 95$ (14.1 gtts$)» White cell count 7,800/cu.mm.
Platelets 217,0GG/cu.mm. Bleeding time 9* (Ivy).
Prothrombin time (Quick) Normal 15". Patient 15n.
Peripheral blood - Normal. Capillary fragility - increased.
Platelet agglutination teat - Negative.
No further history or follow up was available.
No previous blood transfusions or pregnancy,
Nummary. Nbn-thromboeytopenie purpura in a female
aged 49.
67. P.C, (Female) aged 17. This girl had a ♦port-
wine* naevus of her left leg below the knee which was a true
vascular ♦hamartoma*. Plastic surgery was attempted for
cosmetic reasons but, the tumour having been removed, no
healing took place and a series of skin grafting operations
failed. She was investigated haematologically because of
and thus control the oedema, 4 transfusions of human
albumen (75 gas/transfusion) ware given. One month later
they were repeated but this time there was a marked reaction
to each transfusion with vomiting, rigors and unexplained
bouts of coughing. After one of these reactions, scattered
purpuric haemorrhages were noted and at the same tin© his
red cells gave a positive direct Coomb1s Test. There was
no thrombocytopenia (Platelets 207,000/eu.mm). The bleeding
time and capillary fragility were normal.
Investigations by in vitro platelet agglutination
tests showed that blood taken immediately after a transfusion
of human albumen contained an auto-agglutinin against the
patient's own platelet®. The blood taken 2 days later
showed no such auto-agglutinin tut, on the addition of human
albumen (Lister Inst.) to platelet rich plasma, platelet
agglutination occurred and clot retraction was inhibited.
Similarly the patient's serum, which did not agglutinate
normal platelets by itself, did so very strongly when human
albumen (Lister Inst.) was added. Preparations of the
patient's own albumen, American Human Albumen, Bovine, used
in similar concentrations (Experiment 44) did not provoke
agglutination.
(ippmdlI p.35).
In view of these reactions to albumen no further
transfusions were given. 1 month later platelet agglutin¬
ation test were entirely negative.
Prednisolone therapy produced a clinical remission
with a total disappe ranee of the alburainurea and oedema.
This has been maintained for 1 year.
One previous blood transfusion.
this failure of skin grafts to take in the wound edges,
an unexplained 0020 of blood from the wound and some purpura,
of the skin surrounding the wound.
Physical examination showed that the spleen was
not enlarged.
laboratory investigation revealed that she was
mildly anaemic, Hb. 76h (11.2 gms'>) White cell count and
differential ware normal. Platelet count was normal
206,000/cu.mm. bleeding time and capillary fragility were
within normal limits. There was no evidence of any
haeaolytic process and no abnormal proteins were detected.
Her erythrocyte sedimentation rate was raised 79 ma/hr.
Capillary microscopy showed marked clumping of tee red cells
in the circulation. This is an abnormal finding but no
explanation could be offered for this ancraaily. Ho diffuse
or focal telangiectasis could be detected. Platelet
agglutination toot ma nogativo. CoU tltre ,/l6
The original wound began to heal very slowly but
9/12 later it had not yet completely healed and within the
clear tissue that had formed, obvious telangiectasis of
small capillaries were present.
One previous blood transfusion.
Diagnosis. Nonthrombocytopenic purpura
associated with an unexplained failure to heal following
excision of vascular hamartoma of leg.
68. S.H, (Female) aged 5. This child was investigated
because of unexplained intraocularhaemorrhage involving
the anterior chamber? "^c normality was discovered
apart from abnormal capillary fragility. Hb. 95j» (14.1 g®e>)
Platelets 216,000/cu.nm. Platelet agglutination tests -
negative. B.T, (Ivy) 4'.
Ho previous blood transfusion.
Summary. Unexplained intraocular haemorrhage
in a female aged 5»
69. M.Q. (Female) aged 38. This woman had bruised
easily for several years and had latterly suffered from
severe monorrhagia. In October 1953 she developed a
purpuric rash appearing first on the dorsum of the foot and
spreading over the trunk and arms. This persisted for
1 year and in January 1954 a cervical biopsy produced a
marked secondary haemorrhage. The purpura persisted and,
as the patient herself felt that it was exacerbated by
phencbarbitone, she was admitted to hospital for investigation.
Physical examination revealed purpuric haemorrhages mainly
over the feet, ankles and buttocks but there vera a few on
the trunk and thighs. There was no splenomegaly.
Laboratory investigations revealed a normal
platelet count (312,000/cu.mm) and normal bleeding time
and capillazy fragility. All tests of coagulation function
were normal and platelet agglutination tests were negative.
Tests for drug sensitivity to phenobarbitone revealed no
positive results, (Appendix A, p.16).
Capillary Microscopy (hr. E.G. Macfarlane)
suggested that the purpura was unusual in that the area of
extravasated blood appeared to be surrounded by a zone of
congested capillaries. "Adrenoxyl" (Adrenochrome mono
semicarbazome) was given but produced no improvement of
the purpura.
No previous blood transfusion. Previous
pregnancies.
Summary. Non-thronbocytopenic purpura in a woman
aged 38.
90. S.B. (Female) aged 51. For 2 months prior to
examination this patient had developed an acute irritant
rash of her forearms, waist and groins. This had a strong
purpuric element to it and the skin was hyperkeratotic.
Physical examination showed numerous scratch
marks over the affected parts. No other physical
abnormality was detected.
Labppatpyy foveptlKattong. Hb. 113/i (16.7 gms/.).
White blood cells 5,100/cu.mn. Total neutrophils 3,000/cu.ram,
Bleeding Time 3* 15" (Ivy). Capillary Fragility: markedly
increased. Platelets: 189,00Q/cu.ram. Platelet agglutination
test - negative.
No previous blood transfusions or pregnancy.
Nummary. Non-thrombocytopenic purpura in a female
aged 51.
71. A.F. (Female) aged 46. This woman suddenly
developed purpura over her legs and arms, which continued
to appear sporadically over the next 2 months. She had been
taking no drugs.
Physical examination revealed no abnormality apart
from the purpura.
laboratory investigations. Hb. 10C$ (24.8 gras$)
B-globulin fraction*
3 weeks later the platelet agglutination teat was
negative but the abnormal protein pattern persisted*
Ho previous blood transfusion.
'
Summary. Positive platelet agglutination test
in a case of Virus Pneumonia.
APPENDIX D
STATISTICAL ANALYSES
(l am indebted to Mr. IT.T.J, Bailey of the
Department of Biometry, University of
Oxford for his guidance in the preparation
of this Appendix)
In Part II of this thesis the appraisal of the results of
platelet agglutination tests on normal and abnormal bloods
necessitated statistical analyses in order to establish whether
these results supplied information of value or were due to
chance observation.
In all examples this involved the straight-forward
analyses of four groups of related restilts and thus it was
convenient to use the following type of X? (Chi-squared) test
for this purpose.
The experimental results were tabulated according to the
following table:
a b a + b
c d c + d
a+o b+d n a Total
Where a, b, c and d represent the number
of observations in each group, and n the
total number of observations.
With the information derived from this table X^ was determined
by the following formula, using Yates1 correction,
degree of freedom (n ■ 1) using the X^ tables (R.A. Fisher,
1936. Statistical Methods for Research Workers, 6th Edition.
Oliver and Boyd, Edinburgh and London).
It is satisfactory In certain biological experiments to
aocept results as significant when the associated value of P
is less than 5$, and the value of X2 corresponding to a
significance level of 5$ (P? 0.05) is 3*841 for one degree of
freedom.
Analyses of Experimental Results.
A. Analyses of results obtained from Table XL
The numbers of positive platelet agglutination tests were
















Therefore for one degree of freedom P<.0,01
B. Analyses of results obtained from Table XXXIX
(i) The numbers of positive platelet agglutination
tests in the following groups were analysed.
(a) Platelets derived from Group 0 blood cross matched
with serum derived from Group 0, A and B blood.
D3
(b) Platelets derived from Group A and B blood cross




Group 0, A, B serum
Group A or B Platelets
*














X (1) ■ 8.15
Therefore P<0.01
(ii) The number of positive agglutination tests were
in the following groups.
(a) Platelets derived from blood Bhesus group positive and negative








Group Bh ♦ 20 292 312






C. An analysis of the positive agglutination tests
In thrombocytopenia and non-thrombooytopenic syndromes
The differences "between the above two groups ware







Thrombocytopenic group 23 32 55
Nonthrombocytopenic group 6 12 18
'
■ •} ■ ' 29 44 73
^2(1) "
P 70.70
B. An analysis of positive agglutination tests in
relation to splenic enlargement» (Data obtained from Table L)
The pattern of results, in relation to the size of the







normal spleens 15 36 51




E. Analyses of results obtained from Tables LI and LII
relating positive platelet agglutination jests to the response
to Steroid therapy and Splenectomy
The pattern of results could be expressed as follows:
(i) The relationship of positive platelet agglutination







Response k 8 12
Ho response 3 7 10
7 15 22
(ii) The relationship of positive platelet agglutination







Response 4 3 7
Ho response 2 3 5
6 6 12
In each of these tables there is at least one entry-
having an expected value of loss than five observations, e.g.
the lower left expectation in the table relating to
splenectomy is 6x5 / 12 » 2.5* Therefore, it was not
possible to apply the 15? test to these results. while
statistical analysis by other methods could have been done, it
was apparent from the inspection of the tables that the
differences between the groups were not likely to achieve
significance. Therefore, it can be concluded there was no
correlation between the positive platelet agglutination testa,
and the response to Steroid therapy or Splenectomy,
D6
F. Analysis of results obtained from Tables LI1I A & B
This information was analysed in the two sub-divisions
detailed in this table*
(i) The relation of positive platelet agglutination
tests to blood transfusion.































Previous pregnancy 15 (a) 14 (b) 29
Sever pregnant 14 (o) 30 (d) 44
29 44 73 (n)
X *» 2.12
P 7 0.10
